MetLife (MET) 10-K 23 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Feb. 14, 2023	Jun. 30, 2022
Entity Information [Line Items]
Document Type	10-K
Entity Registrant Name	MetLife, Inc.
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-15787
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-4075851
Entity Address, Address Line One	200 Park Avenue,
Entity Address, City or Town	New York,
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10166-0188
City Area Code	212
Local Phone Number	578-9500
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001099219
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		774,362,092
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Public Float			$ 50.1
Documents Incorporated by Reference [Text Block]	DOCUMENTS INCORPORATED BY REFERENCE Part III of this Form 10-K incorporates by reference certain information from the registrant’s definitive proxy statement for the Annual Meeting of Shareholders to be held on June 20, 2023, to be filed by the registrant with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the year ended December 31, 2022.
ICFR Auditor Attestation Flag	true
Common Stock
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01
Trading Symbol	MET
Security Exchange Name	NYSE
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01
Entity Information [Line Items]
Title of 12(b) Security	Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01
Trading Symbol	MET PRA
Security Exchange Name	NYSE
Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E
Trading Symbol	MET PRE
Security Exchange Name	NYSE
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F
Trading Symbol	MET PRF
Security Exchange Name	NYSE
5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, par value $0.01
Entity Information [Line Items]
Title of 12(g) Security	5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, par value $0.01
3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, par value $0.01
Entity Information [Line Items]
Title of 12(g) Security	3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, par value $0.01

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	DELOITTE & TOUCHE LLP
Auditor Firm ID	34
Auditor Location	New York, New York

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Investments:
Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $183 and $91, respectively); and amortized cost: $306,025 and $310,884, respectively	$ 276,780	$ 340,274
Equity securities, at estimated fair value	1,684	1,269
Contractholder-directed equity securities and fair value option securities, at estimated fair value	9,668	12,142
Mortgage loans (net of allowance for credit loss of $527 and $634, respectively; includes $0 and $127, respectively, under the fair value option)	83,763	79,353
Policy loans	8,874	9,111
Real estate and real estate joint ventures (includes $299 and $240, respectively, under the fair value option and $0 and $175, respectively, of real estate held-for-sale)	13,137	12,216
Other limited partnership interests	14,414	14,625
Short-term investments, principally at estimated fair value	4,935	7,176
Other invested assets (net of allowance for credit loss of $26 and $40, respectively; includes $1,926 and $1,930, respectively, of leveraged and direct financing leases; and $326 and $351, respectively, relating to variable interest entities)	20,038	18,655
Total investments	433,293	494,821
Cash and cash equivalents, principally at estimated fair value	20,195	20,047
Accrued investment income	3,446	3,185
Premiums, reinsurance and other receivables	17,461	17,149
Deferred policy acquisition costs and value of business acquired	22,983	16,061
Current income tax recoverable	42	184
Deferred income tax assets	2,830	189
Goodwill	9,297	9,535
Assets held-for-sale	0	7,238
Other assets	11,026	11,426
Separate account assets	146,038	179,873
Total assets	666,611	759,708
Liabilities
Future policy benefits	204,228	199,721
Policyholder account balances	203,082	203,473
Other policy-related balances	19,651	17,751
Policyholder dividends payable	387	478
Policyholder dividend obligation	0	1,682
Payables for collateral under securities loaned and other transactions	20,937	31,920
Short-term debt	175	341
Long-term debt	14,647	13,933
Collateral financing arrangement	716	766
Junior subordinated debt securities	3,158	3,156
Deferred income tax liability	325	9,693
Liabilities held-for-sale	0	6,634
Other liabilities	25,980	22,538
Separate account liabilities	146,038	179,873
Total liabilities	639,324	691,959
Contingencies, Commitments and Guarantees (Note 21)
MetLife, Inc.’s stockholders’ equity:
Preferred stock, par value $0.01 per share; $3,905 aggregate liquidation preference	0	0
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,189,831,471 and 1,186,540,473 shares issued, respectively; 779,098,414 and 825,540,267 shares outstanding, respectively	12	12
Additional paid-in capital	33,616	33,511
Retained earnings	41,953	41,197
Treasury stock, at cost; 410,733,057 and 361,000,206 shares, respectively	(21,458)	(18,157)
Accumulated other comprehensive income (loss)	(27,083)	10,919
Total MetLife, Inc.’s stockholders’ equity	27,040	67,482
Noncontrolling interests	247	267
Total equity	27,287	67,749
Total liabilities and equity	$ 666,611	$ 759,708

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Assets
Amortized Cost	$ 306,025	$ 310,884
Amortized cost of fixed maturity securities valuation allowances	183	91
Mortgage loans valuation allowances	527	634
Residential mortgage loans — FVO	83,763	79,353
Real estate and real estate joint ventures (includes $299 and $240, respectively, under the fair value option and $0 and $175, respectively, of real estate held-for-sale)	13,137	12,216
Real Estate Held-for-sale	0	175
Other Invested Assets - Leveraged and Direct Financing Leases	1,926	1,930
Other invested assets, at estimated fair value	20,038	18,655
Net Investment in Lease, Allowance for Credit Loss	$ 26	$ 40
MetLife, Inc.’s stockholders’ equity:
Preferred stock, par value	$ 0.01	$ 0.01
Preferred Stock, Liquidation Preference, Value	$ 3,905	$ 3,905
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,189,831,471	1,186,540,473
Common stock, shares outstanding	779,098,414	825,540,267
Treasury stock, shares	410,733,057	361,000,206
Residential mortgage loans - FVO
Assets
Residential mortgage loans — FVO	$ 0	$ 127
Real estate and real estate joint venture [Member]
Assets
Real estate and real estate joint ventures (includes $299 and $240, respectively, under the fair value option and $0 and $175, respectively, of real estate held-for-sale)	299	240
Variable interest entities
Assets
Other invested assets, at estimated fair value	$ 326	$ 351

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Premiums	$ 49,397	$ 42,009	$ 42,034
Universal life and investment-type product policy fees	5,585	5,756	5,603
Net investment income	15,916	21,395	17,117
Other revenues	2,634	2,619	1,849
Net investment gains (losses)	(1,262)	1,529	(110)
Net derivative gains (losses)	(2,372)	(2,228)	1,349
Total revenues	69,898	71,080	67,842
Expenses
Policyholder benefits and claims	50,612	43,954	41,461
Interest credited to policyholder account balances	3,692	5,538	5,214
Policyholder dividends	701	876	1,090
Other expenses	12,034	12,586	13,150
Total expenses	67,039	62,954	60,915
Income (loss) before provision for income tax	2,859	8,126	6,927
Provision for income tax expense (benefit)	301	1,551	1,509
Net income (loss)	2,558	6,575	5,418
Less: Net income (loss) attributable to noncontrolling interests	19	21	11
Net income (loss) attributable to MetLife, Inc.	2,539	6,554	5,407
Less: Preferred stock dividends	185	195	202
Preferred stock redemption premium	0	6	14
Net income (loss) available to MetLife, Inc.’s common shareholders	$ 2,354	$ 6,353	$ 5,191
Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
Basic	$ 2.93	$ 7.36	$ 5.72
Diluted	$ 2.91	$ 7.31	$ 5.68

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 2,558	$ 6,575	$ 5,418
Other comprehensive income (loss):
Unrealized investment gains (losses), net of related offsets	(47,831)	(8,171)	5,198
Unrealized gains (losses) on derivatives	(85)	137	(286)
Foreign currency translation adjustments	(1,242)	(1,306)	1,169
Defined benefit plans adjustment	279	328	181
Other comprehensive income (loss), before income tax	(48,879)	(9,012)	6,262
Income tax (expense) benefit related to items of other comprehensive income (loss)	10,871	1,862	(1,237)
Other comprehensive income (loss), net of income tax	(38,008)	(7,150)	5,025
Comprehensive income (loss)	(35,450)	(575)	10,443
Less: Comprehensive income (loss) attributable to noncontrolling interest, net of income tax	13	24	16
Comprehensive income (loss) attributable to MetLife, Inc.	$ (35,463)	$ (599)	$ 10,427

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock at Cost	Accumulated Other Comprehensive Income (Loss)	Total MetLife, Inc.'s Stockholders' Equity	Total MetLife, Inc.'s Stockholders' Equity Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interests
Beginning Balance at Dec. 31, 2019	$ 66,382	$ (121)	$ 0	$ 12	$ 32,680	$ 33,078	$ (121)	$ (12,678)	$ 13,052	$ 66,144	$ (121)	$ 238
Redemption of preferred stock	(989)				(989)					(989)
Preferred stock redemption premium	(14)					(14)				(14)
Preferred stock issuance	1,961				1,961					1,961
Treasury stock acquired in connection with share repurchases	(1,151)							(1,151)		(1,151)
Stock-based compensation	160				160					160
Dividends on preferred stock	$ (202)					(202)				(202)
Dividend Per Share	$ 1.820
Dividends on common stock	$ (1,657)					(1,657)				(1,657)
Change in equity of noncontrolling interests	5									0		5
Net income (loss)	5,418					5,407				5,407		11
Other comprehensive income (loss), net of income tax	5,025								5,020	5,020		5
Ending Balance at Dec. 31, 2020	74,817		0	12	33,812	36,491		(13,829)	18,072	74,558		259
Redemption of preferred stock	(494)				(494)					(494)
Preferred stock redemption premium	(6)					(6)				(6)
Preferred stock issuance	0
Treasury stock acquired in connection with share repurchases	(4,328)							(4,328)		(4,328)
Stock-based compensation	193				193					193
Dividends on preferred stock	$ (195)					(195)				(195)
Dividend Per Share	$ 1.900
Dividends on common stock	$ (1,647)					(1,647)				(1,647)
Change in equity of noncontrolling interests	(16)									0		(16)
Net income (loss)	6,575					6,554				6,554		21
Other comprehensive income (loss), net of income tax	(7,150)								(7,153)	(7,153)		3
Ending Balance at Dec. 31, 2021	67,749		0	12	33,511	41,197		(18,157)	10,919	67,482		267
Preferred stock redemption premium	0
Preferred stock issuance	0
Treasury stock acquired in connection with share repurchases	(3,301)							(3,301)		(3,301)
Stock-based compensation	105				105					105
Dividends on preferred stock	$ (185)					(185)				(185)
Dividend Per Share	$ 1.980
Dividends on common stock	$ (1,598)					(1,598)				(1,598)
Change in equity of noncontrolling interests	(33)									0		(33)
Net income (loss)	2,558					2,539				2,539		19
Other comprehensive income (loss), net of income tax	(38,008)								(38,002)	(38,002)		(6)
Ending Balance at Dec. 31, 2022	$ 27,287		$ 0	$ 12	$ 33,616	$ 41,953		$ (21,458)	$ (27,083)	$ 27,040		$ 247

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income (loss)	$ 2,558	$ 6,575	$ 5,418
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization expenses	673	694	619
Amortization of premiums and accretion of discounts associated with investments, net	(960)	(855)	(816)
(Gains) losses on investments and from sales of businesses, net	1,262	(1,529)	110
(Gains) losses on derivatives, net	4,317	4,190	(656)
(Income) loss from equity method investments, net of dividends or distributions	505	(3,051)	76
Interest credited to policyholder account balances	3,737	5,490	5,348
Universal life and investment-type product policy fees	(3,970)	(3,638)	(3,664)
Change in contractholder-directed equity securities and fair value option securities	1,671	(231)	131
Change in accrued investment income	(357)	(11)	104
Change in premiums, reinsurance and other receivables	256	389	842
Change in deferred policy acquisition costs and value of business acquired, net	(568)	(106)	101
Change in income tax	(591)	598	(11)
Change in other assets	27	(681)	(361)
Change in insurance-related liabilities and policy-related balances	4,058	4,553	5,112
Change in other liabilities	341	71	(1,065)
Other, net	245	138	351
Net cash provided by (used in) operating activities	13,204	12,596	11,639
Cash flows from investing activities
Sales, maturities and repayments of fixed maturity securities available-for-sale	88,937	88,839	77,979
Sales, maturities and repayments of equity securities	873	708	367
Sales, maturities and repayments of mortgage loans	10,779	19,183	11,300
Sales, maturities and repayments of real estate and real estate joint ventures	1,096	1,285	120
Sales, maturities and repayments of other limited partnership interests	1,615	777	597
Sales, maturities and repayments of short-term investments	14,094	20,871	13,776
Purchases of fixed maturity securities available-for-sale	(82,956)	(97,368)	(89,633)
Purchases of equity securities	(1,368)	(451)	(169)
Purchases of mortgage loans	(16,403)	(14,961)	(14,652)
Purchases of real estate and real estate joint ventures	(1,208)	(1,375)	(1,287)
Purchases of other limited partnership interests	(2,674)	(3,227)	(1,979)
Purchases of short-term investments	(11,741)	(24,148)	(14,117)
Cash received in connection with freestanding derivatives	4,524	3,453	4,847
Cash paid in connection with freestanding derivatives	(7,793)	(7,990)	(4,247)
Sales of businesses	590	3,270	0
Purchases of businesses	(35)	0	(1,684)
Purchases of investments in operating joint ventures	(240)	0	0
Net change in policy loans	104	228	250
Net change in other invested assets	(786)	(235)	(176)
Other, net	(28)	(46)	139
Net cash provided by (used in) investing activities	(2,620)	(11,187)	(18,569)
Cash flows from financing activities
Policyholder account balances: Deposits	103,036	96,367	93,497
Policyholder account balances: Withdrawals	(97,886)	(92,540)	(85,251)
Net change in payables for collateral under securities loaned and other transactions	(10,730)	1,883	3,538
Cash received for other transactions with tenors greater than three months	0	0	150
Cash paid for other transactions with tenors greater than three months	0	(100)	(175)
Long-term debt issued	1,013	29	1,124
Long-term debt repaid	(85)	(582)	(99)
Collateral financing arrangement repaid	(50)	(79)	(148)
Financing element on certain derivative instruments and other derivative related transactions, net	(61)	270	(46)
Treasury stock acquired in connection with share repurchases	(3,326)	(4,303)	(1,151)
Preferred stock issued, net of issuance costs	0	0	1,961
Redemption of preferred stock	0	(494)	(989)
Preferred stock redemption premium	0	(6)	(14)
Dividends on preferred stock	(185)	(195)	(202)
Dividends on common stock	(1,598)	(1,647)	(1,657)
Other, net	(236)	22	191
Net cash provided by (used in) financing activities	(10,108)	(1,375)	10,729
Effect of change in foreign currency exchange rates on cash and cash equivalents balances	(397)	(478)	163
Change in cash and cash equivalents	79	(444)	3,962
Cash and cash equivalents, including subsidiaries held-for-sale, beginning of year	20,116	20,560	16,598
Cash and cash equivalents, including subsidiaries held-for-sale, end of year	20,195	20,116	20,560
Cash and cash equivalents, subsidiaries held-for-sale, beginning of year	69	765	0
Cash and cash equivalents, subsidiaries held-for-sale, end of year	0	69	765
Cash and cash equivalents, beginning of year	20,047	19,795	16,598
Cash and cash equivalents, end of year	20,195	20,047	19,795
Supplemental disclosures of cash flow information
Net cash paid for Interest	905	914	891
Net cash paid (received) for Income tax	1,056	1,102	787
Business acquisitions: Assets	0	0	2,190
Business acquisitions: Liabilities	0	0	315
Purchases of businesses	0	0	1,875
Non-cash transactions:
Fixed maturity securities available-for-sale received in connection with pension risk transfer transactions	8,707	423	2,037
Real estate and real estate joint ventures acquired in satisfaction of debt	495	174	10
Increase in equity securities due to in-kind distributions received from other limited partnership interests	96	380	108
Reclassification of certain other invested assets to contractholder-directed equity securities and fair value option securities	$ 0	$ 309	$ 0

Statement of Cash Flows (Statem

Statement of Cash Flows (Statement) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Cash Divested from Deconsolidation	$ 67	$ 611	$ 0
Cash Acquired from Acquisition	$ 4	$ 0	$ 191

Business, Basis of Presentation

Business, Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business, Basis of Presentation and Summary of Significant Accounting Policies	1. Business, Basis of Presentation and Summary of Significant Accounting Policies Business “MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management. MetLife is organized into five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); and MetLife Holdings. Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates. Consolidation The accompanying consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated. Held-for-Sale The Company classifies a business as held-for-sale when management has approved or received approval to sell the business, the sale is probable to occur during the next 12 months at a price that is reasonable in relation to its current estimated fair value and certain other specified criteria are met. The business classified as held-for-sale is recorded at the lower of the carrying value and estimated fair value, less cost to sell. If the carrying value of the business exceeds its estimated fair value, less cost to sell, a loss is recognized and reported in net investment gains (losses). Assets and liabilities related to the business classified as held-for-sale are separately reported in the Company's consolidated balance sheets in the period in which the business is classified as held-for-sale. See Note 3. If a component of the Company has either been disposed of or is classified as held-for-sale and represents a strategic shift that has or will have a major effect on the Company’s operations and financial results, the results of the component are reported in discontinued operations. Separate Accounts Separate accounts are established in conformity with insurance laws. Generally, the assets of the separate accounts cannot be used to settle the liabilities that arise from any other business of the Company. Separate account assets are subject to general account claims only to the extent the value of such assets exceeds the separate account liabilities. The Company reports separately, as assets and liabilities, investments held in separate accounts and liabilities of the separate accounts if: • such separate accounts are legally recognized; • assets supporting the contract liabilities are legally insulated from the Company’s general account liabilities; • investment objectives are directed by the contractholder; and • all investment performance, net of contract fees and assessments, is passed through to the contractholder. The Company reports separate account assets at their fair value which is based on the estimated fair values of the underlying assets comprising the individual separate account portfolios. Investment performance (including investment income, net investment gains (losses) and changes in unrealized gains (losses)) and the corresponding amounts credited to contractholders of such separate accounts are offset within the same line on the statements of operations. Separate accounts credited with a contractual investment return are combined on a line-by-line basis with the Company’s general account assets, liabilities, revenues and expenses and the accounting for these investments is consistent with the methodologies described herein for similar financial instruments held within the general account. Unit-linked separate account investments that are directed by contractholders but do not meet one or more of the other above criteria are included in Contractholder-directed equity securities. The Company’s revenues reflect fees charged to the separate accounts, including mortality charges, risk charges, policy administration fees, investment management fees and surrender charges. Such fees are included in universal life and investment-type product policy fees on the statements of operations. Reclassifications Cash flows from short term investments in the prior years’ Consolidated Statement of Cash Flows, which were previously presented net, have been revised to gross presentation to conform with the current year presentation. The revision in presentation was not material to the previously presented financial statements. Additionally, the deferred income tax asset in the prior years’ Consolidated Balance Sheets, which was previously included in other assets, has been reclassified to conform with the current year presentation. Summary of Significant Accounting Policies The following are the Company’s significant accounting policies with references to notes providing additional information on such policies and critical accounting estimates relating to such policies. Accounting Policy Note Insurance 4 Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles 5 Reinsurance 6 Investments 8 Derivatives 9 Fair Value 10 Goodwill 12 Employee Benefit Plans 18 Income Tax 19 Litigation Contingencies 21 Insurance Future Policy Benefit Liabilities and Policyholder Account Balances The Company establishes liabilities for amounts payable under insurance policies. Generally, amounts are payable over an extended period of time and related liabilities are calculated as the present value of future expected benefits to be paid, reduced by the present value of future expected premiums. Such liabilities are established based on methods and underlying assumptions in accordance with GAAP and applicable actuarial standards. Principal assumptions used in the establishment of liabilities for future policy benefits are mortality, morbidity, policy lapse, renewal, retirement, disability incidence, disability terminations, investment returns, inflation, expenses and other contingent events as appropriate to the respective product type and geographical area. These assumptions are established at the time the policy is issued and are intended to estimate the experience for the period the policy benefits are payable. Utilizing these assumptions, liabilities are established on a block of business basis. For long duration insurance contracts, assumptions such as mortality, morbidity and interest rates are “locked in” upon the issuance of new business. However, significant adverse changes in experience on such contracts may require the establishment of premium deficiency reserves. Such reserves are determined based on the then current assumptions and do not include a provision for adverse deviation. Premium deficiency reserves may also be established for short-duration contracts to provide for expected future losses. These reserves are based on actuarial estimates of the amount of loss inherent in that period, including losses incurred for which claims have not been reported. The provisions for unreported claims are calculated using studies that measure the historical length of time between the incurred date of a claim and its eventual reporting to the Company. Anticipated investment income is considered in the calculation of premium deficiency losses for short-duration contracts. Liabilities for universal and variable life policies with secondary guarantees (“ULSG”) and paid-up guarantees are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the life of the contract based on total expected assessments. The assumptions used in estimating the secondary and paid-up guarantee liabilities are consistent with those used for amortizing deferred policy acquisition costs (“DAC”), and are thus subject to the same variability and risk as further discussed herein. The assumptions of investment performance and volatility for variable products are consistent with historical experience of appropriate underlying equity indices, such as the S&P Global Ratings (“S&P”) 500 Index. The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios. The Company regularly reviews its estimates of liabilities for future policy benefits and compares them with its actual experience. Differences result in changes to the liability balances with related charges or credits to benefit expenses in the period in which the changes occur. Policyholder account balances relate to contracts or contract features where the Company has no significant insurance risk. The Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits that provide the policyholder a minimum return based on their initial deposit adjusted for withdrawals. These guarantees are accounted for as insurance liabilities or as embedded derivatives depending on how and when the benefit is paid. Specifically, a guarantee is accounted for as an embedded derivative if a guarantee is paid without requiring (i) the occurrence of a specific insurable event, or (ii) the policyholder to annuitize. Alternatively, a guarantee is accounted for as an insurance liability if the guarantee is paid only upon either (i) the occurrence of a specific insurable event, or (ii) annuitization. In certain cases, a guarantee may have elements of both an insurance liability and an embedded derivative and in such cases the guarantee is split and accounted for under both models. Guarantees accounted for as insurance liabilities in future policy benefits include guaranteed minimum death benefits (“GMDBs”), the life-contingent portion of guaranteed minimum withdrawal benefits (“GMWBs”), elective annuitizations of guaranteed minimum income benefits (“GMIBs”), and the life contingent portion of GMIBs that require annuitization when the account balance goes to zero. Guarantees accounted for as embedded derivatives in policyholder account balances include guaranteed minimum accumulation benefits (“GMABs”), the non-life contingent portion of GMWBs and certain non-life contingent portions of GMIBs. At inception, the Company attributes to the embedded derivative a portion of the projected future guarantee fees to be collected from the policyholder equal to the present value of projected future guaranteed benefits. Any additional fees represent “excess” fees and are reported in universal life and investment-type product policy fees. Other Policy-Related Balances Other policy-related balances include policy and contract claims, premiums received in advance, unearned revenue liabilities, obligations assumed under structured settlement assignments, policyholder dividends due and unpaid, policyholder dividends left on deposit and negative value of business acquired (“VOBA”). The liability for policy and contract claims generally relates to incurred but not reported (“IBNR”) death, disability, dental and vision claims. In addition, included in other policy-related balances are claims which have been reported but not yet settled for death, disability, dental and vision. The liability for these claims is based on the Company’s estimated ultimate cost of settling all claims. The Company derives estimates for the development of IBNR claims principally from analyses of historical patterns of claims by business line. The methods used to determine these estimates are continually reviewed. Adjustments resulting from this continuous review process and differences between estimates and payments for claims are recognized in policyholder benefits and claims expense in the period in which the estimates are changed or payments are made. The Company accounts for the prepayment of premiums on its individual life, group life and health contracts as premiums received in advance. These amounts are then recognized in premiums when due. The unearned revenue liability relates to universal life and investment-type products and represents policy charges for services to be provided in future periods. The charges are deferred as unearned revenue and amortized using the product’s estimated gross profits and margins, similar to DAC as discussed further herein. Such amortization is recorded in universal life and investment-type product policy fees. See “— Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles” for a discussion of negative VOBA. Recognition of Insurance Revenues and Deposits Premiums related to traditional life, annuity contracts with life contingencies, long-duration accident & health, and credit insurance policies are recognized as revenues when due from policyholders. Policyholder benefits and expenses are provided to recognize profits over the estimated lives of the insurance policies. When premiums are due over a significantly shorter period than the period over which benefits are provided, any excess profit is deferred and recognized into earnings in a constant relationship to insurance in-force or, for annuities, the amount of expected future policy benefit payments. Premiums related to short-duration non-medical health and disability, accident & health, and certain credit insurance contracts are recognized on a pro rata basis over the applicable contract term. Deposits related to universal life and investment-type products are credited to policyholder account balances. Revenues from such contracts consist of fees for mortality, policy administration and surrender charges and are recorded in universal life and investment-type product policy fees in the period in which services are provided. Amounts that are charged to earnings include interest credited and benefit claims incurred in excess of related policyholder account balances. Premiums related to the Company’s former property and casualty contracts are recognized as revenue on a pro rata basis over the applicable contract term. Unearned premiums, representing the portion of premium written related to the unexpired coverage, are included in future policy benefits. See Note 3 for information on the Company’s business dispositions. All revenues and expenses are presented net of reinsurance, as applicable. Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles The Company incurs significant costs in connection with acquiring new and renewal insurance business. Costs that are related directly to the successful acquisition or renewal of insurance contracts are capitalized as DAC. Such costs include: • incremental direct costs of contract acquisition, such as commissions; • the portion of an employee’s total compensation and benefits related to time spent selling, underwriting or processing the issuance of new and renewal insurance business only with respect to actual policies acquired or renewed; • other essential direct costs that would not have been incurred had a policy not been acquired or renewed; and • the costs of direct-response advertising, the primary purpose of which is to elicit sales to customers who could be shown to have responded specifically to the advertising and that results in probable future benefits. All other acquisition-related costs, including those related to general advertising and solicitation, market research, agent training, product development, unsuccessful sales and underwriting efforts, as well as all indirect costs, are expensed as incurred. VOBA is an intangible asset resulting from a business combination that represents the excess of book value over the estimated fair value of acquired insurance, annuity, and investment-type contracts in-force at the acquisition date. The estimated fair value of the acquired liabilities is based on projections, by each block of business, of future policy and contract charges, premiums, mortality and morbidity, separate account performance, surrenders, operating expenses, investment returns, nonperformance risk adjustment and other factors. Actual experience with the purchased business may vary from these projections. DAC and VOBA are amortized as follows: Products: In proportion to the following over estimated lives of the contracts: • Nonparticipating and non-dividend-paying traditional contracts: Actual and expected future gross premiums. • Term insurance • Nonparticipating whole life insurance • Traditional group life insurance • Non-medical health insurance • Accident & health insurance • Participating, dividend-paying traditional contracts Actual and expected future gross margins. • Fixed and variable universal life contracts Actual and expected future gross profits. • Fixed and variable deferred annuity contracts • Credit insurance contracts Actual and future earned premiums. • Property and casualty insurance contracts (prior to the disposition of the Company’s property and casualty business. See Note 3.) • Other short-duration contracts See Note 5 for additional information on DAC and VOBA amortization. Amortization of DAC and VOBA is included in other expenses. The recovery of DAC and VOBA is dependent upon the future profitability of the related business. DAC and VOBA are aggregated on the financial statements for reporting purposes. The Company generally has two different types of sales inducements which are included in other assets: (i) the policyholder receives a bonus whereby the policyholder’s initial account balance is increased by an amount equal to a specified percentage of the customer’s deposit; and (ii) the policyholder receives a higher interest rate using a dollar cost averaging method than would have been received based on the normal general account interest rate credited. The Company defers sales inducements and amortizes them over the life of the policy using the same methodology and assumptions used to amortize DAC. The amortization of sales inducements is included in policyholder benefits and claims. Each year, or more frequently if circumstances indicate a potential recoverability issue exists, the Company reviews deferred sales inducements (“DSI”) to determine the recoverability of the asset. Value of distribution agreements acquired (“VODA”) is reported in other assets and represents the present value of expected future profits associated with the expected future business derived from the distribution agreements acquired as part of a business combination. Value of customer relationships acquired (“VOCRA”) is also reported in other assets and represents the present value of the expected future profits associated with the expected future business acquired through existing customers of the acquired company or business. The VODA and VOCRA associated with past business combinations are amortized over the assets’ useful lives ranging from nine For certain acquired blocks of business, the estimated fair value of the in-force contract obligations exceeded the book value of assumed in-force insurance policy liabilities, resulting in negative VOBA, which is presented separately from VOBA as an additional insurance liability. The estimated fair value of the in-force contract obligations is based on projections by each block of business. Negative VOBA is amortized over the policy period in proportion to the approximate consumption of losses included in the liability usually expressed in terms of insurance in-force or account value. Such amortization is recorded as an offset in other expenses. Reinsurance For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. Cessions under reinsurance agreements do not discharge the Company’s obligations as the primary insurer. The Company reviews all contractual features, including those that may limit the amount of insurance risk to which the reinsurer is subject or features that delay the timely reimbursement of claims. For reinsurance of existing in-force blocks of long-duration contracts that transfer significant insurance risk, the difference, if any, between the amounts paid (received), and the liabilities ceded (assumed) related to the underlying contracts is considered the net cost of reinsurance at the inception of the reinsurance agreement. The net cost of reinsurance is amortized on a basis consistent with the methodologies and assumptions used for amortizing DAC related to the underlying reinsured contracts. Subsequent amounts paid (received) on the reinsurance of in-force blocks, as well as amounts paid (received) related to new business, are recorded as ceded (assumed) premiums; and ceded (assumed) premiums, reinsurance and other receivables (future policy benefits) are established. For prospective reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) are recorded as ceded (assumed) premiums and ceded (assumed) unearned premiums. Ceded (assumed) unearned premiums are reflected as a component of premiums, reinsurance and other receivables (future policy benefits). Such amounts are amortized through earned premiums over the remaining contract period in proportion to the amount of insurance protection provided. For retroactive reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) in excess of the related insurance liabilities ceded (assumed) are recognized immediately as a loss and are reported in the appropriate line item within the statement of operations. Any gain on such retroactive agreement is deferred and is amortized as part of DAC, primarily using the recovery method. Amounts currently recoverable under reinsurance agreements are included in premiums, reinsurance and other receivables and amounts currently payable are included in other liabilities. Assets and liabilities relating to reinsurance agreements with the same reinsurer may be recorded net on the balance sheet, if a right of offset exists within the reinsurance agreement. In the event that reinsurers do not meet their obligations to the Company under the terms of the reinsurance agreements, or when events or changes in circumstances indicate that its carrying amount may not be recoverable, reinsurance recoverable balances could become uncollectible. In such instances, reinsurance recoverable balances are stated net of allowances for uncollectible reinsurance, consistent with credit loss guidance which requires recording an allowance for credit loss (“ACL”). Premiums, fees and policyholder benefits and claims include amounts assumed under reinsurance agreements and are net of reinsurance ceded. Amounts received from reinsurers for policy administration are reported in other expenses. If the Company determines that a reinsurance agreement does not expose the reinsurer to a reasonable possibility of a significant loss from insurance risk, the Company records the agreement using the deposit method of accounting. Deposits received are included in other liabilities and deposits made are included within premiums, reinsurance and other receivables. As amounts are paid or received, consistent with the underlying contracts, the deposit assets or liabilities are adjusted. Interest on such deposits is recorded as other revenues or other expenses, as appropriate. Periodically, the Company evaluates the adequacy of the expected payments or recoveries and adjusts the deposit asset or liability through other revenues or other expenses, as appropriate. Investments Net Investment Income Net investment income includes primarily interest income, including amortization of premium and accretion of discount, prepayment fees, dividend income, rental income and equity method income and is net of related investment expenses. Net investment income also includes, to a lesser extent, (i) realized gains (losses) on investments sold or disposed and (ii) unrealized gains (losses) recognized in earnings, representing changes in estimated fair value, primarily for Unit-linked investments (defined below) and fair value option (“FVO”) securities (“FVO Securities”). Net Investment Gains (Losses) Net investment gains (losses) include primarily (i) realized gains (losses) from sales and disposals of investments, which are determined by specific identification, (ii) intent-to-sell impairment losses on fixed maturity securities available-for-sale (“AFS”) and impairment losses on all other asset classes and, to a lesser extent, (iii) recognized gains (losses). Recognized gains (losses) are primarily comprised of the change in the ACL and unrealized gains (losses) for certain investments for which changes in estimated fair value are recognized in earnings. Changes in the ACL includes both (i) provisions for credit loss on fixed maturity securities AFS, mortgage loans and leveraged and direct financing leases and (ii) subsequent changes in the ACL. Unrealized gains (losses), representing changes in estimated fair value recognized in earnings, primarily relate to equity securities and certain other limited partnership interests and real estate joint ventures. Net investment gains (losses) also include non-investment portfolio gains (losses) which do not relate to the performance of the investment portfolio, including gains (losses) from sales and divestitures of businesses and impairment of property, equipment, leasehold improvements and right-of-use (“ROU”) lease assets. Accrued Investment Income Accrued investment income is presented separately on the consolidated balance sheet and excluded from the carrying value of the related investments, primarily fixed maturity securities and mortgage loans. Fixed Maturity Securities The majority of the Company’s fixed maturity securities are classified as AFS and are reported at their estimated fair value. Changes in the estimated fair value of these securities not recognized in earnings representing unrecognized unrealized investment gains (losses) are recorded as a separate component of other comprehensive income (loss) (“OCI”), net of policy-related amounts and deferred income taxes. All security transactions are recorded on a trade date basis. Sales of securities are determined on a specific identification basis. Interest income and prepayment fees are recognized when earned. Interest income is recognized using an effective yield method giving effect to amortization of premium and accretion of discount, and is based on the estimated economic life of the securities, which for mortgage-backed and asset-backed securities considers the estimated timing and amount of prepayments of the underlying loans. See Note 8 “— Fixed Maturity Securities AFS — Methodology for Amortization of Premium and Accretion of Discount on Structured Products.” The amortization of premium and accretion of discount also take into consideration call and maturity dates. Generally, the accrual of income is ceased and accrued investment income that is considered uncollectible is recognized as a charge within net investment gains (losses) when securities are impaired. The Company periodically evaluates these securities for impairment. The assessment of whether impairments have occurred is based on management’s case-by-case evaluation of the underlying reasons for the decline in estimated fair value as described in Note 8 “— Fixed Maturity Securities AFS — Evaluation of Fixed Maturity Securities AFS for Credit Loss.” For securities in an unrealized loss position, a credit loss is recognized in earnings within net investment gains (losses) when it is anticipated that the amortized cost, excluding accrued investment income, will not be recovered. When either: (i) the Company has the intent to sell the security; or (ii) it is more likely than not that the Company will be required to sell the security before recovery, the reduction of amortized cost and the loss recognized in earnings is the entire difference between the security’s amortized cost and estimated fair value. If neither of these conditions exists, the difference between the amortized cost of the security and the present value of projected future cash flows expected to be collected is recognized in earnings as a credit loss by establishing an ACL with a corresponding charge recorded in net investment gains (losses). However, the ACL is limited by the amount that the fair value is less than the amortized cost. This limitation is known as the “fair value floor.” If the estimated fair value is less than the present value of projected future cash flows expected to be collected, this portion of the decline in value related to other-than-credit factors (“noncredit loss”) is recorded in OCI as an unrecognized loss. For purchased credit deteriorated (“PCD”) fixed maturity securities AFS and financing receivables, an ACL is established at acquisition, which is added to the purchase price to establish the initial amortized cost of the investment and is not recognized in earnings. Equity Securities Equity securities are reported at their estimated fair value, with unrealized gains (losses) representing changes in estimated fair value recognized in net investment gains (losses). Sales of securities are determined on a specific identification basis. Dividends are recognized in net investment income when declared. Contractholder-Directed Equity Securities and Fair Value Option Securities Contractholder-directed equity securities and FVO Securities (collectively, “Unit-linked and FVO Securities”) are investments for which the FVO has been elected, or which are otherwise required to be carried at estimated fair value, and include: • contractholder-directed investments supporting unit-linked variable annuity type liabilities (“Unit-linked investments”) which do not qualify for presentation and reporting as separate account summary total assets and liabilities. These investments are primarily equity securities (including mutual funds). The investment returns on these investments inure to contractholders and are offset by a corresponding change in policyholder account balances through interest credited to policyholder account balances; and • fixed maturity and equity securities held-for-investment by the general account to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. Interest income and dividend income on these investments are included in net investment income. Realized gains (losses) on investments sold or disposed and unrealized gains (losses), representing changes in estimated fair value, are both recognized in net investment income for Unit-linked investments and FVO Securities. Sales of these investments are determined on a specific identification basis. Mortgage Loans The Company recognizes an ACL in earnings within net investment gains (losses) at time of purchase based on expected lifetime credit loss on financing receivables carried at amortized cost, including, but not limited to, mortgage loans and leveraged and direct financing leases, in an amount that represents the portion of the amortized cost basis of such financing receivables that the Company does not expect to collect, resulting in financing receivables being presented at the net amount expected to be collected. The Company disaggregates its mortgage loan investments into three portfolio segments: commercial, agricultural and residential. Also included in commercial mortgage loans are revolving line of credit loans collateralized by commercial properties. The accounting policies that are applicable to all portfolio segments are presented below and the accounting policies related to each of the portfolio segments are included in Note 8. Mortgage loans are stated at unpaid principal balance, adjusted for any unamortized premium or discount, deferred fees or expenses, and are net of ACL. Interest income and prepayment fees are recognized when earned. Interest income is recognized using an effective yield method giving effect to amor

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information	2. Segment Information MetLife is organized into five segments: U.S.; Asia; Latin America; EMEA; and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other. U.S. The U.S. segment offers a broad range of protection products and services aimed at serving the financial needs of customers throughout their lives. These products are sold to corporations and their respective employees, other institutions and their respective members, as well as individuals. The U.S. segment is organized into two businesses: Group Benefits and Retirement and Income Solutions (“RIS”). • The Group Benefits business offers products such as term, variable and universal life insurance, dental, group and individual disability, vision and accident & health insurance. • The RIS business offers a broad range of life and annuity-based insurance and investment products, including stable value and pension risk transfer products, institutional income annuities, structured settlements, longevity reinsurance solutions, benefit funding solutions and capital markets investment products. Asia The Asia segment offers a broad range of products and services to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, accident & health insurance and retirement and savings. Latin America The Latin America segment offers a broad range of products to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance. EMEA The EMEA segment offers products to individuals, corporations, other institutions, and their respective employees, which include life insurance, accident & health insurance, retirement and savings and credit insurance. MetLife Holdings The MetLife Holdings segment consists of operations relating to products and businesses that the Company no longer actively markets in the United States. These include variable, universal, term and whole life insurance, variable, fixed and index-linked annuities, and long-term care insurance. Corporate & Other Corporate & Other contains various start-up, developing and run-off businesses. Also included in Corporate & Other are: the excess capital, as well as certain charges and activities, not allocated to the segments (including external integration and disposition costs, internal resource costs for associates committed to acquisitions and dispositions and enterprise-wide strategic initiatives), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, the elimination of intersegment amounts (which generally relate to affiliated reinsurance, investment expenses and intersegment loans bearing interest rates commensurate with related borrowings), and the Company’s investment management business (through which the Company provides public fixed income, private capital and real estate investment solutions to institutional investors worldwide). Financial Measures and Segment Accounting Policies Adjusted earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also the Company’s GAAP measure of segment performance and is reported below. Adjusted earnings should not be viewed as a substitute for net income (loss). The Company believes the presentation of adjusted earnings, as the Company measures it for management purposes, enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business. Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. The financial measures of adjusted revenues and adjusted expenses focus on the Company’s primary businesses principally by excluding the impact of market volatility, which could distort trends, and revenues and costs related to non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP and other businesses that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP and are referred to as divested businesses. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP. Adjusted revenues also excludes net investment gains (losses) and net derivative gains (losses). Adjusted expenses also excludes goodwill impairments. The following additional adjustments are made to revenues, in the line items indicated, in calculating adjusted revenues: • Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity GMIB fees (“GMIB fees”); • Net investment income: (i) includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment, (ii) excludes post-tax adjusted earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to contractholder-directed equity securities, (iv) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP and (v) includes distributions of profits from certain other limited partnership interests that were previously accounted for under the cost method, but are now accounted for at estimated fair value, where the change in estimated fair value is recognized in net investment gains (losses) under GAAP; and • Other revenues is adjusted for settlements of foreign currency earnings hedges and excludes fees received in association with services provided under transition service agreements (“TSA fees”). The following additional adjustments are made to expenses, in the line items indicated, in calculating adjusted expenses: • Policyholder benefits and claims and policyholder dividends excludes: (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (iii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, (iv) benefits and hedging costs related to GMIBs (“GMIB costs”) and (v) market value adjustments associated with surrenders or terminations of contracts (“Market value adjustments”); • Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes certain amounts related to net investment income earned on contractholder-directed equity securities; • Amortization of DAC and VOBA excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB fees and GMIB costs and (iii) Market value adjustments; • Amortization of negative VOBA excludes amounts related to Market value adjustments; • Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and • Other expenses excludes: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements costs, and (iii) acquisition, integration and other costs. Other expenses includes TSA fees. Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance. The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms. Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the years ended December 31, 2022, 2021 and 2020 and at December 31, 2022 and 2021. The segment accounting policies are the same as those used to prepare the Company’s consolidated financial statements, except for adjusted earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below. Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company’s business. The Company’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. The Company’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards. Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings. Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing. Year Ended December 31, 2022 U.S. Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 35,548 $ 5,568 $ 3,226 $ 1,964 $ 3,066 $ (16) $ 49,356 $ 41 $ 49,397 Universal life and investment-type product policy fees 1,158 1,840 1,175 300 1,057 2 5,532 53 5,585 Net investment income (1) 7,340 3,909 1,593 160 4,971 216 18,189 (2,273) 15,916 Other revenues 1,756 90 39 35 155 396 2,471 163 2,634 Net investment gains (losses) — — — — — — — (1,262) (1,262) Net derivative gains (losses) — — — — — — — (2,372) (2,372) Total revenues 45,802 11,407 6,033 2,459 9,249 598 75,548 (5,650) 69,898 Expenses Policyholder benefits and claims and policyholder dividends 36,273 4,752 3,301 990 6,056 (6) 51,366 (53) 51,313 Interest credited to policyholder account balances 1,789 2,003 335 71 813 — 5,011 (1,319) 3,692 Capitalization of DAC (77) (1,524) (499) (411) (28) (8) (2,547) (11) (2,558) Amortization of DAC and VOBA 59 1,105 339 333 192 9 2,037 (106) 1,931 Amortization of negative VOBA — (36) — (5) — — (41) — (41) Interest expense on debt 9 — 12 — 8 909 938 — 938 Other expenses 3,962 3,153 1,553 1,171 953 709 11,501 263 11,764 Total expenses 42,015 9,453 5,041 2,149 7,994 1,613 68,265 (1,226) 67,039 Provision for income tax expense (benefit) 791 576 231 64 247 (356) 1,553 (1,252) 301 Adjusted earnings $ 2,996 $ 1,378 $ 761 $ 246 $ 1,008 $ (659) 5,730 Adjustments to: Total revenues (5,650) Total expenses 1,226 Provision for income tax (expense) benefit 1,252 Net income (loss) $ 2,558 $ 2,558 At December 31, 2022 U.S. Asia (2) Latin EMEA MetLife Corporate Total (In millions) Total assets $ 252,559 $ 150,134 $ 63,810 $ 16,765 $ 149,739 $ 33,604 $ 666,611 Separate account assets $ 61,030 $ 8,292 $ 39,428 $ 3,314 $ 33,974 $ — $ 146,038 Separate account liabilities $ 61,030 $ 8,292 $ 39,428 $ 3,314 $ 33,974 $ — $ 146,038 __________________ (1) Net investment income from equity method investments represents 5%, 12%, 3% and 6% of segment net investment income for the U.S., Asia, Latin America and MetLife Holdings segments, respectively. (2) Total assets includes $127.1 billion of assets from the Company’s Japan operations which represents 19% of total assets. Year Ended December 31, 2021 U.S. Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 26,358 $ 6,421 $ 2,609 $ 2,271 $ 3,333 $ 35 $ 41,027 $ 982 $ 42,009 Universal life and investment-type product policy fees 1,140 1,814 1,109 395 1,101 2 5,561 195 5,756 Net investment income (1) 8,048 5,052 1,271 215 6,450 244 21,280 115 21,395 Other revenues 1,538 73 41 47 257 420 2,376 243 2,619 Net investment gains (losses) — — — — — — — 1,529 1,529 Net derivative gains (losses) — — — — — — — (2,228) (2,228) Total revenues 37,084 13,360 5,030 2,928 11,141 701 70,244 836 71,080 Expenses Policyholder benefits and claims and policyholder dividends 27,957 5,008 3,143 1,241 6,268 34 43,651 1,179 44,830 Interest credited to policyholder account balances 1,422 1,995 249 86 840 — 4,592 946 5,538 Capitalization of DAC (65) (1,607) (414) (469) (33) (11) (2,599) (119) (2,718) Amortization of DAC and VOBA 60 1,369 285 356 257 9 2,336 219 2,555 Amortization of negative VOBA — (27) — (7) — — (34) — (34) Interest expense on debt 7 — 5 — 5 902 919 1 920 Other expenses 3,632 3,388 1,401 1,324 992 562 11,299 564 11,863 Total expenses 33,013 10,126 4,669 2,531 8,329 1,496 60,164 2,790 62,954 Provision for income tax expense (benefit) 850 936 70 96 570 (591) 1,931 (380) 1,551 Adjusted earnings $ 3,221 $ 2,298 $ 291 $ 301 $ 2,242 $ (204) 8,149 Adjustments to: Total revenues 836 Total expenses (2,790) Provision for income tax (expense) benefit 380 Net income (loss) $ 6,575 $ 6,575 At December 31, 2021 U.S. Asia (2) Latin EMEA MetLife Corporate Total (In millions) Total assets $ 282,741 $ 169,291 $ 59,763 $ 27,038 $ 179,551 $ 41,324 $ 759,708 Separate account assets $ 81,217 $ 10,241 $ 37,632 $ 3,098 $ 47,685 $ — $ 179,873 Separate account liabilities $ 81,217 $ 10,241 $ 37,632 $ 3,098 $ 47,685 $ — $ 179,873 __________________ (1) Net investment income from equity method investments represents 23%, 30%, 7% and 26% of segment net investment income for the U.S., Asia, Latin America and MetLife Holdings segments, respectively. (2) Total assets includes $142.7 billion of assets from the Company’s Japan operations which represents 19% of total assets. Year Ended December 31, 2020 U.S. Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 27,265 $ 6,571 $ 2,265 $ 2,259 $ 3,600 $ 22 $ 41,982 $ 52 $ 42,034 Universal life and investment-type product policy fees 1,070 1,892 994 433 1,073 3 5,465 138 5,603 Net investment income (1) 6,903 3,938 992 269 5,184 42 17,328 (211) 17,117 Other revenues 957 61 38 52 238 344 1,690 159 1,849 Net investment gains (losses) — — — — — — — (110) (110) Net derivative gains (losses) — — — — — — — 1,349 1,349 Total revenues 36,195 12,462 4,289 3,013 10,095 411 66,465 1,377 67,842 Expenses Policyholder benefits and claims and policyholder dividends 26,309 5,213 2,406 1,196 6,738 (3) 41,859 692 42,551 Interest credited to policyholder account balances 1,622 1,834 240 109 868 — 4,673 541 5,214 Capitalization of DAC (453) (1,652) (362) (491) (39) (11) (3,008) (5) (3,013) Amortization of DAC and VOBA 471 1,415 276 454 370 8 2,994 166 3,160 Amortization of negative VOBA — (37) — (8) — — (45) — (45) Interest expense on debt 7 — 4 1 6 895 913 — 913 Other expenses 4,162 3,481 1,318 1,344 942 625 11,872 263 12,135 Total expenses 32,118 10,254 3,882 2,605 8,885 1,514 59,258 1,657 60,915 Provision for income tax expense (benefit) 853 643 127 81 234 (556) 1,382 127 1,509 Adjusted earnings $ 3,224 $ 1,565 $ 280 $ 327 $ 976 $ (547) 5,825 Adjustments to: Total revenues 1,377 Total expenses (1,657) Provision for income tax (expense) benefit (127) Net income (loss) $ 5,418 $ 5,418 __________________ (1) Net investment income from equity method investments represents 5%, 12%, 1% and 5% of segment net investment income for the U.S., Asia, Latin America and MetLife Holdings segments, respectively. The following table presents total premiums, universal life and investment-type product policy fees and other revenues by major product groups of the Company’s segments, as well as Corporate & Other: Years Ended December 31, 2022 2021 2020 (In millions) Life insurance $ 21,969 $ 22,872 $ 21,256 Accident & health insurance 17,453 17,498 15,346 Annuities 16,647 7,499 7,916 Other 1,547 2,515 4,968 Total $ 57,616 $ 50,384 $ 49,486 The following table presents total premiums, universal life and investment-type product policy fees and other revenues associated with the Company’s U.S. and foreign operations: Years Ended December 31, 2022 2021 2020 (In millions) U.S. $ 43,319 $ 35,252 $ 34,717 Foreign: Japan 5,532 6,426 6,750 Other 8,765 8,706 8,019 Total $ 57,616 $ 50,384 $ 49,486 Revenues derived from one U.S. segment customer were $8.1 billion for the year ended December 31, 2022, which represented 14% of consolidated premiums, universal life and investment-type product policy fees and other revenues. The revenue was from a single premium received for a pension risk transfer. Revenues derived from any single customer did not exceed 10% of consolidated premiums, universal life and investment-type product policy fees and other revenues for the years ended December 31, 2021 and 2020.

Dispositions - Dispositions

Dispositions - Dispositions	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Acquisitions and Dispositions	3. Acquisition and Dispositions Acquisition Acquisition of Versant Health On December 30, 2020, the Company completed its acquisition of all of the issued and outstanding capital stock of Versant Health, Inc. (“Versant Health”), a managed vision care company. Versant Health owns the well-established marketplace brands, Davis Vision and Superior Vision. Total revenue of Versant Health represented less than 2% of pro forma total revenue of MetLife for the year ended December 31, 2020 when evaluated as though the acquisition had occurred at the beginning of the earliest period presented. Dispositions Disposition of MetLife Seguros S.A. In September 2021, the Company sold its wholly-owned Argentinian subsidiary, MetLife Seguros S.A. (“MetLife Seguros”). In connection with the sale, a loss of $205 million, net of income tax, was recorded for the year ended December 31, 2021, which is reflected in net investment gains (losses). MetLife Seguros results of operations are reported in the Latin America segment adjusted earnings through the date of sale. Disposition of MetLife Poland and Greece In July 2021, the Company entered into definitive agreements to sell its wholly-owned subsidiaries in Poland and Greece (collectively, “MetLife Poland and Greece”) to NN Group N.V. for $738 million in total consideration, including a pre-closing dividend of $43 million. In January 2022 and April 2022, the Company completed the sales of its wholly-owned subsidiaries in Greece and Poland, respectively. In connection with the sales, a loss of $25 million, net of income tax, was recorded for the year ended December 31, 2022, which was reflected in net investment gains (losses) and resulted in a total loss on the sales of $239 million, net of income tax. MetLife Poland and Greece results of operations are reported in the EMEA segment adjusted earnings through June 30, 2021. See Note 2 for information on accounting for divested business. MetLife Poland and Greece met the criteria in the second quarter of 2021 to be classified as held-for-sale but did not meet the criteria to be classified as discontinued operations. As a result, the related assets and liabilities are included in the separate held-for-sale line items of the asset and liability sections of the consolidated balance sheet until the quarter in which the disposition was completed. The following table summarizes the assets and liabilities held-for-sale: December 31, 2021 (In millions) Assets: Fixed maturity securities available-for-sale $ 2,043 Contractholder-directed equity securities 1,114 Other investments 118 Total investments 3,275 Cash and cash equivalents 69 Deferred policy acquisition costs and value of business acquired 138 Other 259 Separate account assets 3,497 Total assets held-for-sale $ 7,238 Liabilities: Future policy benefits $ 916 Policyholder account balances 2,005 Other policy-related balances 103 Other 113 Separate account liabilities 3,497 Total liabilities held-for-sale $ 6,634 MetLife Poland and Greece income (loss) before provision for income tax as reflected in the consolidated statements of operations was $19 million, $50 million and $30 million for the years ended December 31, 2022, 2021 and 2020, respectively. Disposition of Metropolitan Property and Casualty Insurance Company In December 2020, the Company entered into a definitive agreement to sell its wholly-owned subsidiary, Metropolitan Property and Casualty Insurance Company and certain of its wholly-owned subsidiaries (collectively, “MetLife P&C”) to Farmers Group, Inc. for $3.9 billion. In addition, the Company and the Farmers Exchanges have established a 10-year strategic partnership through which the Farmers Insurance Group will offer its personal line products on MetLife’s U.S. Group Benefits platform which commenced when the transaction closed. MetLife P&C results of operations are reported in the U.S. segment adjusted earnings through December 31, 2020. See Note 2 for more information on divested businesses. In April 2021, the Company completed the sale of MetLife P&C. As a result of the sale, the Company recognized a gain of $1.4 billion ($1.0 billion, net of income tax) in net investment gains (losses) for the year ended December 31, 2021, which includes customary purchase price adjustments recorded after the date of sale. MetLife P&C income (loss) before provision for income tax as reflected in the consolidated statement of operations was $121 million and $399 million for the years ended December 31, 2021 and 2020, respectively. Disposition of Joint-stock Company MetLife Insurance Company In December 2020, the Company entered into an agreement to sell its wholly-owned Russian subsidiary, the Joint-stock Company MetLife Insurance Company (“MetLife Russia”). In connection with the sale, a loss of $133 million, net of income tax, was recorded for the year ended December 31, 2020 and is reflected in net investment gains (losses). MetLife Russia results of operations are reported in the EMEA segment adjusted earnings through December 31, 2020. In January 2021, the Company completed the sale of MetLife Russia. Disposition of MetLife Seguros de Retiro S.A. In October 2020, the Company sold one of its wholly-owned Argentinian subsidiaries, MetLife Seguros de Retiro S.A. (“MetLife Seguros de Retiro”). In connection with the sale, a loss of $162 million, net of income tax, was recorded for the year ended December 31, 2020. This loss was comprised of a $130 million pre-tax loss, which is reflected in net investment gains (losses). Additionally, the $162 million loss included a $32 million net tax charge, which is recorded in the provision for income tax expense (benefit) and included previously deferred tax items and losses which are not recognized for tax purposes. MetLife Seguros de Retiro’s results of operations are reported in the Latin America segment adjusted earnings through June 30, 2020. See Note 2 for information on accounting for divested businesses.

Insurance

Insurance	12 Months Ended
	Dec. 31, 2022
Insurance [Abstract]
Insurance	4. Insurance Insurance Liabilities Insurance liabilities are comprised of future policy benefits, policyholder account balances and other policy-related balances. Information regarding insurance liabilities by segment, as well as Corporate & Other, was as follows at: December 31, 2022 2021 (In millions) U.S. $ 171,693 $ 162,999 Asia 125,523 125,839 Latin America 17,674 15,564 EMEA 10,635 13,031 MetLife Holdings 100,407 102,291 Corporate & Other 1,029 1,221 Total $ 426,961 $ 420,945 Future policy benefits are measured as follows: Product Type: Measurement Assumptions: Participating life Aggregate of (i) net level premium reserves for death and endowment policy benefits (calculated based upon the non-forfeiture interest rate, ranging from 3% to 7% for U.S. businesses and less than 1% to 10% for non-U.S. businesses and mortality rates guaranteed in calculating the cash surrender values described in such contracts); and (ii) the liability for terminal dividends for U.S. businesses. Nonparticipating life Aggregate of the present value of future expected benefit payments and related expenses less the present value of future expected net premiums. Assumptions as to mortality and persistency are based upon the Company’s experience when the basis of the liability is established. Interest rate assumptions for the aggregate future policy benefit liabilities range from 2% to 11% for U.S. businesses and less than 1% to 10% for non-U.S. businesses. Individual and group traditional fixed annuities after annuitization Present value of future expected payments. Interest rate assumptions used in establishing such liabilities range from 1% to 11% for U.S. businesses and less than 1% to 9% for non-U.S. businesses. Non-medical health insurance The net level premium method and assumptions as to future morbidity, withdrawals and interest, which provide a margin for adverse deviation. Interest rate assumptions used in establishing such liabilities range from 1% to 7% (primarily related to U.S. businesses). Disabled lives Present value of benefits method and experience assumptions as to claim terminations, expenses and interest. Interest rate assumptions used in establishing such liabilities range from 2% to 8% for U.S. businesses and less than 1% to 9% for non-U.S. businesses. Participating business represented 2% and 3% of the Company’s life insurance in-force at December 31, 2022 and 2021, respectively. Participating policies represented 11%, 12% and 14% of gross traditional life insurance premiums for the years ended December 31, 2022, 2021 and 2020, respectively. Policyholder account balances are equal to: (i) policy account values, which consist of an accumulation of gross premium payments and investment performance; (ii) credited interest, ranging from less than 1% to 8% for U.S. businesses and less than 1% to 12% for non-U.S. businesses, less expenses, mortality charges and withdrawals; and (iii) fair value adjustments relating to business combinations. Guarantees The Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits. GMABs, the non-life contingent portion of GMWBs and certain non-life contingent portions of GMIBs are accounted for as embedded derivatives in policyholder account balances and are further discussed in Note 9. Guarantees accounted for as insurance liabilities include: Guarantee: Measurement Assumptions: GMDBs • A return of purchase payment upon death even if the account value is reduced to zero. • Present value of expected death benefits in excess of the projected account balance recognizing the excess ratably over the accumulation period based on the present value of total expected assessments. • An enhanced death benefit may be available for an additional fee. • Assumptions are consistent with those used for amortizing DAC, and are thus subject to the same variability and risk. • Investment performance and volatility assumptions are consistent with the historical experience of the appropriate underlying equity index, such as the S&P 500 Index. • Benefit assumptions are based on the average benefits payable over a range of scenarios. GMIBs • After a specified period of time determined at the time of issuance of the variable annuity contract, a minimum accumulation of purchase payments, even if the account value is reduced to zero, that can be annuitized to receive a monthly income stream that is not less than a specified amount. • Present value of expected income benefits in excess of the projected account balance at any future date of annuitization and recognizing the excess ratably over the accumulation period based on present value of total expected assessments. • Certain contracts also provide for a guaranteed lump sum return of purchase premium in lieu of the annuitization benefit. • Assumptions are consistent with those used for estimating GMDB liabilities. • Calculation incorporates an assumption for the percentage of the potential annuitizations that may be elected by the contractholder. GMWBs • A return of purchase payment via partial withdrawals, even if the account value is reduced to zero, provided that cumulative withdrawals in a contract year do not exceed a certain limit. • Expected value of the life contingent payments and expected assessments using assumptions consistent with those used for estimating the GMDB liabilities. • Certain contracts include guaranteed withdrawals that are life contingent. The Company also issues other annuity contracts that apply a lower rate on funds deposited if the contractholder elects to surrender the contract for cash and a higher rate if the contractholder elects to annuitize. These guarantees include benefits that are payable in the event of death, maturity or at annuitization. Certain other annuity contracts contain guaranteed annuitization benefits that may be above what would be provided by the current account value of the contract. Additionally, the Company issues universal and variable life contracts where the Company contractually guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding the liabilities for guarantees (excluding base policy liabilities and embedded derivatives) relating to annuity and universal and variable life contracts was as follows: Annuity Contracts Universal and Variable GMDBs and GMIBs Secondary Paid-Up Total (In millions) Direct and Assumed: Balance at January 1, 2020 $ 465 $ 894 $ 3,762 $ 427 $ 5,548 Incurred guaranteed benefits (1) 195 240 602 26 1,063 Paid guaranteed benefits (21) (5) (99) (45) (170) Balance at December 31, 2020 639 1,129 4,265 408 6,441 Incurred guaranteed benefits (1) 133 87 (37) 43 226 Paid guaranteed benefits (29) (7) (102) (47) (185) Reclassified to liabilities held-for-sale (2) — (32) — — (32) Balance at December 31, 2021 743 1,177 4,126 404 6,450 Incurred guaranteed benefits (1) 247 (269) (261) 104 (179) Paid guaranteed benefits (39) (14) (120) (44) (217) Balance at December 31, 2022 $ 951 $ 894 $ 3,745 $ 464 $ 6,054 Ceded: Balance at January 1, 2020 $ — $ 10 $ 349 $ 281 $ 640 Incurred guaranteed benefits (11) (3) 96 43 125 Paid guaranteed benefits 9 — (18) (32) (41) Balance at December 31, 2020 (2) 7 427 292 724 Incurred guaranteed benefits (6) 2 57 30 83 Paid guaranteed benefits 8 — (33) (34) (59) Reclassified to liabilities held-for-sale (2) — — — — — Balance at December 31, 2021 — 9 451 288 748 Incurred guaranteed benefits (8) (1) 29 33 53 Paid guaranteed benefits 8 — (24) (32) (48) Balance at December 31, 2022 $ — $ 8 $ 456 $ 289 $ 753 Net: Balance at January 1, 2020 $ 465 $ 884 $ 3,413 $ 146 $ 4,908 Incurred guaranteed benefits 206 243 506 (17) 938 Paid guaranteed benefits (30) (5) (81) (13) (129) Balance at December 31, 2020 641 1,122 3,838 116 5,717 Incurred guaranteed benefits 139 85 (94) 13 143 Paid guaranteed benefits (37) (7) (69) (13) (126) Reclassified to liabilities held-for-sale (2) — (32) — — (32) Balance at December 31, 2021 743 1,168 3,675 116 5,702 Incurred guaranteed benefits 255 (268) (290) 71 (232) Paid guaranteed benefits (47) (14) (96) (12) (169) Balance at December 31, 2022 $ 951 $ 886 $ 3,289 $ 175 $ 5,301 __________________ (1) Secondary guarantees include the effects of foreign currency translation of ($268) million, ($260) million and $125 million at December 31, 2022, 2021 and 2020, respectively. (2) See Note 3 for information on the Company’s business dispositions. Information regarding the Company’s guarantee exposure, which includes direct and assumed business, but excludes offsets from hedging or ceded reinsurance, if any, was as follows at: December 31, 2022 2021 In the At In the At (Dollars in millions) Annuity Contracts: Variable Annuity Guarantees: Total account value (1), (2), (3) $ 46,345 $ 16,953 $ 62,281 $ 23,121 Separate account value (1) $ 30,066 $ 15,584 $ 42,043 $ 21,508 Net amount at risk (2) $ 5,338 (4) $ 433 (5) $ 1,490 (4) $ 500 (5) Average attained age of contractholders 68 years 68 years 68 years 66 years Other Annuity Guarantees: Total account value (1), (3) N/A $ 4,101 N/A $ 5,002 Net amount at risk N/A $ 188 (6) N/A $ 196 (6) Average attained age of contractholders N/A 57 years N/A 56 years December 31, 2022 2021 Secondary Paid-Up Secondary Paid-Up (Dollars in millions) Universal and Variable Life Contracts: Total account value (1), (3) $ 11,948 $ 2,570 $ 13,678 $ 2,694 Net amount at risk (7) $ 80,623 $ 11,824 $ 78,762 $ 12,657 Average attained age of policyholders 55 years 67 years 55 years 66 years __________________ (1) The Company’s annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive. (2) Includes amounts, which are not reported on the consolidated balance sheets, from assumed variable annuity guarantees from the Company’s former operating joint venture in Japan. (3) Includes the contractholders’ investments in the general account and separate account, if applicable. (4) Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death. (5) Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved. (6) Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date. (7) Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date. Guarantees — Separate Accounts Account balances of contracts with guarantees were invested in separate account asset classes as follows at: December 31, 2022 2021 (In millions) Fund Groupings: Equity $ 20,875 $ 29,346 Balanced 12,657 17,393 Bond 4,036 5,041 Money Market 305 218 Total $ 37,873 $ 51,998 Obligations Under Funding Agreements The Company issues fixed and floating rate funding agreements, which are denominated in either U.S. dollars or foreign currencies, to certain unconsolidated special purpose entities that have issued either debt securities or commercial paper for which payment of interest and principal is secured by such funding agreements. For the years ended December 31, 2022, 2021 and 2020, the Company issued $48.5 billion, $40.8 billion and $40.4 billion, respectively, and repaid $47.4 billion, $41.2 billion and $36.7 billion, respectively, of such funding agreements. At December 31, 2022 and 2021, liabilities for funding agreements outstanding, which are included in policyholder account balances, were $40.7 billion and $39.5 billion, respectively. Certain of the Company’s subsidiaries are members of FHLBNY. Holdings of common stock of FHLBNY, included in other invested assets, were $729 million and $769 million at December 31, 2022 and 2021, respectively. Certain subsidiaries have also entered into funding agreements with FHLBNY and a subsidiary of the Federal Agricultural Mortgage Corporation, a federally chartered instrumentality of the U.S. (“Farmer Mac”). The liability for such funding agreements is included in policyholder account balances. Information related to such funding agreements was as follows at: Liability Collateral December 31, 2022 2021 2022 2021 (In millions) FHLBNY (1) $ 14,940 $ 15,750 $ 17,857 (2) $ 17,981 (2) Farmer Mac (3) $ 2,050 $ 2,050 $ 2,148 $ 2,159 __________________ (1) Represents funding agreements issued to FHLBNY in exchange for cash and for which it has been granted a lien on certain assets, some of which are in the custody of FHLBNY, including residential mortgage-backed securities (“RMBS”), to collateralize obligations under such funding agreements. The applicable subsidiary of the Company is permitted to withdraw any portion of the collateral in the custody of FHLBNY as long as there is no event of default and the remaining qualified collateral is sufficient to satisfy the collateral maintenance level. Upon any event of default by such subsidiary, FHLBNY’s recovery on the collateral is limited to the amount of such subsidiary’s liability to FHLBNY. (2) Advances are collateralized primarily by mortgage-backed securities presented at estimated fair value. The remaining collateral is mortgage loans presented at carrying value. (3) Represents funding agreements issued to a subsidiary of Farmer Mac. The obligations under these funding agreements are secured by a pledge of certain eligible agricultural mortgage loans and may, under certain circumstances, be secured by other qualified collateral. The amount of collateral presented is at carrying value. U.S. Group Life - Term Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 6,637 $ 6,713 $ 6,719 $ 6,720 $ 6,730 $ 6,720 $ 6,723 $ 6,724 $ 6,726 $ 6,726 $ 1 213,283 2014 6,986 6,919 6,913 6,910 6,914 6,919 6,920 6,918 6,920 1 216,148 2015 7,040 7,015 7,014 7,021 7,024 7,025 7,026 7,026 1 218,782 2016 7,125 7,085 7,095 7,104 7,105 7,104 7,107 2 220,671 2017 7,432 7,418 7,425 7,427 7,428 7,428 3 263,546 2018 7,757 7,655 7,646 7,650 7,651 6 251,446 2019 7,935 7,900 7,907 7,917 11 252,015 2020 8,913 9,367 9,389 23 297,022 2021 10,555 10,795 64 327,725 2022 9,640 1,129 276,784 Total 80,599 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (77,480) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 22 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 3,141 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 5,216 $ 6,614 $ 6,664 $ 6,678 $ 6,711 $ 6,715 $ 6,720 $ 6,721 $ 6,723 $ 6,724 2014 5,428 6,809 6,858 6,869 6,902 6,912 6,915 6,916 6,917 2015 5,524 6,913 6,958 6,974 7,008 7,018 7,022 7,024 2016 5,582 6,980 7,034 7,053 7,086 7,096 7,100 2017 5,761 7,292 7,355 7,374 7,400 7,414 2018 6,008 7,521 7,578 7,595 7,629 2019 6,178 7,756 7,820 7,853 2020 6,862 9,103 9,242 2021 8,008 10,476 2022 7,101 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 77,480 Average Annual Percentage Payout The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Group Life - Term 76.8% 20.8% 0.8% 0.3% 0.5% 0.1% 0.1% —% —% —% Group Long-Term Disability Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 1,008 $ 1,027 $ 1,032 $ 1,049 $ 1,070 $ 1,069 $ 1,044 $ 1,032 $ 1,025 $ 1,027 $ — 21,139 2014 1,076 1,077 1,079 1,101 1,109 1,098 1,097 1,081 1,078 — 22,853 2015 1,082 1,105 1,093 1,100 1,087 1,081 1,067 1,086 — 21,216 2016 1,131 1,139 1,159 1,162 1,139 1,124 1,123 — 17,973 2017 1,244 1,202 1,203 1,195 1,165 1,181 — 16,328 2018 1,240 1,175 1,163 1,147 1,170 — 15,214 2019 1,277 1,212 1,169 1,177 — 15,392 2020 1,253 1,223 1,155 6 15,719 2021 1,552 1,608 43 19,189 2022 1,695 760 9,970 Total 12,300 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (6,251) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 1,496 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 7,545 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 43 $ 234 $ 382 $ 475 $ 551 $ 622 $ 676 $ 722 $ 764 $ 798 2014 51 266 428 526 609 677 732 778 818 2015 50 264 427 524 601 665 718 764 2016 49 267 433 548 628 696 750 2017 56 290 476 579 655 719 2018 54 314 497 594 666 2019 57 342 522 620 2020 59 355 535 2021 95 505 2022 76 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 6,251 Average Annual Percentage Payout The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Group Long-Term Disability 4.8% 21.7% 15.2% 9.0% 7.0% 6.1% 5.0% 4.3% 3.9% 3.3% Significant Methodologies and Assumptions Group Life - Term and Group Long-Term Disability incurred but not paid (“IBNP”) liabilities are developed using a combination of loss ratio and development methods. Claims in the course of settlement are then subtracted from the IBNP liabilities, resulting in the IBNR liabilities. The loss ratio method is used in the period in which the claims are neither sufficient nor credible. In developing the loss ratios, any material rate increases that could change the underlying premium without affecting the estimated incurred losses are taken into account. For periods where sufficient and credible claim data exists, the development method is used based on the claim triangles which categorize claims according to both the period in which they were incurred and the period in which they were paid, adjudicated or reported. The end result is a triangle of known data that is used to develop known completion ratios and factors. Claims paid are then subtracted from the estimated ultimate incurred claims to calculate the IBNP liability. An expense liability is held for the future expenses associated with the payment of incurred but not yet paid claims (IBNR and pending). This is expressed as a percentage of the underlying claims liability and is based on past experience and the anticipated future expense structure. For Group Life - Term, first year incurred claims and allocated loss adjustment expenses decreased in 2022 compared to the 2021 incurral year due to the decline in COVID-19 claims. For Group Long-Term Disability, first year incurred claims and allocated loss adjustment expenses increased in 2022 compared to 2021 incurral year due to the growth in the size of the business. The assumptions used in calculating the unpaid claims and claim adjustment expenses for Group Life - Term and Group Long-Term Disability are updated annually to reflect emerging trends in claim experience. Certain of our Group Life - Term customers have experience-rated contracts, whereby the group sponsor participates in the favorable and/or adverse claim experience, including favorable and/or adverse prior year development. Claim experience adjustments on these contracts are not reflected in the foregoing incurred and paid claim development tables, but are instead reflected as an increase (adverse experience) or decrease (favorable experience) to premiums on the consolidated statements of operations. Liabilities for Group Life - Term unpaid claims and claim adjustment expenses are not discounted. The liabilities for Group Long-Term Disability unpaid claims and claim adjustment expenses were $6.5 billion and $6.2 billion at December 31, 2022 and 2021, respectively. Using interest rates ranging from 3% to 8%, based on the incurral year, the total discount applied to these liabilities was $1.2 billion and $1.1 billion at December 31, 2022 and 2021, respectively. The amount of interest accretion recognized was $ 461 million 518 million 452 million For Group Life - Term, claims were based upon individual death claims. For Group Long-Term Disability, claim frequency was determined by the number of reported claims as identified by a unique claim number assigned to individual claimants. Claim counts initially include claims that do not ultimately result in a liability. These claims are omitted from the claim counts once it is determined that there is no liability. The incurred and paid claims disclosed for the Group Life - Term product includes activity related to the product’s continued protection feature; however, the associated actuarial reserve for future benefit obligations under this feature is excluded from the liability for unpaid claims. The Group Long-Term Disability IBNR, included in the development tables above, was developed using discounted cash flows, and is presented on a discounted basis. Asia Group Disability & Group Life Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 129 $ 130 $ 151 $ 146 $ 145 $ 153 $ 153 $ 156 $ 157 $ 155 $ 5 6,597 2014 257 241 222 222 233 229 230 230 224 8 6,865 2015 243 232 235 229 239 241 245 241 13 6,792 2016 203 206 195 208 210 215 216 19 4,707 2017 263 244 252 270 277 272 30 5,619 2018 321 293 305 315 309 56 5,982 2019 347 324 339 335 79 5,966 2020 385 359 331 127 5,030 2021 367 382 211 5,659 2022 487 399 3,461 Total 2,952 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (2,006) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 11 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 957 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 38 $ 86 $ 105 $ 118 $ 129 $ 142 $ 138 $ 146 $ 149 $ 150 2014 60 125 156 175 197 198 208 213 216 2015 71 134 167 180 204 218 225 229 2016 57 117 134 167 181 190 197 2017 77 138 183 224 240 242 2018 84 155 209 243 252 2019 93 170 221 257 2020 85 153 203 2021 77 171 2022 89 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 2,006 Average Annual Percentage Payout The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Group Disability & Group Life 25.4% 25.3% 14.0% 10.6% 7.0% 3.9% 2.0% 3.0% 1.6% 0.6% Significant Methodologies and Assumptions This business line consists of employer sponsored and industry sponsored Group Life and Group Disability risks. For Group Life, the IBNR liability is determined by using the Bornhuetter-Ferguson Method, with factors derived by examining the experience of historical claims. A pending liability is also calculated for claims that have been reported but have not been paid. A claim eligibility ratio based on past experience is applied to the face amount of individual claims. For Group Disability, the IBNR liability is calculated by applying a percentage to premiums in-force based on the expected delay as evidenced by the experience in the portfolio. The IBNR liability is then allocated back into different incurral years based on historical run-off patterns. As the benefit for this class of business is a regular series of payments, an additional reserve is required for the liability for ongoing benefit payments - claims in course of payment (“CICP”). The assumptions employed in the calculation of the CICP are adjusted for the Company’s own experience. An expense liability is held for the future expenses associated with the payment of incurred but not yet paid claims. This is expressed as a percentage of the underlying claims liability and is based on past experience and the future expense structure. The assumptions used in calculating the unpaid claims and claim adjustment expenses for Group Disability and Group Life are updated annually to reflect emerging trends in claim experience. No additional premiums or return premiums have been accrued as a result of the prior year development. The liabilities for unpaid claims and claim adjustment expenses were $1.3 billion and $1.2 billion at December 31, 2022 and 2021, respectively. These amounts were discounted using interest rates ranging from 1% to 7%, based on the incurral year. The total discount applied to these liabilities was $118 million and $73 million at December 31, 2022 and 2021, respectively. The amount of interest accretion recognized was $22 million for both the years ended December 31, 2022 and 2021, and $24 million for the year ended December 31, 2020. These amounts were reflected in policyholder benefits and claims. The Company tracks claim frequency by the number of reported claims as identified by a unique claim number assigned to individual claimants. Claim counts include claims that do not ultimately result in a liability. A liability is only established for those claims that are expected to result in a liability, based on historical factors. Latin America Protection Life Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 152 $ 215 $ 221 $ 222 $ 221 $ 223 $ 224 $ 224 $ 224 $ 216 $ — 30,204 2014 229 350 360 328 332 332 333 333 324 — 38,375 2015 300 431 401 406 406 407 401 391 — 44,496 2016 318 416 427 434 435 436 426 — 38,800 2017 327 319 319 318 318 308 — 30,819 2018 305 295 293 294 292 1 29,563 2019 329 301 304 301 2 32,017 2020 497 498 502 10 42,318 2021 632 550 34 51,077 2022 436 163 30,066 Total 3,746 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (3,347) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 6 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 405 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 149 $ 208 $ 212 $ 213 $ 212 $ 214 $ 216 $ 217 $ 218 $ 210 2014 204 306 311 314 318 320 321 323 314 2015 244 345 366 373 379 382 383 373 2016 225 402 421 429 431 434 427 2017 194 291 307 310 314 305 2018 153 261 272 277 274 2019 171 260 280 278 2020 216 431 442 2021 326 456 2022 268 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 3,347 Average Annual Percentage Payout The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Protection Life 58.3% 32.3% 4.0% 1.0% 0.5% —% —% (0.5)% (1.1)% (4.0)% Protection Health Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 227 $ 256 $ 258 $ 259 $ 256 $ 256 $ 256 $ 256 $ 256 $ 257 $ — 104,402 2014 236 262 264 262 261 261 262 262 263 — 98,132 2015 203 230 232 231 230 231 231 231 — 87,596 2016 266 306 303 303 303 303 304 — 106,665 2017 385 358 359 358 358 358 — 121,591 2018 412 433 410 409 409 — 144,503 2019 137 179 173 172 1 132,150 2020 497 488 486 5 149,147 2021 638 641 13 167,881 2022 696 67 140,625 Total 3,817 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (3,679) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 1 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 139 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 227 $ 256 $ 258 $ 259 $ 256 $ 256 $ 256 $ 256 $ 256 $ 257 2014 234 260 263 259 259 259 259 259 260 2015 203 230 229 230 230 230 231 231 2016 250 299 302 302 303 303 304 2017 314 354 356 356 357 358 2018 352 401 404 405 407 2019 115 163 166 169 2020 420 475 480 2021 564 624 2022 589 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 3,679 Average Annual Percentage Payout The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Protection Health 84.7% 13.4% 0.8% 0.2% —% 0.1% 0.1% 0.1% 0.2% 0.2% Significant Methodologies and Assumptions The Latin America segment establishes liabilities for unpaid losses, which are equal to the accumulation of unpaid reported claims, plus an estimate for claims IBNR. In general terms, for both the Protection Life and Protection Health products, the methodology for IBNR is the Bornhuetter-Ferguson Method, with factors derived by examining the experience of historical claims. In the more recent incurral months, the credibility is higher on expected loss ratios and lower on claims calculated using the experience-derived factors. The credibility grows for the factors as incurral months become older. For Protection Health products, claim duration can be very long due to the multiple incidences that may occur over time for a single claim. Depending on the characteristics of the product, the number of claims reported per year may or may not be based on the original claim occurrence date for each individual claim. For Protection Life products, claims are based upon individual death claims. The assumptions used in calculating the unpaid claims and claim adjustment expenses for Protection Life and Protection Health are updated annually to reflect emerging trends in claim experience. Certain of our Protection Life customers have experience-rated contracts, whereby the group sponsor participates in the favorable and/or adverse claim experience, including favorable and/or adverse prior year development. Claim experience adjustments on these contracts are not reflected in the foregoing incurred and paid claim development tables, but are instead reflected as an increase (adverse experience) or decrease (favorable experience) to premiums on the consolidated statements of operations. Liabilities for unpaid claims and claim adjustment expenses were not discounted. For Protection Life and Protection Health products, claim counts initially include claims that do not ultimately result in a liability. These claims are omitted from the c

Deferred Policy Acquisition Cos

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles	12 Months Ended
	Dec. 31, 2022
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net [Abstract]
Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles	5. Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles See Note 1 for a description of capitalized acquisition costs. Nonparticipating and Non-Dividend-Paying Traditional Contracts The Company amortizes DAC and VOBA related to these contracts (term insurance, nonparticipating whole life insurance, traditional group life insurance, non-medical health insurance, and accident & health insurance) over the appropriate premium paying period in proportion to the actual and expected future gross premiums that were set at contract issue. The expected premiums are based upon the premium requirement of each policy and assumptions for mortality, morbidity, persistency and investment returns at policy issuance, or policy acquisition (as it relates to VOBA), include provisions for adverse deviation, and are consistent with the assumptions used to calculate future policyholder benefit liabilities. These assumptions are not revised after policy issuance or acquisition unless the DAC or VOBA balance is deemed to be unrecoverable from future expected profits. Absent a premium deficiency, variability in amortization after policy issuance or acquisition is caused only by variability in premium volumes. Participating, Dividend-Paying Traditional Contracts The Company amortizes DAC and VOBA related to these contracts over the estimated lives of the contracts in proportion to actual and expected future gross margins. The amortization includes interest based on rates in effect at inception or acquisition of the contracts. The future gross margins are dependent principally on investment returns, policyholder dividend scales, mortality, persistency, expenses to administer the business, creditworthiness of reinsurance counterparties and certain economic variables, such as inflation. For participating contracts within the closed block (dividend-paying traditional contracts) future gross margins are also dependent upon changes in the policyholder dividend obligation. See Note 7. Of these factors, the Company anticipates that investment returns, expenses, persistency and other factor changes, as well as policyholder dividend scales, are reasonably likely to impact significantly the rate of DAC and VOBA amortization. Each reporting period, the Company updates the estimated gross margins with the actual gross margins for that period. When the actual gross margins change from previously estimated gross margins, the cumulative DAC and VOBA amortization is re-estimated and adjusted by a cumulative charge or credit to current operations. When actual gross margins exceed those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the actual gross margins are below the previously estimated gross margins. Each reporting period, the Company also updates the actual amount of business in-force, which impacts expected future gross margins. When expected future gross margins are below those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the expected future gross margins are above the previously estimated expected future gross margins. Each period, the Company also reviews the estimated gross margins for each block of business to determine the recoverability of DAC and VOBA balances. Fixed and Variable Universal Life Contracts and Fixed and Variable Deferred Annuity Contracts The Company amortizes DAC and VOBA related to these contracts over the estimated lives of the contracts in proportion to actual and expected future gross profits. The amortization includes interest based on rates in effect at inception or acquisition of the contracts. The amount of future gross profits is dependent principally upon returns in excess of the amounts credited to policyholders, mortality, persistency, interest crediting rates, expenses to administer the business, creditworthiness of reinsurance counterparties, the effect of any hedges used and certain economic variables, such as inflation. Of these factors, the Company anticipates that investment returns, expenses and persistency are reasonably likely to significantly impact the rate of DAC and VOBA amortization. Each reporting period, the Company updates the estimated gross profits with the actual gross profits for that period. When the actual gross profits change from previously estimated gross profits, the cumulative DAC and VOBA amortization is re-estimated and adjusted by a cumulative charge or credit to current operations. When actual gross profits exceed those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the actual gross profits are below the previously estimated gross profits. Each reporting period, the Company also updates the actual amount of business remaining in-force, which impacts expected future gross profits. When expected future gross profits are below those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the expected future gross profits are above the previously estimated expected future gross profits. Each period, the Company also reviews the estimated gross profits for each block of business to determine the recoverability of DAC and VOBA balances. Credit Insurance and Other Short-Duration Contracts The Company amortizes DAC for these contracts, which is primarily composed of commissions and certain underwriting expenses, in proportion to actual and future earned premium over the applicable contract term. Factors Impacting Amortization Separate account rates of return on variable universal life contracts and variable deferred annuity contracts affect in-force account balances on such contracts each reporting period, which can result in significant fluctuations in amortization of DAC and VOBA. Returns that are higher than the Company’s long-term expectation produce higher account balances, which increases the Company’s future fee expectations and decreases future benefit payment expectations on minimum death and living benefit guarantees, resulting in higher expected future gross profits. The opposite result occurs when returns are lower than the Company’s long-term expectation. The Company’s practice to determine the impact of gross profits resulting from returns on separate accounts assumes that long-term appreciation in equity markets is not changed by short-term market fluctuations, but is only changed when sustained interim deviations are expected. The Company monitors these events and only changes the assumption when its long-term expectation changes. The Company also periodically reviews other long-term assumptions underlying the projections of estimated gross margins and profits. These assumptions primarily relate to investment returns, policyholder dividend scales, interest crediting rates, mortality, persistency, policyholder behavior and expenses to administer business. Management annually updates assumptions used in the calculation of estimated gross margins and profits which may have significantly changed. If the update of assumptions causes expected future gross margins and profits to increase, DAC and VOBA amortization will decrease, resulting in a current period increase to earnings. The opposite result occurs when the assumption update causes expected future gross margins and profits to decrease. Periodically, the Company modifies product benefits, features, rights or coverages that occur by the exchange of a contract for a new contract, or by amendment, endorsement, or rider to a contract, or by election or coverage within a contract. If such modification, referred to as an internal replacement, substantially changes the contract, the associated DAC or VOBA is written off immediately through income and any new deferrable costs associated with the replacement contract are deferred. If the modification does not substantially change the contract, the DAC or VOBA amortization on the original contract will continue and any acquisition costs associated with the related modification are expensed. Amortization of DAC and VOBA is attributed to net investment gains (losses) and net derivative gains (losses), and to other expenses for the amount of gross margins or profits originating from transactions other than investment gains and losses. Unrealized investment gains and losses represent the amount of DAC and VOBA that would have been amortized if such gains and losses had been recognized. Information regarding DAC and VOBA was as follows: Years Ended December 31, 2022 2021 2020 (In millions) DAC: Balance at January 1, $ 13,643 $ 13,446 $ 14,790 Capitalizations 2,558 2,718 3,013 Amortization related to: Net investment gains (losses) and net derivative gains (losses) 105 (100) (152) Other expenses (1,920) (2,268) (2,773) Total amortization (1,815) (2,368) (2,925) Unrealized investment gains (losses) 7,166 811 (1,312) Effect of foreign currency translation and other (688) (861) 76 Reclassified to assets held-for-sale (1) — (103) (196) Balance at December 31, 20,864 13,643 13,446 VOBA: Balance at January 1, 2,418 2,943 3,043 Amortization related to: Net investment gains (losses) and net derivative gains (losses) — — (2) Other expenses (116) (187) (233) Total amortization (116) (187) (235) Unrealized investment gains (losses) 17 11 (4) Effect of foreign currency translation and other (200) (314) 139 Reclassified to assets held-for-sale (1) — (35) — Balance at December 31, 2,119 2,418 2,943 Total DAC and VOBA: Balance at December 31, $ 22,983 $ 16,061 $ 16,389 __________________ (1) See Note 3 for information on the Company’s dispositions. Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at: December 31, 2022 2021 (In millions) U.S. $ 459 $ 440 Asia 13,384 9,339 Latin America 2,211 2,021 EMEA 1,593 1,623 MetLife Holdings 5,308 2,607 Corporate & Other 28 31 Total $ 22,983 $ 16,061 Information regarding other intangibles was as follows: Years Ended December 31, 2022 2021 2020 (In millions) DSI: Balance at January 1, $ 107 $ 108 $ 158 Capitalization 3 — 6 Amortization (32) (14) (37) Unrealized investment gains (losses) 59 20 (18) Effect of foreign currency translation and other (2) (7) (1) Balance at December 31, $ 135 $ 107 $ 108 VODA and VOCRA: Balance at January 1, $ 972 $ 1,099 $ 335 Acquisitions (1) — — 814 Amortization (92) (100) (41) Effect of foreign currency translation and other (4) (27) (9) Balance at December 31, $ 876 $ 972 $ 1,099 Accumulated amortization $ 667 $ 575 $ 475 Negative VOBA: Balance at January 1, $ 623 $ 738 $ 750 Amortization (41) (34) (45) Effect of foreign currency translation and other (63) (81) 33 Balance at December 31, $ 519 $ 623 $ 738 Accumulated amortization $ 3,383 $ 3,342 $ 3,308 __________________ (1) Primarily related to the acquisition of Versant Health. See Note 3. The estimated future amortization expense (credit) to be reported in other expenses for the next five years is as follows: VOBA VODA and VOCRA Negative VOBA (In millions) 2023 $ 155 $ 86 $ (30) 2024 $ 161 $ 84 $ (29) 2025 $ 153 $ 82 $ (28) 2026 $ 144 $ 80 $ (26) 2027 $ 133 $ 78 $ (25)

Reinsurance

Reinsurance	12 Months Ended
	Dec. 31, 2022
Reinsurance Disclosures [Abstract]
Reinsurance	6. ReinsuranceThe Company enters into reinsurance agreements primarily as a purchaser of reinsurance for its various insurance products and also as a provider of reinsurance for some insurance products issued by third parties. The Company participates in reinsurance activities in order to limit losses, minimize exposure to significant risks and provide additional capacity for future growth. Under the terms of the reinsurance agreements, the reinsurer agrees to reimburse the Company for the ceded amount in the event a claim is paid. Cessions under reinsurance agreements do not discharge the Company’s obligation as the primary insurer. In the event that reinsurers do not meet their obligations under the terms of the reinsurance agreements, reinsurance recoverable balances could become uncollectible. Accounting for reinsurance requires extensive use of assumptions and estimates, particularly related to the future performance of the underlying business and the potential impact of counterparty credit risks. The Company periodically reviews actual and anticipated experience compared to the aforementioned assumptions used to establish assets and liabilities relating to ceded and assumed reinsurance and evaluates the financial strength of counterparties to its reinsurance agreements using criteria similar to that evaluated in the security impairment process discussed in Note 8. U.S. For its Group Benefits business, the Company generally retains most of the risk, with the exception of its Group Term Life business and certain client arrangements. The Company reinsures an 80% quota share of its Group Term Life business for capital management purposes. The majority of the Company’s other reinsurance activity within this business relates to client agreements for employer sponsored captive programs, risk-sharing agreements and multinational pooling. The risks ceded under these agreements are generally quota shares of group life and disability policies. The cessions vary and the Company may cede up to 100% of all the risks of the policies. The Company’s RIS business has engaged in reinsurance activities on an opportunistic basis. In 2020, a U.S. life insurance subsidiary of the Company began reinsuring longevity risks for certain pension products issued by unaffiliated providers located in the United Kingdom (“U.K.”). Asia, Latin America and EMEA For selected large corporate clients, the Company reinsures group employee benefits or credit insurance business with various client-affiliated reinsurance companies, covering policies issued to the employees or customers of the clients. Additionally, the Company cedes and assumes risk with other insurance companies when either company requires a business partner with the appropriate local licensing to issue certain types of policies in certain jurisdictions. In these cases, the assuming company typically underwrites the risks, develops the products and assumes most or all of the risk. The Company also has reinsurance agreements in-force that reinsure a portion of the living and death benefit guarantees issued in connection with variable annuity products. Under these agreements, the Company pays reinsurance fees associated with the guarantees collected from policyholders, and receives reimbursement for benefits paid or accrued in excess of account values, subject to certain limitations. The Company may also reinsure certain risks with external reinsurers depending upon the nature of the risk and local regulatory requirements. MetLife Holdings For its life products, the Company has historically reinsured the mortality risk primarily on an excess of retention basis or on a quota share basis. In addition to reinsuring mortality risk as described above, the Company reinsures other risks, as well as specific coverages. Placement of reinsurance is done primarily on an automatic basis and also on a facultative basis for risks with specified characteristics. The Company also assumes portions of the risk associated with certain whole life policies issued by a former affiliate and reinsures certain term life policies and universal life policies with secondary death benefit guarantees to such former affiliate. For its other products, the Company has a reinsurance agreement in-force to reinsure the living and death benefit guarantees issued in connection with certain variable annuity guarantees from the Company’s former operating joint venture in Japan. Under this agreement, the Company receives reinsurance fees associated with the guarantees collected from policyholders, and provides reimbursement for benefits paid or accrued in excess of account values, subject to certain limitations. Catastrophe Coverage The Company has exposure to catastrophes which could contribute to significant fluctuations in the Company’s results of operations. For the U.S. and EMEA, the Company purchases catastrophe coverage to reinsure risks issued within territories that the Company believes are subject to the greatest catastrophic risks. For its other segments, the Company uses excess of retention and quota share reinsurance agreements to provide greater diversification of risk and minimize exposure to larger risks. Excess of retention reinsurance agreements provide for a portion of a risk to remain with the direct writing company and quota share reinsurance agreements provide for the direct writing company to transfer a fixed percentage of all risks of a class of policies. Reinsurance Recoverables The Company reinsures its business through a diversified group of well-capitalized reinsurers. The Company analyzes recent trends in arbitration and litigation outcomes in disputes, if any, with its reinsurers. The Company monitors ratings and evaluates the financial strength of its reinsurers by analyzing their financial statements. In addition, the reinsurance recoverable balance due from each reinsurer is evaluated as part of the overall monitoring process. Recoverability of reinsurance recoverable balances is evaluated based on these analyses. The Company generally secures large reinsurance recoverable balances with various forms of collateral, including secured trusts, funds withheld accounts and irrevocable letters of credit. These reinsurance recoverable balances are stated net of allowances for uncollectible reinsurance, which at December 31, 2022 and 2021, were not significant. A U.S. life insurance subsidiary of the Company also secured collateral from its counterparties to mitigate counterparty default risk related to its longevity reinsurance agreements. The Company has secured certain reinsurance recoverable balances with various forms of collateral, including secured trusts, funds withheld accounts and irrevocable letters of credit. The Company had $3.9 billion and $3.6 billion of unsecured reinsurance recoverable balances at December 31, 2022 and 2021, respectively. At December 31, 2022, the Company had $6.1 billion of net ceded reinsurance recoverables. Of this total, $4.2 billion, or 69%, were with the Company’s five largest ceded reinsurers, including $2.4 billion of net ceded reinsurance recoverables which were unsecured. At December 31, 2021, the Company had $6.3 billion of net ceded reinsurance recoverables. Of this total, $4.1 billion, or 65%, were with the Company’s five largest ceded reinsurers, including $1.9 billion of net ceded reinsurance recoverables which were unsecured. The Company has reinsured with an unaffiliated third-party reinsurer, 59.25% of the closed block through a modified coinsurance agreement. The Company accounts for this agreement under the deposit method of accounting. The Company, having the right of offset, has offset the modified coinsurance deposit with the deposit recoverable. The amounts on the consolidated statements of operations include the impact of reinsurance. Information regarding the significant effects of reinsurance was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Premiums Direct premiums $ 48,503 $ 41,259 $ 42,201 Reinsurance assumed 3,037 2,907 2,032 Reinsurance ceded (2,143) (2,157) (2,199) Net premiums $ 49,397 $ 42,009 $ 42,034 Universal life and investment-type product policy fees Direct universal life and investment-type product policy fees $ 6,004 $ 6,271 $ 6,122 Reinsurance assumed 76 45 50 Reinsurance ceded (495) (560) (569) Net universal life and investment-type product policy fees $ 5,585 $ 5,756 $ 5,603 Policyholder benefits and claims Direct policyholder benefits and claims $ 50,436 $ 44,035 $ 42,221 Reinsurance assumed 2,612 2,570 1,745 Reinsurance ceded (2,436) (2,651) (2,505) Net policyholder benefits and claims $ 50,612 $ 43,954 $ 41,461 Other expenses Direct other expenses $ 12,013 $ 12,450 $ 13,013 Reinsurance assumed 285 375 371 Reinsurance ceded (264) (239) (234) Net other expenses $ 12,034 $ 12,586 $ 13,150 The amounts on the consolidated balance sheets include the impact of reinsurance. Information regarding the significant effects of reinsurance was as follows at: December 31, 2022 2021 Direct Assumed Ceded Total Direct Assumed Ceded Total (In millions) Assets Premiums, reinsurance and other receivables $ 5,481 $ 1,505 $ 10,475 $ 17,461 $ 4,929 $ 1,789 $ 10,431 $ 17,149 Deferred policy acquisition costs and value of business acquired 22,889 370 (276) 22,983 16,151 227 (317) 16,061 Total assets $ 28,370 $ 1,875 $ 10,199 $ 40,444 $ 21,080 $ 2,016 $ 10,114 $ 33,210 Liabilities Future policy benefits $ 200,355 $ 3,873 $ — $ 204,228 $ 195,915 $ 3,806 $ — $ 199,721 Policyholder account balances 203,013 69 — 203,082 203,391 82 — 203,473 Other policy-related balances 18,472 1,183 (4) 19,651 16,380 1,368 3 17,751 Other liabilities 18,700 2,007 5,273 25,980 15,519 2,139 4,880 22,538 Total liabilities $ 440,540 $ 7,132 $ 5,269 $ 452,941 $ 431,205 $ 7,395 $ 4,883 $ 443,483

Closed Block

Closed Block	12 Months Ended
	Dec. 31, 2022
Closed Block Disclosure [Abstract]
Closed Block	7. Closed Block On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company (“MLIC”) converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC. Assets have been allocated to the closed block in an amount that has been determined to produce cash flows which, together with anticipated revenues from the policies included in the closed block, are reasonably expected to be sufficient to support obligations and liabilities relating to these policies, including, but not limited to, provisions for the payment of claims and certain expenses and taxes, and to provide for the continuation of policyholder dividend scales in effect for 1999, if the experience underlying such dividend scales continues, and for appropriate adjustments in such scales if the experience changes. At least annually, the Company compares actual and projected experience against the experience assumed in the then-current dividend scales. Dividend scales are adjusted periodically to give effect to changes in experience. The closed block assets, the cash flows generated by the closed block assets and the anticipated revenues from the policies in the closed block will benefit only the holders of the policies in the closed block. To the extent that, over time, cash flows from the assets allocated to the closed block and claims and other experience related to the closed block are, in the aggregate, more or less favorable than what was assumed when the closed block was established, total dividends paid to closed block policyholders in the future may be greater than or less than the total dividends that would have been paid to these policyholders if the policyholder dividend scales in effect for 1999 had been continued. Any cash flows in excess of amounts assumed will be available for distribution over time to closed block policyholders and will not be available to stockholders. If the closed block has insufficient funds to make guaranteed policy benefit payments, such payments will be made from assets outside of the closed block. The closed block will continue in effect as long as any policy in the closed block remains in-force. The expected life of the closed block is over 100 years from the Demutualization Date. The Company uses the same accounting principles to account for the participating policies included in the closed block as it used prior to the Demutualization Date. However, the Company establishes a policyholder dividend obligation for earnings that will be paid to policyholders as additional dividends as described below. The excess of closed block liabilities over closed block assets at the Demutualization Date (adjusted to eliminate the impact of related amounts in AOCI) represents the estimated maximum future earnings from the closed block expected to result from operations, attributed net of income tax, to the closed block. Earnings of the closed block are recognized in income over the period the policies and contracts in the closed block remain in-force. Management believes that over time the actual cumulative earnings of the closed block will approximately equal the expected cumulative earnings due to the effect of dividend changes. If, over the period the closed block remains in existence, the actual cumulative earnings of the closed block are greater than the expected cumulative earnings of the closed block, the Company will pay the excess to closed block policyholders as additional policyholder dividends unless offset by future unfavorable experience of the closed block and, accordingly, will recognize only the expected cumulative earnings in income with the excess recorded as a policyholder dividend obligation. If over such period, the actual cumulative earnings of the closed block are less than the expected cumulative earnings of the closed block, the Company will recognize only the actual earnings in income. However, the Company may change policyholder dividend scales in the future, which would be intended to increase future actual earnings until the actual cumulative earnings equal the expected cumulative earnings. Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company’s net income continues to be sensitive to the actual performance of the closed block. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item. Information regarding the closed block liabilities and assets designated to the closed block was as follows at: December 31, 2022 2021 (In millions) Closed Block Liabilities Future policy benefits $ 37,214 $ 38,046 Other policy-related balances 273 290 Policyholder dividends payable 181 253 Policyholder dividend obligation — 1,682 Deferred income tax liability — 210 Other liabilities 455 263 Total closed block liabilities 38,123 40,744 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale, at estimated fair value 19,648 25,669 Equity securities, at estimated fair value 13 21 Mortgage loans 6,564 6,417 Policy loans 4,084 4,191 Real estate and real estate joint ventures 635 565 Other invested assets 692 535 Total investments 31,636 37,398 Cash and cash equivalents 437 126 Accrued investment income 375 384 Premiums, reinsurance and other receivables 52 50 Current income tax recoverable 88 81 Deferred income tax asset 423 — Total assets designated to the closed block 33,011 38,039 Excess of closed block liabilities over assets designated to the closed block 5,112 2,705 AOCI: Unrealized investment gains (losses), net of income tax (1,357) 2,562 Unrealized gains (losses) on derivatives, net of income tax 262 107 Allocated to policyholder dividend obligation, net of income tax — (1,329) Total amounts included in AOCI (1,095) 1,340 Maximum future earnings to be recognized from closed block assets and liabilities $ 4,017 $ 4,045 Information regarding the closed block policyholder dividend obligation was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Balance at January 1, $ 1,682 $ 2,969 $ 2,020 Change in unrealized investment and derivative gains (losses) (1,682) (1,287) 949 Balance at December 31, $ — $ 1,682 $ 2,969 Information regarding the closed block revenues and expenses was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Revenues Premiums $ 1,104 $ 1,298 $ 1,498 Net investment income 1,382 1,541 1,596 Net investment gains (losses) (51) (36) (25) Net derivative gains (losses) 33 18 (17) Total revenues 2,468 2,821 3,052 Expenses Policyholder benefits and claims 1,890 2,150 2,330 Policyholder dividends 453 621 791 Other expenses 90 96 104 Total expenses 2,433 2,867 3,225 Revenues, net of expenses before provision for income tax expense (benefit) 35 (46) (173) Provision for income tax expense (benefit) 7 (10) (36) Revenues, net of expenses and provision for income tax expense (benefit) $ 28 $ (36) $ (137) MLIC charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. MLIC also charges the closed block for expenses of maintaining the policies included in the closed block.

Investments

Investments	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	8. Investments See Note 10 for information about the fair value hierarchy for investments and the related valuation methodologies. Investment Risks and Uncertainties Investments are exposed to the following primary sources of risk: credit, interest rate, liquidity, market valuation, currency and real estate risk. The financial statement risks, stemming from such investment risks, are those associated with the determination of estimated fair values, the diminished ability to sell certain investments in times of strained market conditions, the recognition of ACL and impairments, the recognition of income on certain investments and the potential consolidation of VIEs. The use of different methodologies, assumptions and inputs relating to these financial statement risks may have a material effect on the amounts presented within the consolidated financial statements. The determination of ACL and impairments is highly subjective and is based upon quarterly evaluations and assessments of known and inherent risks associated with the respective asset class. Such evaluations and assessments are revised as conditions change and new information becomes available. The recognition of income on certain investments (e.g. structured securities, including mortgage-backed securities, asset-backed securities and collateralized loan obligations (“ABS & CLO”), certain structured investment transactions and FVO Securities) is dependent upon certain factors such as prepayments and defaults, and changes in such factors could result in changes in amounts to be earned. Fixed Maturity Securities AFS Fixed Maturity Securities AFS by Sector The following table presents fixed maturity securities AFS by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. RMBS includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” December 31, 2022 2021 Amortized Gross Unrealized Estimated Amortized Gross Unrealized (1) Estimated Sector Allowance Gains Losses Allowance Gains Losses (In millions) U.S. corporate $ 88,466 $ (29) $ 1,133 $ 9,540 $ 80,030 $ 82,694 $ (30) $ 10,651 $ 281 $ 93,034 Foreign corporate 59,696 (5) 1,213 8,332 52,572 59,124 (28) 5,275 731 63,640 Foreign government 50,047 (130) 1,876 5,046 46,747 56,848 (19) 5,603 823 61,609 U.S. government and agency 35,658 — 431 3,860 32,229 41,068 — 5,807 276 46,599 RMBS 29,496 — 187 3,518 26,165 29,152 — 1,440 188 30,404 ABS & CLO 17,991 — 23 1,192 16,822 18,443 — 185 59 18,569 Municipals 13,548 — 317 1,713 12,152 11,761 — 2,464 13 14,212 CMBS 11,123 (19) 59 1,100 10,063 11,794 (14) 476 49 12,207 Total fixed maturity securities AFS $ 306,025 $ (183) $ 5,239 $ 34,301 $ 276,780 $ 310,884 $ (91) $ 31,901 $ 2,420 $ 340,274 __________________ (1) Excludes gross unrealized gains (losses) related to assets held-for-sale; these unrealized gains (losses) are included in AOCI as no component of equity is held-for-sale. See Note 3 for information on the Company’s business dispositions. The Company held non-income producing fixed maturity securities AFS with an estimated fair value of $82 million and $22 million at December 31, 2022 and December 31, 2021, respectively, with unrealized gains (losses) of ($3) million and $8 million at December 31, 2022 and December 31, 2021, respectively. Methodology for Amortization of Premium and Accretion of Discount on Structured Products Amortization of premium and accretion of discount on Structured Products considers the estimated timing and amount of prepayments of the underlying loans. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the originally anticipated and the actual prepayments received and currently anticipated. Prepayment assumptions for Structured Products are estimated using inputs obtained from third-party specialists and based on management’s knowledge of the current market. For credit-sensitive and certain prepayment-sensitive Structured Products, the effective yield is recalculated on a prospective basis. For all other Structured Products, the effective yield is recalculated on a retrospective basis. Maturities of Fixed Maturity Securities AFS The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at December 31, 2022: Due in One Due After Due After Due After Structured Total Fixed (In millions) Amortized cost, net of ACL $ 8,235 $ 50,977 $ 54,016 $ 134,023 $ 58,591 $ 305,842 Estimated fair value $ 8,131 $ 49,344 $ 50,498 $ 115,757 $ 53,050 $ 276,780 Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity. Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. December 31, 2022 2021 Less than 12 Months Equal to or Greater than 12 Months Less than 12 Months Equal to or Greater than 12 Months Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 55,210 $ 7,573 $ 6,484 $ 1,965 $ 8,076 $ 165 $ 1,499 $ 116 Foreign corporate 31,932 5,999 8,956 2,332 10,011 404 2,834 327 Foreign government 16,568 2,170 8,308 2,874 7,812 319 5,377 502 U.S. government and agency 20,436 2,784 4,177 1,076 14,419 138 1,571 138 RMBS 16,223 1,890 6,650 1,628 10,363 158 417 30 ABS & CLO 10,924 712 4,326 480 8,150 39 804 20 Municipals 7,277 1,514 482 199 524 10 65 3 CMBS 6,890 764 2,037 335 2,664 31 657 18 Total fixed maturity securities AFS $ 165,460 $ 23,406 $ 41,420 $ 10,889 $ 62,019 $ 1,264 $ 13,224 $ 1,154 Investment grade $ 157,654 $ 22,713 $ 38,785 $ 10,298 $ 58,358 $ 1,123 $ 12,022 $ 1,025 Below investment grade 7,806 693 2,635 591 3,661 141 1,202 129 Total fixed maturity securities AFS $ 165,460 $ 23,406 $ 41,420 $ 10,889 $ 62,019 $ 1,264 $ 13,224 $ 1,154 Total number of securities in an unrealized loss position 15,204 4,303 4,774 979 __________________ (1) Excludes gross unrealized losses related to assets held-for-sale; these unrealized losses are included in AOCI as no component of equity is held-for-sale. See Note 3 for information on the Company’s business dispositions. Evaluation of Fixed Maturity Securities AFS for Credit Loss Evaluation and Measurement Methodologies Management considers a wide range of factors about the security issuer and uses its best judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for near-term recovery. Inherent in management’s evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations used in the credit loss evaluation process include, but are not limited to: (i) the extent to which the estimated fair value has been below amortized cost, (ii) adverse conditions specifically related to a security, an industry sector or sub-sector, or an economically depressed geographic area, adverse change in the financial condition of the issuer of the security, changes in technology, discontinuance of a segment of the business that may affect future earnings, and changes in the quality of credit enhancement, (iii) payment structure of the security and likelihood of the issuer being able to make payments, (iv) failure of the issuer to make scheduled interest and principal payments, (v) whether the issuer, or series of issuers or an industry has suffered a catastrophic loss or has exhausted natural resources, (vi) whether the Company has the intent to sell or will more likely than not be required to sell a particular security before the decline in estimated fair value below amortized cost recovers, (vii) with respect to Structured Products, changes in forecasted cash flows after considering the changes in the financial condition of the underlying loan obligors and quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security, and the payment priority within the tranche structure of the security, (viii) changes in the rating of the security by a rating agency, and (ix) other subjective factors, including concentrations and information obtained from regulators. The methodology and significant inputs used to determine the amount of credit loss are as follows: • The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security at the time of purchase for fixed-rate securities and the spot rate at the date of evaluation of credit loss for floating-rate securities. • When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall credit loss evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s single best estimate, the most likely outcome in a range of possible outcomes, after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security; the likelihood that the issuer can service the interest and principal payments; the quality and amount of any credit enhancements; the security’s position within the capital structure of the issuer; possible corporate restructurings or asset sales by the issuer; any private and public sector programs to restructure foreign government securities and municipals; and changes to the rating of the security or the issuer by rating agencies. • Additional considerations are made when assessing the unique features that apply to certain Structured Products including, but not limited to: the quality of underlying collateral, historical performance of the underlying loan obligors, historical rent and vacancy levels, changes in the financial condition of the underlying loan obligors, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, changes in the quality of credit enhancement and the payment priority within the tranche structure of the security. With respect to securities that have attributes of debt and equity (“perpetual hybrid securities”), consideration is given in the credit loss analysis as to whether there has been any deterioration in the credit of the issuer and the likelihood of recovery in value of the securities that are in a severe unrealized loss position. Consideration is also given as to whether any perpetual hybrid securities with an unrealized loss, regardless of credit rating, have deferred any dividend payments. In periods subsequent to the recognition of an initial ACL on a security, the Company reassesses credit loss quarterly. Subsequent increases or decreases in the expected cash flow from the security result in corresponding decreases or increases in the ACL which are recognized in earnings and reported within net investment gains (losses); however, the previously recorded ACL is not reduced to an amount below zero. Full or partial write-offs are deducted from the ACL in the period the security, or a portion thereof, is considered uncollectible. Recoveries of amounts previously written off are recorded to the ACL in the period received. When the Company has the intent-to-sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost, any ACL is written off and the amortized cost is written down to estimated fair value through a charge within net investment gains (losses), which becomes the new amortized cost of the security. Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position Gross unrealized losses on securities without an ACL increased $31.9 billion for the year ended December 31, 2022 to $34.3 billion primarily due to increases in interest rates, widening credit spreads, and the impact of weakening foreign currencies on certain non-functional currency denominated fixed maturity securities. Gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater were $10.9 billion at December 31, 2022, or 32% of the total gross unrealized losses on securities without an ACL. Investment Grade Fixed Maturity Securities AFS Of the $10.9 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $10.3 billion, or 95%, were related to 3,875 investment grade securities. Unrealized losses on investment grade securities are principally related to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase. Below Investment Grade Fixed Maturity Securities AFS Of the $10.9 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $591 million, or 5%, were related to 428 below investment grade securities. Unrealized losses on below investment grade securities are principally related to U.S. corporate and foreign corporate securities (primarily transportation, consumer and communications) and foreign government securities. These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty, as well as, with respect to fixed-rate securities, rising interest rates since purchase. Management evaluates U.S. corporate and foreign corporate securities based on several factors such as expected cash flows, financial condition and near-term and long-term prospects of the issuers. Management evaluates foreign government securities based on factors impacting the issuers such as expected cash flows, financial condition of the issuers and any country specific economic conditions or public sector programs to restructure foreign government securities. Current Period Evaluation At December 31, 2022, with respect to securities in an unrealized loss position without an ACL, the Company did not intend to sell these securities, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Based on the Company’s current evaluation of its securities in an unrealized loss position without an ACL, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at December 31, 2022. Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation. Rollforward of Allowance for Credit Loss for Fixed Maturity Securities AFS By Sector The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Foreign CMBS Total Year Ended December 31, 2022 (In millions) Balance at January 1, $ 30 $ 28 $ 19 $ 14 $ 91 ACL not previously recorded 13 67 207 5 292 Changes for securities with previously recorded ACL 17 2 (48) — (29) Securities sold or exchanged (9) (93) (37) — (139) Dispositions — — — — — Effect of foreign currency translation — 1 (11) — (10) Write-offs (22) — — — (22) Balance at December 31, $ 29 $ 5 $ 130 $ 19 $ 183 U.S. Foreign Foreign CMBS Total Year Ended December 31, 2021 (In millions) Balance at January 1, $ 44 $ 16 $ 21 $ — $ 81 ACL not previously recorded 48 26 — 11 85 Changes for securities with previously recorded ACL 3 (4) — 3 2 Securities sold or exchanged (52) (10) — — (62) Dispositions (1) — — (2) — (2) Effect of foreign currency translation — — — — — Write-offs (13) — — — (13) Balance at December 31, $ 30 $ 28 $ 19 $ 14 $ 91 __________________ (1) In connection with the disposition of MetLife Seguros, ACL was reduced by $2 million for the year ended December 31, 2021. See Note 3 for additional information on the Company’s business dispositions. Equity Securities The following table presents equity securities by security type. Common stock includes common stock, exchange traded funds, mutual funds and real estate investment trusts. December 31, 2022 2021 Cost Net Unrealized Estimated Cost Net Unrealized Estimated Security Type (In millions) Common stock $ 1,347 $ 195 $ 1,542 $ 784 $ 295 $ 1,079 Non-redeemable preferred stock 148 (6) 142 189 1 190 Total $ 1,495 $ 189 $ 1,684 $ 973 $ 296 $ 1,269 __________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. Contractholder-Directed Equity Securities and FVO Securities The following table presents these investments by asset type. Unit-linked investments are primarily equity securities (including mutual funds). FVO Securities includes fixed maturity and equity securities to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. December 31, 2022 2021 Cost or Net Unrealized Estimated Cost or Net Unrealized Estimated Asset Type (In millions) Unit-linked investments $ 7,945 $ 288 $ 8,233 $ 8,643 $ 1,897 $ 10,540 FVO Securities 1,161 274 1,435 1,243 359 1,602 Total $ 9,106 $ 562 $ 9,668 $ 9,886 $ 2,256 $ 12,142 __________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. Mortgage Loans Mortgage Loans by Portfolio Segment Mortgage loans are summarized as follows at: December 31, 2022 2021 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 52,502 62.7 % $ 50,553 63.7 % Agricultural 19,306 23.0 18,111 22.8 Residential 12,482 14.9 11,196 14.1 Total amortized cost 84,290 100.6 79,860 100.6 Allowance for credit loss (527) (0.6) (634) (0.8) Subtotal mortgage loans, net 83,763 100.0 79,226 99.8 Residential — FVO — — 127 0.2 Total mortgage loans, net $ 83,763 100.0 % $ 79,353 100.0 % The Company elects the FVO for certain residential mortgage loans that are managed on a total return basis, with changes in estimated fair value included in net investment income. See Note 10 for further information. The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($744) million and ($759) million at December 31, 2022 and 2021, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at December 31, 2022 was $219 million, $176 million, and $81 million, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at December 31, 2021 was $180 million, $161 million and $86 million, respectively. Purchases of mortgage loans, consisting primarily of residential mortgage loans, were $3.1 billion, $1.8 billion and $3.3 billion for the years ended December 31, 2022, 2021 and 2020, respectively. See “— Real Estate and Real Estate Joint Ventures” for the carrying value of wholly-owned real estate acquired through foreclosure. In addition, for the year ended December 31, 2022, the Company contributed commercial mortgage loans with an amortized cost of $489 million to joint ventures in anticipation of subsequent foreclosure or deed-in-lieu of foreclosure transactions. During the year, the joint ventures completed foreclosure or deed-in-lieu of foreclosure transactions on loans with an amortized cost of $467 million. The real estate collateralizing these foreclosures or deed-in-lieu of foreclosures had an estimated fair value in excess of amortized cost. As a result of the excess of estimated fair value of the collateral over the amortized cost of the commercial mortgage loans, upon consummating the foreclosures or deed-in-lieu of foreclosure transactions, the joint ventures recognized a gain, of which the Company recognized its pro-rata share of $34 million within net investment gains (losses). Rollforward of Allowance for Credit Loss for Mortgage Loans by Portfolio Segment The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Years Ended December 31, 2022 2021 2020 Commercial Agricultural Residential Total Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance at January 1, $ 340 $ 88 $ 206 $ 634 $ 252 $ 106 $ 232 $ 590 $ 246 $ 52 $ 55 $ 353 Adoption of credit loss guidance — — — — — — — — (118) 35 161 78 Provision (release) (2) 53 (8) 43 88 6 (27) 67 124 22 30 176 Initial credit losses on PCD loans (1) — — — — — — 3 3 — — 18 18 Charge-offs, net of recoveries (120) (22) (8) (150) — (24) (2) (26) — (2) (32) (34) HFS transfer — — — — — — — — — (1) — (1) Balance at December 31, $ 218 $ 119 $ 190 $ 527 $ 340 $ 88 $ 206 $ 634 $ 252 $ 106 $ 232 $ 590 __________________ (1) Represents the initial credit losses on purchased mortgage loans accounted for as PCD. Allowance for Credit Loss Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable) and reasonably expected TDRs (i.e., the Company grants concessions to a borrower that is experiencing financial difficulties) are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Commercial and agricultural mortgage loan ACL are calculated in a similar manner. Within each loan portfolio segment, commercial and agricultural, loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans. For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio. For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated. Commitments to lend: After loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that are not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly. Residential Mortgage Loan Portfolio Segment The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company immediately reverts to industry historical loss experience. For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss. Troubled Debt Restructurings The Company may grant concessions to borrowers experiencing financial difficulties, which, if not significant, are not classified as TDRs

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	9. Derivatives Accounting for Derivatives See Note 1 for a description of the Company’s accounting policies for derivatives an d Note 10 for information about the fair value hierarchy for derivatives. Derivative Strategies The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Derivatives are financial instruments with values derived from interest rates, foreign currency exchange rates, credit spreads and/or other financial indices. Derivatives may be exchange-traded or contracted in the over-the-counter (“OTC”) market. Certain of the Company’s OTC derivatives are cleared and settled through central clearing counterparties (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”). The types of derivatives the Company uses include swaps, forwards, futures and option contracts. To a lesser extent, the Company uses credit default swaps and structured interest rate swaps to synthetically replicate investment risks and returns which are not readily available in the cash markets. Interest Rate Derivatives The Company uses a variety of interest rate derivatives to reduce its exposure to changes in interest rates, including interest rate swaps, interest rate total return swaps, caps, floors, swaptions, futures and forwards. Interest rate swaps are used by the Company primarily to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). In an interest rate swap, the Company agrees with another party to exchange, at specified intervals, the difference between fixed rate and floating rate interest amounts as calculated by reference to an agreed notional amount. The Company utilizes interest rate swaps in fair value, cash flow and nonqualifying hedging relationships. The Company uses structured interest rate swaps to synthetically create investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and a cash instrument such as a U.S. government and agency, or other fixed maturity securities AFS. Structured interest rate swaps are included in interest rate swaps and are not designated as hedging instruments. Interest rate total return swaps are swaps whereby the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and a benchmark interest rate, calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. These transactions are entered into pursuant to master agreements that provide for a single net payment to be made by the counterparty at each due date. Interest rate total return swaps are used by the Company to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). The Company utilizes interest rate total return swaps in nonqualifying hedging relationships. The Company purchases interest rate caps primarily to protect its floating rate liabilities against rises in interest rates above a specified level, and against interest rate exposure arising from mismatches between assets and liabilities, and interest rate floors primarily to protect its minimum rate guarantee liabilities against declines in interest rates below a specified level. In certain instances, the Company locks in the economic impact of existing purchased caps and floors by entering into offsetting written caps and floors. The Company utilizes interest rate caps and floors in nonqualifying hedging relationships. In exchange-traded interest rate (Treasury and swap) futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of interest rate securities, to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts and to pledge initial margin based on futures exchange requirements. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded interest rate (Treasury and swap) futures are used primarily to hedge mismatches between the duration of assets in a portfolio and the duration of liabilities supported by those assets, to hedge against changes in value of securities the Company owns or anticipates acquiring, to hedge against changes in interest rates on anticipated liability issuances by replicating Treasury or swap curve performance, and to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. The Company utilizes exchange-traded interest rate futures in nonqualifying hedging relationships. Swaptions are used by the Company to hedge interest rate risk associated with the Company’s long-term liabilities and invested assets. A swaption is an option to enter into a swap with a forward starting effective date. In certain instances, the Company locks in the economic impact of existing purchased swaptions by entering into offsetting written swaptions. The Company pays a premium for purchased swaptions and receives a premium for written swaptions. The Company utilizes swaptions in nonqualifying hedging relationships. Swaptions are included in interest rate options. The Company enters into interest rate forwards to buy and sell securities. The price is agreed upon at the time of the contract and payment for such a contract is made at a specified future date. The Company utilizes interest rate forwards in cash flow and nonqualifying hedging relationships. A synthetic GIC is a contract that simulates the performance of a traditional GIC through the use of financial instruments. The contractholder owns the underlying assets, and the Company provides a guarantee (or “wrap”) on the participant funds for an annual risk charge. The Company’s maximum exposure to loss on synthetic GICs is the notional amount, in the event the values of all of the underlying assets were reduced to zero. The Company’s risk is substantially lower due to contractual provisions that limit the portfolio to high quality assets, which are pre-approved and monitored for compliance, as well as the collection of risk charges. In addition, the crediting rates reset periodically to amortize market value gains and losses over a period equal to the duration of the wrapped portfolio, subject to a 0% floor. While plan participants may transact at book value, contractholder withdrawals may only occur immediately at market value, or at book value paid over a period of time per contract provisions. Synthetic GICs are not designated as hedging instruments. Foreign Currency Exchange Rate Derivatives The Company uses foreign currency exchange rate derivatives, including foreign currency swaps, foreign currency forwards, currency options and exchange-traded currency futures, to reduce the risk from fluctuations in foreign currency exchange rates associated with its assets and liabilities denominated in foreign currencies. The Company also uses foreign currency derivatives to hedge the foreign currency exchange rate risk associated with certain of its net investments in foreign operations. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company utilizes foreign currency swaps in fair value, cash flow and nonqualifying hedging relationships. In a foreign currency forward transaction, the Company agrees with another party to deliver a specified amount of an identified currency at a specified future date. The price is agreed upon at the time of the contract and payment for such a contract is made at the specified future date. The Company utilizes foreign currency forwards in fair value, NIFO hedges and nonqualifying hedging relationships. The Company enters into currency options that give it the right, but not the obligation, to sell the foreign currency amount in exchange for a functional currency amount within a limited time at a contracted price. The contracts may also be net settled in cash, based on differentials in the foreign currency exchange rate and the strike price. The Company uses currency options to hedge against the foreign currency exposure inherent in certain of its variable annuity products. The Company also uses currency options as an economic hedge of foreign currency exposure related to the Company’s non-U.S. subsidiaries. The Company utilizes currency options in NIFO hedges and nonqualifying hedging relationships. To a lesser extent, the Company uses exchange-traded currency futures to hedge currency mismatches between assets and liabilities, and to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. The Company utilizes exchange-traded currency futures in nonqualifying hedging relationships. Credit Derivatives The Company enters into purchased credit default swaps to hedge against credit-related changes in the value of its investments. In a credit default swap transaction, the Company agrees with another party to pay, at specified intervals, a premium to hedge credit risk. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the delivery of par quantities of the referenced investment equal to the specified swap notional amount in exchange for the payment of cash amounts by the counterparty equal to the par value of the investment surrendered. Credit events vary by type of issuer but typically include bankruptcy, failure to pay debt obligations and involuntary restructuring for corporate obligors, as well as repudiation, moratorium or governmental intervention for sovereign obligors. In each case, payout on a credit default swap is triggered only after the relevant third party, Credit Derivatives Determinations Committee determines that a credit event has occurred. The Company utilizes credit default swaps in nonqualifying hedging relationships. The Company enters into written credit default swaps to synthetically create credit investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and one or more cash instruments, such as U.S. government and agency, or other fixed maturity securities AFS. These credit default swaps are not designated as hedging instruments. The Company enters into forwards to lock in the price to be paid for forward purchases of certain securities. The price is agreed upon at the time of the contract and payment for the contract is made at a specified future date. When the primary purpose of entering into these transactions is to hedge against the risk of changes in purchase price due to changes in credit spreads, the Company designates these transactions as credit forwards. The Company utilizes credit forwards in cash flow hedging relationships. Equity Derivatives The Company uses a variety of equity derivatives to reduce its exposure to equity market risk, including equity index options, equity variance swaps, exchange-traded equity futures and equity total return swaps. Equity index options are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. To hedge against adverse changes in equity indices, the Company enters into contracts to sell the underlying equity index within a limited time at a contracted price. The contracts will be net settled in cash based on differentials in the indices at the time of exercise and the strike price. Certain of these contracts may also contain settlement provisions linked to interest rates. In certain instances, the Company may enter into a combination of transactions to hedge adverse changes in equity indices within a pre-determined range through the purchase and sale of options. The Company utilizes equity index options in nonqualifying hedging relationships. Equity variance swaps are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. In an equity variance swap, the Company agrees with another party to exchange amounts in the future, based on changes in equity volatility over a defined period. The Company utilizes equity variance swaps in nonqualifying hedging relationships. In exchange-traded equity futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of equity securities, to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts and to pledge initial margin based on futures exchange requirements. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded equity futures are used primarily to hedge minimum guarantees embedded in certain variable annuity products issued by the Company. The Company utilizes exchange-traded equity futures in nonqualifying hedging relationships. In an equity total return swap, the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and a benchmark interest rate, calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. The Company uses equity total return swaps to hedge its equity market guarantees in certain of its insurance products. Equity total return swaps can be used as hedges or to synthetically create investments. The Company utilizes equity total return swaps in nonqualifying hedging relationships. Primary Risks Managed by Derivatives The following table presents the primary underlying risk exposure, gross notional amount and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: Primary Underlying Risk Exposure December 31, 2022 2021 Estimated Fair Value Estimated Fair Value Gross Assets Liabilities Gross Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 4,143 $ 1,353 $ 467 $ 3,550 $ 2,164 $ 6 Foreign currency swaps Foreign currency exchange rate 602 82 — 801 11 23 Foreign currency forwards Foreign currency exchange rate 1,336 10 89 1,636 — 58 Subtotal 6,081 1,445 556 5,987 2,175 87 Cash flow hedges: Interest rate swaps Interest rate 4,107 8 262 4,117 6 1 Interest rate forwards Interest rate 7,447 1 1,354 6,889 89 119 Foreign currency swaps Foreign currency exchange rate 42,608 3,554 1,699 41,095 1,600 1,557 Subtotal 54,162 3,563 3,315 52,101 1,695 1,677 NIFO hedges: Foreign currency forwards Foreign currency exchange rate 680 — 38 — — — Currency options Foreign currency exchange rate 3,000 236 — 3,000 139 — Subtotal 3,680 236 38 3,000 139 — Total qualifying hedges 63,923 5,244 3,909 61,088 4,009 1,764 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 31,661 1,660 1,354 38,860 3,644 115 Interest rate floors Interest rate 25,270 125 — 7,701 145 — Interest rate caps Interest rate 48,290 950 — 65,559 124 — Interest rate futures Interest rate 1,453 2 1 1,615 4 — Interest rate options Interest rate 44,391 473 88 11,754 493 10 Interest rate forwards Interest rate 381 — 32 374 — 26 Interest rate total return swaps Interest rate — — — 1,048 9 4 Synthetic GICs Interest rate 46,316 — — 40,121 — — Foreign currency swaps Foreign currency exchange rate 12,815 1,454 383 12,787 768 614 Foreign currency forwards Foreign currency exchange rate 16,195 544 661 16,230 36 666 Currency futures Foreign currency exchange rate 333 8 — 839 — 2 Currency options Foreign currency exchange rate — — — 900 — — Credit default swaps — purchased Credit 2,925 18 79 3,042 13 113 Credit default swaps — written Credit 11,512 133 28 8,626 177 12 Equity futures Equity market 2,988 8 4 4,204 12 5 Equity index options Equity market 16,701 765 323 29,743 1,004 458 Equity variance swaps Equity market 163 4 1 699 17 13 Equity total return swaps Equity market 2,799 23 112 3,025 11 50 Total non-designated or nonqualifying derivatives 264,193 6,167 3,066 247,127 6,457 2,088 Total $ 328,116 $ 11,411 $ 6,975 $ 308,215 $ 10,466 $ 3,852 The Effects of Derivatives on the Consolidated Statements of Operations and Comprehensive Income (Loss) The following table presents the consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, NIFO, nonqualifying hedging relationships and embedded derivatives: Year Ended December 31, 2022 Net Net Net Policyholder Interest Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 9 $ — $ — $ (1,187) $ (26) $ — N/A Hedged items (9) — — 1,127 27 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 109 (220) — — — — N/A Hedged items (110) 217 — — — — N/A Amount excluded from the assessment of hedge effectiveness — 46 — — — — N/A Subtotal (1) 43 — (60) 1 — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (2,367) Amount of gains (losses) reclassified from AOCI into income 59 41 — — — 4 (104) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A 1,784 Amount of gains (losses) reclassified from AOCI into income 6 (609) — — — 1 602 Foreign currency transaction gains (losses) on hedged items — 587 — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 65 19 — — — 5 (85) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A N/A N/A N/A N/A N/A 85 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 47 Subtotal N/A N/A N/A N/A N/A N/A 132 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 3 — (3,879) (88) — — N/A Foreign currency exchange rate derivatives (1) 2 — (368) (4) — — N/A Credit derivatives — purchased (1) — — 75 — — — N/A Credit derivatives — written (1) — — (92) — — — N/A Equity derivatives (1) 45 — 423 250 — — N/A Foreign currency transaction gains (losses) on hedged items — — 282 — — — N/A Subtotal 50 — (3,559) 158 — — N/A Earned income on derivatives 376 — 1,015 150 (145) — — Embedded derivatives (2) N/A N/A 172 — N/A N/A N/A Total $ 490 $ 62 $ (2,372) $ 248 $ (144) $ 5 $ 47 Year Ended December 31, 2021 Net Net Net Policyholder Interest Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 6 $ — $ — $ (456) $ — $ — N/A Hedged items (6) — — 406 — — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 50 (191) — — — — N/A Hedged items (44) 185 — — — — N/A Amount excluded from the assessment of hedge effectiveness — — — — — — N/A Subtotal 6 (6) — (50) — — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (599) Amount of gains (losses) reclassified from AOCI into income 56 84 — — — 3 (143) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A 500 Amount of gains (losses) reclassified from AOCI into income 8 (403) — — — 2 393 Foreign currency transaction gains (losses) on hedged items — 401 — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (14) Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 64 82 — — — 5 137 Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A N/A N/A N/A N/A N/A 97 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 42 Subtotal N/A N/A N/A N/A N/A N/A 139 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 2 — (1,992) (49) — — N/A Foreign currency exchange rate derivatives (1) — — (986) 2 — — N/A Credit derivatives — purchased (1) — — 9 — — — N/A Credit derivatives — written (1) — — 41 — — — N/A Equity derivatives (1) (56) — (1,280) (302) — — N/A Foreign currency transaction gains (losses) on hedged items — — 249 — — — N/A Subtotal (54) — (3,959) (349) — — N/A Earned income on derivatives 151 — 984 213 (159) — — Embedded derivatives (2) N/A N/A 747 — N/A N/A N/A Total $ 167 $ 76 $ (2,228) $ (186) $ (159) $ 5 $ 276 Year Ended December 31, 2020 Net Net Net Policyholder Interest Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (10) $ — $ — $ 360 $ — $ — N/A Hedged items 12 — — (399) — — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (46) 98 — — — — N/A Hedged items 44 (93) — — — — N/A Amount excluded from the assessment of hedge effectiveness — (47) — — — — N/A Subtotal — (42) — (39) — — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ 1,277 Amount of gains (losses) reclassified from AOCI into income 36 121 — — — 2 (159) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (445) Amount of gains (losses) reclassified from AOCI into income 4 851 — — — 2 (857) Foreign currency transaction gains (losses) on hedged items — (765) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (102) Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 40 207 — — — 4 (286) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A N/A N/A N/A N/A N/A 36 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A (20) Subtotal N/A N/A N/A N/A N/A N/A 16 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) (6) — 2,149 55 — — N/A Foreign currency exchange rate derivatives (1) — — (323) (3) — — N/A Credit derivatives — purchased (1) — — (28) — — — N/A Credit derivatives — written (1) — — (106) — — — N/A Equity derivatives (1) (28) — (1,151) (203) — — N/A Foreign currency transaction gains (losses) on hedged items — — (8) — — — N/A Subtotal (34) — 533 (151) — — N/A Earned income on derivatives 217 — 926 190 (152) — — Embedded derivatives (2) N/A N/A (110) — N/A N/A N/A Total $ 223 $ 165 $ 1,349 $ — $ (152) $ 4 $ (270) __________________ (1) Excludes earned income on derivatives. (2) The valuation of guaranteed minimum benefits includes a nonperformance risk adjustment. The amounts included in net derivative gains (losses) in connection with this adjustment wer e $18 million, ($17) million and ($10) million for the years ended December 31, 2022, 2021 and 2020, respectively. Fair Value Hedges The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities; (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities; and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments. The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount Cumulative Amount December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 (In millions) Fixed maturity securities AFS $ 1,411 $ 2,164 $ 1 $ (1) Mortgage loans $ 331 $ 634 $ (19) $ 3 Future policy benefits $ (3,524) $ (4,735) $ 276 $ (877) Policyholder account balances $ (1,080) $ — $ 27 $ — __________________ (1) Includes ($136) million and ($161) million of hedging adjustments on discontinued hedging relationships at December 31, 2022 and 2021, respectively. For the Company’s foreign currency forwards, the change in the estimated fair value of the derivative related to the changes in the difference between the spot price and the forward price is excluded from the assessment of hedge effectiveness. The Company has elected to record changes in estimated fair value of excluded components in earnings. For all other derivatives, all components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. Cash Flow Hedges The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities; (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities; (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments; (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed rate investments; and (v) interest rate swaps and interest rate forwards to hedge forecasted fixed rate borrowings. In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were $30 million, ($1) million and $21 million for the years ended December 31, 2022, 2021 and 2020, respectively. At December 31, 2022 and 2021, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed six years and seven years, respectively. At December 31, 2022 and 2021, the balance in AOCI associated with cash flow hedges was $2.0 billion and $2.1 billion, respectively. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. At December 31, 2022, the Company expected to reclassify $156 million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months. NIFO Hedges The Company uses foreign currency exchange rate derivatives, which may include foreign currency forwards and currency options, to hedge portions of its net investments in foreign operations against adverse movements in exchange rates. The Company also designates a portion of its foreign-denominated debt as a non-derivative hedging instrument of its net investments in foreign operations. The Company assesses hedge effectiveness of its derivatives based upon the change in forward rates and assesses its non-derivative hedging instruments based upon the change in spot rates. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. When net investments in foreign operations are sold or substantially liquidated, the amounts in AOCI are reclassified to the statement of operations. At December 31, 2022 and 2021, the cumulative foreign currency translation gain (loss) recorded in AOCI related to NIFO hedges was $435 million and $303 million, respectively. At December 31, 2022 and 2021, the carrying amount of debt designated as a non-derivative hedging instrument was $318 million and $365 million, respectively. See Note 13 for additional information on foreign-denominated debt. Credit Derivatives In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps. The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: December 31, 2022 2021 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ 3 $ 158 2.2 $ 4 $ 159 3.1 Credit default swaps referencing indices 79 4,251 3.4 17 1,191 2.5 Subtotal 82 4,409 3.4 21 1,350 2.6 Baa Single name credit default swaps (3) 1 81 2.5 2 101 3.4 Credit default swaps referencing indices 28 6,775 5.6 146 6,988 5.0 Subtotal 29 6,856 5.5 148 7,089 5.0 Ba Single name credit default swaps (3) — 62 1.3 1 82 1.2 Credit default swaps referencing indices 2 25 4.0 (1) 20 5.0 Subtotal 2 87 2.1 — 102 2.0 B Credit default swaps referencing indices 2 130 4.7 5 55 4.0 Subtotal 2 130 4.7 5 55 4.0 Caa Credit default swaps referencing indices (10) 30 3.5 (9) 30 4.5 Subtotal (10) 30 3.5 (9) 30 4.5 Total $ 105 $ 11,512 4.7 $ 165 $ 8,626 4.6 __________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals. Credit Risk on Freestanding Derivatives The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s OTC-bilateral derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of Dodd-Frank) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credi

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value	10. Fair Value When developing estimated fair values, the Company considers three broad valuation approaches: (i) the market approach, (ii) the income approach, and (iii) the cost approach. The Company determines the most appropriate valuation approach to use, given what is being measured and the availability of sufficient inputs, giving priority to observable inputs. The Company categorizes its assets and liabilities measured at estimated fair value into a three-level hierarchy, based on the significant input with the lowest level in its valuation. The input levels are as follows: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. The Company defines active markets based on average trading volume for equity securities. The size of the bid/ask spread is used as an indicator of market activity for fixed maturity securities AFS. Level 2 Quoted prices in markets that are not active or inputs that are observable either directly or indirectly. These inputs can include quoted prices for similar assets or liabilities other than quoted prices in Level 1, quoted prices in markets that are not active, or other significant inputs that are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and are significant to the determination of estimated fair value of the assets or liabilities. Unobservable inputs reflect the reporting entity’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. Financial markets are susceptible to severe events evidenced by rapid depreciation in asset values accompanied by a reduction in asset liquidity. The Company’s ability to sell securities, as well as the price ultimately realized for these securities, depends upon the demand and liquidity in the market and increases the use of judgment in determining the estimated fair value of certain securities. Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts. Recurring Fair Value Measurements The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: December 31, 2022 Fair Value Hierarchy Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 67,578 $ 12,452 $ 80,030 Foreign corporate — 40,623 11,949 52,572 Foreign government — 46,644 103 46,747 U.S. government and agency 15,955 16,274 — 32,229 RMBS 4 24,515 1,646 26,165 ABS & CLO — 14,895 1,927 16,822 Municipals — 12,152 — 12,152 CMBS — 9,367 696 10,063 Total fixed maturity securities AFS 15,959 232,048 28,773 276,780 Equity securities 1,293 132 259 1,684 Unit-linked and FVO Securities (1) 7,101 1,780 787 9,668 Short-term investments (2) 3,830 686 57 4,573 Residential mortgage loans — FVO — — — — Other investments — 206 926 1,132 Derivative assets: (3) Interest rate 2 4,570 — 4,572 Foreign currency exchange rate 8 5,670 210 5,888 Credit — 69 82 151 Equity market 8 785 7 800 Total derivative assets 18 11,094 299 11,411 Embedded derivatives within asset host contracts (4) — — 29 29 Separate account assets (5) 65,107 79,703 1,228 146,038 Total assets (6) $ 93,308 $ 325,649 $ 32,358 $ 451,315 Liabilities Derivative liabilities: (3) Interest rate $ 1 $ 3,153 $ 404 $ 3,558 Foreign currency exchange rate — 2,820 50 2,870 Credit — 92 15 107 Equity market 4 436 — 440 Total derivative liabilities 5 6,501 469 6,975 Embedded derivatives within liability host contracts (4) — — 578 578 Separate account liabilities (5) 8 15 18 41 Total liabilities $ 13 $ 6,516 $ 1,065 $ 7,594 December 31, 2021 (7) Fair Value Hierarchy Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 81,266 $ 11,768 $ 93,034 Foreign corporate — 49,973 13,667 63,640 Foreign government — 61,518 91 61,609 U.S. government and agency 25,482 21,117 — 46,599 RMBS 7 27,270 3,127 30,404 ABS & CLO — 16,707 1,862 18,569 Municipals — 14,212 — 14,212 CMBS — 11,325 882 12,207 Total fixed maturity securities AFS 25,489 283,388 31,397 340,274 Equity securities 931 187 151 1,269 Unit-linked and FVO Securities (1) 9,173 2,068 901 12,142 Short-term investments (2) 5,607 950 3 6,560 Residential mortgage loans — FVO — — 127 127 Other investments — 61 898 959 Derivative assets: (3) Interest rate 4 6,577 97 6,678 Foreign currency exchange rate — 2,551 3 2,554 Credit — 173 17 190 Equity market 12 1,025 7 1,044 Total derivative assets 16 10,326 124 10,466 Embedded derivatives within asset host contracts (4) — — 38 38 Separate account assets (5) 76,312 101,424 2,137 179,873 Total assets (6) $ 117,528 $ 398,404 $ 35,776 $ 551,708 Liabilities Derivative liabilities: (3) Interest rate $ — $ 259 $ 22 $ 281 Foreign currency exchange rate 2 2,676 242 2,920 Credit — 113 12 125 Equity market 5 521 — 526 Total derivative liabilities 7 3,569 276 3,852 Embedded derivatives within liability host contracts (4) — — 649 649 Separate account liabilities (5) 7 12 6 25 Total liabilities $ 14 $ 3,581 $ 931 $ 4,526 __________________ (1) Unit-linked and FVO Securities were primarily comprised of Unit-linked investments at both December 31, 2022 and 2021. (2) Short-term investments as presented in the tables above differ from the amounts presented on the consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis. (3) Derivative assets are presented within other invested assets on the consolidated balance sheets and derivative liabilities are presented within other liabilities on the consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (4) Embedded derivatives within asset host contracts are presented within premiums, reinsurance and other receivables on the consolidated balance sheets. Embedded derivatives within liability host contracts are presented within policyholder account balances and other liabilities on the consolidated balance sheets. (5) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (6) Total assets included in the fair value hierarchy exclude other limited partnership interests that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. At December 31, 2022 and 2021, the estimated fair value of such investments was $65 million and $99 million, respectively. The following describes the valuation methodologies used to measure assets and liabilities at fair value. Investments Securities, Short-term Investments and Other Investments When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings and valuation of these securities does not involve management’s judgment. When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based in large part on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments. The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein. The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g. cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs. Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Fixed maturity securities AFS U.S. corporate and Foreign corporate securities Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • illiquidity premium • benchmark yields; spreads off benchmark yields; new issuances; issuer ratings • delta spread adjustments to reflect specific credit-related issues • trades of identical or comparable securities; duration • credit spreads • privately-placed securities are valued using the additional key inputs: • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • market yield curve; call provisions • observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer • independent non-binding broker quotations • delta spread adjustments to reflect specific credit-related issues Foreign government securities, U.S. government and agency securities and Municipals Valuation Approaches: Principally the market approach. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • independent non-binding broker quotations • benchmark U.S. Treasury yield or other yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • the spread off the U.S. Treasury yield curve for the identical security • issuer ratings and issuer spreads; broker-dealer quotations • credit spreads • comparable securities that are actively traded Structured Products Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market and income approaches. Key Inputs: Key Inputs: • quoted prices in markets that are not active • credit spreads • spreads for actively traded securities; spreads off benchmark yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • expected prepayment speeds and volumes • current and forecasted loss severity; ratings; geographic region • independent non-binding broker quotations • weighted average coupon and weighted average maturity • credit ratings • average delinquency rates; DSCR • credit ratings • issuance-specific information, including, but not limited to: • collateral type; structure of the security; vintage of the loans • payment terms of the underlying assets • payment priority within the tranche; deal performance Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Equity securities Valuation Approaches: Principally the market approach. Valuation Approaches: Principally the market and income approaches. Key Input: Key Inputs: • quoted prices in markets that are not considered active • credit ratings; issuance structures • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • independent non-binding broker quotations Unit-linked and FVO Securities, Short-term investments and Other investments Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market and income approaches. Key Inputs: Key Inputs: • Unit-linked and FVO Securities include mutual fund interests without readily determinable fair values given prices are not published publicly. Valuation of these mutual funds is based upon quoted prices or reported NAV provided by the fund managers, which were based on observable inputs. • Unit-linked and FVO Securities, short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments also include certain real estate joint ventures and use the valuation approach and key inputs as described for other limited partnership interests below. • Short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and observable inputs used in their valuation are also similar to those described above. Residential mortgage loans — FVO • N/A Valuation Approaches: Principally the market approach. Valuation Techniques and Key Inputs: These investments are based primarily on matrix pricing or other similar techniques that utilize inputs from mortgage servicers that are unobservable or cannot be derived principally from, or corroborated by, observable market data. Separate account assets and Separate account liabilities (1) Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly Key Input: • N/A • quoted prices or reported NAV provided by the fund managers Other limited partnership interests • N/A Valued giving consideration to the underlying holdings of the partnerships and adjusting, if appropriate. Key Inputs: • liquidity; bid/ask spreads; performance record of the fund manager • other relevant variables that may impact the exit value of the particular partnership interest __________________ (1) Estimated fair value equals carrying value, based on the value of the underlying assets, including: mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, other limited partnership interests, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.” Derivatives The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models. The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. Certain OTC-bilateral and OTC-cleared derivatives may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives. Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income. The credit risk of both the counterparty and the Company are considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period. Freestanding Derivatives Level 2 Valuation Approaches and Key Inputs: This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3. Level 3 Valuation Approaches and Key Inputs: These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows: Instrument Interest Rate Foreign Currency Credit Equity Market Inputs common to Level 2 and Level 3 by instrument type • swap yield curves • swap yield curves • swap yield curves • swap yield curves • basis curves • basis curves • credit curves • spot equity index levels • interest rate volatility (1) • currency spot rates • recovery rates • dividend yield curves • cross currency basis curves • equity volatility (1) • currency volatility (1) Level 3 • swap yield curves (2) • swap yield curves (2) • swap yield curves (2) • dividend yield curves (2) • basis curves (2) • basis curves (2) • credit curves (2) • equity volatility (1), (2) • repurchase rates • cross currency basis curves (2) • credit spreads • correlation between model inputs (1) • interest rate volatility (1), (2) • currency correlation • repurchase rates • currency volatility (1) • independent non-binding broker quotations __________________ (1) Option-based only. (2) Extrapolation beyond the observable limits of the curve(s). Embedded Derivatives Embedded derivatives principally include certain direct, assumed and ceded variable annuity guarantees, equity-indexed annuity contracts, and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income. The Company issues certain variable annuity products with guaranteed minimum benefits. GMWBs, GMABs and certain GMIBs contain embedded derivatives, which are measured at estimated fair value separately from the host variable annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances on the consolidated balance sheets. The Company calculates the fair value of these embedded derivatives, which is estimated as the present value of projected future benefits minus the present value of projected future fees using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the embedded derivative over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. The valuation of these guarantee liabilities includes nonperformance risk adjustments and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions as annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions including, but not limited to, changes in interest rates, equity indices, market volatility and foreign currency exchange rates; changes in nonperformance risk; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, may result in significant fluctuations in the estimated fair value of the guarantees that could materially affect net income. The Company ceded the risk associated with certain of the GMIBs previously described. These reinsurance agreements contain embedded derivatives which are included within premiums, reinsurance and other receivables on the consolidated balance sheets with changes in estimated fair value reported in net derivative gains (losses) or policyholder benefits and claims depending on the statement of operations classification of the direct risk. The value of the embedded derivatives on the ceded risk is determined using a methodology consistent with that described previously for the guarantees directly written by the Company with the exception of the input for nonperformance risk that reflects the credit of the reinsurer. The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the funds withheld liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of these embedded derivatives is included, along with their funds withheld hosts, in other liabilities on the consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income. The Company issues certain annuity contracts which allow the policyholder to participate in returns from equity indices. These equity indexed features are embedded derivatives which are measured at estimated fair value separately from the host fixed annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances on the consolidated balance sheets. The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk. Embedded Derivatives Within Asset and Liability Host Contracts Level 3 Valuation Approaches and Key Inputs: Direct and assumed guaranteed minimum benefits These embedded derivatives are principally valued using the income approach. Valuations are based on option pricing techniques, which utilize significant inputs that may include swap yield curves, currency exchange rates and implied volatilities. These embedded derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Significant unobservable inputs generally include: the extrapolation beyond observable limits of the swap yield curves and implied volatilities, actuarial assumptions for policyholder behavior and mortality and the potential variability in policyholder behavior and mortality, nonperformance risk and cost of capital for purposes of calculating the risk margin. Reinsurance ceded on certain guaranteed minimum benefits These embedded derivatives are principally valued using the income approach. The valuation techniques and significant market standard unobservable inputs used in their valuation are similar to those described above in “— Direct and assumed guaranteed minimum benefits” and also include counterparty credit spreads. Transfers between Levels Overall, transfers between levels occur when there are changes in the observability of inputs and market activity. Transfers into or out of Level 3: Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable. Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: December 31, 2022 December 31, 2021 Impact of Valuation Techniques Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) — - 126 87 1 - 165 109 Increase • Market pricing • Quoted prices (4) 20 - 109 90 — - 117 100 Increase • Consensus pricing • Offered quotes (4) 5 - 99 93 99 - 104 100 Increase RMBS • Market pricing • Quoted prices (4) — - 106 93 — - 121 99 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 3 - 102 91 3 - 110 102 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) 372 - 392 381 151 - 200 188 Increase (7) • Volatility (8) —% - —% —% 1% - 1% 1% Increase (7) Foreign currency exchange rate • Present value techniques • Swap yield (6) 74 - 1,938 208 2 - 305 134 Increase (7) Credit • Present value techniques • Credit spreads (9) 84 - 138 101 96 - 133 109 Decrease (7) • Consensus pricing • Offered quotes (10) Embedded derivatives Direct, assumed and ceded guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0% - 0.17% 0.05% 0% - 0.17% 0.08% Decrease (11) Ages 41 - 60 0.03% - 0.75% 0.20% 0.03% - 0.75% 0.27% Decrease (11) Ages 61 - 115 0.12% - 100% 1.44% 0.12% - 100% 2.08% Decrease (11) • Lapse rates: Durations 1 - 10 0.40% - 37.50% 8.96% 0.25% - 100% 6.30% Decrease (12) Durations 11 - 20 0.50% - 35.75% 6.52% 0.50% - 100% 5.22% Decrease (12) Durations 21 - 116 0.50% - 35.75% 2.89% 0.50% - 100% 5.22% Decrease (12) • Utilization rates 0.20% - 22% 0.38% 0% - 22% 0.22% Increase (13) • Withdrawal rates 0% - 20% 4.02% 0% - 20% 3.72% (14) • Long-term equity volatilities 8.26% - 25% 18.49% 7.69% - 25% 18.60% Increase (15) • Nonperformance risk spread 0.09% - 1.77% 0.75% 0.04% - 1.45% 0.35% Decrease (16) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for embedded derivatives is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For embedded derivatives, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for

Leases Leases

Leases Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lessee, Operating Leases	11. Leases The Company, as lessee, has entered into various lease and sublease agreements primarily for office space. The Company has operating leases with remaining lease terms of less than one year to 12 years. The remaining lease terms for the subleases are less than one year to eight years. ROU Assets and Lease Liabilities ROU assets and lease liabilities for operating leases were: December 31, 2022 December 31, 2021 (In millions) ROU assets $ 961 $ 1,110 Lease liabilities $ 1,147 $ 1,295 Lease Costs The components of operating lease costs were as follows: Years Ended December 31, 2022 2021 2020 (In millions) Operating lease cost $ 246 $ 271 $ 286 Variable lease cost $ 45 $ 32 $ 39 Sublease income $ (103) $ (99) $ (99) Net lease cost $ 188 $ 204 $ 226 The Company recognized lease ROU asset impairment charges of $10 million, $29 million, and $0 for the years ended December 31, 2022, 2021 and 2020, respectively. Other Information Supplemental other information related to operating leases was as follows: December 31, 2022 December 31, 2021 (Dollars in millions) Cash paid for amounts included in the measurement of lease liability - operating cash flows $ 249 $ 273 ROU assets obtained in exchange for new lease liabilities $ 58 $ 63 Weighted-average remaining lease term 6 years 7 years Weighted-average discount rate 3.5 % 3.4 % Maturities of Lease Liabilities Maturities of operating lease liabilities were as follows: December 31, 2022 (In millions) 2023 $ 245 2024 216 2025 198 2026 183 2027 149 Thereafter 252 Total undiscounted cash flows 1,243 Less: interest 96 Present value of lease liability $ 1,147 See Notes 8 and 13 for information about the Company’s investments in leased real estate, leveraged and direct financing leases, and financing lease obligations.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	12. Goodwill Information regarding goodwill by segment, as well as Corporate & Other, was as follows: U.S. Asia (1) Latin EMEA MetLife Corporate Total (In millions) Balance at January 1, 2020 Goodwill $ 1,466 $ 4,636 $ 1,099 $ 1,117 $ 1,567 $ 103 $ 9,988 Accumulated impairment — — — — (680) — (680) Total goodwill, net 1,466 4,636 1,099 1,117 887 103 9,308 Acquisitions (2) 932 — — — — — 932 Effect of foreign currency translation and other — 127 44 29 — — 200 Reclassified to assets held-for-sale (3) (328) — — — — — (328) Balance at December 31, 2020 Goodwill 2,070 4,763 1,143 1,146 1,567 103 10,792 Accumulated impairment — — — — (680) — (680) Total goodwill, net 2,070 4,763 1,143 1,146 887 103 10,112 Effect of foreign currency translation and other — (211) (166) (200) — — (577) Balance at December 31, 2021 Goodwill 2,070 4,552 977 946 1,567 103 10,215 Accumulated impairment — — — — (680) — (680) Total goodwill, net 2,070 4,552 977 946 887 103 9,535 Acquisitions — — — — — 40 40 Effect of foreign currency translation and other — (243) 3 (38) — — (278) Balance at December 31, 2022 Goodwill 2,070 4,309 980 908 1,567 143 9,977 Accumulated impairment — — — — (680) — (680) Total goodwill, net $ 2,070 $ 4,309 $ 980 $ 908 $ 887 $ 143 $ 9,297 __________________ (1) Includes goodwill of $4.2 billion, $4.4 billion and $4.6 billion from the Company’s Japan operations at December 31, 2022, 2021 and 2020, respectively. (2) Primarily related to the acquisition of Versant Health. See Note 3. (3) See Note 3 for information on the disposition of MetLife P&C.

Long-term and Short-term Debt

Long-term and Short-term Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-term and Short-term Debt	13. Long-term and Short-term Debt Long-term and short-term debt outstanding was as follows: December 31, Interest Rates (1) 2022 2021 Range Weighted Maturity Face Unamortized Carrying Face Unamortized Carrying (In millions) Senior notes 0.50 % - 6.50% 4.42% 2023 - 2052 $ 13,671 $ (83) $ 13,588 $ 12,891 $ (77) $ 12,814 Surplus notes 7.63 % - 7.88% 7.79% 2024 - 2025 507 (1) 506 507 (2) 505 Other notes 0.45 % - 7.50% 4.67% 2023 - 2027 500 (3) 497 536 (3) 533 Financing lease obligations 56 — 56 81 — 81 Total long-term debt 14,734 (87) 14,647 14,015 (82) 13,933 Total short-term debt 175 — 175 341 — 341 Total $ 14,909 $ (87) $ 14,822 $ 14,356 $ (82) $ 14,274 __________________ (1) Range of interest rates and weighted average interest rates are for the year ended December 31, 2022. The aggregate maturities of long-term debt at December 31, 2022 for the next five years and thereafter are $1.1 billion in 2023, $1.7 billion in 2024, $1.2 billion in 2025, $539 million in 2026, $51 million in 2027 and $10.0 billion thereafter. Financing lease obligations are collateralized and rank highest in priority, followed by unsecured senior notes and other notes, followed by subordinated debt which consists of junior subordinated debt securities (see Note 15). Payments of interest and principal on the Company’s surplus notes, which are subordinate to all other obligations of the operating company issuing the notes and are senior to obligations of MetLife, Inc., may be made only with the prior approval of the insurance department of the state of domicile of the notes issuer. The Company’s collateral financing arrangement (see Note 14) is supported by surplus notes of a subsidiary and, accordingly, has priority consistent with surplus notes. Certain of the Company’s debt instruments and committed facilities, as well as its $3.0 billion unsecured revolving credit facility (the “Credit Facility”), contain various administrative, reporting, legal and financial covenants. The Company believes it was in compliance with all applicable financial covenants at December 31, 2022. Senior Notes In July 2022, MetLife, Inc. issued $1.0 billion of senior notes due July 2052 which bear interest at a fixed rate of 5.00%, payable semi-annually. In connection with the issuance, MetLife, Inc. incurred $11 million of related costs which will be amortized over the term of the senior notes. In July 2021, MetLife, Inc. redeemed for cash and canceled $500 million aggregate principal amount of its outstanding 3.048% senior notes due December 2022. The Company recorded a premium of $17 million paid in excess of the debt principal and accrued and unpaid interest to other expenses for the year ended December 31, 2021. In March 2020, MetLife, Inc. issued $1.0 billion of senior notes due March 2030 which bear interest at a fixed rate of 4.550%, the interest on which is payable semi-annually. In connection with the issuance, MetLife, Inc. incurred $6 million of related costs which will be amortized over the term of the senior notes. See Note 22 for information on MetLife, Inc.’s senior notes issuance and senior notes redemption subsequent to December 31, 2022. Other Notes At December 31, 2022, MetLife Private Equity Holdings, LLC (“MPEH”), a wholly-owned indirect investment subsidiary of MLIC, was party to a credit agreement providing for $350 million of term loans and $75 million of a revolving loan (the “Credit Agreement”), which matures in September 2026. In March 2020, MPEH borrowed $75 million on a revolving loan under the Credit Agreement and repaid this loan in July 2020. Simultaneously, in July 2020, MPEH borrowed $50 million on the term loan under the Credit Agreement. MPEH has pledged invested assets to secure the loans; however, these loans are non-recourse to MLIC and MetLife, Inc. Short-term Debt Short-term debt with maturities of one year or less was as follows: December 31, 2022 2021 (Dollars in millions) Commercial paper $ 99 $ 100 Short-term borrowings (1) 76 241 Total short-term debt $ 175 $ 341 Average daily balance $ 237 $ 300 Average days outstanding 157 days 155 days __________________ (1) Includes $76 million and $241 million at December 31, 2022 and 2021, respectively, of short-term debt related to repurchase agreements, secured by assets of subsidiaries. For the years ended December 31, 2022, 2021 and 2020, the weighted average interest rate on short-term debt was 5.23%, 1.41% and 2.01%, respectively. Interest Expense Interest expense included in other expenses was $655 million, $647 million and $632 million for the years ended December 31, 2022, 2021 and 2020, respectively. Such amounts do not include interest expense on long-term debt related to the collateral financing arrangement or junior subordinated debt securities. See Notes 14 and 15. Credit and Committed Facilities At December 31, 2022, the Company maintained the Credit Facility, as well as certain committed facilities aggregating $3.2 billion (the “Committed Facilities”). When drawn upon, these facilities bear interest at varying rates in accordance with the respective agreements. Credit Facility The Company’s Credit Facility is used for general corporate purposes, to support the borrowers’ commercial paper programs and for the issuance of letters of credit. Total fees associated with the Credit Facility were $8 million, $10 million and $14 million for the years ended December 31, 2022, 2021 and 2020, respectively, and were included in other expenses. Information on the Credit Facility at December 31, 2022 was as follows: Borrower(s) Expiration Maximum Letters of Drawdowns Unused (In millions) MetLife, Inc. and MetLife Funding, Inc. February 2026 (1) $ 3,000 $ 263 $ — $ 2,737 __________________ (1) All borrowings under the Credit Facility must be repaid by February 26, 2026, except that letters of credit outstanding upon termination may remain outstanding until February 26, 2027. Committed Facilities Letters of credit issued under the Committed Facilities are used for collateral for certain of the Company’s affiliated reinsurance liabilities. Total fees associated with the Committed Facilities, included in other expenses, were $9 million, $12 million and $12 million for the years ended December 31, 2022, 2021 and 2020, respectively. Information on the Committed Facilities at December 31, 2022 was as follows: Account Party/Borrower(s) Expiration Maximum Letters of Drawdowns Unused (In millions) MetLife Reinsurance Company of Vermont and MetLife, Inc. November 2026 (1), (2) $ 350 $ 350 $ — $ — MetLife Reinsurance Company of Vermont and MetLife, Inc. December 2037 (1), (3) 2,896 2,487 — 409 Total $ 3,246 $ 2,837 $ — $ 409 __________________ (1) MetLife, Inc. is a guarantor under the applicable facility. (2) The issuance of additional letters of credit is at the discretion of the counterparty. (3) Capacity at December 31, 2022 of $2.8 billion increases periodically to a maximum of $2.9 billion in 2024, decreases periodically commencing in 2025 to $2.0 billion in 2037, and decreases to $0 at expiration in December 2037. Unused commitment of $409 million is based on maximum capacity. At December 31, 2022, Brighthouse Financial, Inc. and its subsidiaries (“Brighthouse”), a former subsidiary of MetLife, Inc., is a beneficiary of $2.5 billion of letters of credit issued under this facility and, in consideration, Brighthouse reimburses MetLife, Inc. for a portion of the letter of credit fees. In addition to the Committed Facilities, see also “— Other Notes” for information on the Credit Agreement.

Collateral Financing Arrangemen

Collateral Financing Arrangements	12 Months Ended
	Dec. 31, 2022
Secured Debt [Abstract]
Collateral Financing Arrangements	14. Collateral Financing Arrangement Information related to the collateral financing arrangement associated with the closed block (See Note 7) was as follows at: December 31, 2022 2021 (In millions) Surplus notes outstanding (1) $ 716 $ 766 Receivable from unaffiliated financial institution (1) $ 93 $ 100 Pledged collateral (2) $ 43 $ 38 Assets held in trust (2) $ 1,369 $ 1,388 __________________ (1) Carrying value. (2) Estimated fair value. Interest expense on the collateral financing arrangement was $22 million, $11 million and $20 million for the years ended December 31, 2022, 2021 and 2020, respectively, which is included in other expenses. In December 2007, MLIC reinsured a portion of its closed block liabilities to MetLife Reinsurance Company of Charleston (“MRC”), a wholly-owned subsidiary of MetLife, Inc. In connection with this transaction, MRC issued, to investors placed by an unaffiliated financial institution, $2.5 billion in aggregate principal amount of 35-year surplus notes to provide statutory reserve support for the assumed closed block liabilities. Interest on the surplus notes accrues at an annual rate of three-month LIBOR plus 0.55%, payable quarterly. The ability of MRC to make interest and principal payments on the surplus notes is contingent upon South Carolina regulatory approval. Simultaneously with the issuance of the surplus notes, MetLife, Inc. entered into an agreement with the unaffiliated financial institution, under which MetLife, Inc. is entitled to the interest paid by MRC on the surplus notes of three-month LIBOR plus 0.55% in exchange for the payment of three-month LIBOR plus 1.12%, payable quarterly on such amount as adjusted, as described below. MetLife, Inc. may also be required to pledge collateral or make payments to the unaffiliated financial institution related to any decline in the estimated fair value of the surplus notes. Any such payments are accounted for as a receivable and included in other assets on the Company’s consolidated balance sheets and do not reduce the principal amount outstanding of the surplus notes. Such payments, however, reduce the amount of interest payments due from MetLife, Inc. under the agreement. Any payment received from the unaffiliated financial institution reduces the receivable by an amount equal to such payment and also increases the amount of interest payments due from MetLife, Inc. under the agreement. In addition, the unaffiliated financial institution may be required to pledge collateral to MetLife, Inc. related to any increase in the estimated fair value of the surplus notes. For the years ended December 31, 2022, 2021 and 2020, following regulatory approval, MRC repurchased $50 million, $79 million and $148 million, respectively, in aggregate principal amount of the surplus notes. Payments made by the Company in 2022, 2021 and 2020 associated with the repurchases were exclusive of accrued interest on the surplus notes. In connection with the repurchases for the years ended December 31, 2022, 2021 and 2020, the Company received payments in the aggregate amount of $7 million, $10 million and $20 million, respectively, from the unaffiliated financial institution, which reduced the amount receivable from the unaffiliated financial institution by the same amounts. No other payments related to an increase or decrease in the estimated fair value of the surplus notes were made by MetLife, Inc. or received from the unaffiliated financial institution for the years ended December 31, 2022, 2021 or 2020. A majority of the proceeds from the offering of the surplus notes was placed in a trust, which is consolidated by the Company, to support MRC’s statutory obligations associated with the assumed closed block liabilities. For the years ended December 31, 2022 and 2021, MRC transferred $119 million and $78 million, respectively, to the trust out of its general account. For the year ended December 31, 2020, MRC transferred $78 million out of the trust to its general account. The assets are principally invested in fixed maturity securities AFS and are presented as such within the Company’s consolidated balance sheets, with the related income included within net investment income on the Company’s consolidated statements of operations.

Junior Subordinated Debt Securi

Junior Subordinated Debt Securities	12 Months Ended
	Dec. 31, 2022
Junior Subordinated Notes [Abstract]
Junior Subordinated Debt Securities	15. Junior Subordinated Debt Securities Outstanding Junior Subordinated Debt Securities Outstanding junior subordinated debt securities and exchangeable surplus trust securities which are exchangeable for junior subordinated debt securities prior to redemption or repayment, were as follows: December 31, 2022 2021 Issuer Issue Interest Scheduled Interest Rate Final Face Unamortized Carrying Face Unamortized Carrying (In millions) MetLife, Inc. December 2006 6.400% December 2036 LIBOR + 2.205% December 2066 $ 1,250 $ (15) $ 1,235 $ 1,250 $ (16) $ 1,234 MetLife Capital Trust IV (3) December 2007 7.875% December 2037 LIBOR + 3.960% December 2067 700 (13) 687 700 (13) 687 MetLife, Inc. April 2008 9.250% April 2038 LIBOR + 5.540% April 2068 750 (9) 741 750 (9) 741 MetLife, Inc. July 2009 10.750% August 2039 LIBOR + 7.548% August 2069 500 (5) 495 500 (6) 494 Total $ 3,200 $ (42) $ 3,158 $ 3,200 $ (44) $ 3,156 _________________ (1) Prior to the scheduled redemption date, interest is payable semiannually in arrears. (2) In the event the securities are not redeemed on or before the scheduled redemption date, interest will accrue after such date at an annual rate of three-month LIBOR plus the indicated margin, payable quarterly in arrears. On March 5, 2021, the Intercontinental Exchange Benchmark Administration, the administrator of LIBOR, announced that it will cease the publication of three-month U.S. Dollar LIBOR at the end of June 2023. Existing contract fallback provisions, and whether, how, and when the Company develops and adopts alternative reference rates, will influence the effect of any changes to or discontinuation of LIBOR on the Company. (3) MetLife Capital Trust IV is a VIE which is consolidated on the financial statements of the Company. The securities issued by this entity are exchangeable surplus trust securities, which are exchangeable for a like amount of MetLife, Inc.’s junior subordinated debt securities on the scheduled redemption date, mandatorily under certain circumstances, and at any time upon MetLife, Inc. exercising its option to redeem the securities. In connection with each of the securities described above, MetLife, Inc. may redeem or may cause the redemption of the securities (i) in whole or in part, at any time on or after the date five years prior to the scheduled redemption date at their principal amount plus accrued and unpaid interest to, but excluding, the date of redemption, or (ii) in certain circumstances, in whole or in part, prior to the date five years prior to the scheduled redemption date at their principal amount plus accrued and unpaid interest to, but excluding, the date of redemption or, if greater, a make-whole price. MetLife, Inc. also has the right to, and in certain circumstances the requirement to, defer interest payments on the securities for a period up to 10 years. Interest compounds during such periods of deferral. If interest is deferred for more than five consecutive years, MetLife, Inc. is required to use proceeds from the sale of its common stock or warrants on common stock to satisfy this interest payment obligation. In connection with each of the securities described above, MetLife, Inc. entered into a separate replacement capital covenant (“RCC”). As part of each RCC, MetLife, Inc. agreed that it will not repay, redeem, or purchase the securities on or before a date 10 years prior to the final maturity date of each issuance, unless, subject to certain limitations, it has received cash proceeds during a specified period from the sale of specified replacement securities. Each RCC will terminate upon the occurrence of certain events, including an acceleration of the applicable securities due to the occurrence of an event of default. The RCCs are not intended for the benefit of holders of the securities and may not be enforced by them. Rather, each RCC is for the benefit of the holders of a designated series of MetLife, Inc.’s other indebtedness (the “Covered Debt”). Initially, the Covered Debt for each of the securities described above was MetLife, Inc.’s 5.700% senior notes due 2035 (the “5.700% Senior Notes”). As a result of the issuance of MetLife, Inc.’s 10.750% Fixed-to-Floating Rate Junior Subordinated Debentures due 2069 (the “10.750% JSDs”), the 10.750% JSDs became the Covered Debt with respect to, and in accordance with, the terms of the RCC relating to MetLife, Inc.’s 6.40% Fixed-to-Floating Rate Junior Subordinated Debentures due 2066. The 5.700% Senior Notes continue to be the Covered Debt with respect to, and in accordance with, the terms of the RCCs relating to each of MetLife Capital Trust IV’s 7.875% Fixed-to-Floating Rate Exchangeable Surplus Trust Securities, MetLife, Inc.’s 9.250% Fixed-to-Floating Rate Junior Subordinated Debentures and the 10.750% JSDs. MetLife, Inc. also entered into a replacement capital obligation which will commence during the six-month period prior to the scheduled redemption date of each of the securities described above and under which MetLife, Inc. must use reasonable commercial efforts to raise replacement capital to permit repayment of the securities through the issuance of certain qualifying capital securities. Interest expense on outstanding junior subordinated debt securities was $261 million for each of the years ended December 31, 2022, 2021 and 2020, which is included in other expenses.

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Equity	16. Equity Preferred Stock Preferred stock authorized, issued and outstanding was as follows at both December 31, 2022 and 2021: Series Shares Authorized Shares Issued and Outstanding Series A preferred stock 27,600,000 24,000,000 Series D preferred stock 500,000 500,000 Series E preferred stock 32,200 32,200 Series F preferred stock 40,000 40,000 Series G preferred stock 1,000,000 1,000,000 Series A Junior Participating Preferred Stock 10,000,000 — Not designated 160,827,800 — Total 200,000,000 25,572,200 In May 2021, MetLife, Inc. delivered a notice of redemption to the holders of MetLife, Inc.’s 5.25% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series C (the “Series C preferred stock”) pursuant to which it would redeem the remaining 500,000 shares of Series C preferred stock at a redemption price of $1,000 per share. In connection with the redemption, MetLife, Inc. recognized a preferred stock redemption premium of $6 million (calculated as the difference between the carrying value of the Series C preferred stock and the total amount paid by MetLife, Inc. to the holders of the Series C preferred stock in connection with the redemption), which was recorded as a reduction of retained earnings at June 30, 2021. All outstanding shares of Series C preferred stock were redeemed on the dividend payment date of June 15, 2021 for an aggregate redemption price of $500 million in cash. In June 2021, MetLife, Inc. filed a Certificate of Elimination (the “Certificate of Elimination”) of Series C preferred stock with the Secretary of State of the State of Delaware to eliminate all references to the Series C preferred stock in MetLife, Inc.’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), including the related Certificate of Designations. As a result of the filing of the Certificate of Elimination, MetLife, Inc.’s Certificate of Incorporation was amended to eliminate all references therein to the Series C preferred stock, and the shares that were designated to such series were returned to the status of authorized but unissued shares of preferred stock, par value $0.01 per share, of MetLife, Inc., without designation as to series. The Certificate of Elimination does not affect the total number of authorized shares of capital stock of MetLife, Inc. or the total number of authorized shares of preferred stock. In September 2020, MetLife, Inc. delivered a notice of partial redemption to the holders of the Series C preferred stock pursuant to which it would redeem 1,000,000 of its 1,500,000 shares of Series C preferred stock at a redemption price of $1,000 per share, plus an amount equal to accrued but unpaid dividends on the Series C preferred stock to, but excluding, October 10, 2020, the redemption date. In connection with the redemption, MetLife, Inc. recognized a preferred stock redemption premium of $14 million (calculated as the difference between the carrying value of the Series C preferred stock and the total amount paid by MetLife, Inc. to the holders of the Series C preferred stock in connection with the redemption). In October 2020, MetLife, Inc. redeemed and canceled 1,000,000 shares of Series C preferred stock for an aggregate redemption price of $1.0 billion in cash. In September 2020, MetLife, Inc. issued 1,000,000 shares of 3.85% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G (the “Series G preferred stock”) with a $0.01 par value per share and a liquidation preference of $1,000 per share, for aggregate net proceeds of $989 million. In connection with the offering of the Series G preferred stock, MetLife, Inc. incurred approximately $11 million of issuance costs which have been recorded as a reduction of additional paid-in capital. In January 2020, MetLife, Inc. issued 40,000 shares of 4.75% Non-Cumulative Preferred Stock, Series F (the “Series F preferred stock”) with a $0.01 par value per share and a liquidation preference of $25,000 per share, for aggregate net proceeds of $972 million. MetLife, Inc. deposited the Series F preferred stock under a deposit agreement with a depositary, which issued interests in fractional shares of the Series F preferred stock in the form of depositary shares (“Series F Depositary Shares”) evidenced by depositary receipts; each Series F Depositary Share representing 1/1,000th interest in a share of the Series F preferred stock. In connection with the offering of the Series F Depositary Shares, MetLife, Inc. incurred approximately $28 million of issuance costs which have been recorded as a reduction of additional paid-in capital. The outstanding preferred stock ranks senior to MetLife, Inc.’s common stock with respect to the payment of dividends and distributions upon liquidation, dissolution or winding-up. Holders of the outstanding preferred stock are entitled to receive dividend payments only when, as and if declared by MetLife, Inc.’s Board of Directors or a duly authorized committee thereof. Dividends on the preferred stock are not cumulative or mandatory. Accordingly, if dividends are not declared on the preferred stock of the applicable series for any dividend period, then any accrued dividends for that dividend period will cease to accrue and be payable. If a dividend is not declared before the dividend payment date for any such dividend period, MetLife, Inc. will have no obligation to pay dividends accrued for such dividend period whether or not dividends are declared for any future period. No dividends may be paid or declared on MetLife, Inc.’s common stock (or any other securities ranking junior to the preferred stock) and MetLife, Inc. may not purchase, redeem, or otherwise acquire its common stock (or other such junior stock) unless the full dividends for the latest completed dividend period on all outstanding shares of preferred stock, and any parity stock, have been declared and paid or provided for. The table below presents the dividend rates of MetLife, Inc.’s preferred stock outstanding at December 31, 2022: Series Per Annum Dividend Rate A Three-month LIBOR + 1.00%, with floor of 4.00%, payable quarterly in March, June, September and December D 5.875% from issuance date to, but excluding, March 15, 2028, payable semiannually in March and September; three-month LIBOR + 2.959% payable quarterly in March, June, September and December, thereafter E 5.625% from issuance date, payable quarterly in March, June, September and December F 4.750% from issuance date, payable quarterly in March, June, September and December, commencing in June 2020 G 3.850% from issuance date, but excluding, September 15, 2025, payable semiannually in March and September commencing in March 2021; five year treasury rate, reset every five years, + 3.576% payable semiannually in March and September, thereafter In the table above, dividends on each series of preferred stock are payable in arrears for the periods specified, if declared. MetLife, Inc. is prohibited from declaring dividends on the Floating Rate Non-Cumulative Preferred Stock, Series A (the “Series A preferred stock”) if it fails to meet specified capital adequacy, net income and stockholders’ equity levels. See “— Dividend Restrictions — MetLife, Inc.” Holders of the preferred stock do not have voting rights except in certain circumstances, including where the dividends have not been paid for a specified number of dividend payment periods whether or not those periods are consecutive. Under such circumstances, the holders of the preferred stock have certain voting rights with respect to members of the Board of Directors of MetLife, Inc. The preferred stock is not subject to any mandatory redemption, sinking fund, retirement fund, purchase fund or similar provisions. The Series A preferred stock is redeemable at MetLife, Inc.’s option in whole or in part, at a redemption price of $25 per share of Series A preferred stock, plus declared and unpaid dividends. MetLife, Inc. may, at its option, redeem the 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D (the “Series D preferred stock”), (i) in whole but not in part at any time prior to March 15, 2028, within 90 days after the occurrence of a “rating agency event,” at a redemption price equal to $1,020 per share of Series D preferred stock, plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date; (ii) in whole but not in part, at any time prior to March 15, 2028, within 90 days after the occurrence of a “regulatory capital event;” and (iii) in whole or in part, at any time or from time to time, on or after March 15, 2028, in the case of (ii) or (iii), at a redemption price equal to $1,000 per share of Series D preferred stock, plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date. MetLife, Inc. may, at its option, redeem the 5.625% Non-Cumulative Preferred Stock, Series E (the “Series E preferred stock”), (i) in whole but not in part at any time prior to June 15, 2023, within 90 days after the occurrence of a “rating agency event,” at a redemption price equal to $25,500 per share of Series E preferred stock (equivalent to $25.50 per depositary share, each Series E depositary share representing a 1/1,000th interest in a share of the Series E preferred stock (“Series E Depositary Share”)), plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date; (ii) in whole but not in part, at any time prior to June 15, 2023, within 90 days after the occurrence of a “regulatory capital event;” and (iii) in whole or in part, at any time or from time to time, on or after June 15, 2023, in the case of (ii) or (iii), at a redemption price equal to $25,000 per share of Series E preferred stock (equivalent to $25 per Series E Depositary Share), plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date. MetLife, Inc. may, at its option, redeem the Series F preferred stock, (i) in whole but not in part at any time prior to March 15, 2025, within 90 days after the occurrence of a “rating agency event,” at a redemption price equal to $25,500 per share of Series F preferred stock (equivalent to $25.50 per Series F Depositary Share), plus an amount equal to any accrued and unpaid dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, the redemption date, (ii) in whole but not in part, at any time prior to March 15, 2025, within 90 days after the occurrence of a “regulatory capital event;” and (iii) in whole or in part, at any time or from time to time, on or after March 15, 2025, in the case of (ii) or (iii), at a redemption price equal to $25,000 per share of Series F preferred stock (equivalent to $25 per Series F Depositary Share), plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date. MetLife, Inc. may, at its option, redeem the Series G preferred stock, (a) in whole but not in part, at any time, within 90 days after the conclusion of any review or appeal process instituted by the Company following the occurrence of a “rating agency event” or, in the absence of any such review or appeal process, from such “rating agency event,” at a redemption price equal to $1,020 per share of Series G preferred stock, plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date and (b)(i) in whole but not in part, at any time, within 90 days after the occurrence of a “regulatory capital event,” or (ii) in whole or in part, on any dividend payment date, on or after September 15, 2025, in each case, at a redemption price equal to $1,000 per share of Series G preferred stock, plus an amount equal to any dividends per share that have accrued but have not been declared and paid for the then-current dividend period to, but excluding, such redemption date. A “rating agency event” means that any nationally recognized statistical rating organization that then publishes a rating for MetLife, Inc. amends, clarifies or changes the criteria used to assign equity credit to securities like the Series D preferred stock, Series E preferred stock, Series F preferred stock or Series G preferred stock, which results in the lowering of the equity credit assigned to the security, or shortens the length of time that the security is assigned a particular level of equity credit. A “regulatory capital event” could occur as a result of a change or proposed change in laws, rules, regulations or regulatory standards, including capital adequacy rules (or the interpretation or application thereof) of the United States or any political subdivision thereof, including any capital regulator, including but not limited to the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), the Federal Insurance Office, the National Association of Insurance Commissioners (“NAIC”) or any state insurance regulator as may then have group-wide oversight of MetLife, Inc.’s regulatory capital, from those laws, rules, regulations or regulatory standards (or the interpretation or application thereof) in effect as of March 22, 2018, in the case of the Series D preferred stock, June 4, 2018, in the case of the Series E preferred stock, January 15, 2020, in the case of the Series F preferred stock, or September 10, 2020, in the case of the Series G preferred stock, that would create a more than insubstantial risk, as determined by MetLife, Inc., that the security would not be treated as “Tier 1 capital” or as capital with attributes similar to those of Tier 1 capital, except that a “regulatory capital event” will not include a change or proposed change (or the interpretation or application thereof) that would result in the adoption of any criteria substantially the same as the criteria in the capital adequacy rules of the Federal Reserve Board applicable to bank holding companies as of March 22, 2018, in the case of the Series D preferred stock, June 4, 2018, in the case of the Series E preferred stock, January 15, 2020, in the case of the Series F preferred stock, or September 10, 2020, in the case of the Series G preferred stock. The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows: Years Ended December 31, 2022 2021 2020 Series Per Share Aggregate Per Share Aggregate Per Share Aggregate (In millions, except per share data) A $ 1.033 $ 24 $ 1.015 $ 24 $ 1.015 $ 24 C (1) $ — — $ 19.085 10 $ 45.860 59 D $ 58.750 29 $ 58.750 29 $ 58.750 30 E $ 1,406.252 45 $ 1,406.252 45 $ 1,406.252 45 F $ 1,187.500 48 $ 1,187.500 48 $ 1,088.542 44 G $ 38.500 39 $ 39.035 39 $ — — Total $ 185 $ 195 $ 202 __________________ (1) Dividends were paid through the dividend payment date of June 15, 2021, when all outstanding shares of Series C preferred stock were redeemed and eliminated. Common Stock Issuances For the years ended December 31, 2022, 2021 and 2020, MetLife, Inc. issued 3,290,998 shares, 4,926,185 shares and 3,933,989 shares of its common stock for $156 million, $195 million and $153 million, respectively, in connection with stock option exercises and other stock-based awards. There were no shares of common stock issued from treasury stock for any of the years ended December 31, 2022, 2021 or 2020. Repurchase Authorizations MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows: Authorization Remaining at Announcement Date Authorization Amount December 31, 2022 (In millions) May 4, 2022 $ 3,000 $ 1,205 August 4, 2021 $ 3,000 $ — December 11, 2020 $ 3,000 $ — Under these authorizations, MetLife, Inc. may purchase its common stock from the MetLife Policyholder Trust, in the open market (including pursuant to the terms of a pre-set trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934), and in privately negotiated transactions. Common stock repurchases are subject to the discretion of MetLife, Inc.’s Board of Directors and will depend upon the Company’s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value, applicable regulatory approvals, and other legal and accounting factors. For the years ended December 31, 2022, 2021 and 2020, MetLife, Inc. repurchased 49,732,851 shares, 72,296,518 shares and 26,361,487 shares under these repurchase authorizations for $3.3 billion, $4.3 billion, and $1.2 billion, respectively. At December 31, 2021, $25 million of the aforementioned 2021 share repurchases were included in other liabilities, and settled in 2022. At December 31, 2022, MetLife, Inc. had $1.2 billion remaining under its May 2022 common stock repurchase authorization. Dividends For the years ended December 31, 2022, 2021 and 2020, MetLife, Inc. paid dividends on its common stock of $1.6 billion, $1.6 billion and $1.7 billion, respectively. The payment of dividends by MetLife, Inc. to its shareholders is subject to restrictions. See “— Dividend Restrictions — MetLife, Inc.” The funding of the cash dividends and operating expenses of MetLife, Inc. is primarily provided by cash dividends from MetLife, Inc.’s insurance subsidiaries. The statutory capital and surplus, or net assets, of MetLife, Inc.’s insurance subsidiaries are subject to regulatory restrictions except to the extent that dividends are allowed to be paid in a given year without prior regulatory approval. Dividends exceeding these limitations can generally be made subject to regulatory approval. The nature and amount of these dividend restrictions, as well as the statutory capital and surplus of MetLife, Inc.’s U.S. insurance subsidiaries, are disclosed in “— Statutory Equity and Income” and “— Dividend Restrictions — Insurance Operations.” MetLife, Inc.’s principal non-U.S. insurance operations are branches or subsidiaries of American Life Insurance Company (“American Life”), a U.S. insurance subsidiary of the Company. Stock-Based Compensation Plans Plans for Employees and Agents Under the MetLife, Inc. 2015 Stock and Incentive Compensation Plan (the “2015 Stock Plan”), MetLife, Inc. may grant awards to employees and agents in the form of Stock Options, Stock Appreciation Rights, Performance Shares or Performance Share Units, Restricted Stock or Restricted Stock Units, Cash-Based Awards and Stock-Based Awards (each, as applicable, as defined in the 2015 Stock Plan with reference to shares of MetLife, Inc. common stock (“Shares”)). Awards under the 2015 Stock Plan and its predecessor plan, the MetLife, Inc. 2005 Stock and Incentive Compensation Plan (the “2005 Stock Plan”), were outstanding at December 31, 2022. MetLife, Inc. granted all awards to employees and agents in 2022 under the 2015 Stock Plan. The aggregate number of Shares authorized for issuance under the 2015 Stock Plan at December 31, 2022 was 31,886,521. MetLife recognizes compensation expense related to each award under the 2005 Stock Plan or 2015 Stock Plan in one of two ways: • For cash-settled awards and the Performance Shares granted in 2018, MetLife remeasures the compensation expense quarterly. • For other awards, MetLife recognizes an expense based on the number of awards it expects to vest, which represents the awards granted less expected forfeitures over the life of the award, as estimated at the date of grant. Unless MetLife observes a material deviation from the assumed forfeiture rate during the term in which the awards are expensed, MetLife recognizes any adjustment necessary to reflect differences in actual experience in the period the award becomes payable or exercisable. Compensation expense related to awards under the 2005 Stock Plan principally relates to the issuance of Stock Options. Under the 2015 Stock Plan, compensation expense principally relates to Stock Options, Unit Options, Performance Shares, Performance Units, Restricted Stock Units and Restricted Units. MetLife, Inc. granted the majority of each year’s awards under the 2005 Stock Plan and 2015 Stock Plan in the first quarter of the year. Awards that have become payable in Shares but the issuance of which has been deferred (“Deferred Shares”), payable to employees or agents related to awards under all plans equaled 686,770 Shares at December 31, 2022. MetLife granted cash-settled awards based in whole or in part on the price of Shares or changes in the price of Shares (“Phantom Stock-Based Awards”) under the MetLife, Inc. International Unit Option Incentive Plan, the MetLife International Performance Unit Incentive Plan, and the MetLife International Restricted Unit Incentive Plan prior to 2015, and under the 2015 Stock Plan in 2015 and later. Plans for Non-Management Directors Under the MetLife, Inc. 2015 Non-Management Director Stock Compensation Plan (the “2015 Director Stock Plan”), MetLife, Inc. may grant non-management Directors of MetLife, Inc. awards in the form of nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock or Restricted Stock Units, or Stock-Based Awards (each, as applicable, as defined in the 2015 Director Stock Plan with reference to Shares). The only awards MetLife, Inc. granted under the 2015 Director Stock Plan and its predecessor plan, the MetLife, Inc. 2005 Non-Management Director Stock Compensation Plan (the “2005 Director Stock Plan”), through December 31, 2022 were Stock-Based Awards that vested immediately. As a result, no awards under the 2005 Director Stock Plan or 2015 Director Stock Plan remained outstanding at December 31, 2022. The aggregate number of Shares authorized for issuance under the 2015 Director Stock Plan at December 31, 2022 was 1,469,329. MetLife recognizes compensation expense related to awards under the 2015 Director Stock Plan based on the number of Shares awarded. Deferred Shares payable to Directors related to awards under the 2005 Director Stock Plan, 2015 Director Stock Plan, or earlier applicable plans equaled 323,898 Shares at December 31, 2022. Compensation Expense Related to Stock-Based Compensation The components of compensation expense related to stock-based compensation includes compensation expense related to Phantom Stock-Based Awards and excludes the insignificant compensation expense related to the 2015 Director Stock Plan. Those components were: Years Ended December 31, 2022 2021 2020 (In millions) Stock Options and Unit Options $ 7 $ 9 $ 6 Performance Shares and Performance Units (1) 108 98 63 Restricted Stock Units and Restricted Units 69 66 58 Total compensation expense $ 184 $ 173 $ 127 Income tax benefit $ 39 $ 36 $ 27 __________________ (1) The Company may further adjust the number of Performance Shares and Performance Units it expects to vest, and the related compensation expense, if management changes its estimate of the most likely final performance factor. The following table presents the total unrecognized compensation expense related to stock-based compensation and the expected weighted average period over which these expenses will be recognized at: December 31, 2022 Expense Weighted Average (In millions) (Years) Stock Options $ 3 1.78 Performance Shares $ 29 1.68 Restricted Stock Units $ 32 1.83 Equity Awards Stock Options Stock Options are the contingent right of award holders to purchase Shares at a stated price for a limited time. All Stock Options have an exercise price equal to the closing price of a Share reported on the New York Stock Exchange (“NYSE”) on the date of grant and have a maximum term of 10 years. The majority of Stock Options that MetLife, Inc. has granted have become or will become exercisable at a rate of one-third of each award on each of the first three Stock Option Activity A summary of the activity related to Stock Options was as follows: Shares Weighted Weighted Aggregate (Years) (In millions) Outstanding at January 1, 2022 4,268,091 $ 44.02 5.03 $ 79 Granted 402,976 $ 68.96 Exercised (1,259,933) $ 37.79 Expired (2) (6,424) $ 33.35 Forfeited (3) (18,669) $ 60.07 Outstanding at December 31, 2022 3,386,041 $ 49.24 5.58 $ 78 Vested and expected to vest at December 31, 2022 3,376,464 $ 49.20 5.57 $ 78 Exercisable at December 31, 2022 2,533,864 $ 45.25 4.61 $ 69 __________________ (1) The intrinsic value of each Stock Option is the closing price on a particular date less the exercise price of the Stock Option, so long as the difference is greater than zero. The aggregate intrinsic value of all outstanding Stock Options is computed using the closing Share price on December 31, 2022 of $72.37 and December 31, 2021 of $62.49, as applicable. (2) Expired options were exercisable, but unexercised, as of their expiration date. (3) Forfeited awards were either (a) unvested or unexercisable at the end of the awardholder’s employment, where the awardholder did not meet the criteria for post-employment award continuation; or (b) held by awardholders the Company terminated from employment for cause as defined in the terms of the awards. MetLife estimates the fair value of Stock Options on the date of grant using a binomial lattice model. The significant assumptions the Company uses in its binomial lattice model include: expected volatility of the price of Shares; risk-free rate of return; dividend yield on Shares; exercise multiple; and the post-vesting termination rate. MetLife bases expected volatility on an analysis of historical prices of Shares and call options on Shares traded on the open market. The Company uses a weighted-average of the implied volatility for publicly-traded call options with the longest remaining maturity nearest to the money as of each valuation date and the historical volatility, calculated using monthly closing prices of Shares. The Company chose a monthly measurement interval for historical volatility as this interval reflects the Company’s view that employee option exercise decisions are based on longer-term trends in the price of the underlying Shares rather than on daily price movements. The Company’s binomial lattice model incorporates different risk-free rates based on the imputed forward rates for U.S. Treasury Strips for each year over the contractual term of the option. The table below presents the full range of rates that were used for options granted during the respective periods. The Company determines dividend yield based on historical dividend distributions compared to the price of the underlying Shares as of the valuation date and held constant over the life of the Stock Option. The Company’s binomial lattice model incorporates the term of the Stock Options, expected exercise behavior and a post-vesting termination rate, or the rate at which vested options are exercised or expire prematurely due to termination of employment. From these factors, the model derives an expected life of the Stock Option. The model’s exercise behavior is a multiple that reflects the ratio of stock price at the time of exercise over the exercise price of the Stock Option at the time the model expects holders to exercise. The model derives the exercise multiple from actual exercise activity. The model determines the post-vesting termination rate from actual exercise experience and expiration activity under the Incentive Plans. The following table presents the weighted average assumptions, with the exception of risk-free rate (which is expressed as a range), that the model uses to determine the fair value of unexercised Stock Options: Years Ended December 31, 2022 2021 2020 Dividend yield 2.78% 3.20% 3.70% Risk-free rate of return 1.17% - 1.97% 0.08% - 2.48% 1.30% - 1.57% Expected volatility 26.67% 29.72% 25.55% Exercise multiple 1.45 1.44 1.44 Post-vesting termination rate 3.58% 3.58% 3.79% Contractual term (years) 10 10 10 Expected life (years) 6 7 7 Weighted average exercise price of stock options granted $68.96 $57.43 $47.58 Weighted average fair value of stock options granted $15.18 $12.76 $9.02 The following table presents a summary of Stock Option exercise activity: Years Ended December 31, 2022 2021 2020 (In millions) Total intrinsic value of stock options exercised $ 40 $ 60 $ 29 Cash received from exercise of stock options $ 48 $ 119 $ 89 Income tax benefit realized from stock options exercised $ 8 $ 13 $ 6 Performance Shares Performance Shares are units that, if they vest, are multiplied by a performance factor to produce a number of final Shares payable. MetLife accounts for Performance Shares as equity awards. MetLife, Inc. does not credit Performance Shares with dividend-equivalents for dividends paid on Shares. Performance Share awards normally vest in their entirety at the end of the three-year performance period. Vesting is subject to continued service, except for employees who meet specified age and service criteria and in certain other limited circumstances. For awards granted for the 2018 – 2020 performance period, the vested Performance Shares will be multiplied by a performance factor of 0% to 175% that the MetLife, Inc. Compensation Committee will determine in its discretion (subject to MetLife, Inc. meeting threshold performance goals related to its adjusted income or total shareholder return). In doing so, the Compensation Committee may consider MetLife, Inc.’s total shareholder return relative to the performance of its competitors and adjusted return on MetLife, Inc.’s common stockholders’ equity relative to its financial plan. MetLife estimates the fair value of Performance Shares each quarter until they become payable. For awards granted for the 2019 – 2021 and later performance periods in progress through December 31, 2022, the vested Performance Shares will be multiplied by a performance factor of 0% to 175% that the MetLife, Inc. Compensation Committee will determine by (a) the Company’s annual adjusted return on equity performance over the three-year period compared to the Company’s three-year business plan goal; (b) the Company’s total shareholder return over the same three-year period compared to a peer group of companies; and (c) a cap of 100% if the Company’s total shareholder return for the three-year period is zero or less. The Compensation Committee will exclude the impact of a “Significant Event” from the Company’s adjusted return on equity or the business plan goal, to the extent the Committee determines in its informed judgment that the event changed the adjusted return on equity performance factor component. “Significant Events” include accounting changes, business combinations, restructuring, nonrecurring tax events, common share issuance or repurchases, catastrophes, litigation and regulatory settlements, asbestos and environmental events, certain specified classes of non-coupon investments, and other significant nonrecurring, infrequent, or unusual items. The performance factor for the 2019 - 2021 performance period was 141.3%. Restricted Stock Units Restricted Stock Units are units that, if they vest, are payable in an equal number of Shares. MetLife accounts for Restricted Stock Units as equity awards. MetLife, Inc. does not credit Restricted Stock Units with dividend-equivalents for dividends paid on Shares. Accordingly, the estimated fair value of Restricted Stock Units is based upon the closing price of Shares on the date of grant, reduced by the present value of estimated dividends to be paid on that stock. The majority of Restricted Stock Units normally vest in thirds on or shortly after the first three anniversaries of their grant date. Other Restricted Stock Units normally vest in their entirety on the third or later anniversary of their grant date. Vesting is subject to continued service, except for employees who meet specified age and service criteria and in certain other limited circumstances. Performance Share and Restricted Stock Unit Activity The following table presents a summary of Performance Share and Restricted Stock Unit activity: Performance Shares Restricted Stock Units Shares Weighted Units Weighted Outstanding at January 1, 2022 3,848,015 $ 43.74 2,451,046 $ 45.39 Granted 978,422 $ 62.83 893,161 $ 62.60 Forfeited (2) (130,371) $ 51

Other Revenues and Other Expens

Other Revenues and Other Expenses	12 Months Ended
	Dec. 31, 2022
Other Income and Expenses [Abstract]
Other Revenues and Other Expenses Disclosure	17. Other Revenues and Other Expenses Other Revenues Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Vision fee for service arrangements (1) $ 566 $ 546 $ — Prepaid legal plans 471 432 395 Fee-based investment management 396 363 318 Recordkeeping and administrative services (2) 168 213 196 Administrative services-only contracts 238 231 218 Other revenue from service contracts from customers 271 289 227 Total revenues from service contracts from customers 2,110 2,074 1,354 Other 524 545 495 Total other revenues $ 2,634 $ 2,619 $ 1,849 __________________ (1) For information regarding the Company’s acquisition of Versant Health, see Note 3. (2) Related to products and businesses no longer actively marketed by the Company. Receivables related to revenues from service contracts from customers were $226 million and $235 million as of December 31, 2022 and 2021, respectively. Other Expenses Information on other expenses was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Employee related costs (1) $ 3,520 $ 3,515 $ 3,514 Third party staffing costs 1,573 1,423 1,335 General and administrative expenses 700 686 761 Pension, postretirement and postemployment benefit costs 98 147 165 Premium taxes, other taxes, and licenses & fees 608 629 764 Commissions and other variable expenses 5,265 5,463 5,596 Capitalization of DAC (2,558) (2,718) (3,013) Amortization of DAC and VOBA 1,931 2,555 3,160 Amortization of negative VOBA (41) (34) (45) Interest expense on debt 938 920 913 Total other expenses $ 12,034 $ 12,586 $ 13,150 __________________ (1) Includes $93 million, ($144) million and ($147) million for the years ended December 31, 2022, 2021 and 2020, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid. Capitalization of DAC and Amortization of DAC and VOBA See Note 5 for additional information on DAC and VOBA including impacts of capitalization and amortization. See also Note 7 for a description of the DAC amortization impact associated with the closed block.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Employee Benefit Plans	18. Employee Benefit Plans Pension and Other Postretirement Benefit Plans Certain subsidiaries of MetLife, Inc. sponsor a U.S. qualified and various U.S. and non-U.S. nonqualified defined benefit pension plans covering employees who meet specified eligibility requirements. U.S. pension benefits are provided utilizing either a traditional formula or cash balance formula. The traditional formula provides benefits that are primarily based upon years of credited service and final average earnings. The cash balance formula utilizes hypothetical or notional accounts which credit participants with benefits equal to a percentage of eligible pay, as well as interest credits, determined annually based upon the annual rate of interest on 30-year U.S. Treasury securities, for each account balance. In September 2018, the U.S. qualified and nonqualified defined benefit pension plans were amended, effective January 1, 2023, to provide benefits accruals for all active participants under the cash balance formula and to cease future accruals under the traditional formula. The U.S. nonqualified pension plans provide supplemental benefits in excess of limits applicable to a qualified plan. The non-U.S. pension plans generally provide benefits based upon either years of credited service and earnings preceding retirement or points earned on job grades and other factors in years of service. These subsidiaries also provide certain postemployment benefits and certain postretirement medical and life insurance benefits for U.S. and non-U.S. retired employees. U.S. employees of these subsidiaries who were hired prior to 2003 (or, in certain cases, rehired during or after 2003) and meet age and service criteria while working for one of the subsidiaries may become eligible for these other postretirement benefits, at various levels, in accordance with the applicable plans. Virtually all retirees, or their beneficiaries, contribute a portion of the total costs of postretirement medical benefits. U.S. employees hired after 2003 are not eligible for any employer subsidy for postretirement medical benefits. In September 2018, the U.S. postretirement medical and life insurance benefit plans were amended, effective January 1, 2023, to discontinue the accrual of the employer subsidy credits for eligible employees. The benefit obligations, funded status and net periodic benefit costs related to these pension and other postretirement benefits were comprised of the following: December 31, 2022 December 31, 2021 Pension Benefits Other Postretirement Pension Benefits Other Postretirement U.S. Non- Total U.S. Non- Total U.S. Non- Total U.S. Non- Total (In millions) Benefit obligations $ 8,425 $ 873 $ 9,298 $ 758 $ 36 $ 794 $ 11,086 $ 1,096 $ 12,182 $ 1,099 $ 39 $ 1,138 Estimated fair value of plan assets 7,831 463 8,294 1,277 26 1,303 10,392 579 10,971 1,417 26 1,443 Over (under) funded status $ (594) $ (410) $ (1,004) $ 519 $ (10) $ 509 $ (694) $ (517) $ (1,211) $ 318 $ (13) $ 305 Net periodic benefit costs $ 49 $ 73 $ 122 $ (43) $ 1 $ (42) $ 97 $ 97 $ 194 $ (55) $ 2 $ (53) Obligations and Funded Status December 31, 2022 2021 Pension Other Pension Other (In millions) Change in benefit obligations: Benefit obligations at January 1, $ 12,182 $ 1,138 $ 12,873 $ 1,252 Service costs 187 4 215 4 Interest costs 328 34 342 37 Plan participants’ contributions — 32 — 32 Plan amendments 8 — 1 — Net actuarial (gains) losses (2) (2,609) (289) (363) (96) Acquisition, divestitures, settlements and curtailments (45) — (111) 8 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (123) — (110) — Benefit obligations at December 31, 9,298 794 12,182 1,138 Change in plan assets: Estimated fair value of plan assets at January 1, 10,971 1,443 11,256 1,492 Actual return on plan assets (2,095) (43) 310 14 Acquisition, divestitures and settlements (38) — (35) (1) Plan participants’ contributions — 32 — 32 Employer contributions 152 (3) 163 5 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (66) (1) (58) — Estimated fair value of plan assets at December 31, 8,294 1,303 10,971 1,443 Over (under) funded status at December 31, $ (1,004) $ 509 $ (1,211) $ 305 Amounts recognized on the consolidated balance sheets: Other assets $ 428 $ 796 $ 640 $ 788 Other liabilities (1,432) (287) (1,851) (483) Net amount recognized $ (1,004) $ 509 $ (1,211) $ 305 AOCI: Net actuarial (gains) losses $ 2,277 $ (498) $ 2,416 $ (332) Prior service costs (credit) (36) — (55) — AOCI, before income tax $ 2,241 $ (498) $ 2,361 $ (332) Accumulated benefit obligation $ 9,185 N/A $ 11,934 N/A __________________ (1) Includes nonqualified unfunded plans, for which the aggregate PBO was $1.0 billion and $1.3 billion at December 31, 2022 and 2021, respectively. (2) For the year ended December 31, 2022, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions, primarily related to an increase in the discount rate, of ($2.6) billion and ($276) million, respectively, and plan experience of $14 million and ($13) million, respectively. For the year ended December 31, 2021, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions of ($389) million and ($34) million, respectively, demographic assumptions of $0 and ($4) million, respectively, and plan experience of $26 million and ($58) million, respectively. Information for pension plans and other postretirement benefit plans with PBOs and/or accumulated benefit obligations (“ABO”) or APBO in excess of plan assets was as follows at: December 31, 2022 2021 2022 2021 2022 2021 PBO Exceeds Estimated Fair Value ABO Exceeds Estimated Fair Value APBO Exceeds Estimated Fair Value (In millions) Projected benefit obligations $ 1,444 $ 1,840 $ 1,434 $ 1,831 N/A N/A Accumulated benefit obligations $ 1,384 $ 1,740 $ 1,384 $ 1,740 N/A N/A Accumulated postretirement benefit obligations N/A N/A N/A N/A $ 562 $ 813 Estimated fair value of plan assets $ 10 $ 9 $ — $ — $ 276 $ 331 Net Periodic Benefit Costs The components of net periodic benefit costs and other changes in plan assets and benefit obligations recognized in OCI were as follows: Years Ended December 31, 2022 2021 2020 Pension Benefits Other Postretirement Benefits Pension Benefits Other Postretirement Benefits Pension Benefits Other Postretirement Benefits (In millions) Net periodic benefit costs: Service costs $ 187 $ 4 $ 215 $ 4 $ 226 $ 5 Interest costs 328 34 342 37 363 42 Settlement and curtailment (gains) losses 5 — (7) 1 10 — Expected return on plan assets (516) (55) (506) (56) (528) (62) Amortization of net actuarial (gains) losses 129 (25) 162 (39) 189 (74) Amortization of prior service costs (credit) (11) — (12) — (14) (3) Total net periodic benefit costs (credit) 122 (42) 194 (53) 246 (92) Other changes in plan assets and benefit obligations recognized in OCI: Net actuarial (gains) losses 2 (191) (166) (54) (35) (42) Prior service costs (credit) 8 — 1 (1) — — Amortization of net actuarial (gains) losses (129) 25 (162) 39 (189) 74 Amortization of prior service costs (credit) 11 — 12 — 14 3 Settlement and curtailment (gains) losses (5) — (10) 10 (10) — Exchange rate changes (7) — (8) — 5 — Total recognized in OCI (120) (166) (333) (6) (215) 35 Total recognized in net periodic benefit costs and OCI $ 2 $ (208) $ (139) $ (59) $ 31 $ (57) Assumptions Assumptions used in determining benefit obligations for the U.S. plans were as follows: Pension Benefits Other Postretirement Benefits December 31, 2022 Weighted average discount rate 5.60% 5.70% Weighted average interest crediting rate 4.00% N/A Rate of compensation increase 2.50% - 8.00% N/A December 31, 2021 Weighted average discount rate 2.95% 3.05% Weighted average interest crediting rate 3.18% N/A Rate of compensation increase 2.50% - 8.00% N/A Assumptions used in determining net periodic benefit costs for the U.S. plans were as follows: Pension Benefits Other Postretirement Benefits Year Ended December 31, 2022 Weighted average discount rate 2.95% 3.05% Weighted average interest crediting rate 3.43% N/A Weighted average expected rate of return on plan assets 5.00% 3.86% Rate of compensation increase 2.50% - 8.00% N/A Year Ended December 31, 2021 Weighted average discount rate 3.01% 3.14% Weighted average interest crediting rate 3.24% N/A Weighted average expected rate of return on plan assets 5.00% 3.87% Rate of compensation increase 2.50% - 8.00% N/A Year Ended December 31, 2020 Weighted average discount rate 3.30% 3.45% Weighted average interest crediting rate 3.38% N/A Weighted average expected rate of return on plan assets 5.50% 4.31% Rate of compensation increase 2.25% - 8.50% N/A The weighted average discount rate for the U.S. plans is determined annually based on the yield, measured on a yield to worst basis, of a hypothetical portfolio constructed of high quality debt instruments available on the measurement date, which would provide the necessary future cash flows to pay the aggregate PBO when due. The weighted average expected rate of return on plan assets for the U.S. plans is based on anticipated performance of the various asset sectors in which the plans invest, weighted by target allocation percentages. Anticipated future performance is based on long-term historical returns of the plan assets by sector, adjusted for the long-term expectations on the performance of the markets. While the precise expected rate of return derived using this approach will fluctuate from year to year, the policy is to hold this long-term assumption constant as long as it remains within reasonable tolerance from the derived rate. The weighted average expected rate of return on plan assets for use in that plan’s valuation in 2023 is currently anticipated to be 6.25% for U.S. pension benefits and 4.25% for U.S. other postretirement benefits. The weighted average interest crediting rate is determined annually based on the plan selected rate, long-term financial forecasts of that rate and the demographics of the plan participants. The assumed healthcare costs trend rates used in measuring the APBO and net periodic benefit costs were as follows: December 31, 2022 2021 Before Age 65 and Before Age 65 and Following year 5.2 % 3.9 % 5.1 % 3.3 % Ultimate rate to which cost increase is assumed to decline 3.7 % 4.5 % 3.7 % 3.8 % Year in which the ultimate trend rate is reached 2074 2100 2074 2074 Plan Assets Certain U.S. subsidiaries provide employees with benefits under various Employee Retirement Income Security Act of 1974 (“ERISA”) benefit plans. These include qualified pension plans, postretirement medical plans and certain retiree life insurance coverage. The assets of these U.S. subsidiaries’ qualified pension plans are held in an insurance group annuity contract, and the vast majority of the assets of the postretirement medical plan are held in a trust which largely utilizes insurance contracts to hold the assets. All of these contracts are issued by the Company’s insurance affiliates, and the assets under the contracts are held in insurance separate accounts that have been established by the Company. The underlying assets of the separate accounts are principally comprised of cash and cash equivalents, short-term investments, fixed maturity securities AFS, equity securities, derivatives, real estate and private equity investments. The assets backing the retiree life coverage also utilize insurance contracts issued by the Company’s insurance affiliate and are held in a general account Life Insurance Funding Agreement. The insurance contract provider engages investment management firms (“Managers”) to serve as sub-advisors for the separate accounts based on the specific investment needs and requests identified by the plan fiduciary. These Managers have portfolio management discretion over the purchasing and selling of securities and other investment assets pursuant to the respective investment management agreements and guidelines established for each insurance separate account. The assets of the qualified pension plans and postretirement medical plans (the “Invested Plans”) are well diversified across multiple asset categories and across a number of different Managers, with the intent of minimizing risk concentrations within any given asset category or with any of the given Managers. The Invested Plans, other than those held in participant directed investment accounts, are managed in accordance with investment policies consistent with the longer-term nature of related benefit obligations and within prudent risk parameters. Specifically, investment policies are oriented toward (i) maximizing the Invested Plan’s funded status; (ii) minimizing the volatility of the Invested Plan’s funded status; (iii) generating asset returns that exceed liability increases; and (iv) targeting rates of return in excess of a custom benchmark and industry standards over appropriate reference time periods. These goals are expected to be met through identifying appropriate and diversified asset classes and allocations, ensuring adequate liquidity to pay benefits and expenses when due and controlling the costs of administering and managing the Invested Plan’s investments. Independent investment consultants are periodically used to evaluate the investment risk of the Invested Plan’s assets relative to liabilities, analyze the economic and portfolio impact of various asset allocations and management strategies and recommend asset allocations. Derivative contracts may be used to reduce investment risk, to manage duration and to replicate the risk/return profile of an asset or asset class. Derivatives may not be used to leverage a portfolio in any manner, such as to magnify exposure to an asset, asset class, interest rates or any other financial variable. Derivatives are also prohibited for use in creating exposures to securities, currencies, indices or any other financial variable that is otherwise restricted. The table below summarizes the actual weighted average allocation of the estimated fair value of total plan assets by asset class at December 31 for the years indicated and the approved target allocation by major asset class at December 31, 2022 for the Invested Plans: December 31, 2022 2021 U.S. Pension U.S. Other Postretirement Benefits (1) U.S. Pension U.S. Other Target Actual Target Actual Actual Actual Asset Class Fixed maturity securities AFS 85 % 83 % 95 % 96 % 84 % 95 % Equity securities (2) 7 % 6 % 5 % 4 % 7 % 5 % Alternative securities (3) 8 % 11 % — % — % 9 % — % Total assets 100 % 100 % 100 % 100 % __________________ (1) U.S. other postretirement benefits do not reflect postretirement life’s plan assets invested in fixed maturity securities AFS. (2) Equity securities percentage includes derivative assets. (3) Alternative securities primarily include private equity and real estate funds. Estimated Fair Value The pension and other postretirement benefit plan assets are categorized into a three-level fair value hierarchy, as described in Note 10, based upon the significant input with the lowest level in its valuation. The Level 2 asset category includes certain separate accounts that are primarily invested in liquid and readily marketable securities. The estimated fair value of such separate accounts is based upon reported NAV provided by fund managers and this value represents the amount at which transfers into and out of the respective separate account are effected. These separate accounts provide reasonable levels of price transparency and can be corroborated through observable market data. Directly held investments are primarily invested in U.S. and foreign government and corporate securities. The Level 3 asset category includes separate accounts that are invested in assets that provide little or no price transparency due to the infrequency with which the underlying assets trade and generally require additional time to liquidate in an orderly manner. Accordingly, the values for separate accounts invested in these alternative asset classes are based on inputs that cannot be readily derived from or corroborated by observable market data. The pension and other postretirement plan assets measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are summarized as follows: December 31, 2022 Pension Benefits Other Postretirement Benefits Fair Value Hierarchy Fair Value Hierarchy Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: Corporate $ — $ 2,946 $ 55 $ 3,001 $ — $ 205 $ — $ 205 U.S. government bonds 1,462 45 — 1,507 68 — — 68 Foreign bonds — 769 — 769 — 61 — 61 Federal agencies 87 190 — 277 3 1 — 4 Municipals — 159 — 159 — 15 — 15 Short-term investments 12 384 — 396 463 396 — 859 Other (1) 92 598 3 693 8 36 — 44 Total fixed maturity securities AFS 1,653 5,091 58 6,802 542 714 — 1,256 Equity securities 416 151 3 570 47 — — 47 Other investments 40 1 855 896 — — — — Derivative assets 21 1 4 26 — — — — Total assets $ 2,130 $ 5,244 $ 920 $ 8,294 $ 589 $ 714 $ — $ 1,303 December 31, 2021 Pension Benefits Other Postretirement Benefits Fair Value Hierarchy Fair Value Hierarchy Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: Corporate $ — $ 4,305 $ — $ 4,305 $ — $ 222 $ — $ 222 U.S. government bonds 1,824 80 — 1,904 69 — — 69 Foreign bonds — 1,115 1 1,116 — 51 — 51 Federal agencies — 83 — 83 — 10 — 10 Municipals — 248 — 248 — 8 — 8 Short-term investments 142 484 — 626 486 482 — 968 Other (1) 155 627 1 783 14 45 — 59 Total fixed maturity securities AFS 2,121 6,942 2 9,065 569 818 — 1,387 Equity securities 601 283 11 895 55 — — 55 Other investments 42 1 954 997 1 — — 1 Derivative assets 14 — — 14 — — — — Total assets $ 2,778 $ 7,226 $ 967 $ 10,971 $ 625 $ 818 $ — $ 1,443 __________________ (1) Other primarily includes money market securities, mortgage-backed securities, collateralized mortgage obligations and ABS & CLO. A rollforward of all pension and other postretirement benefit plan assets measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs was as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS: Foreign Bonds Corporate Other Equity Securities Other Derivative Assets (In millions) Balance, January 1, 2021 $ — $ — $ — $ — $ 708 $ — Realized gains (losses) — — — — — — Unrealized gains (losses) — — — — 63 — Purchases, sales, issuances and settlements, net 1 — 1 11 183 — Transfers into and/or out of Level 3 — — — — — — Balance, December 31, 2021 $ 1 $ — $ 1 $ 11 $ 954 $ — Realized gains (losses) — — — — — — Unrealized gains (losses) — (1) — — 54 1 Purchases, sales, issuances and settlements, net — 56 3 (8) (153) 3 Transfers into and/or out of Level 3 (1) — (1) — — — Balance, December 31, 2022 $ — $ 55 $ 3 $ 3 $ 855 $ 4 Expected Future Contributions and Benefit Payments It is the subsidiaries’ practice to make contributions to the U.S. qualified pension plan to comply with minimum funding requirements of ERISA. In accordance with such practice, no contributions are expected to be required for 2023. The subsidiaries do not expect to make any discretionary contributions to the qualified pension plan in 2023. For information on employer contributions, see “— Obligations and Funded Status.” Benefit payments due under the U.S. nonqualified pension plans are primarily funded from the subsidiaries’ general assets as they become due under the provisions of the plans, and therefore benefit payments equal employer contributions. The U.S. subsidiaries expect to make contributions of $90 million to fund the benefit payments in 2023. Postretirement benefits are either: (i) not vested under law; (ii) a non-funded obligation of the subsidiaries; or (iii) both. Current regulations do not require funding for these benefits. The subsidiaries use their general assets, net of participant’s contributions, to pay postretirement medical claims as they come due. As permitted under the terms of the governing trust document, the subsidiaries may be reimbursed from plan assets for postretirement medical claims paid from their general assets. The U.S. subsidiaries expect to make contributions of $20 million towards benefit obligations in 2023 to pay postretirement medical claims. Gross benefit payments for the next 10 years, which reflect expected future service where appropriate, are expected to be as follows: Pension Benefits Other Postretirement Benefits (In millions) 2023 $ 713 $ 66 2024 $ 722 $ 63 2025 $ 727 $ 62 2026 $ 742 $ 61 2027 $ 745 $ 59 2028-2032 $ 3,747 $ 279 Defined Contribution Plans Certain subsidiaries sponsor defined contribution plans under which a portion of employee contributions are matched. These subsidiaries contributed $46 million, $88 million and $95 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax	19. Income Tax The provision for income tax was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Current: U.S. federal $ 159 $ 62 $ 271 U.S. state and local 45 38 27 Non-U.S. 1,074 795 882 Subtotal 1,278 895 1,180 Deferred: U.S. federal 536 837 (115) U.S. state and local — (2) 1 Non-U.S. (1,513) (179) 443 Subtotal (977) 656 329 Provision for income tax expense (benefit) $ 301 $ 1,551 $ 1,509 The Company’s income (loss) before income tax expense (benefit) was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Income (loss): U.S. $ 2,681 $ 4,841 $ 2,970 Non-U.S. 178 3,285 3,957 Total $ 2,859 $ 8,126 $ 6,927 The reconciliation of the income tax provision at the U.S. statutory rate to the provision for income tax as reported was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Tax provision at U.S. statutory rate $ 601 $ 1,706 $ 1,455 Tax effect of: Dividend received deduction (20) (40) (34) Tax-exempt income 15 (36) (45) Prior year tax (1), (2) (15) (127) (27) Low income housing tax credits (143) (178) (202) Other tax credits (44) (46) (45) Foreign tax rate differential (3), (4), (5) (110) 267 414 Change in valuation allowance — 1 (5) Other, net 17 4 (2) Provision for income tax expense (benefit) $ 301 $ 1,551 $ 1,509 __________________ (1) As discussed further below, prior year tax primarily includes non-cash benefits related to uncertain tax positions of $32 million and $117 million for the years ended December 31, 2022 and 2021, respectively. (2) For the year ended December 31, 2020, prior year tax primarily includes a $40 million tax benefit related to an Internal Revenue Service (“IRS”) audit matter. (3) For the year ended December 31, 2022, foreign tax rate differential includes tax charges of $12 million related to the U.S. tax on Global Intangible Low-Taxed Income (“GILTI”) of which $33 million is a current year charge offset by a $21 million tax benefit revising the 2021 estimate. (4) For the year ended December 31, 2021, foreign tax rate differential includes tax charges of $50 million related to the disposition of MetLife Poland and Greece, $41 million related to the sale of MetLife Seguros and $30 million related to the U.S. tax on GILTI, which included a $42 million 2021 charge offset by a $12 million tax benefit revising the 2020 estimate. See Note 3 for information on the Company’s business dispositions. (5) For the year ended December 31, 2020, foreign tax rate differential includes tax charges of $60 million and $24 million related to the sales of MetLife Seguros de Retiro and MetLife Russia, respectively, and $43 million related to the U.S. tax on GILTI. See Note 3 for information on the Company’s business dispositions. Deferred income tax represents the tax effect of the differences between the book and tax bases of assets and liabilities. Net deferred income tax assets and liabilities consisted of the following at: December 31, 2022 2021 (In millions) Deferred income tax assets: Policyholder liabilities and receivables $ 1,496 $ 3,787 Net operating loss carryforwards (1) 238 235 Employee benefits 475 583 Capital loss carryforwards 15 9 Tax credit carryforwards (2) 590 825 Net unrealized investment losses 5,319 — Litigation-related and government mandated 90 95 Other 67 — Total gross deferred income tax assets 8,290 5,534 Less: Valuation allowance (1) 291 299 Total net deferred income tax assets 7,999 5,235 Deferred income tax liabilities: Investments, including derivatives 1,691 4,167 Intangibles 1,096 1,188 Net unrealized investment gains — 5,551 DAC 2,707 3,471 Other — 362 Total deferred income tax liabilities 5,494 14,739 Net deferred income tax asset (liability) $ 2,505 $ (9,504) __________________ (1) The Company has recorded a deferred tax asset of $238 million related to U.S. state and non-U.S. net operating loss carryforwards and an offsetting valuation allowance for the year ended December 31, 2022. Certain net operating loss carryforwards will expire between 2023 and 2042, whereas others have an unlimited carryforward period. (2) Tax credit carryforwards for the year ended December 31, 2022 primarily reflect general business credits expiring between 2039 and 2042 and are increased by $44 million related to unrecognized tax benefits. The Company has not provided for U.S. deferred taxes on the remaining excess of book bases over tax bases of certain investments in non-U.S. subsidiaries that are essentially permanent in duration. The amount of deferred tax liability related to the Company’s remaining basis difference in these non-U.S. subsidiaries was $302 million at December 31, 2022. The Company files income tax returns with the U.S. federal government and various U.S. state and local jurisdictions, as well as non-U.S. jurisdictions. The Company is under continuous examination by the IRS and other tax authorities in jurisdictions in which the Company has significant business operations. The income tax years under examination vary by jurisdiction and subsidiary. The Company is no longer subject to U.S. federal, state, or local income tax examinations for years prior to 2017. In material non-U.S. jurisdictions, the Company is no longer subject to income tax examinations for years prior to 2015. In 2021, the Company filed amended Federal income tax returns with the IRS for MetLife, Inc. and subsidiaries for tax years 2014 through 2016. In 2022, the IRS reviewed and acknowledged acceptance of the 2014 through 2016 amended Federal income tax returns and closed the years to further audit. Accordingly, in 2022, the Company recorded a non-cash benefit to net income of $70 million, net of tax, comprised of a $67 million tax benefit recorded in provision for income tax expense (benefit) and a $4 million interest benefit ($3 million, net of tax) included in other expenses. In 2021, the Company filed amended Federal income tax returns with the IRS for MetLife, Inc. and subsidiaries for tax years 2010 through 2013. In 2021, the IRS reviewed and acknowledged acceptance of the 2010 through 2013 amended Federal income tax returns and closed the years to further audit. Accordingly, in 2021, the Company recorded a non-cash benefit to net income of $53 million in provision for income tax expense (benefit). In addition, in 2021, the IRS concluded its Federal income tax audit of American Life for tax years 2010 through 2013. Accordingly, in 2021, the Company recorded a non-cash benefit to net income of $42 million, net of tax, comprised of a $34 million tax benefit recorded in provision for income tax expense (benefit) and a $10 million interest benefit ($8 million, net of tax) included in other expenses. The Company filed refund claims in 2017 with the IRS for 2000 through 2002 to recover tax and interest predominantly related to the disallowance of certain foreign tax credits for which the Company received a statutory notice of deficiency in 2015 and paid the tax thereon. The disallowed foreign tax credits relate to certain non-U.S. investments held by MLIC in support of its life insurance business through a U.K. investment subsidiary that was structured as a joint venture until early 2009. In 2020, the Company received refunds from these claims filed in 2017, and as a result, the Company recorded a $28 million interest benefit ($22 million, net of tax) included in other expenses. The Company’s overall liability for unrecognized tax benefits may increase or decrease in the next 12 months. For example, U.S. federal tax legislation and regulation could impact unrecognized tax benefits. A reasonable estimate of the increase or decrease cannot be made at this time. However, the Company continues to believe that the ultimate resolution of the pending issues will not result in a material change to its consolidated financial statements, although the resolution of income tax matters could impact the Company’s effective tax rate for a particular future period. A reconciliation of the beginning and ending amount of unrecognized tax benefits was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Balance at January 1, $ 163 $ 272 $ 256 Additions for tax positions of prior years 42 19 16 Reductions for tax positions of prior years (1) (93) (112) (1) Additions for tax positions of current year 22 5 12 Reductions for tax positions of current year (3) (18) — Settlements with tax authorities (2) (3) (1) Lapses of statute of limitations — — (10) Balance at December 31, $ 129 $ 163 $ 272 Unrecognized tax benefits that, if recognized, would impact the effective rate $ 80 $ 103 $ 203 __________________ (1) The decreases in 2022 and 2021 are primarily related to non-cash benefits from tax audit settlements. The Company classifies interest accrued related to unrecognized tax benefits in interest expense, included within other expenses. Interest was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Interest expense (benefit) recognized on the consolidated statements of operations (1) $ — $ (36) $ 12 December 31, 2022 2021 (In millions) Interest included in other liabilities on the consolidated balance sheets $ 15 $ 15 __________________ (1) For the year ended December 31, 2021, the interest benefit is primarily related to a tax audit settlement of $10 million which was recorded in other expenses and a reclassification of $26 million to current income tax payable.

Earnings Per Common Share

Earnings Per Common Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Common Share	20. Earnings Per Common Share The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share: Years Ended December 31, 2022 2021 2020 (In millions, except per share data) Weighted Average Shares: Weighted average common stock outstanding - basic 803.2 862.7 907.8 Incremental common shares from assumed exercise or issuance of stock-based awards 5.7 6.7 5.4 Weighted average common stock outstanding - diluted 808.9 869.4 913.2 Net Income (Loss): Net income (loss) $ 2,558 $ 6,575 $ 5,418 Less: Net income (loss) attributable to noncontrolling interests 19 21 11 Less: Preferred stock dividends 185 195 202 Preferred stock redemption premium — 6 14 Net income (loss) available to MetLife, Inc.’s common shareholders $ 2,354 $ 6,353 $ 5,191 Basic $ 2.93 $ 7.36 $ 5.72 Diluted $ 2.91 $ 7.31 $ 5.68

Contingencies, Commitments and

Contingencies, Commitments and Guarantees	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies, Commitments and Guarantees	21. Contingencies, Commitments and Guarantees Contingencies Litigation The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor, broker-dealer, and taxpayer. The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the United States where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries. It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. In certain circumstances where liabilities have been established there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at December 31, 2022. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods. Matters as to Which an Estimate Can Be Made For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of December 31, 2022, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million. Matters as to Which an Estimate Cannot Be Made For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews. Asbestos-Related Claims MLIC is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. MLIC has never engaged in the business of manufacturing or selling asbestos-containing products, nor has MLIC issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of MLIC’s employees during the period from the 1920s through approximately the 1950s and allege that MLIC learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. MLIC believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against MLIC. MLIC’s defenses include that: (i) MLIC owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of MLIC; (iii) MLIC’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against MLIC, while other trial courts have denied MLIC’s motions. There can be no assurance that MLIC will receive favorable decisions on motions in the future. While most cases brought to date have settled, MLIC intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials. The approximate total number of asbestos personal injury claims pending against MLIC as of the dates indicated, the approximate number of new claims during the years ended on those dates and the approximate total settlement payments made to resolve asbestos personal injury claims at or during those years are set forth in the following table: December 31, 2022 2021 2020 (In millions, except number of claims) Asbestos personal injury claims at year end 58,073 58,785 60,618 Number of new claims during the year 2,610 2,824 2,496 Settlement payments during the year (1) $ 50.5 $ 53.0 $ 52.9 __________________ (1) Settlement payments represent payments made by MLIC during the year in connection with settlements made in that year and in prior years. Amounts do not include MLIC’s attorneys’ fees and expenses. The number of asbestos cases that may be brought, the aggregate amount of any liability that MLIC may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year. The ability of MLIC to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against MLIC when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts. The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position. The Company believes adequate provision has been made in its consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. MLIC’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis. MLIC reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, MLIC has updated its recorded liability for asbestos-related claims to $320 million at December 31, 2022. The recorded liability was $372 million at December 31, 2021. Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017) Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the State of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., MLIC, and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. The Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and MLIC’s motion to dismiss and remanded the case to the trial court where the Relator has filed an amended complaint. The Company intends to defend the action vigorously. Matters Related to Group Annuity Benefits and Assumed Variable Annuity Guarantee Reserves In 2018, the Company announced that it identified two material weaknesses in its internal control over financial reporting related to the practices and procedures for estimating reserves for certain group annuity benefits and the calculation of reserves associated with certain variable annuity guarantees assumed from the former operating joint venture in Japan. Several regulators have made inquiries into these issues and it is possible that other jurisdictions may pursue similar investigations or inquiries. The Company could be exposed to lawsuits and additional legal actions relating to these issues. These may result in payments, including damages, fines, penalties, interest and other amounts assessed or awarded by courts or regulatory authorities under applicable escheat, tax, securities, ERISA, or other laws or regulations. The Company could incur significant costs in connection with these actions. Commitments Mortgage Loan Commitments The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $3.4 billion and $4.6 billion at December 31, 2022 and 2021, respectively. Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments The Company commits to fund partnership investments and to lend funds under bank credit facilities, bridge loans and private corporate bond investments. The amounts of these unfunded commitments were $9.4 billion and $9.1 billion at December 31, 2022 and 2021, respectively. Guarantees In the normal course of its business, the Company has provided certain indemnities and guarantees to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $329 million, with a cumulative maximum of $634 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities or guarantees. In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future. The Company also has minimum fund yield requirements on certain pension funds. Since these guarantees are not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. The Company’s recorded liabilities were $20 million at both December 31, 2022 and 2021, for indemnities and guarantees.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events [Text Block]	22. Subsequent Events Senior Notes In February 2023, MetLife, Inc. redeemed for cash and canceled $1.0 billion aggregate principal amount of its outstanding 4.368% senior notes due September 2023. In January 2023, MetLife, Inc. issued $1.0 billion of senior notes due January 2054 which bear interest at a fixed rate of 5.250%, payable semi-annually. In connection with the issuance, MetLife, Inc. incurred $11 million of related costs which will be amortized over the term of the senior notes.

Consolidated Summary of Investm

Consolidated Summary of Investments - Other Than Investments in Related Parties	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Consolidated Summary of Investments - Other Than Investments in Related Parties	MetLife, Inc. Schedule I Consolidated Summary of Investments — Other Than Investments in Related Parties December 31, 2022 (In millions) Types of Investments Cost or Estimated Fair Amount at Fixed maturity securities AFS: Bonds: Foreign government $ 50,047 $ 46,747 $ 46,747 U.S. government and agency 35,658 32,229 32,229 Public utilities 11,476 10,717 10,717 Municipals 13,548 12,152 12,152 All other corporate bonds 135,710 120,916 120,916 Total bonds 246,439 222,761 222,761 Mortgage-backed, asset-backed and collateralized loan obligations securities 58,610 53,050 53,050 Redeemable preferred stock 976 969 969 Total fixed maturity securities AFS 306,025 276,780 276,780 Unit-linked and FVO Securities 9,106 9,668 9,668 Equity securities: Common stock: Industrial, miscellaneous and all other 335 504 504 Banks, trust and insurance companies 1,012 1,036 1,036 Public utilities — 2 2 Non-redeemable preferred stock 148 142 142 Total equity securities 1,495 1,684 1,684 Mortgage loans 84,290 83,763 Policy loans 8,874 8,874 Real estate and real estate joint ventures 12,955 12,955 Real estate acquired in satisfaction of debt 182 182 Other limited partnership interests 14,414 14,414 Short-term investments 4,870 4,935 Other invested assets 20,064 20,038 Total investments $ 462,275 $ 433,293 __________________ (1) Unit-linked and FVO Securities are primarily equity securities (including mutual funds) and fixed maturity securities. Amortized cost for fixed maturity securities AFS, Unit-linked and FVO Securities, mortgage loans, policy loans and short-term investments represents original cost reduced by repayments and adjusted for amortization of premium or accretion of discount; for equity securities, cost represents original cost; for real estate, cost represents original cost reduced by impairments and depreciation; for real estate joint ventures and other limited partnership interests, cost represents original cost reduced for impairments and adjusted for equity in earnings and distributions.

Condensed Financial Information

Condensed Financial Information (Parent Company)	12 Months Ended
	Dec. 31, 2022
Condensed Financial Information Disclosure [Abstract]
Condensed Financial Information (Parent Company)	MetLife, Inc. Schedule II Condensed Financial Information (Parent Company Only) December 31, 2022 and 2021 (In millions, except share and per share data) 2022 2021 Condensed Balance Sheets Assets Investments: Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $3,877 and $2,742, respectively) $ 3,729 $ 2,745 Other invested assets, at estimated fair value 376 314 Total investments 4,105 3,059 Cash and cash equivalents 1,290 1,961 Accrued investment income 20 4 Investment in subsidiaries 39,895 80,165 Loans to subsidiaries 95 35 Other assets 724 798 Total assets $ 46,129 $ 86,022 Liabilities and Stockholders’ Equity Liabilities Payables for collateral under derivatives transactions $ 154 $ 153 Long-term debt — unaffiliated 13,588 12,814 Long-term debt — affiliated 1,676 1,884 Junior subordinated debt securities 2,465 2,463 Other liabilities 1,206 1,226 Total liabilities 19,089 18,540 Stockholders’ Equity Preferred stock, par value $0.01 per share; $3,905 aggregate liquidation preference — — Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,189,831,471 and 1,186,540,473 shares issued, respectively; 779,098,414 and 825,540,267 shares outstanding, respectively 12 12 Additional paid-in capital 33,616 33,511 Retained earnings 41,953 41,197 Treasury stock, at cost; 410,733,057 and 361,000,206 shares, respectively (21,458) (18,157) Accumulated other comprehensive income (loss) (27,083) 10,919 Total stockholders’ equity 27,040 67,482 Total liabilities and stockholders’ equity $ 46,129 $ 86,022 See accompanying notes to the condensed financial information. MetLife, Inc. Schedule II Condensed Financial Information — (continued) (Parent Company Only) Years Ended December 31, 2022, 2021 and 2020 (In millions) 2022 2021 2020 Condensed Statements of Operations Revenues Net investment income $ 58 $ 25 $ 50 Other revenues 17 19 29 Net investment gains (losses) 332 1,655 (154) Net derivative gains (losses) 129 116 (61) Total revenues 536 1,815 (136) Expenses Interest expense 829 847 833 Other expenses 79 207 154 Total expenses 908 1,054 987 Income (loss) before provision for income tax and equity in earnings of subsidiaries (372) 761 (1,123) Provision for income tax (expense) benefit 37 (202) 267 Equity in earnings of subsidiaries 2,874 5,995 6,263 Net income (loss) 2,539 6,554 5,407 Less: Preferred stock dividends 185 195 202 Preferred stock redemption premium — 6 14 Net income (loss) available to common shareholders $ 2,354 $ 6,353 $ 5,191 Comprehensive income (loss) $ (35,463) $ (599) $ 10,427 See accompanying notes to the condensed financial information. MetLife, Inc. Schedule II Condensed Financial Information — (continued) (Parent Company Only) Years Ended December 31, 2022, 2021 and 2020 (In millions) 2022 2021 2020 Condensed Statements of Cash Flows Cash flows from operating activities Net income (loss) $ 2,539 $ 6,554 $ 5,407 Earnings of subsidiaries (2,874) (5,995) (6,263) Dividends from subsidiaries 5,168 4,830 3,970 (Gains) losses on investments and from sales of businesses, net (332) (1,655) 154 Other, net (73) 23 211 Net cash provided by (used in) operating activities 4,428 3,757 3,479 Cash flows from investing activities Sales and maturities of fixed maturity securities available-for-sale 1,609 5,078 3,693 Purchases of fixed maturity securities available-for-sale (2,757) (4,371) (3,858) Cash received in connection with freestanding derivatives 296 111 71 Cash paid in connection with freestanding derivatives (103) (27) (100) Sales of businesses — 3,902 — Purchases of businesses — — (1,875) Expense paid on behalf of subsidiaries (10) (15) (15) Receipts on loans to subsidiaries 150 195 100 Issuances of loans to subsidiaries (210) (230) — Returns of capital from subsidiaries 8 13 16 Capital contributions to subsidiaries (5) (88) (422) Net change in short-term investments — 156 4 Other, net 15 9 (2) Net cash provided by (used in) investing activities (1,007) 4,733 (2,388) Cash flows from financing activities Net change in payables for collateral under derivative transactions 1 88 49 Long-term debt issued 1,000 496 1,246 Long-term debt repaid — (996) (251) Treasury stock acquired in connection with share repurchases (3,326) (4,303) (1,151) Preferred stock issued, net of issuance costs — — 1,961 Redemption of preferred stock — (494) (989) Preferred stock redemption premium — (6) (14) Dividends on preferred stock (185) (195) (202) Dividends on common stock (1,598) (1,647) (1,657) Other, net 16 87 (19) Net cash provided by (used in) financing activities (4,092) (6,970) (1,027) Change in cash and cash equivalents (671) 1,520 64 Cash and cash equivalents, beginning of year 1,961 441 377 Cash and cash equivalents, end of year $ 1,290 $ 1,961 $ 441 MetLife, Inc. Schedule II Condensed Financial Information — (continued) (Parent Company Only) Years Ended December 31, 2022, 2021 and 2020 (In millions) 2022 2021 2020 Supplemental disclosures of cash flow information Net cash paid (received) for: Interest $ 800 $ 853 $ 815 Income tax: Amounts paid to (received from) subsidiaries, net $ (214) $ (110) $ (392) Income tax paid (received) by MetLife, Inc., net 85 128 96 Total income tax, net $ (129) $ 18 $ (296) Non-cash transactions: Dividends from subsidiary $ — $ 14 $ 341 Returns of capital from subsidiaries $ 12 $ 7 $ 13 Capital contributions to subsidiaries $ 11 $ 15 $ 1 MetLife, Inc. Schedule II Notes to the Condensed Financial Information (Parent Company Only) The condensed financial information of MetLife, Inc. (parent company only) should be read in conjunction with the consolidated financial statements of MetLife, Inc. and its subsidiaries and the notes thereto (the “Consolidated Financial Statements”). These condensed unconsolidated financial statements reflect the results of operations, financial position and cash flows for MetLife, Inc. Investments in subsidiaries are accounted for using the equity method of accounting. The preparation of these condensed unconsolidated financial statements in conformity with GAAP requires management to adopt accounting policies and make certain estimates and assumptions. The most important of these estimates and assumptions relate to the fair value measurements, the accounting for goodwill and the provision for potential losses that may arise from litigation and regulatory proceedings and tax audits, which may affect the amounts reported in the condensed unconsolidated financial statements and accompanying notes. Actual results could differ from these estimates. In April 2021, MetLife, Inc. received $3.9 billion in cash in connection with the disposition of MetLife P&C. In December 2020, MetLife, Inc. paid $1.8 billion in cash in connection with the acquisition of Versant Health. See Note 3 of the Notes to the Consolidated Financial Statements for additional information on acquisitions and dispositions. MetLife, Inc. lends funds as necessary, through credit agreements or otherwise to its subsidiaries, some of which are regulated, to meet their capital requirements or to provide liquidity. Payments of interest and principal on surplus notes of regulated subsidiaries, which are subordinate to all other obligations of the issuing company, may be made only with the prior approval of the insurance department of the state of domicile. During 2022 and 2021, under an existing credit facility, MetLife Services and Solutions, LLC issued $150 million and $195 million, respectively, in short-term notes to MetLife, Inc. which were repaid by September 2022 and August 2021, respectively. The short-term notes bore interest at six-month LIBOR plus 1.00%. In December 2022 and 2021, Missouri Reinsurance, Inc. (“MoRe”), issued to MetLife, Inc. a $60 million 5.23% promissory note and a $35 million 2.12% promissory note, respectively. Both notes are payable semi-annually and mature in December 2024. Interest income earned on loans to subsidiaries of $2 million, $1 million and $2 million for the years ended December 31, 2022, 2021 and 2020, respectively, is included in net investment income. Interest Expense Interest expense was comprised of the following: Years Ended December 31, 2022 2021 2020 (In millions) Long-term debt — unaffiliated $ 583 $ 590 $ 570 Long-term debt — affiliated 37 47 52 Collateral financing arrangements 4 5 6 Junior subordinated debt securities 205 205 205 Total $ 829 $ 847 $ 833 See Notes 14 and 15 of the Notes to the Consolidated Financial Statements for information on the collateral financing arrangement and junior subordinated debt securities. MetLife, Inc. is party to various capital support commitments and guarantees with certain of its subsidiaries. Under these arrangements, MetLife, Inc. has agreed to cause each such entity to meet specified capital and surplus levels or has guaranteed certain contractual obligations. MetLife, Inc. guarantees the obligations of MoRe, under a retrocession agreement with RGA Reinsurance (Barbados) Inc., pursuant to which MoRe retrocedes a portion of the closed block liabilities associated with industrial life and ordinary life insurance policies that it assumed from MLIC. MetLife, Inc. guarantees the obligations of MetLife Reinsurance Company of Bermuda, Ltd. (“MrB”), a Bermuda insurance affiliate and an indirect, wholly-owned subsidiary of MetLife, Inc. under a reinsurance agreement with Mitsui Sumitomo Primary Life Insurance Co., Ltd. (“Mitsui”), a former affiliate that is now an unaffiliated third party, under which MrB reinsures certain variable annuity business written by Mitsui. MetLife, Inc. guarantees the obligations of MrB in an aggregate amount up to $1.0 billion, under a reinsurance agreement with MetLife Europe d.a.c., in respect of MrB’s reinsurance of the guaranteed living benefits and guaranteed death benefits associated with certain Unit-linked investments issued by MetLife Europe d.a.c. MetLife, Inc., in connection with MRV’s reinsurance of certain universal life and term life insurance risks, committed to the Vermont Department of Banking, Insurance, Securities and Health Care Administration to take necessary action to cause the two protected cells of MRV to maintain total adjusted capital in an amount that is equal to or greater than 200% of each such protected cell’s authorized control level RBC, as defined in Vermont state insurance statutes. MetLife, Inc., in connection with the collateral financing arrangement associated with MRC’s reinsurance of a portion of the liabilities associated with the closed block, committed to the South Carolina Department of Insurance to make capital contributions, if necessary, to MRC so that MRC may at all times maintain its total adjusted capital in an amount that is equal to or greater than 200% of the Company Action Level RBC, as defined in South Carolina state insurance statutes as in effect on the date of determination or December 31, 2007, whichever calculation produces the greater capital requirement, or as otherwise required by the South Carolina Department of Insurance. See Note 14 of the Notes to the Consolidated Financial Statements. MetLife, Inc. guarantees obligations arising from OTC-bilateral derivatives of MrB. MrB is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. MrB uses a variety of strategies to manage these risks, including the use of derivatives. Further, MrB’s derivatives are subject to industry standard netting agreements and collateral agreements that limit the unsecured portion of any open derivative position. On a net counterparty basis at December 31, 2022 and 2021, derivative transactions with positive mark-to-market values (in-the-money) were $174 million and $255 million, respectively, and derivative transactions with negative mark-to-market values (out-of-the-money) were $181 million and $116 million, respectively. To secure the obligations represented by the out-of-the-money transactions, MrB had provided collateral to its counterparties with an estimated fair value of $181 million and $114 million at December 31, 2022 and 2021, respectively. Accordingly, unsecured derivative liabilities guaranteed by MetLife, Inc. were $0 and $2 million at December 31, 2022 and 2021, respectively. MetLife, Inc. also guarantees the obligations of certain of its subsidiaries under committed facilities with third-party banks. See Note 13 of the Notes to the Consolidated Financial Statements.

Consolidated Supplementary Insu

Consolidated Supplementary Insurance Information	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Abstract]
Consolidated Supplementary Insurance Information	MetLife, Inc. Schedule III Consolidated Supplementary Insurance Information December 31, 2022 and 2021 (In millions) Segment DAC Future Policy Benefits, Policyholder Policyholder Unearned Unearned 2022 U.S. $ 459 $ 91,767 $ 79,926 $ — $ 352 $ 36 Asia 13,384 41,308 84,215 72 1,889 3,677 Latin America 2,211 12,181 5,493 — 2 829 EMEA 1,593 3,391 7,244 — 14 530 MetLife Holdings 5,308 74,181 26,226 315 158 195 Corporate & Other 28 1,051 (22) — — — Total $ 22,983 $ 223,879 $ 203,082 $ 387 $ 2,415 $ 5,267 2021 U.S. $ 440 $ 85,108 $ 77,891 $ — $ 325 $ 38 Asia 9,339 42,103 83,736 85 2,386 790 Latin America 2,021 10,541 5,023 — 1 797 EMEA 1,623 3,639 9,392 — 21 553 MetLife Holdings 2,607 76,523 27,450 393 159 190 Corporate & Other 31 1,240 (19) — — — Total $ 16,061 $ 219,154 $ 203,473 $ 478 $ 2,892 $ 2,368 __________________ (1) Amounts are included within the future policy benefits, other policy-related balances and policyholder dividend obligation column. (2) Includes premiums received in advance. MetLife, Inc. Schedule III Consolidated Supplementary Insurance Information — (continued) Years Ended December 31, 2022, 2021 and 2020 (In millions) Segment Premiums and Net Policyholder Amortization of Other 2022 U.S. $ 36,706 $ 6,980 $ 38,056 $ 59 $ 3,894 Asia 7,367 3,571 6,347 1,042 1,593 Latin America 4,401 1,318 4,046 339 1,057 EMEA 2,324 (864) 126 340 780 MetLife Holdings 4,198 4,690 5,735 142 1,629 Corporate & Other (14) 221 (6) 9 1,851 Total $ 54,982 $ 15,916 $ 54,304 $ 1,931 $ 10,804 2021 U.S. $ 28,363 $ 7,738 $ 29,987 $ 158 $ 3,707 Asia 8,308 5,110 7,295 1,404 1,751 Latin America 3,718 1,207 3,442 285 989 EMEA 2,825 932 2,162 382 900 MetLife Holdings 4,514 6,157 6,571 317 1,839 Corporate & Other 37 251 35 9 1,721 Total $ 47,765 $ 21,395 $ 49,492 $ 2,555 $ 10,907 2020 U.S. $ 28,335 $ 6,563 $ 27,966 $ 471 $ 3,716 Asia 8,554 3,931 7,249 1,468 1,825 Latin America 3,257 991 2,857 276 971 EMEA 2,709 697 1,623 452 860 MetLife Holdings 4,757 4,900 6,983 485 1,976 Corporate & Other 25 35 (3) 8 1,732 Total $ 47,637 $ 17,117 $ 46,675 $ 3,160 $ 11,080 ______________ (1) Includes other expenses and policyholder dividends, excluding amortization of DAC and VOBA charged to other expenses.

Consolidated Reinsurance

Consolidated Reinsurance	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract]
Consolidated Reinsurance	MetLife, Inc. Schedule IV Consolidated Reinsurance December 31, 2022, 2021 and 2020 (Dollars in millions) Gross Amount Ceded Assumed Net Amount % Amount Assumed to Net 2022 Life insurance in-force $ 5,371,318 $ 390,521 $ 647,646 $ 5,628,443 11.5 % Insurance premium Life insurance (1) $ 31,656 $ 1,422 $ 2,518 $ 32,752 7.7 % Accident & health insurance 16,801 715 519 16,605 3.1 % Property and casualty insurance 46 6 — 40 — % Total insurance premium $ 48,503 $ 2,143 $ 3,037 $ 49,397 6.1 % 2021 Life insurance in-force $ 5,273,869 $ 394,023 $ 662,901 $ 5,542,747 12.0 % Insurance premium Life insurance (1) $ 23,597 $ 1,490 $ 2,346 $ 24,453 9.6 % Accident & health insurance 16,752 639 553 16,666 3.3 % Property and casualty insurance 910 28 8 890 0.9 % Total insurance premium $ 41,259 $ 2,157 $ 2,907 $ 42,009 6.9 % 2020 Life insurance in-force $ 5,222,988 $ 442,381 $ 597,903 $ 5,378,510 11.1 % Insurance premium Life insurance (1) $ 23,629 $ 1,620 $ 1,809 $ 23,818 7.6 % Accident & health insurance 14,958 516 208 14,650 1.4 % Property and casualty insurance 3,614 63 15 3,566 0.4 % Total insurance premium $ 42,201 $ 2,199 $ 2,032 $ 42,034 4.8 % __________________ (1) Includes annuities with life contingencies.

Business, Basis of Presentati_2

Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.
Consolidation of Subsidiaries	Consolidation The accompanying consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated.
Held-for-Sale	Held-for-SaleThe Company classifies a business as held-for-sale when management has approved or received approval to sell the business, the sale is probable to occur during the next 12 months at a price that is reasonable in relation to its current estimated fair value and certain other specified criteria are met. The business classified as held-for-sale is recorded at the lower of the carrying value and estimated fair value, less cost to sell. If the carrying value of the business exceeds its estimated fair value, less cost to sell, a loss is recognized and reported in net investment gains (losses). Assets and liabilities related to the business classified as held-for-sale are separately reported in the Company's consolidated balance sheets in the period in which the business is classified as held-for-sale. See Note 3. If a component of the Company has either been disposed of or is classified as held-for-sale and represents a strategic shift that has or will have a major effect on the Company’s operations and financial results, the results of the component are reported in discontinued operations.
Separate Accounts	Separate Accounts Separate accounts are established in conformity with insurance laws. Generally, the assets of the separate accounts cannot be used to settle the liabilities that arise from any other business of the Company. Separate account assets are subject to general account claims only to the extent the value of such assets exceeds the separate account liabilities. The Company reports separately, as assets and liabilities, investments held in separate accounts and liabilities of the separate accounts if: • such separate accounts are legally recognized; • assets supporting the contract liabilities are legally insulated from the Company’s general account liabilities; • investment objectives are directed by the contractholder; and • all investment performance, net of contract fees and assessments, is passed through to the contractholder. The Company reports separate account assets at their fair value which is based on the estimated fair values of the underlying assets comprising the individual separate account portfolios. Investment performance (including investment income, net investment gains (losses) and changes in unrealized gains (losses)) and the corresponding amounts credited to contractholders of such separate accounts are offset within the same line on the statements of operations. Separate accounts credited with a contractual investment return are combined on a line-by-line basis with the Company’s general account assets, liabilities, revenues and expenses and the accounting for these investments is consistent with the methodologies described herein for similar financial instruments held within the general account. Unit-linked separate account investments that are directed by contractholders but do not meet one or more of the other above criteria are included in Contractholder-directed equity securities. The Company’s revenues reflect fees charged to the separate accounts, including mortality charges, risk charges, policy administration fees, investment management fees and surrender charges. Such fees are included in universal life and investment-type product policy fees on the statements of operations.
Future Policy Benefit Liabilities and Policyholder Account Balances	Future Policy Benefit Liabilities and Policyholder Account Balances The Company establishes liabilities for amounts payable under insurance policies. Generally, amounts are payable over an extended period of time and related liabilities are calculated as the present value of future expected benefits to be paid, reduced by the present value of future expected premiums. Such liabilities are established based on methods and underlying assumptions in accordance with GAAP and applicable actuarial standards. Principal assumptions used in the establishment of liabilities for future policy benefits are mortality, morbidity, policy lapse, renewal, retirement, disability incidence, disability terminations, investment returns, inflation, expenses and other contingent events as appropriate to the respective product type and geographical area. These assumptions are established at the time the policy is issued and are intended to estimate the experience for the period the policy benefits are payable. Utilizing these assumptions, liabilities are established on a block of business basis. For long duration insurance contracts, assumptions such as mortality, morbidity and interest rates are “locked in” upon the issuance of new business. However, significant adverse changes in experience on such contracts may require the establishment of premium deficiency reserves. Such reserves are determined based on the then current assumptions and do not include a provision for adverse deviation. Premium deficiency reserves may also be established for short-duration contracts to provide for expected future losses. These reserves are based on actuarial estimates of the amount of loss inherent in that period, including losses incurred for which claims have not been reported. The provisions for unreported claims are calculated using studies that measure the historical length of time between the incurred date of a claim and its eventual reporting to the Company. Anticipated investment income is considered in the calculation of premium deficiency losses for short-duration contracts. Liabilities for universal and variable life policies with secondary guarantees (“ULSG”) and paid-up guarantees are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the life of the contract based on total expected assessments. The assumptions used in estimating the secondary and paid-up guarantee liabilities are consistent with those used for amortizing deferred policy acquisition costs (“DAC”), and are thus subject to the same variability and risk as further discussed herein. The assumptions of investment performance and volatility for variable products are consistent with historical experience of appropriate underlying equity indices, such as the S&P Global Ratings (“S&P”) 500 Index. The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios. The Company regularly reviews its estimates of liabilities for future policy benefits and compares them with its actual experience. Differences result in changes to the liability balances with related charges or credits to benefit expenses in the period in which the changes occur. Future policy benefits are measured as follows: Product Type: Measurement Assumptions: Participating life Aggregate of (i) net level premium reserves for death and endowment policy benefits (calculated based upon the non-forfeiture interest rate, ranging from 3% to 7% for U.S. businesses and less than 1% to 10% for non-U.S. businesses and mortality rates guaranteed in calculating the cash surrender values described in such contracts); and (ii) the liability for terminal dividends for U.S. businesses. Nonparticipating life Aggregate of the present value of future expected benefit payments and related expenses less the present value of future expected net premiums. Assumptions as to mortality and persistency are based upon the Company’s experience when the basis of the liability is established. Interest rate assumptions for the aggregate future policy benefit liabilities range from 2% to 11% for U.S. businesses and less than 1% to 10% for non-U.S. businesses. Individual and group traditional fixed annuities after annuitization Present value of future expected payments. Interest rate assumptions used in establishing such liabilities range from 1% to 11% for U.S. businesses and less than 1% to 9% for non-U.S. businesses. Non-medical health insurance The net level premium method and assumptions as to future morbidity, withdrawals and interest, which provide a margin for adverse deviation. Interest rate assumptions used in establishing such liabilities range from 1% to 7% (primarily related to U.S. businesses). Disabled lives Present value of benefits method and experience assumptions as to claim terminations, expenses and interest. Interest rate assumptions used in establishing such liabilities range from 2% to 8% for U.S. businesses and less than 1% to 9% for non-U.S. businesses.
Variable Annuity Guaranteed Minimum Benefits	The Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits that provide the policyholder a minimum return based on their initial deposit adjusted for withdrawals. These guarantees are accounted for as insurance liabilities or as embedded derivatives depending on how and when the benefit is paid. Specifically, a guarantee is accounted for as an embedded derivative if a guarantee is paid without requiring (i) the occurrence of a specific insurable event, or (ii) the policyholder to annuitize. Alternatively, a guarantee is accounted for as an insurance liability if the guarantee is paid only upon either (i) the occurrence of a specific insurable event, or (ii) annuitization. In certain cases, a guarantee may have elements of both an insurance liability and an embedded derivative and in such cases the guarantee is split and accounted for under both models. Guarantees accounted for as insurance liabilities in future policy benefits include guaranteed minimum death benefits (“GMDBs”), the life-contingent portion of guaranteed minimum withdrawal benefits (“GMWBs”), elective annuitizations of guaranteed minimum income benefits (“GMIBs”), and the life contingent portion of GMIBs that require annuitization when the account balance goes to zero. Guarantees accounted for as embedded derivatives in policyholder account balances include guaranteed minimum accumulation benefits (“GMABs”), the non-life contingent portion of GMWBs and certain non-life contingent portions of GMIBs. At inception, the Company attributes to the embedded derivative a portion of the projected future guarantee fees to be collected from the policyholder equal to the present value of projected future guaranteed benefits. Any additional fees represent “excess” fees and are reported in universal life and investment-type product policy fees. The Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits. GMABs, the non-life contingent portion of GMWBs and certain non-life contingent portions of GMIBs are accounted for as embedded derivatives in policyholder account balances and are further discussed in Note 9. Guarantees accounted for as insurance liabilities include: Guarantee: Measurement Assumptions: GMDBs • A return of purchase payment upon death even if the account value is reduced to zero. • Present value of expected death benefits in excess of the projected account balance recognizing the excess ratably over the accumulation period based on the present value of total expected assessments. • An enhanced death benefit may be available for an additional fee. • Assumptions are consistent with those used for amortizing DAC, and are thus subject to the same variability and risk. • Investment performance and volatility assumptions are consistent with the historical experience of the appropriate underlying equity index, such as the S&P 500 Index. • Benefit assumptions are based on the average benefits payable over a range of scenarios. GMIBs • After a specified period of time determined at the time of issuance of the variable annuity contract, a minimum accumulation of purchase payments, even if the account value is reduced to zero, that can be annuitized to receive a monthly income stream that is not less than a specified amount. • Present value of expected income benefits in excess of the projected account balance at any future date of annuitization and recognizing the excess ratably over the accumulation period based on present value of total expected assessments. • Certain contracts also provide for a guaranteed lump sum return of purchase premium in lieu of the annuitization benefit. • Assumptions are consistent with those used for estimating GMDB liabilities. • Calculation incorporates an assumption for the percentage of the potential annuitizations that may be elected by the contractholder. GMWBs • A return of purchase payment via partial withdrawals, even if the account value is reduced to zero, provided that cumulative withdrawals in a contract year do not exceed a certain limit. • Expected value of the life contingent payments and expected assessments using assumptions consistent with those used for estimating the GMDB liabilities. • Certain contracts include guaranteed withdrawals that are life contingent.
Other Policy-Related Balances	Other Policy-Related Balances Other policy-related balances include policy and contract claims, premiums received in advance, unearned revenue liabilities, obligations assumed under structured settlement assignments, policyholder dividends due and unpaid, policyholder dividends left on deposit and negative value of business acquired (“VOBA”). The liability for policy and contract claims generally relates to incurred but not reported (“IBNR”) death, disability, dental and vision claims. In addition, included in other policy-related balances are claims which have been reported but not yet settled for death, disability, dental and vision. The liability for these claims is based on the Company’s estimated ultimate cost of settling all claims. The Company derives estimates for the development of IBNR claims principally from analyses of historical patterns of claims by business line. The methods used to determine these estimates are continually reviewed. Adjustments resulting from this continuous review process and differences between estimates and payments for claims are recognized in policyholder benefits and claims expense in the period in which the estimates are changed or payments are made. The Company accounts for the prepayment of premiums on its individual life, group life and health contracts as premiums received in advance. These amounts are then recognized in premiums when due. The unearned revenue liability relates to universal life and investment-type products and represents policy charges for services to be provided in future periods. The charges are deferred as unearned revenue and amortized using the product’s estimated gross profits and margins, similar to DAC as discussed further herein. Such amortization is recorded in universal life and investment-type product policy fees.
Recognition of Insurance Revenues and Deposits	Recognition of Insurance Revenues and Deposits Premiums related to traditional life, annuity contracts with life contingencies, long-duration accident & health, and credit insurance policies are recognized as revenues when due from policyholders. Policyholder benefits and expenses are provided to recognize profits over the estimated lives of the insurance policies. When premiums are due over a significantly shorter period than the period over which benefits are provided, any excess profit is deferred and recognized into earnings in a constant relationship to insurance in-force or, for annuities, the amount of expected future policy benefit payments. Premiums related to short-duration non-medical health and disability, accident & health, and certain credit insurance contracts are recognized on a pro rata basis over the applicable contract term. Deposits related to universal life and investment-type products are credited to policyholder account balances. Revenues from such contracts consist of fees for mortality, policy administration and surrender charges and are recorded in universal life and investment-type product policy fees in the period in which services are provided. Amounts that are charged to earnings include interest credited and benefit claims incurred in excess of related policyholder account balances. Premiums related to the Company’s former property and casualty contracts are recognized as revenue on a pro rata basis over the applicable contract term. Unearned premiums, representing the portion of premium written related to the unexpired coverage, are included in future policy benefits. See Note 3 for information on the Company’s business dispositions. All revenues and expenses are presented net of reinsurance, as applicable.
Deferred Policy Acquisition Costs and Value of Business Acquired	Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles The Company incurs significant costs in connection with acquiring new and renewal insurance business. Costs that are related directly to the successful acquisition or renewal of insurance contracts are capitalized as DAC. Such costs include: • incremental direct costs of contract acquisition, such as commissions; • the portion of an employee’s total compensation and benefits related to time spent selling, underwriting or processing the issuance of new and renewal insurance business only with respect to actual policies acquired or renewed; • other essential direct costs that would not have been incurred had a policy not been acquired or renewed; and • the costs of direct-response advertising, the primary purpose of which is to elicit sales to customers who could be shown to have responded specifically to the advertising and that results in probable future benefits. All other acquisition-related costs, including those related to general advertising and solicitation, market research, agent training, product development, unsuccessful sales and underwriting efforts, as well as all indirect costs, are expensed as incurred. VOBA is an intangible asset resulting from a business combination that represents the excess of book value over the estimated fair value of acquired insurance, annuity, and investment-type contracts in-force at the acquisition date. The estimated fair value of the acquired liabilities is based on projections, by each block of business, of future policy and contract charges, premiums, mortality and morbidity, separate account performance, surrenders, operating expenses, investment returns, nonperformance risk adjustment and other factors. Actual experience with the purchased business may vary from these projections. DAC and VOBA are amortized as follows: Products: In proportion to the following over estimated lives of the contracts: • Nonparticipating and non-dividend-paying traditional contracts: Actual and expected future gross premiums. • Term insurance • Nonparticipating whole life insurance • Traditional group life insurance • Non-medical health insurance • Accident & health insurance • Participating, dividend-paying traditional contracts Actual and expected future gross margins. • Fixed and variable universal life contracts Actual and expected future gross profits. • Fixed and variable deferred annuity contracts • Credit insurance contracts Actual and future earned premiums. • Property and casualty insurance contracts (prior to the disposition of the Company’s property and casualty business. See Note 3.) • Other short-duration contracts See Note 5 for additional information on DAC and VOBA amortization. Amortization of DAC and VOBA is included in other expenses. The recovery of DAC and VOBA is dependent upon the future profitability of the related business. DAC and VOBA are aggregated on the financial statements for reporting purposes. Nonparticipating and Non-Dividend-Paying Traditional Contracts The Company amortizes DAC and VOBA related to these contracts (term insurance, nonparticipating whole life insurance, traditional group life insurance, non-medical health insurance, and accident & health insurance) over the appropriate premium paying period in proportion to the actual and expected future gross premiums that were set at contract issue. The expected premiums are based upon the premium requirement of each policy and assumptions for mortality, morbidity, persistency and investment returns at policy issuance, or policy acquisition (as it relates to VOBA), include provisions for adverse deviation, and are consistent with the assumptions used to calculate future policyholder benefit liabilities. These assumptions are not revised after policy issuance or acquisition unless the DAC or VOBA balance is deemed to be unrecoverable from future expected profits. Absent a premium deficiency, variability in amortization after policy issuance or acquisition is caused only by variability in premium volumes. Participating, Dividend-Paying Traditional Contracts The Company amortizes DAC and VOBA related to these contracts over the estimated lives of the contracts in proportion to actual and expected future gross margins. The amortization includes interest based on rates in effect at inception or acquisition of the contracts. The future gross margins are dependent principally on investment returns, policyholder dividend scales, mortality, persistency, expenses to administer the business, creditworthiness of reinsurance counterparties and certain economic variables, such as inflation. For participating contracts within the closed block (dividend-paying traditional contracts) future gross margins are also dependent upon changes in the policyholder dividend obligation. See Note 7. Of these factors, the Company anticipates that investment returns, expenses, persistency and other factor changes, as well as policyholder dividend scales, are reasonably likely to impact significantly the rate of DAC and VOBA amortization. Each reporting period, the Company updates the estimated gross margins with the actual gross margins for that period. When the actual gross margins change from previously estimated gross margins, the cumulative DAC and VOBA amortization is re-estimated and adjusted by a cumulative charge or credit to current operations. When actual gross margins exceed those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the actual gross margins are below the previously estimated gross margins. Each reporting period, the Company also updates the actual amount of business in-force, which impacts expected future gross margins. When expected future gross margins are below those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the expected future gross margins are above the previously estimated expected future gross margins. Each period, the Company also reviews the estimated gross margins for each block of business to determine the recoverability of DAC and VOBA balances. Fixed and Variable Universal Life Contracts and Fixed and Variable Deferred Annuity Contracts The Company amortizes DAC and VOBA related to these contracts over the estimated lives of the contracts in proportion to actual and expected future gross profits. The amortization includes interest based on rates in effect at inception or acquisition of the contracts. The amount of future gross profits is dependent principally upon returns in excess of the amounts credited to policyholders, mortality, persistency, interest crediting rates, expenses to administer the business, creditworthiness of reinsurance counterparties, the effect of any hedges used and certain economic variables, such as inflation. Of these factors, the Company anticipates that investment returns, expenses and persistency are reasonably likely to significantly impact the rate of DAC and VOBA amortization. Each reporting period, the Company updates the estimated gross profits with the actual gross profits for that period. When the actual gross profits change from previously estimated gross profits, the cumulative DAC and VOBA amortization is re-estimated and adjusted by a cumulative charge or credit to current operations. When actual gross profits exceed those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the actual gross profits are below the previously estimated gross profits. Each reporting period, the Company also updates the actual amount of business remaining in-force, which impacts expected future gross profits. When expected future gross profits are below those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the expected future gross profits are above the previously estimated expected future gross profits. Each period, the Company also reviews the estimated gross profits for each block of business to determine the recoverability of DAC and VOBA balances. Credit Insurance and Other Short-Duration Contracts The Company amortizes DAC for these contracts, which is primarily composed of commissions and certain underwriting expenses, in proportion to actual and future earned premium over the applicable contract term. Factors Impacting Amortization Separate account rates of return on variable universal life contracts and variable deferred annuity contracts affect in-force account balances on such contracts each reporting period, which can result in significant fluctuations in amortization of DAC and VOBA. Returns that are higher than the Company’s long-term expectation produce higher account balances, which increases the Company’s future fee expectations and decreases future benefit payment expectations on minimum death and living benefit guarantees, resulting in higher expected future gross profits. The opposite result occurs when returns are lower than the Company’s long-term expectation. The Company’s practice to determine the impact of gross profits resulting from returns on separate accounts assumes that long-term appreciation in equity markets is not changed by short-term market fluctuations, but is only changed when sustained interim deviations are expected. The Company monitors these events and only changes the assumption when its long-term expectation changes. The Company also periodically reviews other long-term assumptions underlying the projections of estimated gross margins and profits. These assumptions primarily relate to investment returns, policyholder dividend scales, interest crediting rates, mortality, persistency, policyholder behavior and expenses to administer business. Management annually updates assumptions used in the calculation of estimated gross margins and profits which may have significantly changed. If the update of assumptions causes expected future gross margins and profits to increase, DAC and VOBA amortization will decrease, resulting in a current period increase to earnings. The opposite result occurs when the assumption update causes expected future gross margins and profits to decrease. Periodically, the Company modifies product benefits, features, rights or coverages that occur by the exchange of a contract for a new contract, or by amendment, endorsement, or rider to a contract, or by election or coverage within a contract. If such modification, referred to as an internal replacement, substantially changes the contract, the associated DAC or VOBA is written off immediately through income and any new deferrable costs associated with the replacement contract are deferred. If the modification does not substantially change the contract, the DAC or VOBA amortization on the original contract will continue and any acquisition costs associated with the related modification are expensed. Amortization of DAC and VOBA is attributed to net investment gains (losses) and net derivative gains (losses), and to other expenses for the amount of gross margins or profits originating from transactions other than investment gains and losses. Unrealized investment gains and losses represent the amount of DAC and VOBA that would have been amortized if such gains and losses had been recognized.
Intangible Assets Arising from Insurance Contracts Acquired in Business Combination, Policy	Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles The Company incurs significant costs in connection with acquiring new and renewal insurance business. Costs that are related directly to the successful acquisition or renewal of insurance contracts are capitalized as DAC. Such costs include: • incremental direct costs of contract acquisition, such as commissions; • the portion of an employee’s total compensation and benefits related to time spent selling, underwriting or processing the issuance of new and renewal insurance business only with respect to actual policies acquired or renewed; • other essential direct costs that would not have been incurred had a policy not been acquired or renewed; and • the costs of direct-response advertising, the primary purpose of which is to elicit sales to customers who could be shown to have responded specifically to the advertising and that results in probable future benefits. All other acquisition-related costs, including those related to general advertising and solicitation, market research, agent training, product development, unsuccessful sales and underwriting efforts, as well as all indirect costs, are expensed as incurred. VOBA is an intangible asset resulting from a business combination that represents the excess of book value over the estimated fair value of acquired insurance, annuity, and investment-type contracts in-force at the acquisition date. The estimated fair value of the acquired liabilities is based on projections, by each block of business, of future policy and contract charges, premiums, mortality and morbidity, separate account performance, surrenders, operating expenses, investment returns, nonperformance risk adjustment and other factors. Actual experience with the purchased business may vary from these projections. DAC and VOBA are amortized as follows: Products: In proportion to the following over estimated lives of the contracts: • Nonparticipating and non-dividend-paying traditional contracts: Actual and expected future gross premiums. • Term insurance • Nonparticipating whole life insurance • Traditional group life insurance • Non-medical health insurance • Accident & health insurance • Participating, dividend-paying traditional contracts Actual and expected future gross margins. • Fixed and variable universal life contracts Actual and expected future gross profits. • Fixed and variable deferred annuity contracts • Credit insurance contracts Actual and future earned premiums. • Property and casualty insurance contracts (prior to the disposition of the Company’s property and casualty business. See Note 3.) • Other short-duration contracts See Note 5 for additional information on DAC and VOBA amortization. Amortization of DAC and VOBA is included in other expenses. The recovery of DAC and VOBA is dependent upon the future profitability of the related business. DAC and VOBA are aggregated on the financial statements for reporting purposes. See Note 1 for a description of capitalized acquisition costs. Nonparticipating and Non-Dividend-Paying Traditional Contracts The Company amortizes DAC and VOBA related to these contracts (term insurance, nonparticipating whole life insurance, traditional group life insurance, non-medical health insurance, and accident & health insurance) over the appropriate premium paying period in proportion to the actual and expected future gross premiums that were set at contract issue. The expected premiums are based upon the premium requirement of each policy and assumptions for mortality, morbidity, persistency and investment returns at policy issuance, or policy acquisition (as it relates to VOBA), include provisions for adverse deviation, and are consistent with the assumptions used to calculate future policyholder benefit liabilities. These assumptions are not revised after policy issuance or acquisition unless the DAC or VOBA balance is deemed to be unrecoverable from future expected profits. Absent a premium deficiency, variability in amortization after policy issuance or acquisition is caused only by variability in premium volumes. Participating, Dividend-Paying Traditional Contracts The Company amortizes DAC and VOBA related to these contracts over the estimated lives of the contracts in proportion to actual and expected future gross margins. The amortization includes interest based on rates in effect at inception or acquisition of the contracts. The future gross margins are dependent principally on investment returns, policyholder dividend scales, mortality, persistency, expenses to administer the business, creditworthiness of reinsurance counterparties and certain economic variables, such as inflation. For participating contracts within the closed block (dividend-paying traditional contracts) future gross margins are also dependent upon changes in the policyholder dividend obligation. See Note 7. Of these factors, the Company anticipates that investment returns, expenses, persistency and other factor changes, as well as policyholder dividend scales, are reasonably likely to impact significantly the rate of DAC and VOBA amortization. Each reporting period, the Company updates the estimated gross margins with the actual gross margins for that period. When the actual gross margins change from previously estimated gross margins, the cumulative DAC and VOBA amortization is re-estimated and adjusted by a cumulative charge or credit to current operations. When actual gross margins exceed those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the actual gross margins are below the previously estimated gross margins. Each reporting period, the Company also updates the actual amount of business in-force, which impacts expected future gross margins. When expected future gross margins are below those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the expected future gross margins are above the previously estimated expected future gross margins. Each period, the Company also reviews the estimated gross margins for each block of business to determine the recoverability of DAC and VOBA balances. Fixed and Variable Universal Life Contracts and Fixed and Variable Deferred Annuity Contracts The Company amortizes DAC and VOBA related to these contracts over the estimated lives of the contracts in proportion to actual and expected future gross profits. The amortization includes interest based on rates in effect at inception or acquisition of the contracts. The amount of future gross profits is dependent principally upon returns in excess of the amounts credited to policyholders, mortality, persistency, interest crediting rates, expenses to administer the business, creditworthiness of reinsurance counterparties, the effect of any hedges used and certain economic variables, such as inflation. Of these factors, the Company anticipates that investment returns, expenses and persistency are reasonably likely to significantly impact the rate of DAC and VOBA amortization. Each reporting period, the Company updates the estimated gross profits with the actual gross profits for that period. When the actual gross profits change from previously estimated gross profits, the cumulative DAC and VOBA amortization is re-estimated and adjusted by a cumulative charge or credit to current operations. When actual gross profits exceed those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the actual gross profits are below the previously estimated gross profits. Each reporting period, the Company also updates the actual amount of business remaining in-force, which impacts expected future gross profits. When expected future gross profits are below those previously estimated, the DAC and VOBA amortization will increase, resulting in a current period charge to earnings. The opposite result occurs when the expected future gross profits are above the previously estimated expected future gross profits. Each period, the Company also reviews the estimated gross profits for each block of business to determine the recoverability of DAC and VOBA balances. Credit Insurance and Other Short-Duration Contracts The Company amortizes DAC for these contracts, which is primarily composed of commissions and certain underwriting expenses, in proportion to actual and future earned premium over the applicable contract term. Factors Impacting Amortization Separate account rates of return on variable universal life contracts and variable deferred annuity contracts affect in-force account balances on such contracts each reporting period, which can result in significant fluctuations in amortization of DAC and VOBA. Returns that are higher than the Company’s long-term expectation produce higher account balances, which increases the Company’s future fee expectations and decreases future benefit payment expectations on minimum death and living benefit guarantees, resulting in higher expected future gross profits. The opposite result occurs when returns are lower than the Company’s long-term expectation. The Company’s practice to determine the impact of gross profits resulting from returns on separate accounts assumes that long-term appreciation in equity markets is not changed by short-term market fluctuations, but is only changed when sustained interim deviations are expected. The Company monitors these events and only changes the assumption when its long-term expectation changes. The Company also periodically reviews other long-term assumptions underlying the projections of estimated gross margins and profits. These assumptions primarily relate to investment returns, policyholder dividend scales, interest crediting rates, mortality, persistency, policyholder behavior and expenses to administer business. Management annually updates assumptions used in the calculation of estimated gross margins and profits which may have significantly changed. If the update of assumptions causes expected future gross margins and profits to increase, DAC and VOBA amortization will decrease, resulting in a current period increase to earnings. The opposite result occurs when the assumption update causes expected future gross margins and profits to decrease. Periodically, the Company modifies product benefits, features, rights or coverages that occur by the exchange of a contract for a new contract, or by amendment, endorsement, or rider to a contract, or by election or coverage within a contract. If such modification, referred to as an internal replacement, substantially changes the contract, the associated DAC or VOBA is written off immediately through income and any new deferrable costs associated with the replacement contract are deferred. If the modification does not substantially change the contract, the DAC or VOBA amortization on the original contract will continue and any acquisition costs associated with the related modification are expensed. Amortization of DAC and VOBA is attributed to net investment gains (losses) and net derivative gains (losses), and to other expenses for the amount of gross margins or profits originating from transactions other than investment gains and losses. Unrealized investment gains and losses represent the amount of DAC and VOBA that would have been amortized if such gains and losses had been recognized.
Deferred Sales Inducements	The Company generally has two different types of sales inducements which are included in other assets: (i) the policyholder receives a bonus whereby the policyholder’s initial account balance is increased by an amount equal to a specified percentage of the customer’s deposit; and (ii) the policyholder receives a higher interest rate using a dollar cost averaging method than would have been received based on the normal general account interest rate credited. The Company defers sales inducements and amortizes them over the life of the policy using the same methodology and assumptions used to amortize DAC. The amortization of sales inducements is included in policyholder benefits and claims. Each year, or more frequently if circumstances indicate a potential recoverability issue exists, the Company reviews deferred sales inducements (“DSI”) to determine the recoverability of the asset.
Value of Distribution Agreements and Customer Relationships Acquired	Value of distribution agreements acquired (“VODA”) is reported in other assets and represents the present value of expected future profits associated with the expected future business derived from the distribution agreements acquired as part of a business combination. Value of customer relationships acquired (“VOCRA”) is also reported in other assets and represents the present value of the expected future profits associated with the expected future business acquired through existing customers of the acquired company or business. The VODA and VOCRA associated with past business combinations are amortized over the assets’ useful lives ranging from nine
Reinsurance	Reinsurance For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. Cessions under reinsurance agreements do not discharge the Company’s obligations as the primary insurer. The Company reviews all contractual features, including those that may limit the amount of insurance risk to which the reinsurer is subject or features that delay the timely reimbursement of claims. For reinsurance of existing in-force blocks of long-duration contracts that transfer significant insurance risk, the difference, if any, between the amounts paid (received), and the liabilities ceded (assumed) related to the underlying contracts is considered the net cost of reinsurance at the inception of the reinsurance agreement. The net cost of reinsurance is amortized on a basis consistent with the methodologies and assumptions used for amortizing DAC related to the underlying reinsured contracts. Subsequent amounts paid (received) on the reinsurance of in-force blocks, as well as amounts paid (received) related to new business, are recorded as ceded (assumed) premiums; and ceded (assumed) premiums, reinsurance and other receivables (future policy benefits) are established. For prospective reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) are recorded as ceded (assumed) premiums and ceded (assumed) unearned premiums. Ceded (assumed) unearned premiums are reflected as a component of premiums, reinsurance and other receivables (future policy benefits). Such amounts are amortized through earned premiums over the remaining contract period in proportion to the amount of insurance protection provided. For retroactive reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) in excess of the related insurance liabilities ceded (assumed) are recognized immediately as a loss and are reported in the appropriate line item within the statement of operations. Any gain on such retroactive agreement is deferred and is amortized as part of DAC, primarily using the recovery method. Amounts currently recoverable under reinsurance agreements are included in premiums, reinsurance and other receivables and amounts currently payable are included in other liabilities. Assets and liabilities relating to reinsurance agreements with the same reinsurer may be recorded net on the balance sheet, if a right of offset exists within the reinsurance agreement. In the event that reinsurers do not meet their obligations to the Company under the terms of the reinsurance agreements, or when events or changes in circumstances indicate that its carrying amount may not be recoverable, reinsurance recoverable balances could become uncollectible. In such instances, reinsurance recoverable balances are stated net of allowances for uncollectible reinsurance, consistent with credit loss guidance which requires recording an allowance for credit loss (“ACL”). Premiums, fees and policyholder benefits and claims include amounts assumed under reinsurance agreements and are net of reinsurance ceded. Amounts received from reinsurers for policy administration are reported in other expenses. If the Company determines that a reinsurance agreement does not expose the reinsurer to a reasonable possibility of a significant loss from insurance risk, the Company records the agreement using the deposit method of accounting. Deposits received are included in other liabilities and deposits made are included within premiums, reinsurance and other receivables. As amounts are paid or received, consistent with the underlying contracts, the deposit assets or liabilities are adjusted. Interest on such deposits is recorded as other revenues or other expenses, as appropriate. Periodically, the Company evaluates the adequacy of the expected payments or recoveries and adjusts the deposit asset or liability through other revenues or other expenses, as appropriate.
Investments	Investments Net Investment Income Net investment income includes primarily interest income, including amortization of premium and accretion of discount, prepayment fees, dividend income, rental income and equity method income and is net of related investment expenses. Net investment income also includes, to a lesser extent, (i) realized gains (losses) on investments sold or disposed and (ii) unrealized gains (losses) recognized in earnings, representing changes in estimated fair value, primarily for Unit-linked investments (defined below) and fair value option (“FVO”) securities (“FVO Securities”). Net Investment Gains (Losses) Net investment gains (losses) include primarily (i) realized gains (losses) from sales and disposals of investments, which are determined by specific identification, (ii) intent-to-sell impairment losses on fixed maturity securities available-for-sale (“AFS”) and impairment losses on all other asset classes and, to a lesser extent, (iii) recognized gains (losses). Recognized gains (losses) are primarily comprised of the change in the ACL and unrealized gains (losses) for certain investments for which changes in estimated fair value are recognized in earnings. Changes in the ACL includes both (i) provisions for credit loss on fixed maturity securities AFS, mortgage loans and leveraged and direct financing leases and (ii) subsequent changes in the ACL. Unrealized gains (losses), representing changes in estimated fair value recognized in earnings, primarily relate to equity securities and certain other limited partnership interests and real estate joint ventures. Net investment gains (losses) also include non-investment portfolio gains (losses) which do not relate to the performance of the investment portfolio, including gains (losses) from sales and divestitures of businesses and impairment of property, equipment, leasehold improvements and right-of-use (“ROU”) lease assets. Accrued Investment Income Accrued investment income is presented separately on the consolidated balance sheet and excluded from the carrying value of the related investments, primarily fixed maturity securities and mortgage loans. Fixed Maturity Securities The majority of the Company’s fixed maturity securities are classified as AFS and are reported at their estimated fair value. Changes in the estimated fair value of these securities not recognized in earnings representing unrecognized unrealized investment gains (losses) are recorded as a separate component of other comprehensive income (loss) (“OCI”), net of policy-related amounts and deferred income taxes. All security transactions are recorded on a trade date basis. Sales of securities are determined on a specific identification basis. Interest income and prepayment fees are recognized when earned. Interest income is recognized using an effective yield method giving effect to amortization of premium and accretion of discount, and is based on the estimated economic life of the securities, which for mortgage-backed and asset-backed securities considers the estimated timing and amount of prepayments of the underlying loans. See Note 8 “— Fixed Maturity Securities AFS — Methodology for Amortization of Premium and Accretion of Discount on Structured Products.” The amortization of premium and accretion of discount also take into consideration call and maturity dates. Generally, the accrual of income is ceased and accrued investment income that is considered uncollectible is recognized as a charge within net investment gains (losses) when securities are impaired. The Company periodically evaluates these securities for impairment. The assessment of whether impairments have occurred is based on management’s case-by-case evaluation of the underlying reasons for the decline in estimated fair value as described in Note 8 “— Fixed Maturity Securities AFS — Evaluation of Fixed Maturity Securities AFS for Credit Loss.” For securities in an unrealized loss position, a credit loss is recognized in earnings within net investment gains (losses) when it is anticipated that the amortized cost, excluding accrued investment income, will not be recovered. When either: (i) the Company has the intent to sell the security; or (ii) it is more likely than not that the Company will be required to sell the security before recovery, the reduction of amortized cost and the loss recognized in earnings is the entire difference between the security’s amortized cost and estimated fair value. If neither of these conditions exists, the difference between the amortized cost of the security and the present value of projected future cash flows expected to be collected is recognized in earnings as a credit loss by establishing an ACL with a corresponding charge recorded in net investment gains (losses). However, the ACL is limited by the amount that the fair value is less than the amortized cost. This limitation is known as the “fair value floor.” If the estimated fair value is less than the present value of projected future cash flows expected to be collected, this portion of the decline in value related to other-than-credit factors (“noncredit loss”) is recorded in OCI as an unrecognized loss. For purchased credit deteriorated (“PCD”) fixed maturity securities AFS and financing receivables, an ACL is established at acquisition, which is added to the purchase price to establish the initial amortized cost of the investment and is not recognized in earnings. Equity Securities Equity securities are reported at their estimated fair value, with unrealized gains (losses) representing changes in estimated fair value recognized in net investment gains (losses). Sales of securities are determined on a specific identification basis. Dividends are recognized in net investment income when declared. Contractholder-Directed Equity Securities and Fair Value Option Securities Contractholder-directed equity securities and FVO Securities (collectively, “Unit-linked and FVO Securities”) are investments for which the FVO has been elected, or which are otherwise required to be carried at estimated fair value, and include: • contractholder-directed investments supporting unit-linked variable annuity type liabilities (“Unit-linked investments”) which do not qualify for presentation and reporting as separate account summary total assets and liabilities. These investments are primarily equity securities (including mutual funds). The investment returns on these investments inure to contractholders and are offset by a corresponding change in policyholder account balances through interest credited to policyholder account balances; and • fixed maturity and equity securities held-for-investment by the general account to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. Interest income and dividend income on these investments are included in net investment income. Realized gains (losses) on investments sold or disposed and unrealized gains (losses), representing changes in estimated fair value, are both recognized in net investment income for Unit-linked investments and FVO Securities. Sales of these investments are determined on a specific identification basis. Mortgage Loans The Company recognizes an ACL in earnings within net investment gains (losses) at time of purchase based on expected lifetime credit loss on financing receivables carried at amortized cost, including, but not limited to, mortgage loans and leveraged and direct financing leases, in an amount that represents the portion of the amortized cost basis of such financing receivables that the Company does not expect to collect, resulting in financing receivables being presented at the net amount expected to be collected. The Company disaggregates its mortgage loan investments into three portfolio segments: commercial, agricultural and residential. Also included in commercial mortgage loans are revolving line of credit loans collateralized by commercial properties. The accounting policies that are applicable to all portfolio segments are presented below and the accounting policies related to each of the portfolio segments are included in Note 8. Mortgage loans are stated at unpaid principal balance, adjusted for any unamortized premium or discount, deferred fees or expenses, and are net of ACL. Interest income and prepayment fees are recognized when earned. Interest income is recognized using an effective yield method giving effect to amortization of premium and deferred expenses and accretion of discount and deferred fees. The Company ceases to accrue interest when the collection of interest is not considered probable, which is based on a current evaluation of the status of the borrower, including the number of days past due. When a loan is placed on non-accrual status, uncollected past due accrued interest income that is considered uncollectible is charged-off against net investment income. Generally, the accrual of interest income resumes after all delinquent amounts are paid and management believes all future principal and interest payments will be collected. The Company records cash receipts on non-accruing loans in accordance with the loan agreement. The Company records charge-offs of mortgage loan balances not considered collectible upon the realization of a credit loss, for commercial and agricultural mortgage loans typically through foreclosure or after a decision is made to sell a loan, and for residential mortgage loans, typically after considering the individual consumer’s financial status. The charge-off is recorded in net investment gains (losses), net of amounts recognized in ACL. Cash recoveries on principal amounts previously charged-off are generally reported in net investment gains (losses). Also included in mortgage loans are residential mortgage loans for which the FVO was elected, and which are stated at estimated fair value. Changes in estimated fair value are recognized in net investment income. Mortgage loans that are designated as held-for-sale are carried at the lower of amortized cost or estimated fair value. Policy Loans Policy loans are stated at unpaid principal balances. Interest income is recognized as earned using the contractual interest rate. Generally, accrued interest is capitalized on the policy’s anniversary date. Valuation allowances are not established for policy loans, as they are fully collateralized by the cash surrender value of the underlying insurance policies. Any unpaid principal and accrued interest are deducted from the cash surrender value or the death benefit prior to settlement of the insurance policy. Real Estate Real estate is stated at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis, without any provision for salvage value, over the estimated useful life of the asset (typically up to 55 years). Rental income is recognized on a straight-line basis over the term of the respective leases. The Company periodically reviews its real estate for impairment and tests for recoverability whenever events or changes in circumstances indicate the carrying value may not be recoverable. Properties whose carrying values are greater than their estimated undiscounted cash flows are written down to their estimated fair value, which is generally computed using the present value of expected future cash flows discounted at a rate commensurate with the underlying risks. Real estate for which the Company commits to a plan to sell within one year and actively markets in its current condition for a reasonable price in comparison to its estimated fair value is classified as held-for-sale and is not depreciated. Real estate held-for-sale is stated at the lower of depreciated cost or estimated fair value less expected disposition costs. Real Estate Joint Ventures and Other Limited Partnership Interests The Company uses the equity method of accounting or the FVO for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations but does not hold a controlling financial interest, including when the Company is not deemed the primary beneficiary of a VIE. Under the equity method, the Company recognizes in earnings within net investment income its share of the investee’s earnings. Contributions paid by the Company increase carrying value and distributions received by the Company reduce carrying value. The Company generally recognizes its share of the investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. The Company accounts for its interest in real estate joint ventures and other limited partnership interests in which it has virtually no influence over the investee’s operations at estimated fair value. Unrealized gains (losses), representing changes in estimated fair value of these investments, are recognized in earnings within net investment gains (losses). Due to the nature and structure of these investments, they do not meet the characteristics of an equity security in accordance with applicable accounting guidance. The Company consolidates real estate joint ventures and other limited partnership interests of which it holds a controlling financial interest, or it is deemed the primary beneficiary of a VIE. Assets of certain consolidated real estate joint ventures and other limited partnership interests are recorded at estimated fair value. The Company elects the FVO for certain real estate joint ventures that are managed on a total return basis. Unrealized gains (losses) representing changes in estimated fair value for real estate joint ventures and other limited partnership interests recorded at estimated fair value are recognized in net investment income. The Company routinely evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount is not recoverable and exceeds its estimated fair value. When it is determined an equity method investment has had a loss in value that is other than temporary, an impairment is recognized. Such an impairment is charged to net investment gains (losses). Short-term Investments Short-term investments include highly liquid securities and other investments with remaining maturities of one year or less, but greater than three months, at the time of purchase. Securities included within short-term investments are stated at estimated fair value, while other investments included within short-term investments are stated at amortized cost less ACL, which approximates estimated fair value. Other Invested Assets Other invested assets consist principally of the following: • Freestanding derivatives with positive estimated fair values which are described in “— Derivatives” below. • Tax credit and renewable energy partnerships which derive a significant source of investment return in the form of income tax credits or other tax incentives. Where tax credits are guaranteed by a creditworthy third party, the investment is accounted for under the effective yield method. Otherwise, the investment is accounted for under the equity method. See Note 19. • Annuities funding structured settlement claims represent annuities funding claims assumed by the Company in its capacity as a structured settlements assignment company. The annuities are stated at their contract value, which represents the present value of the future periodic claim payments to be provided. The net investment income recognized reflects the amortization of discount of the annuity at its implied effective interest rate. • Investments in operating joint ventures that engage in insurance underwriting activities are accounted for under the equity method. • Direct financing leases net investment is equal to the minimum lease payment receivables plus the unguaranteed residual value, less the unearned income, less ACL. Income is recognized by applying the pre-tax internal rate of return to the investment balance. The Company regularly reviews its minimum lease payment receivables for credit loss and residual value for impairments. Certain direct financing leases are linked to inflation. • Leveraged leases net investment is equal to the minimum lease payment receivables plus the unguaranteed residual value, less the unearned income, less ACL and is reported net of non-recourse debt. Income is recognized by applying the leveraged lease’s estimated rate of return to the net investment in the lease in those periods in which the net investment at the beginning of the period is positive. Leveraged leases derive investment returns in part from their income tax benefit. The Company regularly reviews its minimum lease payment receivables for credit loss and residual value for impairments. • Investments in Federal Home Loan Bank of New York (“FHLBNY”) common stock are carried at redemption value and are considered restricted investments until redeemed by FHLBNY. Dividends are recognized in net investment income when declared. • Funds withheld represent a receivable for amounts contractually withheld by ceding companies in accordance with reinsurance agreements. The Company recognizes interest on funds withheld at rates defined by the terms of the agreement which may be contractually specified or directly related to the underlying investments. Securities Lending Transactions and Repurchase Agreements The Company accounts for securities lending transactions and repurchase agreements as financing arrangements and the associated liability is recorded at the amount of cash received. The securities loaned or sold under these agreements are included in invested assets. Income and expenses associated with securities lending transactions and repurchase agreements are recognized as investment income and investment expense, respectively, within net investment income. Securities Lending Transactions The Company enters into securities lending transactions, whereby securities are loaned to unaffiliated financial institutions. The Company obtains collateral at the inception of the loan, usually cash, in an amount generally equal to 102% of the estimated fair value of the securities loaned, and maintains it at a level greater than or equal to 100% for the duration of the loan. Securities loaned under such transactions may be sold or re-pledged by the transferee. The Company is liable to return to the counterparties the cash collateral received. Security collateral on deposit from counterparties in connection with securities lending transactions may not be sold or re-pledged, unless the counterparty is in default, and is not reflected on the Company’s consolidated financial statements. The Company monitors the ratio of the collateral held to the estimated fair value of the securities loaned on a daily basis and additional collateral is obtained as necessary throughout the duration of the loan. Repurchase Agreements The Company participates in short-term repurchase agreements with unaffiliated financial institutions. Under these agreements, the Company sells securities and receives cash in an amount generally equal to 85% to 100% of the estimated fair value of the securities sold at the inception of the transaction, with a simultaneous agreement to repurchase such securities at a future date or on demand in an amount equal to the cash initially received plus interest. The Company monitors the ratio of the cash held to the estimated fair value of the securities sold throughout the duration of the transaction and additional cash or securities are obtained as necessary. Securities sold under such transactions may be sold or re-pledged by the transferee. Investment Risks and Uncertainties Investments are exposed to the following primary sources of risk: credit, interest rate, liquidity, market valuation, currency and real estate risk. The financial statement risks, stemming from such investment risks, are those associated with the determination of estimated fair values, the diminished ability to sell certain investments in times of strained market conditions, the recognition of ACL and impairments, the recognition of income on certain investments and the potential consolidation of VIEs. The use of different methodologies, assumptions and inputs relating to these financial statement risks may have a material effect on the amounts presented within the consolidated financial statements. The determination of ACL and impairments is highly subjective and is based upon quarterly evaluations and assessments of known and inherent risks associated with the respective asset class. Such evaluations and assessments are revised as conditions change and new information becomes available. The recognition of income on certain investments (e.g. structured securities, including mortgage-backed securities, asset-backed securities and collateralized loan obligations (“ABS & CLO”), certain structured investment transactions and FVO Securities) is dependent upon certain factors such as prepayments and defaults, and changes in such factors could result in changes in amounts to be earned. Methodology for Amortization of Premium and Accretion of Discount on Structured Products Amortization of premium and accretion of discount on Structured Products considers the estimated timing and amount of prepayments of the underlying loans. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the originally anticipated and the actual prepayments received and currently anticipated. Prepayment assumptions for Structured Products are estimated using inputs obtained from third-party specialists and based on management’s knowledge of the current market. For credit-sensitive and certain prepayment-sensitive Structured Products, the effective yield is recalculated on a prospective basis. For all other Structured Products, the effective yield is recalculated on a retrospective basis. Evaluation of Fixed Maturity Securities AFS for Credit Loss Evaluation and Measurement Methodologies Management considers a wide range of factors about the security issuer and uses its best judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for near-term recovery. Inherent in management’s evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations used in the credit loss evaluation process include, but are not limited to: (i) the extent to which the estimated fair value has been below amortized cost, (ii) adverse conditions specifically related to a security, an industry sector or sub-sector, or an economically depressed geographic area, adverse change in the financial condition of the issuer of the security, changes in technology, discontinuance of a segment of the business that may affect future earnings, and changes in the quality of credit enhancement, (iii) payment structure of the security and likelihood of the issuer being able to make payments, (iv) failure of the issuer to make scheduled interest and principal payments, (v) whether the issuer, or series of issuers or an industry has suffered a catastrophic loss or has exhausted natural resources, (vi) whether the Company has the intent to sell or will more likely than not be required to sell a particular security before the decline in estimated fair value below amortized cost recovers, (vii) with respect to Structured Products, changes in forecasted cash flows after considering the changes in the financial condition of the underlying loan obligors and quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security, and the payment priority within the tranche structure of the security, (viii) changes in the rating of the security by a rating agency, and (ix) other subjective factors, including concentrations and information obtained from regulators. The methodology and significant inputs used to determine the amount of credit loss are as follows: • The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security at the time of purchase for fixed-rate securities and the spot rate at the date of evaluation of credit loss for floating-rate securities. • When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall credit loss evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s single best estimate, the most likely outcome in a range of possible outcomes, after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security; the likelihood that the issuer can service the interest and principal payments; the quality and amount of any credit enhancements; the security’s position within the capital structure of the issuer; possible corporate restructurings or asset sales by the issuer; any private and public sector programs to restructure foreign government securities and municipals; and changes to the rating of the security or the issuer by rating agencies. • Additional considerations are made when assessing the unique features that apply to certain Structured Products including, but not limited to: the quality of underlying collateral, historical performance of the underlying loan obligors, historical rent and vacancy levels, changes in the financial condition of the underlying loan obligors, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, changes in the quality of credit enhancement and the payment priority within the tranche structure of the security. With respect to securities that have attributes of debt and equity (“perpetual hybrid securities”), consideration is given in the credit loss analysis as to whether there has been any deterioration in the credit of the issuer and the likelihood of recovery in value of the securities that are in a severe unrealized loss position. Consideration is also given as to whether any perpetual hybrid securities with an unrealized loss, regardless of credit rating, have deferred any dividend payments. Allowance for Credit Loss Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable) and reasonably expected TDRs (i.e., the Company grants concessions to a borrower that is experiencing financial difficulties) are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Commercial and agricultural mortgage loan ACL are calculated in a similar manner. Within each loan portfolio segment, commercial and agricultural, loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are
Derivatives	Derivatives Freestanding Derivatives Freestanding derivatives are carried on the Company’s balance sheet either as assets within other invested assets or as liabilities within other liabilities at estimated fair value. The Company does not offset the estimated fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement. Accruals on derivatives are generally recorded in accrued investment income or within other liabilities. However, accruals that are not scheduled to settle within one year are included with the derivative’s carrying value in other invested assets or other liabilities. If a derivative is not designated as an accounting hedge or its use in managing risk does not qualify for hedge accounting, changes in the estimated fair value of the derivative are reported in net derivative gains (losses) except as follows: Statement of Operations Presentation: Derivative: Policyholder benefits and claims • Economic hedges of variable annuity guarantees included in future policy benefits Net investment income • Economic hedges of equity method investments in joint ventures • Derivatives held within Unit-linked investments • Economic hedges of FVO Securities which are linked to equity indices Hedge Accounting To qualify for hedge accounting, at the inception of the hedging relationship, the Company formally documents its risk management objective and strategy for undertaking the hedging transaction, as well as its designation of the hedge. Hedge designation and financial statement presentation of changes in estimated fair value of the hedging derivatives are as follows: • Fair value hedge - a hedge of the estimated fair value of a recognized asset or liability - in the same line item as the earnings effect of the hedged item. The carrying value of the hedged recognized asset or liability is adjusted for changes in its estimated fair value due to the hedged risk. • Cash flow hedge - a hedge of a forecasted transaction or of the variability of cash flows to be received or paid related to a recognized asset or liability - in OCI and reclassified into the statement of operations when the Company’s earnings are affected by the variability in cash flows of the hedged item. • Net investment in a foreign operation (“NIFO”) hedge - in OCI, consistent with the translation adjustment for the hedged net investment in the foreign operation. The changes in estimated fair values of the hedging derivatives are exclusive of any accruals that are separately reported on the statement of operations within interest income or interest expense to match the location of the hedged item. Accruals on derivatives in net investment hedges are recognized in OCI. In its hedge documentation, the Company sets forth how the hedging instrument is expected to hedge the designated risks related to the hedged item and sets forth the method that will be used to retrospectively and prospectively assess the hedging instrument’s effectiveness. A derivative designated as a hedging instrument must be assessed as being highly effective in offsetting the designated risk of the hedged item. Hedge effectiveness is formally assessed at inception and at least quarterly throughout the life of the designated hedging relationship. Assessments of hedge effectiveness are also subject to interpretation and estimation and different interpretations or estimates may have a material effect on the amount reported in net income. The Company discontinues hedge accounting prospectively when: (i) it is determined that the derivative is no longer highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item; (ii) the derivative expires, is sold, terminated, or exercised; (iii) it is no longer probable that the hedged forecasted transaction will occur; or (iv) the derivative is de-designated as a hedging instrument. When hedge accounting is discontinued because it is determined that the derivative is not highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized in net derivative gains (losses). The carrying value of the hedged recognized asset or liability under a fair value hedge is no longer adjusted for changes in its estimated fair value due to the hedged risk, and the cumulative adjustment to its carrying value is amortized into income over the remaining life of the hedged item. The changes in estimated fair value of derivatives related to discontinued cash flow hedges remain in OCI unless it is probable that the hedged forecasted transaction will not occur. When hedge accounting is discontinued because it is no longer probable that the forecasted transactions will occur on the anticipated date or within two months of that date, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized currently in net derivative gains (losses). Deferred gains and losses of a derivative recorded in OCI pursuant to the discontinued cash flow hedge of a forecasted transaction that is no longer probable of occurring are recognized immediately in net investment gains (losses). In all other situations in which hedge accounting is discontinued, the derivative is carried at its estimated fair value on the balance sheet, with changes in its estimated fair value recognized in the current period as net derivative gains (losses). Embedded Derivatives The Company issues certain products, which include variable annuities, and investment contracts and is a party to certain reinsurance agreements that have embedded derivatives. The Company assesses each identified embedded derivative to determine whether it is required to be bifurcated. The embedded derivative is bifurcated from the host contract and accounted for as a freestanding derivative if: • the combined instrument is not accounted for in its entirety at estimated fair value with changes in estimated fair value recorded in earnings; • the terms of the embedded derivative are not clearly and closely related to the economic characteristics of the host contract; and • a separate instrument with the same terms as the embedded derivative would qualify as a derivative instrument. Such embedded derivatives are carried on the balance sheet at estimated fair value with the host contract and changes in their estimated fair value are generally reported in net derivative gains (losses). If the Company is unable to properly identify and measure an embedded derivative for separation from its host contract, the entire contract is carried on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income. Additionally, the Company may elect to carry an entire contract on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income if that contract contains an embedded derivative that requires bifurcation. At inception, the Company attributes to the embedded derivative a portion of the projected future guarantee fees to be collected from the policyholder equal to the present value of projected future guaranteed benefits. Any additional fees represent “excess” fees and are reported in universal life and investment-type product policy fees. Cash Flow Hedges The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities; (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities; (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments; (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed rate investments; and (v) interest rate swaps and interest rate forwards to hedge forecasted fixed rate borrowings. Credit Risk on Freestanding Derivatives The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s OTC-bilateral derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of Dodd-Frank) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, effective September 1, 2021, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians. The Company’s OTC-cleared derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 10 for a description of the impact of credit risk on the valuation of derivatives.
Fair Value	Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. In most cases, the exit price and the transaction (or entry) price will be the same at initial recognition. Subsequent to initial recognition, fair values are based on unadjusted quoted prices for identical assets or liabilities in active markets that are readily and regularly obtainable. When such unadjusted quoted prices are not available, estimated fair values are based on quoted prices in markets that are not active, quoted prices for similar but not identical assets or liabilities, or other observable inputs. If these inputs are not available, or observable inputs are not determinable, unobservable inputs and/or adjustments to observable inputs requiring significant management judgment are used to determine the estimated fair value of assets and liabilities. These unobservable inputs can be based on management’s judgment, assumptions or estimation and may not be observable in market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing the assets.
Fair Value Transfer	Transfers between Levels Overall, transfers between levels occur when there are changes in the observability of inputs and market activity. Transfers into or out of Level 3: Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.
Goodwill	Goodwill Goodwill represents the future economic benefits arising from net assets acquired in a business combination that are not individually identified and recognized. Goodwill is calculated as the excess of the cost of the acquired entity over the estimated fair value of such assets acquired and liabilities assumed. Goodwill is not amortized, but is tested for impairment at least annually, or more frequently if events or circumstances indicate that there may be justification for conducting an interim test. The Company performs its annual goodwill impairment testing during the third quarter based upon data as of the close of the second quarter. Goodwill associated with a business acquisition is not tested for impairment during the year the business is acquired unless there is a significant identified impairment event. The Company tests goodwill for impairment by performing a qualitative assessment and/or a quantitative test. The qualitative impairment assessment is an assessment of historical information and relevant current events and circumstances, including economic, industry and market considerations, to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company may elect not to perform the qualitative impairment assessment for some or all of its reporting units and perform a quantitative impairment test. In performing the quantitative impairment test, the Company may determine the fair values of its reporting units by applying a market multiple, discounted cash flow, and/or an actuarial-based valuation approach. The valuation methodologies utilized are subject to key judgments and assumptions that are sensitive to change. The impairment test is performed at the reporting unit level, which is the operating segment or a business one level below the operating segment, if discrete financial information is prepared and regularly reviewed by management at that level. For purposes of goodwill impairment testing, if the carrying value of a reporting unit exceeds its estimated fair value, an impairment charge would be recognized for the amount by which the carrying value exceeds the reporting unit’s fair value; however, the loss recognized would not exceed the total amount of goodwill allocated to that reporting unit. Additionally, the Company will consider income tax effects from any tax deductible goodwill on the carrying value of the reporting unit when measuring the goodwill impairment loss, if applicable. On an ongoing basis, the Company evaluates potential triggering events that may affect the estimated fair value of the Company’s reporting units to assess whether any goodwill impairment exists. Deteriorating or adverse economic, industry and market conditions for certain reporting units may have a significant impact on the estimated fair value of these reporting units and could result in future impairments of goodwill.
Employee Benefit Plans	Employee Benefit Plans Certain subsidiaries of MetLife, Inc. sponsor defined benefit pension plans and other postretirement benefit plans covering eligible employees. Measurement dates used for all of the subsidiaries’ defined benefit pension and other postretirement benefit plans correspond with the fiscal year ends of sponsoring subsidiaries, which is December 31 for U.S. and non-U.S. subsidiaries. The Company recognizes the funded status of each of its defined benefit pension and other postretirement benefit plans, measured as the difference between the fair value of plan assets and the benefit obligation, which is the projected benefit obligation (“PBO”) for pension benefits and the accumulated postretirement benefit obligation (“APBO”) for other postretirement benefits in other assets or other liabilities. Actuarial gains and losses result from differences between each plan’s actual experience and the assumed experience on plan assets or PBO/APBO during a particular period and are recorded in accumulated OCI (“AOCI”). To the extent such gains and losses exceed 10% of the greater of the PBO/APBO or the estimated fair value of plan assets, the excess is amortized into net periodic benefit costs, generally over the average projected future service years of the active employees. In addition, prior service costs (credit) are recognized in AOCI at the time of the amendment and then amortized to net periodic benefit costs over the average projected future service years of the active employees. Net periodic benefit costs are determined using management’s estimates and actuarial assumptions and are comprised of service cost, interest cost, settlement and curtailment costs, expected return on plan assets, amortization of net actuarial (gains) losses, and amortization of prior service costs (credit). Fair value is used to determine the expected return on plan assets. The subsidiaries also sponsor defined contribution plans for substantially all U.S. employees under which a portion of employee contributions is matched. Applicable matching contributions are made each payroll period. Accordingly, the Company recognizes compensation cost for current matching contributions. As all contributions are transferred currently as earned to the defined contribution plans, no liability for matching contributions is recognized on the balance sheets.
Income Tax	Income Tax MetLife, Inc. and its includable life insurance and non-life insurance subsidiaries file a consolidated U.S. federal income tax return in accordance with the provisions of the Internal Revenue Code of 1986, as amended. Non-includable subsidiaries file either separate individual corporate tax returns or separate consolidated tax returns. The Company’s accounting for income taxes represents management’s best estimate of various events and transactions. Deferred tax assets and liabilities resulting from temporary differences between the financial reporting and tax bases of assets and liabilities are measured at the balance sheet date using enacted tax rates expected to apply to taxable income in the years the temporary differences are expected to reverse. The realization of deferred tax assets depends upon the existence of sufficient taxable income within the carryback or carryforward periods under the tax law in the applicable tax jurisdiction. Valuation allowances are established against deferred tax assets when management determines, based on available information, that it is more likely than not that deferred income tax assets will not be realized. Significant judgment is required in determining whether valuation allowances should be established, as well as the amount of such allowances. When making such determination, the Company considers many factors, including: • the nature, frequency, and amount of cumulative financial reporting income and losses in recent years; • the jurisdiction in which the deferred tax asset was generated; • the length of time that carryforward can be utilized in the various taxing jurisdictions; • future taxable income exclusive of reversing temporary differences and carryforwards; • future reversals of existing taxable temporary differences; • taxable income in prior carryback years; and • tax planning strategies, including the intent and ability to hold certain AFS debt securities until they recover in value. The Company may be required to change its provision for income taxes when estimates used in determining valuation allowances on deferred tax assets significantly change or when receipt of new information indicates the need for adjustment in valuation allowances. Additionally, the effect of changes in tax laws, tax regulations, or interpretations of such laws or regulations, is recognized in net income tax expense (benefit) in the period of change. The Company determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded on the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likely of being realized upon settlement. Unrecognized tax benefits due to tax uncertainties that do not meet the threshold are included within other liabilities and are charged to earnings in the period that such determination is made.
Litigation Contingencies	Litigation Contingencies The Company is a defendant in a large number of litigation matters and is involved in a number of regulatory investigations. Liabilities are established when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Except as otherwise disclosed in Note 21, legal costs are recognized as incurred. On a quarterly and annual basis, the Company reviews relevant information with respect to liabilities for litigation, regulatory investigations and litigation-related contingencies to be reflected on the Company’s consolidated financial statements.
Stock-based Compensation	Stock-Based Compensation The Company grants certain employees and directors stock-based compensation awards under various plans, subject to vesting conditions. The Company recognizes compensation expense in an amount fixed at grant date or remeasured quarterly as described in Note 16. The Company generally recognizes this expense over the vesting period. However, the Company truncates the expense period to the date the employee attained age-and-service criteria to exercise or receive payment for the award regardless of continued employment. In such a case, the Company does not accelerate award exercise or payment timing. The Company also takes an estimation of forfeitures into account. MetLife estimates the fair value of Stock Options on the date of grant using a binomial lattice model. The significant assumptions the Company uses in its binomial lattice model include: expected volatility of the price of Shares; risk-free rate of return; dividend yield on Shares; exercise multiple; and the post-vesting termination rate. MetLife bases expected volatility on an analysis of historical prices of Shares and call options on Shares traded on the open market. The Company uses a weighted-average of the implied volatility for publicly-traded call options with the longest remaining maturity nearest to the money as of each valuation date and the historical volatility, calculated using monthly closing prices of Shares. The Company chose a monthly measurement interval for historical volatility as this interval reflects the Company’s view that employee option exercise decisions are based on longer-term trends in the price of the underlying Shares rather than on daily price movements. The Company’s binomial lattice model incorporates different risk-free rates based on the imputed forward rates for U.S. Treasury Strips for each year over the contractual term of the option. The table below presents the full range of rates that were used for options granted during the respective periods. The Company determines dividend yield based on historical dividend distributions compared to the price of the underlying Shares as of the valuation date and held constant over the life of the Stock Option.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid securities and other investments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Securities included within cash equivalents are stated at estimated fair value, while other investments included within cash equivalents are stated at amortized cost which approximates estimated fair value.
Property, Equipment, Leasehold Improvements and Computer Software	Property, Equipment, Leasehold Improvements and Computer Software Property, equipment and leasehold improvements, which are included in other assets, are stated at cost, less accumulated depreciation and amortization. Depreciation is determined using the straight-line method over the estimated useful lives of the assets, as appropriate. The estimated life is generally 40 years for company occupied real estate property, the shorter of the useful life or remaining lease term up to 10 years for leasehold improvements, and from three Computer software, which is included in other assets, is stated at cost, less accumulated amortization. Purchased software costs, as well as certain internal and external costs incurred to develop internal-use computer software during the application development stage, are capitalized. Such costs are amortized over a four
Leases	Leases The Company, as lessee, has entered into various lease and sublease agreements for office space and equipment. At contract inception, the Company determines that an arrangement contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. For contracts that contain a lease, the Company recognizes the ROU asset in other assets and the lease liability in other liabilities. The Company evaluates whether a ROU asset is impaired when events or changes in circumstances indicate that its carrying amount may not be recoverable. Leases with an initial term of 12 months or less are not recorded on the balance sheet and the associated lease costs are recorded as an expense on a straight-line basis over the lease term. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are determined using the Company’s incremental borrowing rate based upon information available at commencement date to recognize the present value of lease payments over the lease term. ROU assets also include lease payments and excludes lease incentives. Lease terms may include options to extend or terminate the lease and are included in the lease measurement when it is reasonably certain that the Company will exercise that option. The Company has lease agreements with lease and non-lease components. The Company does not separate lease and non-lease components and accounts for these items as a single lease component for all asset classes. The majority of the Company’s leases and subleases are operating leases related to office space. The Company recognizes lease expense for operating leases on a straight-line basis over the lease term.
Other Revenues	Other Revenues Other revenues primarily include fees related to service contracts from customers for vision fee for service arrangements, prepaid legal plans, administrative services-only contracts, and investment management services. Substantially all of the revenue from the services is recognized over time as the applicable services are provided or are made available to the customers. The revenue recognized includes variable consideration to the extent it is probable that a significant reversal will not occur. In addition to the service fees, other revenues also include certain stable value fees and other miscellaneous revenues. These fees and miscellaneous revenues are recognized as earned.
Policyholder Dividends	Policyholder Dividends Policyholder dividends are approved annually by the insurance subsidiaries’ boards of directors. The aggregate amount of policyholder dividends is related to actual interest, mortality, morbidity and expense experience for the year, as well as management’s judgment as to the appropriate level of statutory surplus to be retained by the insurance subsidiaries.
Foreign Currency	Foreign Currency Assets, liabilities and operations of foreign affiliates and subsidiaries, as well as investments accounted for under the equity method, are recorded based on the functional currency of each entity. The determination of the functional currency is made based on the appropriate economic and management indicators. For most of the Company’s foreign operations, the local currency is the functional currency. For certain other foreign operations, such as Japan, the local currency and one or more other currencies qualify as functional currencies. Assets and liabilities of foreign affiliates and subsidiaries are translated from the functional currency to U.S. dollars at the exchange rates in effect at each year-end and revenues and expenses are translated at the average exchange rates during the year. The resulting translation adjustments are charged or credited directly to OCI, net of applicable taxes. Gains and losses from foreign currency transactions, including the effect of re-measurement of monetary assets and liabilities to the appropriate functional currency, are reported as part of net investment gains (losses) in the period in which they occur.
Earnings Per Common Share	Earnings Per Common Share Basic earnings per common share are computed based on the weighted average number of common shares, or their equivalent, outstanding during the period. Diluted earnings per common share include the dilutive effect of the assumed exercise or issuance of stock-based awards using the treasury stock method. Under the treasury stock method, exercise or issuance of stock-based awards is assumed to occur with the proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.
Closed Block	On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company (“MLIC”) converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC. Assets have been allocated to the closed block in an amount that has been determined to produce cash flows which, together with anticipated revenues from the policies included in the closed block, are reasonably expected to be sufficient to support obligations and liabilities relating to these policies, including, but not limited to, provisions for the payment of claims and certain expenses and taxes, and to provide for the continuation of policyholder dividend scales in effect for 1999, if the experience underlying such dividend scales continues, and for appropriate adjustments in such scales if the experience changes. At least annually, the Company compares actual and projected experience against the experience assumed in the then-current dividend scales. Dividend scales are adjusted periodically to give effect to changes in experience. The closed block assets, the cash flows generated by the closed block assets and the anticipated revenues from the policies in the closed block will benefit only the holders of the policies in the closed block. To the extent that, over time, cash flows from the assets allocated to the closed block and claims and other experience related to the closed block are, in the aggregate, more or less favorable than what was assumed when the closed block was established, total dividends paid to closed block policyholders in the future may be greater than or less than the total dividends that would have been paid to these policyholders if the policyholder dividend scales in effect for 1999 had been continued. Any cash flows in excess of amounts assumed will be available for distribution over time to closed block policyholders and will not be available to stockholders. If the closed block has insufficient funds to make guaranteed policy benefit payments, such payments will be made from assets outside of the closed block. The closed block will continue in effect as long as any policy in the closed block remains in-force. The expected life of the closed block is over 100 years from the Demutualization Date. The Company uses the same accounting principles to account for the participating policies included in the closed block as it used prior to the Demutualization Date. However, the Company establishes a policyholder dividend obligation for earnings that will be paid to policyholders as additional dividends as described below. The excess of closed block liabilities over closed block assets at the Demutualization Date (adjusted to eliminate the impact of related amounts in AOCI) represents the estimated maximum future earnings from the closed block expected to result from operations, attributed net of income tax, to the closed block. Earnings of the closed block are recognized in income over the period the policies and contracts in the closed block remain in-force. Management believes that over time the actual cumulative earnings of the closed block will approximately equal the expected cumulative earnings due to the effect of dividend changes. If, over the period the closed block remains in existence, the actual cumulative earnings of the closed block are greater than the expected cumulative earnings of the closed block, the Company will pay the excess to closed block policyholders as additional policyholder dividends unless offset by future unfavorable experience of the closed block and, accordingly, will recognize only the expected cumulative earnings in income with the excess recorded as a policyholder dividend obligation. If over such period, the actual cumulative earnings of the closed block are less than the expected cumulative earnings of the closed block, the Company will recognize only the actual earnings in income. However, the Company may change policyholder dividend scales in the future, which would be intended to increase future actual earnings until the actual cumulative earnings equal the expected cumulative earnings. Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company’s net income continues to be sensitive to the actual performance of the closed block.
New Accounting Pronouncements	Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s consolidated financial statements. Adopted Accounting Pronouncements The table below describes the impacts of the ASUs adopted by the Company, effective January 1, 2022. Standard Description Effective Date and Method of Adoption Impact on Financial Statements ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting ; as clarified and amended by ASU 2021-01, Reference Rate Reform (Topic 848): Scope; as amended by ASU 2022-06, Reference Rate Reform (Topic 848)—Deferral of the Sunset Date of Topic 848 The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, with certain exceptions. ASU 2021-01 amends the scope of the recent reference rate reform guidance. New optional expedients allow derivative instruments impacted by changes in the interest rate used for margining, discounting, or contract price alignment to qualify for certain optional relief. The amendments in ASU 2022-06 extend the sunset date of the reference rate reform optional expedients and exceptions to December 31, 2024. Effective for contract modifications made between March 12, 2020 and December 31, 2024. The guidance has reduced the operational and financial impacts of contract modifications that replace a reference rate, such as London Interbank Offered Rate (“LIBOR”), affected by reference rate reform. Contract modifications for invested assets and derivative instruments occurred during 2021 and 2022 and will continue into 2023. Based on actions taken to date, the adoption of the guidance has not had a material impact on the Company’s consolidated financial statements. The Company does not expect the adoption of this guidance to have a material ongoing impact on its consolidated financial statements.
Reclassification	Reclassifications Cash flows from short term investments in the prior years’ Consolidated Statement of Cash Flows, which were previously presented net, have been revised to gross presentation to conform with the current year presentation. The revision in presentation was not material to the previously presented financial statements. Additionally, the deferred income tax asset in the prior years’ Consolidated Balance Sheets, which was previously included in other assets, has been reclassified to conform with the current year presentation.

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Reporting Information, by Segment	Year Ended December 31, 2022 U.S. Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 35,548 $ 5,568 $ 3,226 $ 1,964 $ 3,066 $ (16) $ 49,356 $ 41 $ 49,397 Universal life and investment-type product policy fees 1,158 1,840 1,175 300 1,057 2 5,532 53 5,585 Net investment income (1) 7,340 3,909 1,593 160 4,971 216 18,189 (2,273) 15,916 Other revenues 1,756 90 39 35 155 396 2,471 163 2,634 Net investment gains (losses) — — — — — — — (1,262) (1,262) Net derivative gains (losses) — — — — — — — (2,372) (2,372) Total revenues 45,802 11,407 6,033 2,459 9,249 598 75,548 (5,650) 69,898 Expenses Policyholder benefits and claims and policyholder dividends 36,273 4,752 3,301 990 6,056 (6) 51,366 (53) 51,313 Interest credited to policyholder account balances 1,789 2,003 335 71 813 — 5,011 (1,319) 3,692 Capitalization of DAC (77) (1,524) (499) (411) (28) (8) (2,547) (11) (2,558) Amortization of DAC and VOBA 59 1,105 339 333 192 9 2,037 (106) 1,931 Amortization of negative VOBA — (36) — (5) — — (41) — (41) Interest expense on debt 9 — 12 — 8 909 938 — 938 Other expenses 3,962 3,153 1,553 1,171 953 709 11,501 263 11,764 Total expenses 42,015 9,453 5,041 2,149 7,994 1,613 68,265 (1,226) 67,039 Provision for income tax expense (benefit) 791 576 231 64 247 (356) 1,553 (1,252) 301 Adjusted earnings $ 2,996 $ 1,378 $ 761 $ 246 $ 1,008 $ (659) 5,730 Adjustments to: Total revenues (5,650) Total expenses 1,226 Provision for income tax (expense) benefit 1,252 Net income (loss) $ 2,558 $ 2,558 At December 31, 2022 U.S. Asia (2) Latin EMEA MetLife Corporate Total (In millions) Total assets $ 252,559 $ 150,134 $ 63,810 $ 16,765 $ 149,739 $ 33,604 $ 666,611 Separate account assets $ 61,030 $ 8,292 $ 39,428 $ 3,314 $ 33,974 $ — $ 146,038 Separate account liabilities $ 61,030 $ 8,292 $ 39,428 $ 3,314 $ 33,974 $ — $ 146,038 __________________ (1) Net investment income from equity method investments represents 5%, 12%, 3% and 6% of segment net investment income for the U.S., Asia, Latin America and MetLife Holdings segments, respectively. (2) Total assets includes $127.1 billion of assets from the Company’s Japan operations which represents 19% of total assets. Year Ended December 31, 2021 U.S. Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 26,358 $ 6,421 $ 2,609 $ 2,271 $ 3,333 $ 35 $ 41,027 $ 982 $ 42,009 Universal life and investment-type product policy fees 1,140 1,814 1,109 395 1,101 2 5,561 195 5,756 Net investment income (1) 8,048 5,052 1,271 215 6,450 244 21,280 115 21,395 Other revenues 1,538 73 41 47 257 420 2,376 243 2,619 Net investment gains (losses) — — — — — — — 1,529 1,529 Net derivative gains (losses) — — — — — — — (2,228) (2,228) Total revenues 37,084 13,360 5,030 2,928 11,141 701 70,244 836 71,080 Expenses Policyholder benefits and claims and policyholder dividends 27,957 5,008 3,143 1,241 6,268 34 43,651 1,179 44,830 Interest credited to policyholder account balances 1,422 1,995 249 86 840 — 4,592 946 5,538 Capitalization of DAC (65) (1,607) (414) (469) (33) (11) (2,599) (119) (2,718) Amortization of DAC and VOBA 60 1,369 285 356 257 9 2,336 219 2,555 Amortization of negative VOBA — (27) — (7) — — (34) — (34) Interest expense on debt 7 — 5 — 5 902 919 1 920 Other expenses 3,632 3,388 1,401 1,324 992 562 11,299 564 11,863 Total expenses 33,013 10,126 4,669 2,531 8,329 1,496 60,164 2,790 62,954 Provision for income tax expense (benefit) 850 936 70 96 570 (591) 1,931 (380) 1,551 Adjusted earnings $ 3,221 $ 2,298 $ 291 $ 301 $ 2,242 $ (204) 8,149 Adjustments to: Total revenues 836 Total expenses (2,790) Provision for income tax (expense) benefit 380 Net income (loss) $ 6,575 $ 6,575 At December 31, 2021 U.S. Asia (2) Latin EMEA MetLife Corporate Total (In millions) Total assets $ 282,741 $ 169,291 $ 59,763 $ 27,038 $ 179,551 $ 41,324 $ 759,708 Separate account assets $ 81,217 $ 10,241 $ 37,632 $ 3,098 $ 47,685 $ — $ 179,873 Separate account liabilities $ 81,217 $ 10,241 $ 37,632 $ 3,098 $ 47,685 $ — $ 179,873 __________________ (1) Net investment income from equity method investments represents 23%, 30%, 7% and 26% of segment net investment income for the U.S., Asia, Latin America and MetLife Holdings segments, respectively. (2) Total assets includes $142.7 billion of assets from the Company’s Japan operations which represents 19% of total assets. Year Ended December 31, 2020 U.S. Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 27,265 $ 6,571 $ 2,265 $ 2,259 $ 3,600 $ 22 $ 41,982 $ 52 $ 42,034 Universal life and investment-type product policy fees 1,070 1,892 994 433 1,073 3 5,465 138 5,603 Net investment income (1) 6,903 3,938 992 269 5,184 42 17,328 (211) 17,117 Other revenues 957 61 38 52 238 344 1,690 159 1,849 Net investment gains (losses) — — — — — — — (110) (110) Net derivative gains (losses) — — — — — — — 1,349 1,349 Total revenues 36,195 12,462 4,289 3,013 10,095 411 66,465 1,377 67,842 Expenses Policyholder benefits and claims and policyholder dividends 26,309 5,213 2,406 1,196 6,738 (3) 41,859 692 42,551 Interest credited to policyholder account balances 1,622 1,834 240 109 868 — 4,673 541 5,214 Capitalization of DAC (453) (1,652) (362) (491) (39) (11) (3,008) (5) (3,013) Amortization of DAC and VOBA 471 1,415 276 454 370 8 2,994 166 3,160 Amortization of negative VOBA — (37) — (8) — — (45) — (45) Interest expense on debt 7 — 4 1 6 895 913 — 913 Other expenses 4,162 3,481 1,318 1,344 942 625 11,872 263 12,135 Total expenses 32,118 10,254 3,882 2,605 8,885 1,514 59,258 1,657 60,915 Provision for income tax expense (benefit) 853 643 127 81 234 (556) 1,382 127 1,509 Adjusted earnings $ 3,224 $ 1,565 $ 280 $ 327 $ 976 $ (547) 5,825 Adjustments to: Total revenues 1,377 Total expenses (1,657) Provision for income tax (expense) benefit (127) Net income (loss) $ 5,418 $ 5,418 __________________ (1) Net investment income from equity method investments represents 5%, 12%, 1% and 5% of segment net investment income for the U.S., Asia, Latin America and MetLife Holdings segments, respectively.
Revenue from External Customers by Products and Services	The following table presents total premiums, universal life and investment-type product policy fees and other revenues by major product groups of the Company’s segments, as well as Corporate & Other: Years Ended December 31, 2022 2021 2020 (In millions) Life insurance $ 21,969 $ 22,872 $ 21,256 Accident & health insurance 17,453 17,498 15,346 Annuities 16,647 7,499 7,916 Other 1,547 2,515 4,968 Total $ 57,616 $ 50,384 $ 49,486
Revenue from External Customers by Geographic Areas	The following table presents total premiums, universal life and investment-type product policy fees and other revenues associated with the Company’s U.S. and foreign operations: Years Ended December 31, 2022 2021 2020 (In millions) U.S. $ 43,319 $ 35,252 $ 34,717 Foreign: Japan 5,532 6,426 6,750 Other 8,765 8,706 8,019 Total $ 57,616 $ 50,384 $ 49,486

Dispositions - Dispositions (Ta

Dispositions - Dispositions (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	The following table summarizes the assets and liabilities held-for-sale: December 31, 2021 (In millions) Assets: Fixed maturity securities available-for-sale $ 2,043 Contractholder-directed equity securities 1,114 Other investments 118 Total investments 3,275 Cash and cash equivalents 69 Deferred policy acquisition costs and value of business acquired 138 Other 259 Separate account assets 3,497 Total assets held-for-sale $ 7,238 Liabilities: Future policy benefits $ 916 Policyholder account balances 2,005 Other policy-related balances 103 Other 113 Separate account liabilities 3,497 Total liabilities held-for-sale $ 6,634

Insurance (Tables)

Insurance (Tables)	12 Months Ended
	Dec. 31, 2022
Insurance [Abstract]
Insurance Liabilities	Insurance liabilities are comprised of future policy benefits, policyholder account balances and other policy-related balances. Information regarding insurance liabilities by segment, as well as Corporate & Other, was as follows at: December 31, 2022 2021 (In millions) U.S. $ 171,693 $ 162,999 Asia 125,523 125,839 Latin America 17,674 15,564 EMEA 10,635 13,031 MetLife Holdings 100,407 102,291 Corporate & Other 1,029 1,221 Total $ 426,961 $ 420,945
Liabilities for Guarantees	Information regarding the liabilities for guarantees (excluding base policy liabilities and embedded derivatives) relating to annuity and universal and variable life contracts was as follows: Annuity Contracts Universal and Variable GMDBs and GMIBs Secondary Paid-Up Total (In millions) Direct and Assumed: Balance at January 1, 2020 $ 465 $ 894 $ 3,762 $ 427 $ 5,548 Incurred guaranteed benefits (1) 195 240 602 26 1,063 Paid guaranteed benefits (21) (5) (99) (45) (170) Balance at December 31, 2020 639 1,129 4,265 408 6,441 Incurred guaranteed benefits (1) 133 87 (37) 43 226 Paid guaranteed benefits (29) (7) (102) (47) (185) Reclassified to liabilities held-for-sale (2) — (32) — — (32) Balance at December 31, 2021 743 1,177 4,126 404 6,450 Incurred guaranteed benefits (1) 247 (269) (261) 104 (179) Paid guaranteed benefits (39) (14) (120) (44) (217) Balance at December 31, 2022 $ 951 $ 894 $ 3,745 $ 464 $ 6,054 Ceded: Balance at January 1, 2020 $ — $ 10 $ 349 $ 281 $ 640 Incurred guaranteed benefits (11) (3) 96 43 125 Paid guaranteed benefits 9 — (18) (32) (41) Balance at December 31, 2020 (2) 7 427 292 724 Incurred guaranteed benefits (6) 2 57 30 83 Paid guaranteed benefits 8 — (33) (34) (59) Reclassified to liabilities held-for-sale (2) — — — — — Balance at December 31, 2021 — 9 451 288 748 Incurred guaranteed benefits (8) (1) 29 33 53 Paid guaranteed benefits 8 — (24) (32) (48) Balance at December 31, 2022 $ — $ 8 $ 456 $ 289 $ 753 Net: Balance at January 1, 2020 $ 465 $ 884 $ 3,413 $ 146 $ 4,908 Incurred guaranteed benefits 206 243 506 (17) 938 Paid guaranteed benefits (30) (5) (81) (13) (129) Balance at December 31, 2020 641 1,122 3,838 116 5,717 Incurred guaranteed benefits 139 85 (94) 13 143 Paid guaranteed benefits (37) (7) (69) (13) (126) Reclassified to liabilities held-for-sale (2) — (32) — — (32) Balance at December 31, 2021 743 1,168 3,675 116 5,702 Incurred guaranteed benefits 255 (268) (290) 71 (232) Paid guaranteed benefits (47) (14) (96) (12) (169) Balance at December 31, 2022 $ 951 $ 886 $ 3,289 $ 175 $ 5,301 __________________ (1) Secondary guarantees include the effects of foreign currency translation of ($268) million, ($260) million and $125 million at December 31, 2022, 2021 and 2020, respectively. (2) See Note 3 for information on the Company’s business dispositions.
Fund Groupings	Account balances of contracts with guarantees were invested in separate account asset classes as follows at: December 31, 2022 2021 (In millions) Fund Groupings: Equity $ 20,875 $ 29,346 Balanced 12,657 17,393 Bond 4,036 5,041 Money Market 305 218 Total $ 37,873 $ 51,998
Guarantees related to Annuity, Universal and Variable Life Contracts	Information regarding the Company’s guarantee exposure, which includes direct and assumed business, but excludes offsets from hedging or ceded reinsurance, if any, was as follows at: December 31, 2022 2021 In the At In the At (Dollars in millions) Annuity Contracts: Variable Annuity Guarantees: Total account value (1), (2), (3) $ 46,345 $ 16,953 $ 62,281 $ 23,121 Separate account value (1) $ 30,066 $ 15,584 $ 42,043 $ 21,508 Net amount at risk (2) $ 5,338 (4) $ 433 (5) $ 1,490 (4) $ 500 (5) Average attained age of contractholders 68 years 68 years 68 years 66 years Other Annuity Guarantees: Total account value (1), (3) N/A $ 4,101 N/A $ 5,002 Net amount at risk N/A $ 188 (6) N/A $ 196 (6) Average attained age of contractholders N/A 57 years N/A 56 years December 31, 2022 2021 Secondary Paid-Up Secondary Paid-Up (Dollars in millions) Universal and Variable Life Contracts: Total account value (1), (3) $ 11,948 $ 2,570 $ 13,678 $ 2,694 Net amount at risk (7) $ 80,623 $ 11,824 $ 78,762 $ 12,657 Average attained age of policyholders 55 years 67 years 55 years 66 years __________________ (1) The Company’s annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive. (2) Includes amounts, which are not reported on the consolidated balance sheets, from assumed variable annuity guarantees from the Company’s former operating joint venture in Japan. (3) Includes the contractholders’ investments in the general account and separate account, if applicable. (4) Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death. (5) Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved. (6) Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date. (7) Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date.
Schedule of liability recorded and collateral pledged for funding agreements	Certain subsidiaries have also entered into funding agreements with FHLBNY and a subsidiary of the Federal Agricultural Mortgage Corporation, a federally chartered instrumentality of the U.S. (“Farmer Mac”). The liability for such funding agreements is included in policyholder account balances. Information related to such funding agreements was as follows at: Liability Collateral December 31, 2022 2021 2022 2021 (In millions) FHLBNY (1) $ 14,940 $ 15,750 $ 17,857 (2) $ 17,981 (2) Farmer Mac (3) $ 2,050 $ 2,050 $ 2,148 $ 2,159 __________________ (1) Represents funding agreements issued to FHLBNY in exchange for cash and for which it has been granted a lien on certain assets, some of which are in the custody of FHLBNY, including residential mortgage-backed securities (“RMBS”), to collateralize obligations under such funding agreements. The applicable subsidiary of the Company is permitted to withdraw any portion of the collateral in the custody of FHLBNY as long as there is no event of default and the remaining qualified collateral is sufficient to satisfy the collateral maintenance level. Upon any event of default by such subsidiary, FHLBNY’s recovery on the collateral is limited to the amount of such subsidiary’s liability to FHLBNY. (2) Advances are collateralized primarily by mortgage-backed securities presented at estimated fair value. The remaining collateral is mortgage loans presented at carrying value. (3) Represents funding agreements issued to a subsidiary of Farmer Mac. The obligations under these funding agreements are secured by a pledge of certain eligible agricultural mortgage loans and may, under certain circumstances, be secured by other qualified collateral. The amount of collateral presented is at carrying value. Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value and were as follows at: December 31, 2022 2021 (In millions) Invested assets on deposit (regulatory deposits) $ 1,514 $ 1,872 Invested assets held in trust (external reinsurance agreements) (1) 881 1,114 Invested assets pledged as collateral (2) 25,442 24,261 Total invested assets on deposit, held in trust and pledged as collateral $ 27,837 $ 27,247 __________________ (1) Represents assets held in trust related to third-party reinsurance agreements. Excludes assets held in trust related to reinsurance agreements between wholly-owned subsidiaries of $1.9 billion and $2.1 billion at December 31, 2022 and 2021, respectively. (2) The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements (see Note 4), derivative transactions (see Note 9), secured debt and short-term debt related to repurchase agreements (see Note 13), and a collateral financing arrangement (see Note 14).
Short-duration Insurance Contracts, Claims Development	Group Life - Term Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 6,637 $ 6,713 $ 6,719 $ 6,720 $ 6,730 $ 6,720 $ 6,723 $ 6,724 $ 6,726 $ 6,726 $ 1 213,283 2014 6,986 6,919 6,913 6,910 6,914 6,919 6,920 6,918 6,920 1 216,148 2015 7,040 7,015 7,014 7,021 7,024 7,025 7,026 7,026 1 218,782 2016 7,125 7,085 7,095 7,104 7,105 7,104 7,107 2 220,671 2017 7,432 7,418 7,425 7,427 7,428 7,428 3 263,546 2018 7,757 7,655 7,646 7,650 7,651 6 251,446 2019 7,935 7,900 7,907 7,917 11 252,015 2020 8,913 9,367 9,389 23 297,022 2021 10,555 10,795 64 327,725 2022 9,640 1,129 276,784 Total 80,599 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (77,480) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 22 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 3,141 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 5,216 $ 6,614 $ 6,664 $ 6,678 $ 6,711 $ 6,715 $ 6,720 $ 6,721 $ 6,723 $ 6,724 2014 5,428 6,809 6,858 6,869 6,902 6,912 6,915 6,916 6,917 2015 5,524 6,913 6,958 6,974 7,008 7,018 7,022 7,024 2016 5,582 6,980 7,034 7,053 7,086 7,096 7,100 2017 5,761 7,292 7,355 7,374 7,400 7,414 2018 6,008 7,521 7,578 7,595 7,629 2019 6,178 7,756 7,820 7,853 2020 6,862 9,103 9,242 2021 8,008 10,476 2022 7,101 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 77,480 Group Long-Term Disability Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 1,008 $ 1,027 $ 1,032 $ 1,049 $ 1,070 $ 1,069 $ 1,044 $ 1,032 $ 1,025 $ 1,027 $ — 21,139 2014 1,076 1,077 1,079 1,101 1,109 1,098 1,097 1,081 1,078 — 22,853 2015 1,082 1,105 1,093 1,100 1,087 1,081 1,067 1,086 — 21,216 2016 1,131 1,139 1,159 1,162 1,139 1,124 1,123 — 17,973 2017 1,244 1,202 1,203 1,195 1,165 1,181 — 16,328 2018 1,240 1,175 1,163 1,147 1,170 — 15,214 2019 1,277 1,212 1,169 1,177 — 15,392 2020 1,253 1,223 1,155 6 15,719 2021 1,552 1,608 43 19,189 2022 1,695 760 9,970 Total 12,300 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (6,251) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 1,496 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 7,545 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 43 $ 234 $ 382 $ 475 $ 551 $ 622 $ 676 $ 722 $ 764 $ 798 2014 51 266 428 526 609 677 732 778 818 2015 50 264 427 524 601 665 718 764 2016 49 267 433 548 628 696 750 2017 56 290 476 579 655 719 2018 54 314 497 594 666 2019 57 342 522 620 2020 59 355 535 2021 95 505 2022 76 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 6,251 Group Disability & Group Life Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 129 $ 130 $ 151 $ 146 $ 145 $ 153 $ 153 $ 156 $ 157 $ 155 $ 5 6,597 2014 257 241 222 222 233 229 230 230 224 8 6,865 2015 243 232 235 229 239 241 245 241 13 6,792 2016 203 206 195 208 210 215 216 19 4,707 2017 263 244 252 270 277 272 30 5,619 2018 321 293 305 315 309 56 5,982 2019 347 324 339 335 79 5,966 2020 385 359 331 127 5,030 2021 367 382 211 5,659 2022 487 399 3,461 Total 2,952 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (2,006) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 11 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 957 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 38 $ 86 $ 105 $ 118 $ 129 $ 142 $ 138 $ 146 $ 149 $ 150 2014 60 125 156 175 197 198 208 213 216 2015 71 134 167 180 204 218 225 229 2016 57 117 134 167 181 190 197 2017 77 138 183 224 240 242 2018 84 155 209 243 252 2019 93 170 221 257 2020 85 153 203 2021 77 171 2022 89 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 2,006 Protection Life Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 152 $ 215 $ 221 $ 222 $ 221 $ 223 $ 224 $ 224 $ 224 $ 216 $ — 30,204 2014 229 350 360 328 332 332 333 333 324 — 38,375 2015 300 431 401 406 406 407 401 391 — 44,496 2016 318 416 427 434 435 436 426 — 38,800 2017 327 319 319 318 318 308 — 30,819 2018 305 295 293 294 292 1 29,563 2019 329 301 304 301 2 32,017 2020 497 498 502 10 42,318 2021 632 550 34 51,077 2022 436 163 30,066 Total 3,746 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (3,347) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 6 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 405 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 149 $ 208 $ 212 $ 213 $ 212 $ 214 $ 216 $ 217 $ 218 $ 210 2014 204 306 311 314 318 320 321 323 314 2015 244 345 366 373 379 382 383 373 2016 225 402 421 429 431 434 427 2017 194 291 307 310 314 305 2018 153 261 272 277 274 2019 171 260 280 278 2020 216 431 442 2021 326 456 2022 268 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 3,347 Protection Health Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance At December 31, 2022 Years Ended December 31, Total IBNR Cumulative (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (Dollars in millions) 2013 $ 227 $ 256 $ 258 $ 259 $ 256 $ 256 $ 256 $ 256 $ 256 $ 257 $ — 104,402 2014 236 262 264 262 261 261 262 262 263 — 98,132 2015 203 230 232 231 230 231 231 231 — 87,596 2016 266 306 303 303 303 303 304 — 106,665 2017 385 358 359 358 358 358 — 121,591 2018 412 433 410 409 409 — 144,503 2019 137 179 173 172 1 132,150 2020 497 488 486 5 149,147 2021 638 641 13 167,881 2022 696 67 140,625 Total 3,817 Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance (3,679) All outstanding liabilities for incurral years prior to 2013, net of reinsurance 1 Total unpaid claims and claim adjustment expenses, net of reinsurance $ 139 Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance Years Ended December 31, (Unaudited) Incurral Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 (In millions) 2013 $ 227 $ 256 $ 258 $ 259 $ 256 $ 256 $ 256 $ 256 $ 256 $ 257 2014 234 260 263 259 259 259 259 259 260 2015 203 230 229 230 230 230 231 231 2016 250 299 302 302 303 303 304 2017 314 354 356 356 357 358 2018 352 401 404 405 407 2019 115 163 166 169 2020 420 475 480 2021 564 624 2022 589 Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance $ 3,679
Short-duration Insurance Contracts, Schedule of Historical Claims Duration	The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Group Life - Term 76.8% 20.8% 0.8% 0.3% 0.5% 0.1% 0.1% —% —% —% The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Group Long-Term Disability 4.8% 21.7% 15.2% 9.0% 7.0% 6.1% 5.0% 4.3% 3.9% 3.3% The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Group Disability & Group Life 25.4% 25.3% 14.0% 10.6% 7.0% 3.9% 2.0% 3.0% 1.6% 0.6% The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Protection Life 58.3% 32.3% 4.0% 1.0% 0.5% —% —% (0.5)% (1.1)% (4.0)% The following is supplementary information about average historical claims duration at December 31, 2022: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance Years 1 2 3 4 5 6 7 8 9 10 Protection Health 84.7% 13.4% 0.8% 0.2% —% 0.1% 0.1% 0.1% 0.2% 0.2%
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability	The reconciliation of the net incurred and paid claims development tables to the liability for unpaid claims and claims adjustment expenses on the consolidated balance sheet was as follows at: December 31, 2022 (In millions) Short-Duration: Unpaid claims and allocated claims adjustment expenses, net of reinsurance: U.S.: Group Life - Term $ 3,141 Group Long-Term Disability 7,545 Total $ 10,686 Asia - Group Disability & Group Life 957 Latin America: Protection Life 405 Protection Health 139 Total 544 Other insurance lines - all segments combined 1,938 Total unpaid claims and allocated claims adjustment expenses, net of reinsurance 14,125 Reinsurance recoverables on unpaid claims: U.S.: Group Life - Term 8 Group Long-Term Disability 205 Total 213 Asia - Group Disability & Group Life 427 Latin America: Protection Life 11 Protection Health 18 Total 29 Other insurance lines - all segments combined 289 Total reinsurance recoverable on unpaid claims 958 Total unpaid claims and allocated claims adjustment expense 15,083 Unallocated claims adjustment expenses 3 Discounting (1,326) Liability for unpaid claims and claim adjustment liabilities - short-duration 13,760 Liability for unpaid claims and claim adjustment liabilities - all long-duration lines 6,653 Total liability for unpaid claims and claim adjustment expense (included in future policy benefits and other policy-related balances) $ 20,413
Liabilities for Unpaid Claims and Claim Expenses	Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Balance at January 1, $ 20,013 $ 18,591 $ 19,216 Less: Reinsurance recoverables 3,121 2,417 2,377 Net balance at January 1, 16,892 16,174 16,839 Incurred related to: Current year 27,285 28,270 27,272 Prior years (1) 766 934 192 Total incurred 28,051 29,204 27,464 Paid related to: Current year (20,051) (21,111) (20,230) Prior years (7,395) (7,256) (6,241) Total paid (27,446) (28,367) (26,471) Reclassified to liabilities held-for-sale (2) — (55) (1,658) Dispositions (2) — (64) — Net balance at December 31, 17,497 16,892 16,174 Add: Reinsurance recoverables 2,916 3,121 2,417 Balance at December 31, $ 20,413 $ 20,013 $ 18,591 __________________ (1) For the years ended December 31, 2022, 2021 and 2020, incurred claim activity and claim adjustment expenses associated with prior years increased due to events incurred in prior years but reported in the current year. The increases in both 2022 and 2021 incurred claim activity and claim adjustment expenses associated with prior years is primarily due to the impacts related to the COVID-19 pandemic, partially offset by additional premiums recorded for experience-rated contracts that are not reflected in the table above. (2) See Note 3 for information on the Company’s business dispositions.

Deferred Policy Acquisition C_2

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net [Abstract]
Schedule of Deferred Policy Acquisition Costs and Value of Business Acquired	Information regarding DAC and VOBA was as follows: Years Ended December 31, 2022 2021 2020 (In millions) DAC: Balance at January 1, $ 13,643 $ 13,446 $ 14,790 Capitalizations 2,558 2,718 3,013 Amortization related to: Net investment gains (losses) and net derivative gains (losses) 105 (100) (152) Other expenses (1,920) (2,268) (2,773) Total amortization (1,815) (2,368) (2,925) Unrealized investment gains (losses) 7,166 811 (1,312) Effect of foreign currency translation and other (688) (861) 76 Reclassified to assets held-for-sale (1) — (103) (196) Balance at December 31, 20,864 13,643 13,446 VOBA: Balance at January 1, 2,418 2,943 3,043 Amortization related to: Net investment gains (losses) and net derivative gains (losses) — — (2) Other expenses (116) (187) (233) Total amortization (116) (187) (235) Unrealized investment gains (losses) 17 11 (4) Effect of foreign currency translation and other (200) (314) 139 Reclassified to assets held-for-sale (1) — (35) — Balance at December 31, 2,119 2,418 2,943 Total DAC and VOBA: Balance at December 31, $ 22,983 $ 16,061 $ 16,389 __________________ (1) See Note 3 for information on the Company’s dispositions.
Schedule of Deferred Policy Acquisition Costs and Value of Business Acquired	Information regarding DAC and VOBA was as follows: Years Ended December 31, 2022 2021 2020 (In millions) DAC: Balance at January 1, $ 13,643 $ 13,446 $ 14,790 Capitalizations 2,558 2,718 3,013 Amortization related to: Net investment gains (losses) and net derivative gains (losses) 105 (100) (152) Other expenses (1,920) (2,268) (2,773) Total amortization (1,815) (2,368) (2,925) Unrealized investment gains (losses) 7,166 811 (1,312) Effect of foreign currency translation and other (688) (861) 76 Reclassified to assets held-for-sale (1) — (103) (196) Balance at December 31, 20,864 13,643 13,446 VOBA: Balance at January 1, 2,418 2,943 3,043 Amortization related to: Net investment gains (losses) and net derivative gains (losses) — — (2) Other expenses (116) (187) (233) Total amortization (116) (187) (235) Unrealized investment gains (losses) 17 11 (4) Effect of foreign currency translation and other (200) (314) 139 Reclassified to assets held-for-sale (1) — (35) — Balance at December 31, 2,119 2,418 2,943 Total DAC and VOBA: Balance at December 31, $ 22,983 $ 16,061 $ 16,389 __________________ (1) See Note 3 for information on the Company’s dispositions.
Information regarding Deferred Policy Acquisition Costs and Value of Business Acquired by Segment	Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at: December 31, 2022 2021 (In millions) U.S. $ 459 $ 440 Asia 13,384 9,339 Latin America 2,211 2,021 EMEA 1,593 1,623 MetLife Holdings 5,308 2,607 Corporate & Other 28 31 Total $ 22,983 $ 16,061
Deferred Sales Inducements of Business Acquired	Information regarding other intangibles was as follows: Years Ended December 31, 2022 2021 2020 (In millions) DSI: Balance at January 1, $ 107 $ 108 $ 158 Capitalization 3 — 6 Amortization (32) (14) (37) Unrealized investment gains (losses) 59 20 (18) Effect of foreign currency translation and other (2) (7) (1) Balance at December 31, $ 135 $ 107 $ 108 VODA and VOCRA: Balance at January 1, $ 972 $ 1,099 $ 335 Acquisitions (1) — — 814 Amortization (92) (100) (41) Effect of foreign currency translation and other (4) (27) (9) Balance at December 31, $ 876 $ 972 $ 1,099 Accumulated amortization $ 667 $ 575 $ 475 Negative VOBA: Balance at January 1, $ 623 $ 738 $ 750 Amortization (41) (34) (45) Effect of foreign currency translation and other (63) (81) 33 Balance at December 31, $ 519 $ 623 $ 738 Accumulated amortization $ 3,383 $ 3,342 $ 3,308 __________________ (1) Primarily related to the acquisition of Versant Health. See Note 3.
Value of Distribution Agreements and Customer Relationships Acquired and Negative Value of Business Acquired	Information regarding other intangibles was as follows: Years Ended December 31, 2022 2021 2020 (In millions) DSI: Balance at January 1, $ 107 $ 108 $ 158 Capitalization 3 — 6 Amortization (32) (14) (37) Unrealized investment gains (losses) 59 20 (18) Effect of foreign currency translation and other (2) (7) (1) Balance at December 31, $ 135 $ 107 $ 108 VODA and VOCRA: Balance at January 1, $ 972 $ 1,099 $ 335 Acquisitions (1) — — 814 Amortization (92) (100) (41) Effect of foreign currency translation and other (4) (27) (9) Balance at December 31, $ 876 $ 972 $ 1,099 Accumulated amortization $ 667 $ 575 $ 475 Negative VOBA: Balance at January 1, $ 623 $ 738 $ 750 Amortization (41) (34) (45) Effect of foreign currency translation and other (63) (81) 33 Balance at December 31, $ 519 $ 623 $ 738 Accumulated amortization $ 3,383 $ 3,342 $ 3,308 __________________ (1) Primarily related to the acquisition of Versant Health. See Note 3.
Estimated Future Amortization Expense (Credit)	The estimated future amortization expense (credit) to be reported in other expenses for the next five years is as follows: VOBA VODA and VOCRA Negative VOBA (In millions) 2023 $ 155 $ 86 $ (30) 2024 $ 161 $ 84 $ (29) 2025 $ 153 $ 82 $ (28) 2026 $ 144 $ 80 $ (26) 2027 $ 133 $ 78 $ (25)

Reinsurance (Tables)

Reinsurance (Tables)	12 Months Ended
	Dec. 31, 2022
Reinsurance Disclosures [Abstract]
Effect of reinsurance	The amounts on the consolidated statements of operations include the impact of reinsurance. Information regarding the significant effects of reinsurance was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Premiums Direct premiums $ 48,503 $ 41,259 $ 42,201 Reinsurance assumed 3,037 2,907 2,032 Reinsurance ceded (2,143) (2,157) (2,199) Net premiums $ 49,397 $ 42,009 $ 42,034 Universal life and investment-type product policy fees Direct universal life and investment-type product policy fees $ 6,004 $ 6,271 $ 6,122 Reinsurance assumed 76 45 50 Reinsurance ceded (495) (560) (569) Net universal life and investment-type product policy fees $ 5,585 $ 5,756 $ 5,603 Policyholder benefits and claims Direct policyholder benefits and claims $ 50,436 $ 44,035 $ 42,221 Reinsurance assumed 2,612 2,570 1,745 Reinsurance ceded (2,436) (2,651) (2,505) Net policyholder benefits and claims $ 50,612 $ 43,954 $ 41,461 Other expenses Direct other expenses $ 12,013 $ 12,450 $ 13,013 Reinsurance assumed 285 375 371 Reinsurance ceded (264) (239) (234) Net other expenses $ 12,034 $ 12,586 $ 13,150 The amounts on the consolidated balance sheets include the impact of reinsurance. Information regarding the significant effects of reinsurance was as follows at: December 31, 2022 2021 Direct Assumed Ceded Total Direct Assumed Ceded Total (In millions) Assets Premiums, reinsurance and other receivables $ 5,481 $ 1,505 $ 10,475 $ 17,461 $ 4,929 $ 1,789 $ 10,431 $ 17,149 Deferred policy acquisition costs and value of business acquired 22,889 370 (276) 22,983 16,151 227 (317) 16,061 Total assets $ 28,370 $ 1,875 $ 10,199 $ 40,444 $ 21,080 $ 2,016 $ 10,114 $ 33,210 Liabilities Future policy benefits $ 200,355 $ 3,873 $ — $ 204,228 $ 195,915 $ 3,806 $ — $ 199,721 Policyholder account balances 203,013 69 — 203,082 203,391 82 — 203,473 Other policy-related balances 18,472 1,183 (4) 19,651 16,380 1,368 3 17,751 Other liabilities 18,700 2,007 5,273 25,980 15,519 2,139 4,880 22,538 Total liabilities $ 440,540 $ 7,132 $ 5,269 $ 452,941 $ 431,205 $ 7,395 $ 4,883 $ 443,483

Closed Block (Tables)

Closed Block (Tables)	12 Months Ended
	Dec. 31, 2022
Closed Block Disclosure [Abstract]
Closed block liabilities and assets	Information regarding the closed block liabilities and assets designated to the closed block was as follows at: December 31, 2022 2021 (In millions) Closed Block Liabilities Future policy benefits $ 37,214 $ 38,046 Other policy-related balances 273 290 Policyholder dividends payable 181 253 Policyholder dividend obligation — 1,682 Deferred income tax liability — 210 Other liabilities 455 263 Total closed block liabilities 38,123 40,744 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale, at estimated fair value 19,648 25,669 Equity securities, at estimated fair value 13 21 Mortgage loans 6,564 6,417 Policy loans 4,084 4,191 Real estate and real estate joint ventures 635 565 Other invested assets 692 535 Total investments 31,636 37,398 Cash and cash equivalents 437 126 Accrued investment income 375 384 Premiums, reinsurance and other receivables 52 50 Current income tax recoverable 88 81 Deferred income tax asset 423 — Total assets designated to the closed block 33,011 38,039 Excess of closed block liabilities over assets designated to the closed block 5,112 2,705 AOCI: Unrealized investment gains (losses), net of income tax (1,357) 2,562 Unrealized gains (losses) on derivatives, net of income tax 262 107 Allocated to policyholder dividend obligation, net of income tax — (1,329) Total amounts included in AOCI (1,095) 1,340 Maximum future earnings to be recognized from closed block assets and liabilities $ 4,017 $ 4,045
Closed block policyholder dividend obligation	Information regarding the closed block policyholder dividend obligation was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Balance at January 1, $ 1,682 $ 2,969 $ 2,020 Change in unrealized investment and derivative gains (losses) (1,682) (1,287) 949 Balance at December 31, $ — $ 1,682 $ 2,969
Closed block revenues and expenses	Information regarding the closed block revenues and expenses was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Revenues Premiums $ 1,104 $ 1,298 $ 1,498 Net investment income 1,382 1,541 1,596 Net investment gains (losses) (51) (36) (25) Net derivative gains (losses) 33 18 (17) Total revenues 2,468 2,821 3,052 Expenses Policyholder benefits and claims 1,890 2,150 2,330 Policyholder dividends 453 621 791 Other expenses 90 96 104 Total expenses 2,433 2,867 3,225 Revenues, net of expenses before provision for income tax expense (benefit) 35 (46) (173) Provision for income tax expense (benefit) 7 (10) (36) Revenues, net of expenses and provision for income tax expense (benefit) $ 28 $ (36) $ (137)

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Fixed Maturity Securities AFS by Sector	The following table presents fixed maturity securities AFS by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. RMBS includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” December 31, 2022 2021 Amortized Gross Unrealized Estimated Amortized Gross Unrealized (1) Estimated Sector Allowance Gains Losses Allowance Gains Losses (In millions) U.S. corporate $ 88,466 $ (29) $ 1,133 $ 9,540 $ 80,030 $ 82,694 $ (30) $ 10,651 $ 281 $ 93,034 Foreign corporate 59,696 (5) 1,213 8,332 52,572 59,124 (28) 5,275 731 63,640 Foreign government 50,047 (130) 1,876 5,046 46,747 56,848 (19) 5,603 823 61,609 U.S. government and agency 35,658 — 431 3,860 32,229 41,068 — 5,807 276 46,599 RMBS 29,496 — 187 3,518 26,165 29,152 — 1,440 188 30,404 ABS & CLO 17,991 — 23 1,192 16,822 18,443 — 185 59 18,569 Municipals 13,548 — 317 1,713 12,152 11,761 — 2,464 13 14,212 CMBS 11,123 (19) 59 1,100 10,063 11,794 (14) 476 49 12,207 Total fixed maturity securities AFS $ 306,025 $ (183) $ 5,239 $ 34,301 $ 276,780 $ 310,884 $ (91) $ 31,901 $ 2,420 $ 340,274 __________________ (1) Excludes gross unrealized gains (losses) related to assets held-for-sale; these unrealized gains (losses) are included in AOCI as no component of equity is held-for-sale. See Note 3 for information on the Company’s business dispositions.
Available-for-sale fixed maturity securities by contractual maturity date	The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at December 31, 2022: Due in One Due After Due After Due After Structured Total Fixed (In millions) Amortized cost, net of ACL $ 8,235 $ 50,977 $ 54,016 $ 134,023 $ 58,591 $ 305,842 Estimated fair value $ 8,131 $ 49,344 $ 50,498 $ 115,757 $ 53,050 $ 276,780
Continuous Gross Unrealized Losses for Fixed Maturity Securities Available-for-Sale	The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. December 31, 2022 2021 Less than 12 Months Equal to or Greater than 12 Months Less than 12 Months Equal to or Greater than 12 Months Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 55,210 $ 7,573 $ 6,484 $ 1,965 $ 8,076 $ 165 $ 1,499 $ 116 Foreign corporate 31,932 5,999 8,956 2,332 10,011 404 2,834 327 Foreign government 16,568 2,170 8,308 2,874 7,812 319 5,377 502 U.S. government and agency 20,436 2,784 4,177 1,076 14,419 138 1,571 138 RMBS 16,223 1,890 6,650 1,628 10,363 158 417 30 ABS & CLO 10,924 712 4,326 480 8,150 39 804 20 Municipals 7,277 1,514 482 199 524 10 65 3 CMBS 6,890 764 2,037 335 2,664 31 657 18 Total fixed maturity securities AFS $ 165,460 $ 23,406 $ 41,420 $ 10,889 $ 62,019 $ 1,264 $ 13,224 $ 1,154 Investment grade $ 157,654 $ 22,713 $ 38,785 $ 10,298 $ 58,358 $ 1,123 $ 12,022 $ 1,025 Below investment grade 7,806 693 2,635 591 3,661 141 1,202 129 Total fixed maturity securities AFS $ 165,460 $ 23,406 $ 41,420 $ 10,889 $ 62,019 $ 1,264 $ 13,224 $ 1,154 Total number of securities in an unrealized loss position 15,204 4,303 4,774 979 __________________ (1) Excludes gross unrealized losses related to assets held-for-sale; these unrealized losses are included in AOCI as no component of equity is held-for-sale. See Note 3 for information on the Company’s business dispositions.
Debt Securities, Available-for-sale, Allowance for Credit Loss	The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Foreign CMBS Total Year Ended December 31, 2022 (In millions) Balance at January 1, $ 30 $ 28 $ 19 $ 14 $ 91 ACL not previously recorded 13 67 207 5 292 Changes for securities with previously recorded ACL 17 2 (48) — (29) Securities sold or exchanged (9) (93) (37) — (139) Dispositions — — — — — Effect of foreign currency translation — 1 (11) — (10) Write-offs (22) — — — (22) Balance at December 31, $ 29 $ 5 $ 130 $ 19 $ 183 U.S. Foreign Foreign CMBS Total Year Ended December 31, 2021 (In millions) Balance at January 1, $ 44 $ 16 $ 21 $ — $ 81 ACL not previously recorded 48 26 — 11 85 Changes for securities with previously recorded ACL 3 (4) — 3 2 Securities sold or exchanged (52) (10) — — (62) Dispositions (1) — — (2) — (2) Effect of foreign currency translation — — — — — Write-offs (13) — — — (13) Balance at December 31, $ 30 $ 28 $ 19 $ 14 $ 91 __________________ (1) In connection with the disposition of MetLife Seguros, ACL was reduced by $2 million for the year ended December 31, 2021. See Note 3 for additional information on the Company’s business dispositions.
Debt Securities, Trading, and Equity Securities, FV-NI	The following table presents equity securities by security type. Common stock includes common stock, exchange traded funds, mutual funds and real estate investment trusts. December 31, 2022 2021 Cost Net Unrealized Estimated Cost Net Unrealized Estimated Security Type (In millions) Common stock $ 1,347 $ 195 $ 1,542 $ 784 $ 295 $ 1,079 Non-redeemable preferred stock 148 (6) 142 189 1 190 Total $ 1,495 $ 189 $ 1,684 $ 973 $ 296 $ 1,269 __________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. The following table presents these investments by asset type. Unit-linked investments are primarily equity securities (including mutual funds). FVO Securities includes fixed maturity and equity securities to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. December 31, 2022 2021 Cost or Net Unrealized Estimated Cost or Net Unrealized Estimated Asset Type (In millions) Unit-linked investments $ 7,945 $ 288 $ 8,233 $ 8,643 $ 1,897 $ 10,540 FVO Securities 1,161 274 1,435 1,243 359 1,602 Total $ 9,106 $ 562 $ 9,668 $ 9,886 $ 2,256 $ 12,142 __________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI.
Disclosure of Mortgage Loans Net of Valuation Allowance	Mortgage loans are summarized as follows at: December 31, 2022 2021 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 52,502 62.7 % $ 50,553 63.7 % Agricultural 19,306 23.0 18,111 22.8 Residential 12,482 14.9 11,196 14.1 Total amortized cost 84,290 100.6 79,860 100.6 Allowance for credit loss (527) (0.6) (634) (0.8) Subtotal mortgage loans, net 83,763 100.0 79,226 99.8 Residential — FVO — — 127 0.2 Total mortgage loans, net $ 83,763 100.0 % $ 79,353 100.0 %
Allowance for Loan and Lease Losses, Provision for Loss, Net	The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Years Ended December 31, 2022 2021 2020 Commercial Agricultural Residential Total Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance at January 1, $ 340 $ 88 $ 206 $ 634 $ 252 $ 106 $ 232 $ 590 $ 246 $ 52 $ 55 $ 353 Adoption of credit loss guidance — — — — — — — — (118) 35 161 78 Provision (release) (2) 53 (8) 43 88 6 (27) 67 124 22 30 176 Initial credit losses on PCD loans (1) — — — — — — 3 3 — — 18 18 Charge-offs, net of recoveries (120) (22) (8) (150) — (24) (2) (26) — (2) (32) (34) HFS transfer — — — — — — — — — (1) — (1) Balance at December 31, $ 218 $ 119 $ 190 $ 527 $ 340 $ 88 $ 206 $ 634 $ 252 $ 106 $ 232 $ 590 __________________ (1) Represents the initial credit losses on purchased mortgage loans accounted for as PCD.
Disclosure of the mortgage loans portfolio segment by the recorded investment, prior to valuation allowances, by credit quality indicator categories	The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at December 31, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 5,081 $ 5,633 $ 3,496 $ 5,195 $ 4,866 $ 13,237 $ 2,860 $ 40,368 76.9 % 65% to 75% 2,321 1,227 1,073 1,613 1,360 1,872 — 9,466 18.0 76% to 80% 64 19 99 467 290 287 — 1,226 2.3 Greater than 80% 33 40 18 421 151 779 — 1,442 2.8 Total $ 7,499 $ 6,919 $ 4,686 $ 7,696 $ 6,667 $ 16,175 $ 2,860 $ 52,502 100.0 % DSCR: > 1.20x $ 6,705 $ 6,410 $ 4,441 $ 7,123 $ 5,981 $ 14,107 $ 2,860 $ 47,627 90.7 % 1.00x - 1.20x 667 128 115 436 274 963 — 2,583 4.9 <1.00x 127 381 130 137 412 1,105 — 2,292 4.4 Total $ 7,499 $ 6,919 $ 4,686 $ 7,696 $ 6,667 $ 16,175 $ 2,860 $ 52,502 100.0 % The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at December 31, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 2,594 $ 2,708 $ 2,600 $ 1,690 $ 2,364 $ 4,276 $ 1,171 $ 17,403 90.1 % 65% to 75% 177 320 347 177 93 494 131 1,739 9.0 76% to 80% — — — — — 11 — 11 0.1 Greater than 80% — — 29 76 — 44 4 153 0.8 Total $ 2,771 $ 3,028 $ 2,976 $ 1,943 $ 2,457 $ 4,825 $ 1,306 $ 19,306 100.0 % The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at December 31, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) Performance indicators: Performing $ 2,071 $ 1,450 $ 374 $ 982 $ 439 $ 6,693 $ — $ 12,009 96.2 % Nonperforming (1) 12 9 10 48 15 379 — 473 3.8 Total $ 2,083 $ 1,459 $ 384 $ 1,030 $ 454 $ 7,072 $ — $ 12,482 100.0 % __________________ (1) Includes residential mortgage loans in process of foreclosure of $146 million and $70 million at December 31, 2022 and 2021, respectively.
Schedule of Past Due and Non-Accrual Mortgage Loans	The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows: Past Due Past Due and Still Nonaccrual Portfolio Segment December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 (In millions) Commercial $ 6 $ 13 $ 6 $ 13 $ 169 $ 155 Agricultural 124 124 21 16 131 225 Residential 473 450 12 8 462 442 Total $ 603 $ 587 $ 39 $ 37 $ 762 $ 822
Purchased Financial Assets with Credit Deterioration	The following table reconciles the contractual principal to the purchase price of PCD investments: Year Ended December 31, 2022 Contractual ACL at Non-Credit Purchase (In millions) PCD residential mortgage loans $ 48 $ — $ (3) $ 45
Disclosure of Real Estate and Real Estate Joint Ventures	Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated: December 31, Years Ended December 31, 2022 2021 2022 2021 2020 Income Type Carrying Value Income (In millions) Wholly-owned real estate: Leased real estate $ 4,523 $ 5,146 $ 392 $ 429 $ 435 Other real estate 487 474 252 199 133 Real estate joint ventures 8,127 6,596 556 326 (36) Total real estate and real estate joint ventures $ 13,137 $ 12,216 $ 1,200 $ 954 $ 532
Schedule of Operating Leases by Property Type	Leased real estate investments and income earned, by property type, were as follows at and for the periods indicated: December 31, Years Ended December 31, 2022 2021 2022 2021 2020 Property Type Carrying Value Income (In millions) Leased real estate investments: Office $ 2,206 $ 2,322 $ 183 $ 196 $ 188 Retail 804 938 60 75 93 Apartment 625 828 56 66 62 Land 562 635 26 28 25 Industrial 254 339 62 58 56 Hotel 72 84 5 6 5 Other — — — — 6 Total leased real estate investments $ 4,523 $ 5,146 $ 392 $ 429 $ 435
Components of Leveraged and Direct Financing Leases	Investment in leveraged and direct financing leases consisted of the following at: December 31, 2022 2021 Leveraged Direct Leveraged Direct (In millions) Lease receivables, net (1) $ 477 $ 1,750 $ 542 $ 1,755 Estimated residual values 517 39 560 39 Subtotal 994 1,789 1,102 1,794 Unearned income (245) (586) (284) (642) Investment in leases, before ACL 749 1,203 818 1,152 ACL (18) (8) (31) (9) Investment in leases, net of ACL $ 731 $ 1,195 $ 787 $ 1,143 __________________
Schedule of Net Income From Investment In Leveraged and Direct Financing Leases	The components of income from investment in leveraged and direct financing leases, excluding net investment gains (losses), were as follows: Years Ended December 31, 2022 2021 2020 Leveraged Direct Leveraged Direct Leveraged Direct (In millions) Lease investment income $ 35 $ 129 $ 34 $ 96 $ 39 $ 106 Less: Income tax expense 7 27 7 20 8 22 Lease investment income, net of income tax $ 28 $ 102 $ 27 $ 76 $ 31 $ 84
Fair Value, Concentration of Risk	Investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at estimated fair value, were in fixed income securities of the following foreign governments and their agencies: December 31, 2022 2021 (In millions) Japan $ 24,295 $ 32,723 South Korea $ 5,887 $ 7,117 Mexico $ 3,463 N/A
Securities Lending and Repurchase Agreements	A summary of these transactions and agreements accounted for as secured borrowings were as follows: December 31, 2022 2021 Securities (1) Securities (1) Agreement Type Estimated Cash Reinvestment Estimated Cash Reinvestment (In millions) Securities lending $ 11,756 $ 12,092 $ 11,833 $ 20,654 $ 21,055 $ 21,319 Repurchase agreements $ 3,176 $ 3,125 $ 3,057 $ 3,416 $ 3,325 $ 3,357 __________________ (1) These securities were included within fixed maturity securities AFS and short-term investments at December 31, 2022 and within fixed maturity securities AFS at December 31, 2021. (2) The liability for cash collateral is included within payables for collateral under securities loaned and other transactions. Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows: December 31, 2022 2021 Remaining Maturities Remaining Maturities Security Type Open (1) 1 Month Over 1 Month to 6 Months Over 6 Months to 1 Year Total Open (1) 1 Month Over 1 Month to 6 Months Over 6 Months to 1 Year Total (In millions) Cash collateral liability by security type: Securities lending: U.S. government and agency $ 1,945 $ 5,448 $ 3,101 $ — $ 10,494 $ 5,900 $ 7,052 $ 7,055 $ — $ 20,007 Foreign government — 422 922 — 1,344 — 285 762 — 1,047 Agency RMBS — 63 191 — 254 — — — — — U.S. corporate — — — — — 1 — — — 1 Total $ 1,945 $ 5,933 $ 4,214 $ — $ 12,092 $ 5,901 $ 7,337 $ 7,817 $ — $ 21,055 Repurchase agreements: U.S. government and agency $ — $ 3,125 $ — $ — $ 3,125 $ — $ 3,325 $ — $ — $ 3,325 __________________ (1) The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.
Invested Assets on Deposit, Held in Trust and Pledged as Collateral	Certain subsidiaries have also entered into funding agreements with FHLBNY and a subsidiary of the Federal Agricultural Mortgage Corporation, a federally chartered instrumentality of the U.S. (“Farmer Mac”). The liability for such funding agreements is included in policyholder account balances. Information related to such funding agreements was as follows at: Liability Collateral December 31, 2022 2021 2022 2021 (In millions) FHLBNY (1) $ 14,940 $ 15,750 $ 17,857 (2) $ 17,981 (2) Farmer Mac (3) $ 2,050 $ 2,050 $ 2,148 $ 2,159 __________________ (1) Represents funding agreements issued to FHLBNY in exchange for cash and for which it has been granted a lien on certain assets, some of which are in the custody of FHLBNY, including residential mortgage-backed securities (“RMBS”), to collateralize obligations under such funding agreements. The applicable subsidiary of the Company is permitted to withdraw any portion of the collateral in the custody of FHLBNY as long as there is no event of default and the remaining qualified collateral is sufficient to satisfy the collateral maintenance level. Upon any event of default by such subsidiary, FHLBNY’s recovery on the collateral is limited to the amount of such subsidiary’s liability to FHLBNY. (2) Advances are collateralized primarily by mortgage-backed securities presented at estimated fair value. The remaining collateral is mortgage loans presented at carrying value. (3) Represents funding agreements issued to a subsidiary of Farmer Mac. The obligations under these funding agreements are secured by a pledge of certain eligible agricultural mortgage loans and may, under certain circumstances, be secured by other qualified collateral. The amount of collateral presented is at carrying value. Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value and were as follows at: December 31, 2022 2021 (In millions) Invested assets on deposit (regulatory deposits) $ 1,514 $ 1,872 Invested assets held in trust (external reinsurance agreements) (1) 881 1,114 Invested assets pledged as collateral (2) 25,442 24,261 Total invested assets on deposit, held in trust and pledged as collateral $ 27,837 $ 27,247 __________________ (1) Represents assets held in trust related to third-party reinsurance agreements. Excludes assets held in trust related to reinsurance agreements between wholly-owned subsidiaries of $1.9 billion and $2.1 billion at December 31, 2022 and 2021, respectively. (2) The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements (see Note 4), derivative transactions (see Note 9), secured debt and short-term debt related to repurchase agreements (see Note 13), and a collateral financing arrangement (see Note 14).
Schedule of Variable Interest Entities	The following table presents the total assets and total liabilities relating to investment related VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at: December 31, 2022 2021 Asset Type Total Total Total Total (In millions) Investment funds (primarily other invested assets) $ 266 $ 1 $ 292 $ 1 Renewable energy partnership (primarily other invested assets) 76 — 79 — Other investments (primarily other assets) — — 1 — Total $ 342 $ 1 $ 372 $ 1 Unconsolidated VIEs The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at: December 31, 2022 2021 Asset Type Carrying Maximum Carrying Maximum (In millions) Fixed maturity securities AFS (2) $ 51,422 $ 51,422 $ 62,654 $ 62,654 Other limited partnership interests 13,244 18,906 13,287 20,720 Other invested assets 1,310 1,387 1,257 1,314 Other investments 945 948 776 926 Total $ 66,921 $ 72,663 $ 77,974 $ 85,614 __________________ (1) The maximum exposure to loss relating to fixed maturity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee. (2) For variable interests in Structured Products included within fixed maturity securities AFS, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.
Components of Net Investment Income	The composition of net investment income by asset type was as follows: Years Ended December 31, Asset Type 2022 2021 2020 (In millions) Fixed maturity securities AFS $ 11,490 $ 10,996 $ 11,304 Equity securities 36 36 50 FVO Securities (127) 167 140 Mortgage loans 3,539 3,435 3,518 Policy loans 460 474 498 Real estate and real estate joint ventures 1,200 954 532 Other limited partnership interests 858 4,927 1,000 Cash, cash equivalents and short-term investments 358 103 213 Operating joint ventures 51 77 93 Other 633 223 255 Subtotal investment income 18,498 21,392 17,603 Less: Investment expenses 1,284 949 1,054 Subtotal, net 17,214 20,443 16,549 Unit-linked investments (1,298) 952 568 Net investment income $ 15,916 $ 21,395 $ 17,117 Net Investment Income (“NII”) Information Net realized and unrealized gains (losses) recognized in NII: Net realized gains (losses) from sales and disposals (primarily FVO Securities and Unit-linked investments) $ 155 $ 518 $ 422 Net unrealized gains (losses) from changes in estimated fair value (primarily FVO Securities and Unit-linked investments) (1,586) 616 233 Net realized and unrealized gains (losses) recognized in NII $ (1,431) $ 1,134 $ 655 Changes in estimated fair value subsequent to purchase of FVO Securities and Unit-linked investments still held at the end of the respective periods and recognized in NII $ (1,286) $ 730 $ 489 Equity method investments NII (primarily real estate joint ventures, other limited partnership interests, tax credit and renewable energy partnerships and operating joint ventures) $ 1,305 $ 5,136 $ 829
Components of Net Investment Gains (Losses)	The composition of net investment gains (losses) by asset type and transaction type was as follows: Years Ended December 31, Asset Type 2022 2021 2020 (In millions) Fixed maturity securities AFS $ (1,912) $ 66 $ 297 Equity securities (133) 108 (137) Mortgage loans 21 (18) (213) Real estate and real estate joint ventures (excluding changes in estimated fair value) 653 502 7 Other limited partnership interests (excluding changes in estimated fair value) 53 (6) (15) Other gains (losses) 178 131 198 Subtotal (1,140) 783 137 Change in estimated fair value of other limited partnership interests and real estate joint ventures (14) 45 (4) Non-investment portfolio gains (losses) (1) (108) 701 (243) Subtotal (122) 746 (247) Net investment gains (losses) $ (1,262) $ 1,529 $ (110) Transaction Type Realized gains (losses) on investments sold or disposed $ (880) $ 711 $ 634 Impairment (losses) (40) (24) (63) Recognized gains (losses): Change in allowance for credit loss recognized in earnings (134) (86) (280) Unrealized net gains (losses) recognized in earnings (100) 227 (158) Total recognized gains (losses) (234) 141 (438) Non-investment portfolio gains (losses) (1) (108) 701 (243) Net investment gains (losses) $ (1,262) $ 1,529 $ (110) Net Investment Gains (Losses) (“NIGL”) Information Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in NIGL $ (89) $ 77 $ (127) Other gains (losses) include: Gains (losses) on disposed investments which were previously in a qualified cash flow hedge relationship $ 38 $ 88 $ 129 Gains (losses) on leveraged leases and renewable energy partnerships $ 33 $ 12 $ 87 Foreign currency gains (losses) $ 182 $ (10) $ 79 Net Realized Investment Gains (Losses) From Sales and Disposals of Investments Recognized in NIGL $ (880) $ 711 $ 634 Recognized in NII 155 518 422 Net realized investment gains (losses) from sales and disposals of investments $ (725) $ 1,229 $ 1,056 __________________ (1) See Note 3 for information regarding the Company’s business dispositions.
Schedule of Realized Gain (Loss)	The composition of net investment gains (losses) for these securities is as follows : Years Ended December 31, Fixed Maturity Securities AFS 2022 2021 2020 (In millions) Proceeds $ 67,754 $ 54,612 $ 40,809 Gross investment gains $ 935 $ 761 $ 1,125 Gross investment (losses) (2,704) (656) (674) Realized gains (losses) on sales and disposals (1,769) 105 451 Net credit loss (provision) release (change in ACL recognized in earnings) (103) (15) (91) Impairment (losses) (40) (24) (63) Net credit loss (provision) release and impairment (losses) (143) (39) (154) Net investment gains (losses) $ (1,912) $ 66 $ 297 Equity Securities Realized gains (losses) on sales and disposals $ (47) $ (69) $ 16 Unrealized net gains (losses) recognized in earnings (86) 177 (153) Net investment gains (losses) $ (133) $ 108 $ (137)

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	The following table presents the primary underlying risk exposure, gross notional amount and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: Primary Underlying Risk Exposure December 31, 2022 2021 Estimated Fair Value Estimated Fair Value Gross Assets Liabilities Gross Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 4,143 $ 1,353 $ 467 $ 3,550 $ 2,164 $ 6 Foreign currency swaps Foreign currency exchange rate 602 82 — 801 11 23 Foreign currency forwards Foreign currency exchange rate 1,336 10 89 1,636 — 58 Subtotal 6,081 1,445 556 5,987 2,175 87 Cash flow hedges: Interest rate swaps Interest rate 4,107 8 262 4,117 6 1 Interest rate forwards Interest rate 7,447 1 1,354 6,889 89 119 Foreign currency swaps Foreign currency exchange rate 42,608 3,554 1,699 41,095 1,600 1,557 Subtotal 54,162 3,563 3,315 52,101 1,695 1,677 NIFO hedges: Foreign currency forwards Foreign currency exchange rate 680 — 38 — — — Currency options Foreign currency exchange rate 3,000 236 — 3,000 139 — Subtotal 3,680 236 38 3,000 139 — Total qualifying hedges 63,923 5,244 3,909 61,088 4,009 1,764 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 31,661 1,660 1,354 38,860 3,644 115 Interest rate floors Interest rate 25,270 125 — 7,701 145 — Interest rate caps Interest rate 48,290 950 — 65,559 124 — Interest rate futures Interest rate 1,453 2 1 1,615 4 — Interest rate options Interest rate 44,391 473 88 11,754 493 10 Interest rate forwards Interest rate 381 — 32 374 — 26 Interest rate total return swaps Interest rate — — — 1,048 9 4 Synthetic GICs Interest rate 46,316 — — 40,121 — — Foreign currency swaps Foreign currency exchange rate 12,815 1,454 383 12,787 768 614 Foreign currency forwards Foreign currency exchange rate 16,195 544 661 16,230 36 666 Currency futures Foreign currency exchange rate 333 8 — 839 — 2 Currency options Foreign currency exchange rate — — — 900 — — Credit default swaps — purchased Credit 2,925 18 79 3,042 13 113 Credit default swaps — written Credit 11,512 133 28 8,626 177 12 Equity futures Equity market 2,988 8 4 4,204 12 5 Equity index options Equity market 16,701 765 323 29,743 1,004 458 Equity variance swaps Equity market 163 4 1 699 17 13 Equity total return swaps Equity market 2,799 23 112 3,025 11 50 Total non-designated or nonqualifying derivatives 264,193 6,167 3,066 247,127 6,457 2,088 Total $ 328,116 $ 11,411 $ 6,975 $ 308,215 $ 10,466 $ 3,852
Components of Net Derivatives Gains (Losses)	The following table presents the consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, NIFO, nonqualifying hedging relationships and embedded derivatives: Year Ended December 31, 2022 Net Net Net Policyholder Interest Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 9 $ — $ — $ (1,187) $ (26) $ — N/A Hedged items (9) — — 1,127 27 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 109 (220) — — — — N/A Hedged items (110) 217 — — — — N/A Amount excluded from the assessment of hedge effectiveness — 46 — — — — N/A Subtotal (1) 43 — (60) 1 — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (2,367) Amount of gains (losses) reclassified from AOCI into income 59 41 — — — 4 (104) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A 1,784 Amount of gains (losses) reclassified from AOCI into income 6 (609) — — — 1 602 Foreign currency transaction gains (losses) on hedged items — 587 — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 65 19 — — — 5 (85) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A N/A N/A N/A N/A N/A 85 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 47 Subtotal N/A N/A N/A N/A N/A N/A 132 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 3 — (3,879) (88) — — N/A Foreign currency exchange rate derivatives (1) 2 — (368) (4) — — N/A Credit derivatives — purchased (1) — — 75 — — — N/A Credit derivatives — written (1) — — (92) — — — N/A Equity derivatives (1) 45 — 423 250 — — N/A Foreign currency transaction gains (losses) on hedged items — — 282 — — — N/A Subtotal 50 — (3,559) 158 — — N/A Earned income on derivatives 376 — 1,015 150 (145) — — Embedded derivatives (2) N/A N/A 172 — N/A N/A N/A Total $ 490 $ 62 $ (2,372) $ 248 $ (144) $ 5 $ 47 Year Ended December 31, 2021 Net Net Net Policyholder Interest Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 6 $ — $ — $ (456) $ — $ — N/A Hedged items (6) — — 406 — — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 50 (191) — — — — N/A Hedged items (44) 185 — — — — N/A Amount excluded from the assessment of hedge effectiveness — — — — — — N/A Subtotal 6 (6) — (50) — — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (599) Amount of gains (losses) reclassified from AOCI into income 56 84 — — — 3 (143) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A 500 Amount of gains (losses) reclassified from AOCI into income 8 (403) — — — 2 393 Foreign currency transaction gains (losses) on hedged items — 401 — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (14) Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 64 82 — — — 5 137 Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A N/A N/A N/A N/A N/A 97 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 42 Subtotal N/A N/A N/A N/A N/A N/A 139 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 2 — (1,992) (49) — — N/A Foreign currency exchange rate derivatives (1) — — (986) 2 — — N/A Credit derivatives — purchased (1) — — 9 — — — N/A Credit derivatives — written (1) — — 41 — — — N/A Equity derivatives (1) (56) — (1,280) (302) — — N/A Foreign currency transaction gains (losses) on hedged items — — 249 — — — N/A Subtotal (54) — (3,959) (349) — — N/A Earned income on derivatives 151 — 984 213 (159) — — Embedded derivatives (2) N/A N/A 747 — N/A N/A N/A Total $ 167 $ 76 $ (2,228) $ (186) $ (159) $ 5 $ 276 Year Ended December 31, 2020 Net Net Net Policyholder Interest Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (10) $ — $ — $ 360 $ — $ — N/A Hedged items 12 — — (399) — — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (46) 98 — — — — N/A Hedged items 44 (93) — — — — N/A Amount excluded from the assessment of hedge effectiveness — (47) — — — — N/A Subtotal — (42) — (39) — — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ 1,277 Amount of gains (losses) reclassified from AOCI into income 36 121 — — — 2 (159) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (445) Amount of gains (losses) reclassified from AOCI into income 4 851 — — — 2 (857) Foreign currency transaction gains (losses) on hedged items — (765) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (102) Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 40 207 — — — 4 (286) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A N/A N/A N/A N/A N/A 36 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A (20) Subtotal N/A N/A N/A N/A N/A N/A 16 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) (6) — 2,149 55 — — N/A Foreign currency exchange rate derivatives (1) — — (323) (3) — — N/A Credit derivatives — purchased (1) — — (28) — — — N/A Credit derivatives — written (1) — — (106) — — — N/A Equity derivatives (1) (28) — (1,151) (203) — — N/A Foreign currency transaction gains (losses) on hedged items — — (8) — — — N/A Subtotal (34) — 533 (151) — — N/A Earned income on derivatives 217 — 926 190 (152) — — Embedded derivatives (2) N/A N/A (110) — N/A N/A N/A Total $ 223 $ 165 $ 1,349 $ — $ (152) $ 4 $ (270) __________________ (1) Excludes earned income on derivatives. (2) The valuation of guaranteed minimum benefits includes a nonperformance risk adjustment. The amounts included in net derivative gains (losses) in connection with this adjustment wer e $18 million, ($17) million and ($10) million for the years ended December 31, 2022, 2021 and 2020, respectively.
Net derivatives gains (losses) recognized on fair value derivatives and the related hedged items	The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount Cumulative Amount December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 (In millions) Fixed maturity securities AFS $ 1,411 $ 2,164 $ 1 $ (1) Mortgage loans $ 331 $ 634 $ (19) $ 3 Future policy benefits $ (3,524) $ (4,735) $ 276 $ (877) Policyholder account balances $ (1,080) $ — $ 27 $ — __________________ (1) Includes ($136) million and ($161) million of hedging adjustments on discontinued hedging relationships at December 31, 2022 and 2021, respectively.
Schedule of estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps	The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: December 31, 2022 2021 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ 3 $ 158 2.2 $ 4 $ 159 3.1 Credit default swaps referencing indices 79 4,251 3.4 17 1,191 2.5 Subtotal 82 4,409 3.4 21 1,350 2.6 Baa Single name credit default swaps (3) 1 81 2.5 2 101 3.4 Credit default swaps referencing indices 28 6,775 5.6 146 6,988 5.0 Subtotal 29 6,856 5.5 148 7,089 5.0 Ba Single name credit default swaps (3) — 62 1.3 1 82 1.2 Credit default swaps referencing indices 2 25 4.0 (1) 20 5.0 Subtotal 2 87 2.1 — 102 2.0 B Credit default swaps referencing indices 2 130 4.7 5 55 4.0 Subtotal 2 130 4.7 5 55 4.0 Caa Credit default swaps referencing indices (10) 30 3.5 (9) 30 4.5 Subtotal (10) 30 3.5 (9) 30 4.5 Total $ 105 $ 11,512 4.7 $ 165 $ 8,626 4.6 __________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals.
Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral	The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: December 31, 2022 2021 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 11,438 $ 6,628 $ 10,132 $ 3,798 OTC-cleared (1) 121 342 448 24 Exchange-traded 18 5 16 7 Total gross estimated fair value of derivatives presented on the consolidated balance sheets (1) 11,577 6,975 10,596 3,829 Gross amounts not offset on the consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (4,579) (4,579) (2,204) (2,204) OTC-cleared (33) (33) (6) (6) Exchange-traded (1) (1) (2) (2) Cash collateral: (3), (4) OTC-bilateral (5,432) — (6,948) — OTC-cleared (35) (295) (421) (13) Exchange-traded — (3) — (3) Securities collateral: (5) OTC-bilateral (1,322) (2,024) (891) (1,473) OTC-cleared — (14) — (5) Exchange-traded — (1) — (2) Net amount after application of master netting agreements and collateral $ 175 $ 25 $ 124 $ 121 __________________ (1) At December 31, 2022 and 2021, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $166 million and $130 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $0 and ($23) million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the centralized clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. For certain collateral agreements, cash collateral is pledged to the Company as initial margin on its OTC-bilateral derivatives. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At December 31, 2022 and 2021, the Company received excess cash collateral of $252 million and $172 million, respectively, and provided excess cash collateral of $125 million and $126 million, respectively, which is not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at December 31, 2022, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At December 31, 2022 and 2021, the Company received excess securities collateral with an estimated fair value of $398 million and $160 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At December 31, 2022 and 2021, the Company provided excess securities collateral with an estimated fair value of $1.2 billion and $243 million, respectively, for its OTC-bilateral derivatives, $1.0 billion and $1.2 billion, respectively, for its OTC-cleared derivatives, and $184 million and $185 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.
Derivative Instruments, Gain (Loss) [Line Items]
Schedule of Derivative Instruments	December 31, 2022 2021 Derivatives Subject to Credit-Contingent Provisions Derivatives Not Subject to Credit-Contingent Provisions Total Derivatives Subject to Credit-Contingent Provisions Derivatives Not Subject to Credit-Contingent Provisions Total (In millions) Estimated fair value of derivatives in a net liability position (1) $ 2,049 $ — $ 2,049 $ 1,386 $ 209 $ 1,595 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 2,267 $ — $ 2,267 $ 1,370 $ 221 $ 1,591 __________________ (1) After taking into consideration the existence of netting agreements.
Net Embedded Derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Schedule of Derivative Instruments	The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: December 31, Balance Sheet Location 2022 2021 (In millions) Embedded derivatives within asset host contracts: Ceded guaranteed minimum benefits Premiums, reinsurance and other receivables $ 29 $ 38 Embedded derivatives within liability host contracts: Direct guaranteed minimum benefits Policyholder account balances $ 467 $ 324 Assumed guaranteed minimum benefits Policyholder account balances 94 98 Funds withheld on ceded reinsurance Other liabilities (123) 57 Fixed annuities with equity indexed returns Policyholder account balances 140 165 Other guarantees Policyholder account balances — 5 Total $ 578 $ 649

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Recurring Fair Value Measurements	The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: December 31, 2022 Fair Value Hierarchy Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 67,578 $ 12,452 $ 80,030 Foreign corporate — 40,623 11,949 52,572 Foreign government — 46,644 103 46,747 U.S. government and agency 15,955 16,274 — 32,229 RMBS 4 24,515 1,646 26,165 ABS & CLO — 14,895 1,927 16,822 Municipals — 12,152 — 12,152 CMBS — 9,367 696 10,063 Total fixed maturity securities AFS 15,959 232,048 28,773 276,780 Equity securities 1,293 132 259 1,684 Unit-linked and FVO Securities (1) 7,101 1,780 787 9,668 Short-term investments (2) 3,830 686 57 4,573 Residential mortgage loans — FVO — — — — Other investments — 206 926 1,132 Derivative assets: (3) Interest rate 2 4,570 — 4,572 Foreign currency exchange rate 8 5,670 210 5,888 Credit — 69 82 151 Equity market 8 785 7 800 Total derivative assets 18 11,094 299 11,411 Embedded derivatives within asset host contracts (4) — — 29 29 Separate account assets (5) 65,107 79,703 1,228 146,038 Total assets (6) $ 93,308 $ 325,649 $ 32,358 $ 451,315 Liabilities Derivative liabilities: (3) Interest rate $ 1 $ 3,153 $ 404 $ 3,558 Foreign currency exchange rate — 2,820 50 2,870 Credit — 92 15 107 Equity market 4 436 — 440 Total derivative liabilities 5 6,501 469 6,975 Embedded derivatives within liability host contracts (4) — — 578 578 Separate account liabilities (5) 8 15 18 41 Total liabilities $ 13 $ 6,516 $ 1,065 $ 7,594 December 31, 2021 (7) Fair Value Hierarchy Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 81,266 $ 11,768 $ 93,034 Foreign corporate — 49,973 13,667 63,640 Foreign government — 61,518 91 61,609 U.S. government and agency 25,482 21,117 — 46,599 RMBS 7 27,270 3,127 30,404 ABS & CLO — 16,707 1,862 18,569 Municipals — 14,212 — 14,212 CMBS — 11,325 882 12,207 Total fixed maturity securities AFS 25,489 283,388 31,397 340,274 Equity securities 931 187 151 1,269 Unit-linked and FVO Securities (1) 9,173 2,068 901 12,142 Short-term investments (2) 5,607 950 3 6,560 Residential mortgage loans — FVO — — 127 127 Other investments — 61 898 959 Derivative assets: (3) Interest rate 4 6,577 97 6,678 Foreign currency exchange rate — 2,551 3 2,554 Credit — 173 17 190 Equity market 12 1,025 7 1,044 Total derivative assets 16 10,326 124 10,466 Embedded derivatives within asset host contracts (4) — — 38 38 Separate account assets (5) 76,312 101,424 2,137 179,873 Total assets (6) $ 117,528 $ 398,404 $ 35,776 $ 551,708 Liabilities Derivative liabilities: (3) Interest rate $ — $ 259 $ 22 $ 281 Foreign currency exchange rate 2 2,676 242 2,920 Credit — 113 12 125 Equity market 5 521 — 526 Total derivative liabilities 7 3,569 276 3,852 Embedded derivatives within liability host contracts (4) — — 649 649 Separate account liabilities (5) 7 12 6 25 Total liabilities $ 14 $ 3,581 $ 931 $ 4,526 __________________ (1) Unit-linked and FVO Securities were primarily comprised of Unit-linked investments at both December 31, 2022 and 2021. (2) Short-term investments as presented in the tables above differ from the amounts presented on the consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis. (3) Derivative assets are presented within other invested assets on the consolidated balance sheets and derivative liabilities are presented within other liabilities on the consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (4) Embedded derivatives within asset host contracts are presented within premiums, reinsurance and other receivables on the consolidated balance sheets. Embedded derivatives within liability host contracts are presented within policyholder account balances and other liabilities on the consolidated balance sheets. (5) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (6) Total assets included in the fair value hierarchy exclude other limited partnership interests that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. At December 31, 2022 and 2021, the estimated fair value of such investments was $65 million and $99 million, respectively. (7) Excludes amounts reclassified to assets held-for-sale or liabilities held-for-sale. Assets held-for-sale and liabilities held-for-sale are valued on a basis consistent with similar assets and liabilities described herein. See Note 3 for information on the Company’s business dispositions.
Fair Value Inputs, Quantitative Information	The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: December 31, 2022 December 31, 2021 Impact of Valuation Techniques Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) — - 126 87 1 - 165 109 Increase • Market pricing • Quoted prices (4) 20 - 109 90 — - 117 100 Increase • Consensus pricing • Offered quotes (4) 5 - 99 93 99 - 104 100 Increase RMBS • Market pricing • Quoted prices (4) — - 106 93 — - 121 99 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 3 - 102 91 3 - 110 102 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) 372 - 392 381 151 - 200 188 Increase (7) • Volatility (8) —% - —% —% 1% - 1% 1% Increase (7) Foreign currency exchange rate • Present value techniques • Swap yield (6) 74 - 1,938 208 2 - 305 134 Increase (7) Credit • Present value techniques • Credit spreads (9) 84 - 138 101 96 - 133 109 Decrease (7) • Consensus pricing • Offered quotes (10) Embedded derivatives Direct, assumed and ceded guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0% - 0.17% 0.05% 0% - 0.17% 0.08% Decrease (11) Ages 41 - 60 0.03% - 0.75% 0.20% 0.03% - 0.75% 0.27% Decrease (11) Ages 61 - 115 0.12% - 100% 1.44% 0.12% - 100% 2.08% Decrease (11) • Lapse rates: Durations 1 - 10 0.40% - 37.50% 8.96% 0.25% - 100% 6.30% Decrease (12) Durations 11 - 20 0.50% - 35.75% 6.52% 0.50% - 100% 5.22% Decrease (12) Durations 21 - 116 0.50% - 35.75% 2.89% 0.50% - 100% 5.22% Decrease (12) • Utilization rates 0.20% - 22% 0.38% 0% - 22% 0.22% Increase (13) • Withdrawal rates 0% - 20% 4.02% 0% - 20% 3.72% (14) • Long-term equity volatilities 8.26% - 25% 18.49% 7.69% - 25% 18.60% Increase (15) • Nonperformance risk spread 0.09% - 1.77% 0.75% 0.04% - 1.45% 0.35% Decrease (16) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for embedded derivatives is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For embedded derivatives, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates. (6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation. (7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions. (8) Ranges represent the underlying interest rate volatility quoted in percentage points. Since this valuation methodology uses an equivalent of LIBOR for secured overnight financing rate volatility, presenting a range is more representative of the unobservable input used in the valuation. (9) Represents the risk quoted in basis points of a credit default event on the underlying instrument. Credit derivatives with significant unobservable inputs are primarily comprised of written credit default swaps. (10) At both December 31, 2022 and 2021, independent non-binding broker quotations were used in the determination of 1% or less of the total net derivative estimated fair value. (11) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (12) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (13) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (14) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value. (15) Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (16) Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the embedded derivative.
Fair Value, Measured on Recurring Basis, Unobservable Input Reconciliation	The following tables summarize the change of all assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Foreign Structured Equity Unit-linked and FVO (In millions) Balance, January 1, 2021 $ 24,101 $ 117 $ 5,289 $ 150 $ 701 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (34) — 46 27 101 Total realized/unrealized gains (losses) included in AOCI (1,334) (2) (26) — — Purchases (3) 4,988 1 1,824 12 42 Sales (3) (1,543) (8) (1,326) (35) (18) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 179 12 358 — 86 Transfers out of Level 3 (4) (922) (29) (294) (3) (11) Balance, December 31, 2021 25,435 91 5,871 151 901 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (7) (38) 29 16 (133) Total realized/unrealized gains (losses) included in AOCI (6,221) (13) (478) — — Purchases (3) 5,273 36 967 108 28 Sales (3) (1,762) (9) (984) (14) (24) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 2,127 46 251 — 23 Transfers out of Level 3 (4) (444) (10) (1,387) (2) (8) Balance, December 31, 2022 $ 24,401 $ 103 $ 4,269 $ 259 $ 787 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2020 (5) $ (48) $ (1) $ 54 $ 2 $ 69 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2021 (5) $ (5) $ — $ 42 $ 13 $ 101 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2022 (5) $ (3) $ (38) $ 27 $ 11 $ (131) Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2020 (5) $ 1,754 $ (1) $ 47 $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2021 (5) $ (1,293) $ (2) $ (24) $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2022 (5) $ (6,136) $ (13) $ (450) $ — $ — Gains (Losses) Data for the year ended December 31, 2020: Total realized/unrealized gains (losses) included in net income (loss) (1), (2) $ (88) $ (2) $ 49 $ 12 $ 67 Total realized/unrealized gains (losses) included in AOCI $ 1,774 $ (1) $ 41 $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Short-term Residential Mortgage Other Net Net Embedded Separate (In millions) Balance, January 1, 2021 $ 43 $ 165 $ 573 $ 594 $ (1,141) $ 1,079 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 1 (5) 94 (460) 747 29 Total realized/unrealized gains (losses) included in AOCI (3) — — (334) 27 — Purchases (3) 2 — 348 30 — 1,056 Sales (3) (37) (11) (92) — — (44) Issuances (3) — — — (13) — (2) Settlements (3) — (22) — 32 (244) 6 Transfers into Level 3 (4) — — — 1 — 10 Transfers out of Level 3 (4) (3) — (25) (2) — (3) Balance, December 31, 2021 3 127 898 (152) (611) 2,131 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — (8) 57 238 172 61 Total realized/unrealized gains (losses) included in AOCI — — — (537) 22 — Purchases (3) 56 — 246 82 — 202 Sales (3) (2) (108) (177) — — (1,164) Issuances (3) — — — (3) — (2) Settlements (3) — (11) — 201 (132) 4 Transfers into Level 3 (4) — — — — — 1 Transfers out of Level 3 (4) — — (98) 1 — (23) Balance, December 31, 2022 $ 57 $ — $ 926 $ (170) $ (549) $ 1,210 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2020 (5) $ (7) $ 3 $ 24 $ 67 $ (124) $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2021 (5) $ — $ (10) $ 89 $ (361) $ 746 $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2022 (5) $ — $ — $ 56 $ 325 $ 171 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2020 (5) $ 4 $ — $ — $ 579 $ (33) $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2021 (5) $ — $ — $ — $ (128) $ 27 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at December 31, 2022 (5) $ — $ — $ — $ (459) $ 22 $ — Gains (Losses) Data for the year ended December 31, 2020: Total realized/unrealized gains (losses) included in net income (loss) (1), (2) $ (7) $ 9 $ 19 $ 279 $ (110) $ (5) Total realized/unrealized gains (losses) included in AOCI $ 4 $ — $ — $ 761 $ (34) $ — __________________ (1) Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses), while changes in estimated fair value of Unit-linked and FVO Securities and residential mortgage loans — FVO are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (2) Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward. (3) Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements. (4) Items transferred into and then out of Level 3 in the same period are excluded from the rollforward. (5) Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (6) Comprised of U.S. and foreign corporate securities. (7) Freestanding derivative assets and liabilities are presented net for purposes of the rollforward. (8) Embedded derivative assets and liabilities are presented net for purposes of the rollforward. (9) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss). Separate account assets and liabilities are presented net for the purposes of the rollforward.
Fair Value Option	The following table presents information for residential mortgage loans which are accounted for under the FVO and were initially measured at fair value. December 31, 2022 2021 (In millions) Unpaid principal balance $ — $ 130 Difference between estimated fair value and unpaid principal balance — (3) Carrying value at estimated fair value $ — $ 127 Loans in nonaccrual status $ — $ 32 Loans more than 90 days past due $ — $ 14 Loans in nonaccrual status or more than 90 days past due, or both — difference between aggregate estimated fair value and unpaid principal balance $ — $ (7)
Nonrecurring Fair Value Measurements	The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment), using significant unobservable inputs (Level 3). December 31, 2022 2021 (in millions) Carrying value after measurement Mortgage loans (1) $ 263 $ 328 Other assets (2) $ 1 $ 82 Years Ended December 31, 2022 2021 2020 (in millions) Realized gains (losses) net: Mortgage loans (1) $ (13) $ (116) $ (127) Other assets (2) $ (14) $ (74) $ — __________________ (1) Estimated fair values for impaired mortgage loans are based on estimated fair value of the underlying collateral. (2) The Company recognized impairments related to the abandonment of certain leased office space and the related leasehold improvements.
Fair Value of Financial Instruments Carried at Other Than Fair Value	The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at: December 31, 2022 Fair Value Hierarchy Carrying Level 1 Level 2 Level 3 Total (In millions) Assets Mortgage loans (1) $ 83,763 $ — $ — $ 78,694 $ 78,694 Policy loans $ 8,874 $ — $ — $ 9,682 $ 9,682 Other invested assets $ 946 $ — $ 729 $ 217 $ 946 Premiums, reinsurance and other receivables $ 2,905 $ — $ 1,042 $ 1,921 $ 2,963 Other assets $ 267 $ — $ 90 $ 175 $ 265 Liabilities Policyholder account balances $ 125,039 $ — $ — $ 118,694 $ 118,694 Long-term debt $ 14,591 $ — $ 14,241 $ — $ 14,241 Collateral financing arrangement $ 716 $ — $ — $ 591 $ 591 Junior subordinated debt securities $ 3,158 $ — $ 3,502 $ — $ 3,502 Other liabilities $ 2,908 $ — $ 1,377 $ 1,793 $ 3,170 Separate account liabilities $ 81,976 $ — $ 81,976 $ — $ 81,976 December 31, 2021 (2) Fair Value Hierarchy Carrying Level 1 Level 2 Level 3 Total (In millions) Assets Mortgage loans (1) $ 79,226 $ — $ — $ 82,788 $ 82,788 Policy loans $ 9,111 $ — $ — $ 10,751 $ 10,751 Other invested assets $ 1,025 $ — $ 769 $ 256 $ 1,025 Premiums, reinsurance and other receivables $ 2,262 $ — $ 492 $ 1,962 $ 2,454 Other assets $ 290 $ — $ 101 $ 190 $ 291 Liabilities Policyholder account balances $ 123,865 $ — $ — $ 127,728 $ 127,728 Long-term debt $ 13,852 $ — $ 16,621 $ — $ 16,621 Collateral financing arrangement $ 766 $ — $ — $ 630 $ 630 Junior subordinated debt securities $ 3,156 $ — $ 4,447 $ — $ 4,447 Other liabilities $ 2,143 $ — $ 514 $ 2,321 $ 2,835 Separate account liabilities $ 95,619 $ — $ 95,619 $ — $ 95,619 _________________ (1) Includes mortgage loans measured at estimated fair value on a nonrecurring basis and excludes mortgage loans measured at estimated fair value on a recurring basis. (2) Excludes amounts reclassified to assets held-for-sale or liabilities held-for-sale. See Note 3 for information on the Company’s business dispositions.

Leases Leases (Tables)

Leases Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lease, Cost	ROU assets and lease liabilities for operating leases were: December 31, 2022 December 31, 2021 (In millions) ROU assets $ 961 $ 1,110 Lease liabilities $ 1,147 $ 1,295 The components of operating lease costs were as follows: Years Ended December 31, 2022 2021 2020 (In millions) Operating lease cost $ 246 $ 271 $ 286 Variable lease cost $ 45 $ 32 $ 39 Sublease income $ (103) $ (99) $ (99) Net lease cost $ 188 $ 204 $ 226 Supplemental other information related to operating leases was as follows: December 31, 2022 December 31, 2021 (Dollars in millions) Cash paid for amounts included in the measurement of lease liability - operating cash flows $ 249 $ 273 ROU assets obtained in exchange for new lease liabilities $ 58 $ 63 Weighted-average remaining lease term 6 years 7 years Weighted-average discount rate 3.5 % 3.4 %
Lessee, Operating Lease, Liability, Maturity	Maturities of operating lease liabilities were as follows: December 31, 2022 (In millions) 2023 $ 245 2024 216 2025 198 2026 183 2027 149 Thereafter 252 Total undiscounted cash flows 1,243 Less: interest 96 Present value of lease liability $ 1,147

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Rollforward and by Segment	Information regarding goodwill by segment, as well as Corporate & Other, was as follows: U.S. Asia (1) Latin EMEA MetLife Corporate Total (In millions) Balance at January 1, 2020 Goodwill $ 1,466 $ 4,636 $ 1,099 $ 1,117 $ 1,567 $ 103 $ 9,988 Accumulated impairment — — — — (680) — (680) Total goodwill, net 1,466 4,636 1,099 1,117 887 103 9,308 Acquisitions (2) 932 — — — — — 932 Effect of foreign currency translation and other — 127 44 29 — — 200 Reclassified to assets held-for-sale (3) (328) — — — — — (328) Balance at December 31, 2020 Goodwill 2,070 4,763 1,143 1,146 1,567 103 10,792 Accumulated impairment — — — — (680) — (680) Total goodwill, net 2,070 4,763 1,143 1,146 887 103 10,112 Effect of foreign currency translation and other — (211) (166) (200) — — (577) Balance at December 31, 2021 Goodwill 2,070 4,552 977 946 1,567 103 10,215 Accumulated impairment — — — — (680) — (680) Total goodwill, net 2,070 4,552 977 946 887 103 9,535 Acquisitions — — — — — 40 40 Effect of foreign currency translation and other — (243) 3 (38) — — (278) Balance at December 31, 2022 Goodwill 2,070 4,309 980 908 1,567 143 9,977 Accumulated impairment — — — — (680) — (680) Total goodwill, net $ 2,070 $ 4,309 $ 980 $ 908 $ 887 $ 143 $ 9,297 __________________ (1) Includes goodwill of $4.2 billion, $4.4 billion and $4.6 billion from the Company’s Japan operations at December 31, 2022, 2021 and 2020, respectively. (2) Primarily related to the acquisition of Versant Health. See Note 3. (3) See Note 3 for information on the disposition of MetLife P&C.

Long-term and Short-term Debt (

Long-term and Short-term Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-term and Short-term debt outstanding	Long-term and short-term debt outstanding was as follows: December 31, Interest Rates (1) 2022 2021 Range Weighted Maturity Face Unamortized Carrying Face Unamortized Carrying (In millions) Senior notes 0.50 % - 6.50% 4.42% 2023 - 2052 $ 13,671 $ (83) $ 13,588 $ 12,891 $ (77) $ 12,814 Surplus notes 7.63 % - 7.88% 7.79% 2024 - 2025 507 (1) 506 507 (2) 505 Other notes 0.45 % - 7.50% 4.67% 2023 - 2027 500 (3) 497 536 (3) 533 Financing lease obligations 56 — 56 81 — 81 Total long-term debt 14,734 (87) 14,647 14,015 (82) 13,933 Total short-term debt 175 — 175 341 — 341 Total $ 14,909 $ (87) $ 14,822 $ 14,356 $ (82) $ 14,274 __________________ (1) Range of interest rates and weighted average interest rates are for the year ended December 31, 2022.
Schedule of Short-term Debt	Short-term Debt Short-term debt with maturities of one year or less was as follows: December 31, 2022 2021 (Dollars in millions) Commercial paper $ 99 $ 100 Short-term borrowings (1) 76 241 Total short-term debt $ 175 $ 341 Average daily balance $ 237 $ 300 Average days outstanding 157 days 155 days __________________
Schedule of Line of Credit Facilities	Information on the Credit Facility at December 31, 2022 was as follows: Borrower(s) Expiration Maximum Letters of Drawdowns Unused (In millions) MetLife, Inc. and MetLife Funding, Inc. February 2026 (1) $ 3,000 $ 263 $ — $ 2,737 __________________ (1) All borrowings under the Credit Facility must be repaid by February 26, 2026, except that letters of credit outstanding upon termination may remain outstanding until February 26, 2027.
Committed Facilities	Information on the Committed Facilities at December 31, 2022 was as follows: Account Party/Borrower(s) Expiration Maximum Letters of Drawdowns Unused (In millions) MetLife Reinsurance Company of Vermont and MetLife, Inc. November 2026 (1), (2) $ 350 $ 350 $ — $ — MetLife Reinsurance Company of Vermont and MetLife, Inc. December 2037 (1), (3) 2,896 2,487 — 409 Total $ 3,246 $ 2,837 $ — $ 409 __________________ (1) MetLife, Inc. is a guarantor under the applicable facility. (2) The issuance of additional letters of credit is at the discretion of the counterparty. (3) Capacity at December 31, 2022 of $2.8 billion increases periodically to a maximum of $2.9 billion in 2024, decreases periodically commencing in 2025 to $2.0 billion in 2037, and decreases to $0 at expiration in December 2037. Unused commitment of $409 million is based on maximum capacity. At December 31, 2022, Brighthouse Financial, Inc. and its subsidiaries (“Brighthouse”), a former subsidiary of MetLife, Inc., is a beneficiary of $2.5 billion of letters of credit issued under this facility and, in consideration, Brighthouse reimburses MetLife, Inc. for a portion of the letter of credit fees.

Collateral Financing Arrangem_2

Collateral Financing Arrangements Collateral Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Secured Debt [Abstract]
CFA Associated with Closed Block	Information related to the collateral financing arrangement associated with the closed block (See Note 7) was as follows at: December 31, 2022 2021 (In millions) Surplus notes outstanding (1) $ 716 $ 766 Receivable from unaffiliated financial institution (1) $ 93 $ 100 Pledged collateral (2) $ 43 $ 38 Assets held in trust (2) $ 1,369 $ 1,388 __________________ (1) Carrying value. (2) Estimated fair value.

Junior Subordinated Debt Secu_2

Junior Subordinated Debt Securities (Tables)	12 Months Ended
	Dec. 31, 2022
Junior Subordinated Notes [Abstract]
Outstanding Junior Subordinated Debt Securities	Outstanding junior subordinated debt securities and exchangeable surplus trust securities which are exchangeable for junior subordinated debt securities prior to redemption or repayment, were as follows: December 31, 2022 2021 Issuer Issue Interest Scheduled Interest Rate Final Face Unamortized Carrying Face Unamortized Carrying (In millions) MetLife, Inc. December 2006 6.400% December 2036 LIBOR + 2.205% December 2066 $ 1,250 $ (15) $ 1,235 $ 1,250 $ (16) $ 1,234 MetLife Capital Trust IV (3) December 2007 7.875% December 2037 LIBOR + 3.960% December 2067 700 (13) 687 700 (13) 687 MetLife, Inc. April 2008 9.250% April 2038 LIBOR + 5.540% April 2068 750 (9) 741 750 (9) 741 MetLife, Inc. July 2009 10.750% August 2039 LIBOR + 7.548% August 2069 500 (5) 495 500 (6) 494 Total $ 3,200 $ (42) $ 3,158 $ 3,200 $ (44) $ 3,156 _________________ (1) Prior to the scheduled redemption date, interest is payable semiannually in arrears. (2) In the event the securities are not redeemed on or before the scheduled redemption date, interest will accrue after such date at an annual rate of three-month LIBOR plus the indicated margin, payable quarterly in arrears. On March 5, 2021, the Intercontinental Exchange Benchmark Administration, the administrator of LIBOR, announced that it will cease the publication of three-month U.S. Dollar LIBOR at the end of June 2023. Existing contract fallback provisions, and whether, how, and when the Company develops and adopts alternative reference rates, will influence the effect of any changes to or discontinuation of LIBOR on the Company. (3) MetLife Capital Trust IV is a VIE which is consolidated on the financial statements of the Company. The securities issued by this entity are exchangeable surplus trust securities, which are exchangeable for a like amount of MetLife, Inc.’s junior subordinated debt securities on the scheduled redemption date, mandatorily under certain circumstances, and at any time upon MetLife, Inc. exercising its option to redeem the securities.

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Stock by Class	Preferred stock authorized, issued and outstanding was as follows at both December 31, 2022 and 2021: Series Shares Authorized Shares Issued and Outstanding Series A preferred stock 27,600,000 24,000,000 Series D preferred stock 500,000 500,000 Series E preferred stock 32,200 32,200 Series F preferred stock 40,000 40,000 Series G preferred stock 1,000,000 1,000,000 Series A Junior Participating Preferred Stock 10,000,000 — Not designated 160,827,800 — Total 200,000,000 25,572,200
Components of compensation expense related to stock based compensation	Compensation Expense Related to Stock-Based Compensation The components of compensation expense related to stock-based compensation includes compensation expense related to Phantom Stock-Based Awards and excludes the insignificant compensation expense related to the 2015 Director Stock Plan. Those components were: Years Ended December 31, 2022 2021 2020 (In millions) Stock Options and Unit Options $ 7 $ 9 $ 6 Performance Shares and Performance Units (1) 108 98 63 Restricted Stock Units and Restricted Units 69 66 58 Total compensation expense $ 184 $ 173 $ 127 Income tax benefit $ 39 $ 36 $ 27 __________________
Total unrecognized compensation expense related to stock based compensation and the expected weighted average period over which the expenses will be recognized	The following table presents the total unrecognized compensation expense related to stock-based compensation and the expected weighted average period over which these expenses will be recognized at: December 31, 2022 Expense Weighted Average (In millions) (Years) Stock Options $ 3 1.78 Performance Shares $ 29 1.68 Restricted Stock Units $ 32 1.83
Activity related to Stock Options	Stock Option Activity A summary of the activity related to Stock Options was as follows: Shares Weighted Weighted Aggregate (Years) (In millions) Outstanding at January 1, 2022 4,268,091 $ 44.02 5.03 $ 79 Granted 402,976 $ 68.96 Exercised (1,259,933) $ 37.79 Expired (2) (6,424) $ 33.35 Forfeited (3) (18,669) $ 60.07 Outstanding at December 31, 2022 3,386,041 $ 49.24 5.58 $ 78 Vested and expected to vest at December 31, 2022 3,376,464 $ 49.20 5.57 $ 78 Exercisable at December 31, 2022 2,533,864 $ 45.25 4.61 $ 69 __________________ (1) The intrinsic value of each Stock Option is the closing price on a particular date less the exercise price of the Stock Option, so long as the difference is greater than zero. The aggregate intrinsic value of all outstanding Stock Options is computed using the closing Share price on December 31, 2022 of $72.37 and December 31, 2021 of $62.49, as applicable. (2) Expired options were exercisable, but unexercised, as of their expiration date. (3) Forfeited awards were either (a) unvested or unexercisable at the end of the awardholder’s employment, where the awardholder did not meet the criteria for post-employment award continuation; or (b) held by awardholders the Company terminated from employment for cause as defined in the terms of the awards. The following table presents a summary of Stock Option exercise activity: Years Ended December 31, 2022 2021 2020 (In millions) Total intrinsic value of stock options exercised $ 40 $ 60 $ 29 Cash received from exercise of stock options $ 48 $ 119 $ 89 Income tax benefit realized from stock options exercised $ 8 $ 13 $ 6
Weighted average assumptions used to determine the fair value of Stock Options issued	The following table presents the weighted average assumptions, with the exception of risk-free rate (which is expressed as a range), that the model uses to determine the fair value of unexercised Stock Options: Years Ended December 31, 2022 2021 2020 Dividend yield 2.78% 3.20% 3.70% Risk-free rate of return 1.17% - 1.97% 0.08% - 2.48% 1.30% - 1.57% Expected volatility 26.67% 29.72% 25.55% Exercise multiple 1.45 1.44 1.44 Post-vesting termination rate 3.58% 3.58% 3.79% Contractual term (years) 10 10 10 Expected life (years) 6 7 7 Weighted average exercise price of stock options granted $68.96 $57.43 $47.58 Weighted average fair value of stock options granted $15.18 $12.76 $9.02
Performance Share and Restricted Stock Unit Activity	Performance Share and Restricted Stock Unit Activity The following table presents a summary of Performance Share and Restricted Stock Unit activity: Performance Shares Restricted Stock Units Shares Weighted Units Weighted Outstanding at January 1, 2022 3,848,015 $ 43.74 2,451,046 $ 45.39 Granted 978,422 $ 62.83 893,161 $ 62.60 Forfeited (2) (130,371) $ 51.20 (127,184) $ 52.97 Payable (3) (1,489,328) $ 39.38 (1,217,059) $ 43.71 Outstanding at December 31, 2022 3,206,738 $ 51.26 1,999,964 $ 53.62 Vested and expected to vest at December 31, 2022 3,161,138 $ 51.15 1,967,910 $ 53.56 __________________ (1) Values for awards outstanding at January 1, 2022, represent weighted average number of awards multiplied by their fair value per Share at December 31, 2021. Otherwise, all values represent weighted average of number of awards multiplied by the fair value per Share at December 31, 2022. Fair value of Performance Shares and Restricted Stock Units on December 31, 2022 was equal to Grant Date fair value. (2) Forfeited awards were either (a) unvested or unexercisable at the end of the awardholder’s employment, where the awardholder did not meet the criteria for post-employment award continuation; or (b) held by awardholders the Company terminated from employment for cause as defined in the terms of the awards. (3) Includes both Shares paid and Deferred Shares.
Liability Award Unit Activity	Liability Award Activity The following table presents a summary of Liability Awards activity: Unit Performance Restricted Outstanding at January 1, 2022 124,986 448,986 514,556 Granted 13,192 115,057 216,980 Exercised (23,800) — — Expired (1) (59,647) — — Forfeited (2) — (15,223) (30,580) Paid — (156,900) (259,401) Outstanding at December 31, 2022 54,731 391,920 441,555 Vested and expected to vest at December 31, 2022 54,359 382,702 431,164 __________________ (1) Expired options were exercisable, but unexercised, as of their expiration date. (2) Forfeited awards were either (a) unvested or unexercisable at the end of the awardholder’s employment, where the awardholder did not meet the criteria for post-employment award continuation; or (b) held by awardholders the Company terminated from employment for cause as defined in the terms of the awards.
Schedules of statutory net income, capital and surplus and reserve strengthening by subsidiary	Statutory net income (loss) was as follows: Years Ended December 31, Company State of Domicile 2022 2021 2020 (In millions) Metropolitan Life Insurance Company New York $ 2,737 $ 3,513 $ 3,392 American Life Insurance Company Delaware $ 824 $ 48 $ 980 Metropolitan Property and Casualty Insurance Company (1) Rhode Island N/A N/A $ 336 Metropolitan Tower Life Insurance Company Nebraska $ 232 $ 185 $ (237) Other Various $ 91 $ 76 $ 84 __________________ (1) See Note 3 for information on the Company’s business dispositions. Statutory capital and surplus was as follows at: December 31, Company 2022 2021 (In millions) Metropolitan Life Insurance Company $ 10,869 $ 11,804 American Life Insurance Company $ 5,040 $ 5,584 Metropolitan Tower Life Insurance Company $ 1,896 $ 1,638 Other $ 209 $ 193
Dividend Payment Restrictions	The table below sets forth the dividends permitted to be paid by MetLife, Inc.’s primary insurance subsidiaries without insurance regulatory approval and the actual dividends paid: 2023 2022 2021 Company Permitted Without Paid (2) Paid (2) (In millions) Metropolitan Life Insurance Company $ 2,471 $ 3,539 $ 3,393 American Life Insurance Company $ 499 $ 1,289 $ 1,135 Metropolitan Property and Casualty Insurance Company N/A N/A $ 35 (3) Metropolitan Tower Life Insurance Company $ 189 $ — $ — __________________ (1) Reflects dividend amounts that may be paid by the end of 2023 without prior regulatory approval. (2) Reflects all amounts paid, including those where regulatory approval was obtained as required. (3) Consists of the stock of a subsidiary paid to MetLife, Inc. See Note 3 for information on the Company’s business dispositions.
Components of Accumulated Other Comprehensive Income (Loss)	Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc. was as follows: Unrealized Unrealized Gains Foreign Defined Total (In millions) Balance at December 31, 2019 $ 18,283 $ 1,698 $ (4,927) $ (2,002) $ 13,052 OCI before reclassifications 5,775 730 1,002 95 7,602 Deferred income tax benefit (expense) (1,349) (257) (36) (22) (1,664) AOCI before reclassifications, net of income tax 22,709 2,171 (3,961) (1,929) 18,990 Amounts reclassified from AOCI (357) (1,016) — 86 (1,287) Deferred income tax benefit (expense) 83 358 — (20) 421 Amounts reclassified from AOCI, net of income tax (274) (658) — 66 (866) Sale of subsidiaries, net of income tax (1) (218) — 166 — (52) Balance at December 31, 2020 22,217 1,513 (3,795) (1,863) 18,072 OCI before reclassifications (7,829) (113) (1,567) 237 (9,272) Deferred income tax benefit (expense) 1,918 18 (53) (46) 1,837 AOCI before reclassifications, net of income tax 16,306 1,418 (5,415) (1,672) 10,637 Amounts reclassified from AOCI (125) 250 — 91 216 Deferred income tax benefit (expense) 29 (39) — (17) (27) Amounts reclassified from AOCI, net of income tax (96) 211 — 74 189 Sale of subsidiaries, net of income tax (1) (168) — 261 — 93 Balance at December 31, 2021 16,042 1,629 (5,154) (1,598) 10,919 OCI before reclassifications (49,427) (583) (1,629) 188 (51,451) Deferred income tax benefit (expense) 11,304 89 (16) (39) 11,338 AOCI before reclassifications, net of income tax (22,081) 1,135 (6,799) (1,449) (29,194) Amounts reclassified from AOCI 1,607 498 — 93 2,198 Deferred income tax benefit (expense) (368) (76) — (19) (463) Amounts reclassified from AOCI, net of income tax 1,239 422 — 74 1,735 Sale of subsidiaries, net of income tax (1) (9) — 387 (2) 376 Balance at December 31, 2022 $ (20,851) $ 1,557 $ (6,412) $ (1,377) $ (27,083) __________________ (1) See Note 3 for information on the Company’s business dispositions . For information on offsets to investments related to policyholder liabilities, DAC, VOBA and DSI, see “— Net Unrealized Investment Gains (losses).”
Reclassification out of Accumulated Other Comprehensive Income (Loss)	Information regarding amounts reclassified out of each component of AOCI was as follows: Years Ended December 31, 2022 2021 2020 AOCI Components Amounts Reclassified from AOCI Consolidated Statements of (In millions) Net unrealized investment gains (losses): Net unrealized investment gains (losses) $ (1,802) $ 72 $ 362 Net investment gains (losses) Net unrealized investment gains (losses) 7 (16) (24) Net investment income Net unrealized investment gains (losses) 188 69 19 Net derivative gains (losses) Net unrealized investment gains (losses), before income tax (1,607) 125 357 Income tax (expense) benefit 368 (29) (83) Net unrealized investment gains (losses), net of income tax (1,239) 96 274 Unrealized gains (losses) on derivatives - cash flow hedges: Interest rate derivatives 59 56 36 Net investment income Interest rate derivatives 41 84 121 Net investment gains (losses) Interest rate derivatives 4 3 2 Other expenses Foreign currency exchange rate derivatives 6 8 4 Net investment income Foreign currency exchange rate derivatives (609) (403) 851 Net investment gains (losses) Foreign currency exchange rate derivatives 1 2 2 Other expenses Gains (losses) on cash flow hedges, before income tax (498) (250) 1,016 Income tax (expense) benefit 76 39 (358) Gains (losses) on cash flow hedges, net of income tax (422) (211) 658 Defined benefit plans adjustment: (1) Amortization of net actuarial gains (losses) (104) (120) (105) Amortization of prior service (costs) credit 11 29 19 Amortization of defined benefit plan items, before income tax (93) (91) (86) Income tax (expense) benefit 19 17 20 Amortization of defined benefit plan items, net of income tax (74) (74) (66) Total reclassifications, net of income tax $ (1,735) $ (189) $ 866 __________________ (1) These AOCI components are included in the computation of net periodic benefit costs. See Note 18.
Preferred Stock Dividend Rates	The table below presents the dividend rates of MetLife, Inc.’s preferred stock outstanding at December 31, 2022: Series Per Annum Dividend Rate A Three-month LIBOR + 1.00%, with floor of 4.00%, payable quarterly in March, June, September and December D 5.875% from issuance date to, but excluding, March 15, 2028, payable semiannually in March and September; three-month LIBOR + 2.959% payable quarterly in March, June, September and December, thereafter E 5.625% from issuance date, payable quarterly in March, June, September and December F 4.750% from issuance date, payable quarterly in March, June, September and December, commencing in June 2020 G 3.850% from issuance date, but excluding, September 15, 2025, payable semiannually in March and September commencing in March 2021; five year treasury rate, reset every five years, + 3.576% payable semiannually in March and September, thereafter
Class of Treasury Stock	MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows: Authorization Remaining at Announcement Date Authorization Amount December 31, 2022 (In millions) May 4, 2022 $ 3,000 $ 1,205 August 4, 2021 $ 3,000 $ — December 11, 2020 $ 3,000 $ —
Dividends Declared [Table Text Block]	The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows: Years Ended December 31, 2022 2021 2020 Series Per Share Aggregate Per Share Aggregate Per Share Aggregate (In millions, except per share data) A $ 1.033 $ 24 $ 1.015 $ 24 $ 1.015 $ 24 C (1) $ — — $ 19.085 10 $ 45.860 59 D $ 58.750 29 $ 58.750 29 $ 58.750 30 E $ 1,406.252 45 $ 1,406.252 45 $ 1,406.252 45 F $ 1,187.500 48 $ 1,187.500 48 $ 1,088.542 44 G $ 38.500 39 $ 39.035 39 $ — — Total $ 185 $ 195 $ 202 __________________ (1) Dividends were paid through the dividend payment date of June 15, 2021, when all outstanding shares of Series C preferred stock were redeemed and eliminated.
Unrealized Gain (Loss) on Investments [Table Text Block]	The components of net unrealized investment gains (losses), included in AOCI, were as follows: Years Ended December 31, 2022 2021 2020 (In millions) Fixed maturity securities AFS $ (29,262) $ 29,461 $ 44,415 Derivatives 1,976 2,061 1,924 Other 549 389 267 Subtotal (26,737) 31,911 46,606 Amounts allocated from: Policyholder liabilities (1) (1,487) (4,978) (10,797) DAC, VOBA and DSI 4,034 (3,208) (4,050) Subtotal 2,547 (8,186) (14,847) Deferred income tax benefit (expense) 4,914 (6,031) (8,009) Net unrealized investment gains (losses) (19,276) 17,694 23,750 Net unrealized investment gains (losses) attributable to noncontrolling interests (18) (23) (20) Net unrealized investment gains (losses) attributable to MetLife, Inc. $ (19,294) $ 17,671 $ 23,730 __________________ (1) Includes unearned revenue liabilities.

Other Revenues and Other Expe_2

Other Revenues and Other Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Other Income and Expenses [Abstract]
Disaggregation of Revenue	Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Vision fee for service arrangements (1) $ 566 $ 546 $ — Prepaid legal plans 471 432 395 Fee-based investment management 396 363 318 Recordkeeping and administrative services (2) 168 213 196 Administrative services-only contracts 238 231 218 Other revenue from service contracts from customers 271 289 227 Total revenues from service contracts from customers 2,110 2,074 1,354 Other 524 545 495 Total other revenues $ 2,634 $ 2,619 $ 1,849 __________________ (1) For information regarding the Company’s acquisition of Versant Health, see Note 3. (2) Related to products and businesses no longer actively marketed by the Company.
Other Expenses	Information on other expenses was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Employee related costs (1) $ 3,520 $ 3,515 $ 3,514 Third party staffing costs 1,573 1,423 1,335 General and administrative expenses 700 686 761 Pension, postretirement and postemployment benefit costs 98 147 165 Premium taxes, other taxes, and licenses & fees 608 629 764 Commissions and other variable expenses 5,265 5,463 5,596 Capitalization of DAC (2,558) (2,718) (3,013) Amortization of DAC and VOBA 1,931 2,555 3,160 Amortization of negative VOBA (41) (34) (45) Interest expense on debt 938 920 913 Total other expenses $ 12,034 $ 12,586 $ 13,150 __________________ (1) Includes $93 million, ($144) million and ($147) million for the years ended December 31, 2022, 2021 and 2020, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Net periodic benefit costs and other changes in plan assets and benefit obligations recognized in other comprehensive income (loss)	The benefit obligations, funded status and net periodic benefit costs related to these pension and other postretirement benefits were comprised of the following: December 31, 2022 December 31, 2021 Pension Benefits Other Postretirement Pension Benefits Other Postretirement U.S. Non- Total U.S. Non- Total U.S. Non- Total U.S. Non- Total (In millions) Benefit obligations $ 8,425 $ 873 $ 9,298 $ 758 $ 36 $ 794 $ 11,086 $ 1,096 $ 12,182 $ 1,099 $ 39 $ 1,138 Estimated fair value of plan assets 7,831 463 8,294 1,277 26 1,303 10,392 579 10,971 1,417 26 1,443 Over (under) funded status $ (594) $ (410) $ (1,004) $ 519 $ (10) $ 509 $ (694) $ (517) $ (1,211) $ 318 $ (13) $ 305 Net periodic benefit costs $ 49 $ 73 $ 122 $ (43) $ 1 $ (42) $ 97 $ 97 $ 194 $ (55) $ 2 $ (53) The components of net periodic benefit costs and other changes in plan assets and benefit obligations recognized in OCI were as follows: Years Ended December 31, 2022 2021 2020 Pension Benefits Other Postretirement Benefits Pension Benefits Other Postretirement Benefits Pension Benefits Other Postretirement Benefits (In millions) Net periodic benefit costs: Service costs $ 187 $ 4 $ 215 $ 4 $ 226 $ 5 Interest costs 328 34 342 37 363 42 Settlement and curtailment (gains) losses 5 — (7) 1 10 — Expected return on plan assets (516) (55) (506) (56) (528) (62) Amortization of net actuarial (gains) losses 129 (25) 162 (39) 189 (74) Amortization of prior service costs (credit) (11) — (12) — (14) (3) Total net periodic benefit costs (credit) 122 (42) 194 (53) 246 (92) Other changes in plan assets and benefit obligations recognized in OCI: Net actuarial (gains) losses 2 (191) (166) (54) (35) (42) Prior service costs (credit) 8 — 1 (1) — — Amortization of net actuarial (gains) losses (129) 25 (162) 39 (189) 74 Amortization of prior service costs (credit) 11 — 12 — 14 3 Settlement and curtailment (gains) losses (5) — (10) 10 (10) — Exchange rate changes (7) — (8) — 5 — Total recognized in OCI (120) (166) (333) (6) (215) 35 Total recognized in net periodic benefit costs and OCI $ 2 $ (208) $ (139) $ (59) $ 31 $ (57)
Benefit Plan Obligations, Assets, Funded Status, Accumulated Other Comprehensive Income (Loss) and Accumulated Benefit Obligation	Obligations and Funded Status December 31, 2022 2021 Pension Other Pension Other (In millions) Change in benefit obligations: Benefit obligations at January 1, $ 12,182 $ 1,138 $ 12,873 $ 1,252 Service costs 187 4 215 4 Interest costs 328 34 342 37 Plan participants’ contributions — 32 — 32 Plan amendments 8 — 1 — Net actuarial (gains) losses (2) (2,609) (289) (363) (96) Acquisition, divestitures, settlements and curtailments (45) — (111) 8 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (123) — (110) — Benefit obligations at December 31, 9,298 794 12,182 1,138 Change in plan assets: Estimated fair value of plan assets at January 1, 10,971 1,443 11,256 1,492 Actual return on plan assets (2,095) (43) 310 14 Acquisition, divestitures and settlements (38) — (35) (1) Plan participants’ contributions — 32 — 32 Employer contributions 152 (3) 163 5 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (66) (1) (58) — Estimated fair value of plan assets at December 31, 8,294 1,303 10,971 1,443 Over (under) funded status at December 31, $ (1,004) $ 509 $ (1,211) $ 305 Amounts recognized on the consolidated balance sheets: Other assets $ 428 $ 796 $ 640 $ 788 Other liabilities (1,432) (287) (1,851) (483) Net amount recognized $ (1,004) $ 509 $ (1,211) $ 305 AOCI: Net actuarial (gains) losses $ 2,277 $ (498) $ 2,416 $ (332) Prior service costs (credit) (36) — (55) — AOCI, before income tax $ 2,241 $ (498) $ 2,361 $ (332) Accumulated benefit obligation $ 9,185 N/A $ 11,934 N/A __________________ (1) Includes nonqualified unfunded plans, for which the aggregate PBO was $1.0 billion and $1.3 billion at December 31, 2022 and 2021, respectively. (2) For the year ended December 31, 2022, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions, primarily related to an increase in the discount rate, of ($2.6) billion and ($276) million, respectively, and plan experience of $14 million and ($13) million, respectively. For the year ended December 31, 2021, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions of ($389) million and ($34) million, respectively, demographic assumptions of $0 and ($4) million, respectively, and plan experience of $26 million and ($58) million, respectively.
Benefit Plan Obligations, Assets, Funded Status, Accumulated Other Comprehensive Income (Loss) and Accumulated Benefit Obligation	Obligations and Funded Status December 31, 2022 2021 Pension Other Pension Other (In millions) Change in benefit obligations: Benefit obligations at January 1, $ 12,182 $ 1,138 $ 12,873 $ 1,252 Service costs 187 4 215 4 Interest costs 328 34 342 37 Plan participants’ contributions — 32 — 32 Plan amendments 8 — 1 — Net actuarial (gains) losses (2) (2,609) (289) (363) (96) Acquisition, divestitures, settlements and curtailments (45) — (111) 8 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (123) — (110) — Benefit obligations at December 31, 9,298 794 12,182 1,138 Change in plan assets: Estimated fair value of plan assets at January 1, 10,971 1,443 11,256 1,492 Actual return on plan assets (2,095) (43) 310 14 Acquisition, divestitures and settlements (38) — (35) (1) Plan participants’ contributions — 32 — 32 Employer contributions 152 (3) 163 5 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (66) (1) (58) — Estimated fair value of plan assets at December 31, 8,294 1,303 10,971 1,443 Over (under) funded status at December 31, $ (1,004) $ 509 $ (1,211) $ 305 Amounts recognized on the consolidated balance sheets: Other assets $ 428 $ 796 $ 640 $ 788 Other liabilities (1,432) (287) (1,851) (483) Net amount recognized $ (1,004) $ 509 $ (1,211) $ 305 AOCI: Net actuarial (gains) losses $ 2,277 $ (498) $ 2,416 $ (332) Prior service costs (credit) (36) — (55) — AOCI, before income tax $ 2,241 $ (498) $ 2,361 $ (332) Accumulated benefit obligation $ 9,185 N/A $ 11,934 N/A __________________ (1) Includes nonqualified unfunded plans, for which the aggregate PBO was $1.0 billion and $1.3 billion at December 31, 2022 and 2021, respectively. (2) For the year ended December 31, 2022, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions, primarily related to an increase in the discount rate, of ($2.6) billion and ($276) million, respectively, and plan experience of $14 million and ($13) million, respectively. For the year ended December 31, 2021, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions of ($389) million and ($34) million, respectively, demographic assumptions of $0 and ($4) million, respectively, and plan experience of $26 million and ($58) million, respectively.
Benefit Plan Obligations, Assets, Funded Status, Accumulated Other Comprehensive Income (Loss) and Accumulated Benefit Obligation	Obligations and Funded Status December 31, 2022 2021 Pension Other Pension Other (In millions) Change in benefit obligations: Benefit obligations at January 1, $ 12,182 $ 1,138 $ 12,873 $ 1,252 Service costs 187 4 215 4 Interest costs 328 34 342 37 Plan participants’ contributions — 32 — 32 Plan amendments 8 — 1 — Net actuarial (gains) losses (2) (2,609) (289) (363) (96) Acquisition, divestitures, settlements and curtailments (45) — (111) 8 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (123) — (110) — Benefit obligations at December 31, 9,298 794 12,182 1,138 Change in plan assets: Estimated fair value of plan assets at January 1, 10,971 1,443 11,256 1,492 Actual return on plan assets (2,095) (43) 310 14 Acquisition, divestitures and settlements (38) — (35) (1) Plan participants’ contributions — 32 — 32 Employer contributions 152 (3) 163 5 Benefits paid (630) (125) (665) (99) Effect of foreign currency translation (66) (1) (58) — Estimated fair value of plan assets at December 31, 8,294 1,303 10,971 1,443 Over (under) funded status at December 31, $ (1,004) $ 509 $ (1,211) $ 305 Amounts recognized on the consolidated balance sheets: Other assets $ 428 $ 796 $ 640 $ 788 Other liabilities (1,432) (287) (1,851) (483) Net amount recognized $ (1,004) $ 509 $ (1,211) $ 305 AOCI: Net actuarial (gains) losses $ 2,277 $ (498) $ 2,416 $ (332) Prior service costs (credit) (36) — (55) — AOCI, before income tax $ 2,241 $ (498) $ 2,361 $ (332) Accumulated benefit obligation $ 9,185 N/A $ 11,934 N/A __________________ (1) Includes nonqualified unfunded plans, for which the aggregate PBO was $1.0 billion and $1.3 billion at December 31, 2022 and 2021, respectively. (2) For the year ended December 31, 2022, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions, primarily related to an increase in the discount rate, of ($2.6) billion and ($276) million, respectively, and plan experience of $14 million and ($13) million, respectively. For the year ended December 31, 2021, significant sources of actuarial (gains) losses for pension and other postretirement benefits include the impact of changes to the financial assumptions of ($389) million and ($34) million, respectively, demographic assumptions of $0 and ($4) million, respectively, and plan experience of $26 million and ($58) million, respectively.
Accumulated benefit obligations in excess of fair value of plan assets	Information for pension plans and other postretirement benefit plans with PBOs and/or accumulated benefit obligations (“ABO”) or APBO in excess of plan assets was as follows at: December 31, 2022 2021 2022 2021 2022 2021 PBO Exceeds Estimated Fair Value ABO Exceeds Estimated Fair Value APBO Exceeds Estimated Fair Value (In millions) Projected benefit obligations $ 1,444 $ 1,840 $ 1,434 $ 1,831 N/A N/A Accumulated benefit obligations $ 1,384 $ 1,740 $ 1,384 $ 1,740 N/A N/A Accumulated postretirement benefit obligations N/A N/A N/A N/A $ 562 $ 813 Estimated fair value of plan assets $ 10 $ 9 $ — $ — $ 276 $ 331
Defined benefit plan pension plans with projected benefit obligations in excess of plan assets	Information for pension plans and other postretirement benefit plans with PBOs and/or accumulated benefit obligations (“ABO”) or APBO in excess of plan assets was as follows at: December 31, 2022 2021 2022 2021 2022 2021 PBO Exceeds Estimated Fair Value ABO Exceeds Estimated Fair Value APBO Exceeds Estimated Fair Value (In millions) Projected benefit obligations $ 1,444 $ 1,840 $ 1,434 $ 1,831 N/A N/A Accumulated benefit obligations $ 1,384 $ 1,740 $ 1,384 $ 1,740 N/A N/A Accumulated postretirement benefit obligations N/A N/A N/A N/A $ 562 $ 813 Estimated fair value of plan assets $ 10 $ 9 $ — $ — $ 276 $ 331
Net periodic benefit costs and other changes in plan assets and benefit obligations recognized in other comprehensive income (loss)	The components of net periodic benefit costs and other changes in plan assets and benefit obligations recognized in OCI were as follows: Years Ended December 31, 2022 2021 2020 Pension Benefits Other Postretirement Benefits Pension Benefits Other Postretirement Benefits Pension Benefits Other Postretirement Benefits (In millions) Net periodic benefit costs: Service costs $ 187 $ 4 $ 215 $ 4 $ 226 $ 5 Interest costs 328 34 342 37 363 42 Settlement and curtailment (gains) losses 5 — (7) 1 10 — Expected return on plan assets (516) (55) (506) (56) (528) (62) Amortization of net actuarial (gains) losses 129 (25) 162 (39) 189 (74) Amortization of prior service costs (credit) (11) — (12) — (14) (3) Total net periodic benefit costs (credit) 122 (42) 194 (53) 246 (92) Other changes in plan assets and benefit obligations recognized in OCI: Net actuarial (gains) losses 2 (191) (166) (54) (35) (42) Prior service costs (credit) 8 — 1 (1) — — Amortization of net actuarial (gains) losses (129) 25 (162) 39 (189) 74 Amortization of prior service costs (credit) 11 — 12 — 14 3 Settlement and curtailment (gains) losses (5) — (10) 10 (10) — Exchange rate changes (7) — (8) — 5 — Total recognized in OCI (120) (166) (333) (6) (215) 35 Total recognized in net periodic benefit costs and OCI $ 2 $ (208) $ (139) $ (59) $ 31 $ (57)
Assumptions used in determining benefit obligations and net periodic benefit costs	Assumptions used in determining benefit obligations for the U.S. plans were as follows: Pension Benefits Other Postretirement Benefits December 31, 2022 Weighted average discount rate 5.60% 5.70% Weighted average interest crediting rate 4.00% N/A Rate of compensation increase 2.50% - 8.00% N/A December 31, 2021 Weighted average discount rate 2.95% 3.05% Weighted average interest crediting rate 3.18% N/A Rate of compensation increase 2.50% - 8.00% N/A Assumptions used in determining net periodic benefit costs for the U.S. plans were as follows: Pension Benefits Other Postretirement Benefits Year Ended December 31, 2022 Weighted average discount rate 2.95% 3.05% Weighted average interest crediting rate 3.43% N/A Weighted average expected rate of return on plan assets 5.00% 3.86% Rate of compensation increase 2.50% - 8.00% N/A Year Ended December 31, 2021 Weighted average discount rate 3.01% 3.14% Weighted average interest crediting rate 3.24% N/A Weighted average expected rate of return on plan assets 5.00% 3.87% Rate of compensation increase 2.50% - 8.00% N/A Year Ended December 31, 2020 Weighted average discount rate 3.30% 3.45% Weighted average interest crediting rate 3.38% N/A Weighted average expected rate of return on plan assets 5.50% 4.31% Rate of compensation increase 2.25% - 8.50% N/A
Assumed healthcare costs trend rates	The assumed healthcare costs trend rates used in measuring the APBO and net periodic benefit costs were as follows: December 31, 2022 2021 Before Age 65 and Before Age 65 and Following year 5.2 % 3.9 % 5.1 % 3.3 % Ultimate rate to which cost increase is assumed to decline 3.7 % 4.5 % 3.7 % 3.8 % Year in which the ultimate trend rate is reached 2074 2100 2074 2074
Plan Assets	The table below summarizes the actual weighted average allocation of the estimated fair value of total plan assets by asset class at December 31 for the years indicated and the approved target allocation by major asset class at December 31, 2022 for the Invested Plans: December 31, 2022 2021 U.S. Pension U.S. Other Postretirement Benefits (1) U.S. Pension U.S. Other Target Actual Target Actual Actual Actual Asset Class Fixed maturity securities AFS 85 % 83 % 95 % 96 % 84 % 95 % Equity securities (2) 7 % 6 % 5 % 4 % 7 % 5 % Alternative securities (3) 8 % 11 % — % — % 9 % — % Total assets 100 % 100 % 100 % 100 % __________________ (1) U.S. other postretirement benefits do not reflect postretirement life’s plan assets invested in fixed maturity securities AFS. (2) Equity securities percentage includes derivative assets. (3) Alternative securities primarily include private equity and real estate funds. The pension and other postretirement plan assets measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are summarized as follows: December 31, 2022 Pension Benefits Other Postretirement Benefits Fair Value Hierarchy Fair Value Hierarchy Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: Corporate $ — $ 2,946 $ 55 $ 3,001 $ — $ 205 $ — $ 205 U.S. government bonds 1,462 45 — 1,507 68 — — 68 Foreign bonds — 769 — 769 — 61 — 61 Federal agencies 87 190 — 277 3 1 — 4 Municipals — 159 — 159 — 15 — 15 Short-term investments 12 384 — 396 463 396 — 859 Other (1) 92 598 3 693 8 36 — 44 Total fixed maturity securities AFS 1,653 5,091 58 6,802 542 714 — 1,256 Equity securities 416 151 3 570 47 — — 47 Other investments 40 1 855 896 — — — — Derivative assets 21 1 4 26 — — — — Total assets $ 2,130 $ 5,244 $ 920 $ 8,294 $ 589 $ 714 $ — $ 1,303 December 31, 2021 Pension Benefits Other Postretirement Benefits Fair Value Hierarchy Fair Value Hierarchy Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (In millions) Assets Fixed maturity securities AFS: Corporate $ — $ 4,305 $ — $ 4,305 $ — $ 222 $ — $ 222 U.S. government bonds 1,824 80 — 1,904 69 — — 69 Foreign bonds — 1,115 1 1,116 — 51 — 51 Federal agencies — 83 — 83 — 10 — 10 Municipals — 248 — 248 — 8 — 8 Short-term investments 142 484 — 626 486 482 — 968 Other (1) 155 627 1 783 14 45 — 59 Total fixed maturity securities AFS 2,121 6,942 2 9,065 569 818 — 1,387 Equity securities 601 283 11 895 55 — — 55 Other investments 42 1 954 997 1 — — 1 Derivative assets 14 — — 14 — — — — Total assets $ 2,778 $ 7,226 $ 967 $ 10,971 $ 625 $ 818 $ — $ 1,443 __________________ (1) Other primarily includes money market securities, mortgage-backed securities, collateralized mortgage obligations and ABS & CLO.
Rollforward fair value measurement using significant unobservable outputs (level 3)	A rollforward of all pension and other postretirement benefit plan assets measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs was as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS: Foreign Bonds Corporate Other Equity Securities Other Derivative Assets (In millions) Balance, January 1, 2021 $ — $ — $ — $ — $ 708 $ — Realized gains (losses) — — — — — — Unrealized gains (losses) — — — — 63 — Purchases, sales, issuances and settlements, net 1 — 1 11 183 — Transfers into and/or out of Level 3 — — — — — — Balance, December 31, 2021 $ 1 $ — $ 1 $ 11 $ 954 $ — Realized gains (losses) — — — — — — Unrealized gains (losses) — (1) — — 54 1 Purchases, sales, issuances and settlements, net — 56 3 (8) (153) 3 Transfers into and/or out of Level 3 (1) — (1) — — — Balance, December 31, 2022 $ — $ 55 $ 3 $ 3 $ 855 $ 4
Defined benefit plan estimated future benefit payments	Gross benefit payments for the next 10 years, which reflect expected future service where appropriate, are expected to be as follows: Pension Benefits Other Postretirement Benefits (In millions) 2023 $ 713 $ 66 2024 $ 722 $ 63 2025 $ 727 $ 62 2026 $ 742 $ 61 2027 $ 745 $ 59 2028-2032 $ 3,747 $ 279

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Provision for income tax from continuing operations	The provision for income tax was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Current: U.S. federal $ 159 $ 62 $ 271 U.S. state and local 45 38 27 Non-U.S. 1,074 795 882 Subtotal 1,278 895 1,180 Deferred: U.S. federal 536 837 (115) U.S. state and local — (2) 1 Non-U.S. (1,513) (179) 443 Subtotal (977) 656 329 Provision for income tax expense (benefit) $ 301 $ 1,551 $ 1,509
Income (loss) from continuing operations before income tax expense (benefit) from domestic and foreign operations	The Company’s income (loss) before income tax expense (benefit) was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Income (loss): U.S. $ 2,681 $ 4,841 $ 2,970 Non-U.S. 178 3,285 3,957 Total $ 2,859 $ 8,126 $ 6,927
Income tax for continuing operations effective rate reconciliation	The reconciliation of the income tax provision at the U.S. statutory rate to the provision for income tax as reported was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Tax provision at U.S. statutory rate $ 601 $ 1,706 $ 1,455 Tax effect of: Dividend received deduction (20) (40) (34) Tax-exempt income 15 (36) (45) Prior year tax (1), (2) (15) (127) (27) Low income housing tax credits (143) (178) (202) Other tax credits (44) (46) (45) Foreign tax rate differential (3), (4), (5) (110) 267 414 Change in valuation allowance — 1 (5) Other, net 17 4 (2) Provision for income tax expense (benefit) $ 301 $ 1,551 $ 1,509 __________________ (1) As discussed further below, prior year tax primarily includes non-cash benefits related to uncertain tax positions of $32 million and $117 million for the years ended December 31, 2022 and 2021, respectively. (2) For the year ended December 31, 2020, prior year tax primarily includes a $40 million tax benefit related to an Internal Revenue Service (“IRS”) audit matter. (3) For the year ended December 31, 2022, foreign tax rate differential includes tax charges of $12 million related to the U.S. tax on Global Intangible Low-Taxed Income (“GILTI”) of which $33 million is a current year charge offset by a $21 million tax benefit revising the 2021 estimate. (4) For the year ended December 31, 2021, foreign tax rate differential includes tax charges of $50 million related to the disposition of MetLife Poland and Greece, $41 million related to the sale of MetLife Seguros and $30 million related to the U.S. tax on GILTI, which included a $42 million 2021 charge offset by a $12 million tax benefit revising the 2020 estimate. See Note 3 for information on the Company’s business dispositions. (5) For the year ended December 31, 2020, foreign tax rate differential includes tax charges of $60 million and $24 million related to the sales of MetLife Seguros de Retiro and MetLife Russia, respectively, and $43 million related to the U.S. tax on GILTI. See Note 3 for information on the Company’s business dispositions.
Components of deferred tax assets and liabilities	Deferred income tax represents the tax effect of the differences between the book and tax bases of assets and liabilities. Net deferred income tax assets and liabilities consisted of the following at: December 31, 2022 2021 (In millions) Deferred income tax assets: Policyholder liabilities and receivables $ 1,496 $ 3,787 Net operating loss carryforwards (1) 238 235 Employee benefits 475 583 Capital loss carryforwards 15 9 Tax credit carryforwards (2) 590 825 Net unrealized investment losses 5,319 — Litigation-related and government mandated 90 95 Other 67 — Total gross deferred income tax assets 8,290 5,534 Less: Valuation allowance (1) 291 299 Total net deferred income tax assets 7,999 5,235 Deferred income tax liabilities: Investments, including derivatives 1,691 4,167 Intangibles 1,096 1,188 Net unrealized investment gains — 5,551 DAC 2,707 3,471 Other — 362 Total deferred income tax liabilities 5,494 14,739 Net deferred income tax asset (liability) $ 2,505 $ (9,504) __________________ (1) The Company has recorded a deferred tax asset of $238 million related to U.S. state and non-U.S. net operating loss carryforwards and an offsetting valuation allowance for the year ended December 31, 2022. Certain net operating loss carryforwards will expire between 2023 and 2042, whereas others have an unlimited carryforward period. (2) Tax credit carryforwards for the year ended December 31, 2022 primarily reflect general business credits expiring between 2039 and 2042 and are increased by $44 million related to unrecognized tax benefits.
Reconciliation of unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Balance at January 1, $ 163 $ 272 $ 256 Additions for tax positions of prior years 42 19 16 Reductions for tax positions of prior years (1) (93) (112) (1) Additions for tax positions of current year 22 5 12 Reductions for tax positions of current year (3) (18) — Settlements with tax authorities (2) (3) (1) Lapses of statute of limitations — — (10) Balance at December 31, $ 129 $ 163 $ 272 Unrecognized tax benefits that, if recognized, would impact the effective rate $ 80 $ 103 $ 203 __________________ (1) The decreases in 2022 and 2021 are primarily related to non-cash benefits from tax audit settlements. Interest was as follows: Years Ended December 31, 2022 2021 2020 (In millions) Interest expense (benefit) recognized on the consolidated statements of operations (1) $ — $ (36) $ 12 December 31, 2022 2021 (In millions) Interest included in other liabilities on the consolidated balance sheets $ 15 $ 15 __________________ (1) For the year ended December 31, 2021, the interest benefit is primarily related to a tax audit settlement of $10 million which was recorded in other expenses and a reclassification of $26 million to current income tax payable.

Earnings Per Common Share (Tabl

Earnings Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Common Share	The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share: Years Ended December 31, 2022 2021 2020 (In millions, except per share data) Weighted Average Shares: Weighted average common stock outstanding - basic 803.2 862.7 907.8 Incremental common shares from assumed exercise or issuance of stock-based awards 5.7 6.7 5.4 Weighted average common stock outstanding - diluted 808.9 869.4 913.2 Net Income (Loss): Net income (loss) $ 2,558 $ 6,575 $ 5,418 Less: Net income (loss) attributable to noncontrolling interests 19 21 11 Less: Preferred stock dividends 185 195 202 Preferred stock redemption premium — 6 14 Net income (loss) available to MetLife, Inc.’s common shareholders $ 2,354 $ 6,353 $ 5,191 Basic $ 2.93 $ 7.36 $ 5.72 Diluted $ 2.91 $ 7.31 $ 5.68

Contingencies, Commitments an_2

Contingencies, Commitments and Guarantees (Tables)	12 Months Ended
	Dec. 31, 2022
Asbestos Related Claims
Loss Contingencies [Line Items]
Schedule of Loss Contingencies by Contingency	The approximate total number of asbestos personal injury claims pending against MLIC as of the dates indicated, the approximate number of new claims during the years ended on those dates and the approximate total settlement payments made to resolve asbestos personal injury claims at or during those years are set forth in the following table: December 31, 2022 2021 2020 (In millions, except number of claims) Asbestos personal injury claims at year end 58,073 58,785 60,618 Number of new claims during the year 2,610 2,824 2,496 Settlement payments during the year (1) $ 50.5 $ 53.0 $ 52.9 __________________ (1) Settlement payments represent payments made by MLIC during the year in connection with settlements made in that year and in prior years. Amounts do not include MLIC’s attorneys’ fees and expenses.

Business, Basis of Presentati_3

Business, Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of segments | Segment	5
Property, Plant and Equipment [Line Items]
Cost basis of property, equipment and leasehold improvements	$ 2,500	$ 2,700
Accumulated depreciation and amortization of property, equipment and leasehold improvements	1,600	1,600
Depreciation and amortization expense	171	192	$ 194
Finite-Lived Intangible Assets [Line Items]
Operating Lease, Right-of-Use Asset, Amortization Expense	$ 3	45	0
Maximum
Real Estate Held-for-investment And Accumulated Depreciation [Line Items]
Real Estate Held-for-investment And Accumulated Depreciation Life Used For Depreciation	55 years
Building
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Leasehold Improvements | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Other Capitalized Property Plant and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Other Capitalized Property Plant and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
VODA and VOCRA | Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization period	9 years
VODA and VOCRA | Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization period	40 years
Computer Software, Intangible Asset
Finite-Lived Intangible Assets [Line Items]
Amortization period	4 years
Cost basis of computer software	$ 4,400	4,000
Accumulated amortization of computer software	2,800	2,700
Amortization expense related to computer software	$ 252	$ 234	$ 207

Business, Basis of Presentati_4

Business, Basis of Presentation and Summary of Significant Accounting Policies - Future Adoption (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 27,287	$ 67,749		$ 74,817	$ 66,382
Accumulated Other Comprehensive Income (Loss), Net of Tax	(27,083)	10,919		$ 18,072	13,052
Retained Earnings (Accumulated Deficit)	$ 41,953	$ 41,197
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest					$ (121)
Cumulative Effect, Period of Adoption, Adjustment | Pro Forma | Accounting Standards Update 2018-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest			$ (22,500)
Accumulated Other Comprehensive Income (Loss), Net of Tax			(17,500)
Retained Earnings (Accumulated Deficit)			$ (5,000)

Segment Information (Earnings)

Segment Information (Earnings) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Premiums	$ 49,397	$ 42,009	$ 42,034
Universal life and investment-type product policy fees	5,585	5,756	5,603
Net investment income	15,916	21,395	17,117
Other revenues	2,634	2,619	1,849
Net investment gains (losses)	(1,262)	1,529	(110)
Net derivative gains (losses)	(2,372)	(2,228)	1,349
Total revenues	69,898	71,080	67,842
Expenses
Policyholder benefits and claims and policyholder dividends	51,313	44,830	42,551
Interest credited to policyholder account balances	3,692	5,538	5,214
Capitalization of DAC	(2,558)	(2,718)	(3,013)
Amortization of DAC and VOBA	1,931	2,555	3,160
Amortization of negative VOBA	(41)	(34)	(45)
Interest expense on debt	938	920	913
Other expenses	11,764	11,863	12,135
Total expenses	67,039	62,954	60,915
Provision for income tax expense (benefit)	301	1,551	1,509
Net income (loss)	2,558	6,575	5,418
U.S.
Expenses
Amortization of DAC and VOBA	59	158	471
Asia
Expenses
Amortization of DAC and VOBA	1,042	1,404	1,468
Latin America
Expenses
Amortization of DAC and VOBA	339	285	276
EMEA
Expenses
Amortization of DAC and VOBA	340	382	452
MetLife Holdings
Expenses
Amortization of DAC and VOBA	142	317	485
Corporate & Other
Expenses
Amortization of DAC and VOBA	9	9	8
Operating Segments
Revenues
Premiums	49,356	41,027	41,982
Universal life and investment-type product policy fees	5,532	5,561	5,465
Net investment income	18,189	21,280	17,328
Other revenues	2,471	2,376	1,690
Net investment gains (losses)	0	0	0
Net derivative gains (losses)	0	0	0
Total revenues	75,548	70,244	66,465
Expenses
Policyholder benefits and claims and policyholder dividends	51,366	43,651	41,859
Interest credited to policyholder account balances	5,011	4,592	4,673
Capitalization of DAC	(2,547)	(2,599)	(3,008)
Amortization of DAC and VOBA	2,037	2,336	2,994
Amortization of negative VOBA	(41)	(34)	(45)
Interest expense on debt	938	919	913
Other expenses	11,501	11,299	11,872
Total expenses	68,265	60,164	59,258
Provision for income tax expense (benefit)	1,553	1,931	1,382
Adjusted earnings	5,730	8,149	5,825
Operating Segments | U.S.
Revenues
Premiums	35,548	26,358	27,265
Universal life and investment-type product policy fees	1,158	1,140	1,070
Net investment income	7,340	8,048	6,903
Other revenues	1,756	1,538	957
Net investment gains (losses)	0	0	0
Net derivative gains (losses)	0	0	0
Total revenues	45,802	37,084	36,195
Expenses
Policyholder benefits and claims and policyholder dividends	36,273	27,957	26,309
Interest credited to policyholder account balances	1,789	1,422	1,622
Capitalization of DAC	(77)	(65)	(453)
Amortization of DAC and VOBA	59	60	471
Amortization of negative VOBA	0	0	0
Interest expense on debt	9	7	7
Other expenses	3,962	3,632	4,162
Total expenses	42,015	33,013	32,118
Provision for income tax expense (benefit)	791	850	853
Adjusted earnings	2,996	3,221	3,224
Operating Segments | Asia
Revenues
Premiums	5,568	6,421	6,571
Universal life and investment-type product policy fees	1,840	1,814	1,892
Net investment income	3,909	5,052	3,938
Other revenues	90	73	61
Net investment gains (losses)	0	0	0
Net derivative gains (losses)	0	0	0
Total revenues	11,407	13,360	12,462
Expenses
Policyholder benefits and claims and policyholder dividends	4,752	5,008	5,213
Interest credited to policyholder account balances	2,003	1,995	1,834
Capitalization of DAC	(1,524)	(1,607)	(1,652)
Amortization of DAC and VOBA	1,105	1,369	1,415
Amortization of negative VOBA	(36)	(27)	(37)
Interest expense on debt	0	0	0
Other expenses	3,153	3,388	3,481
Total expenses	9,453	10,126	10,254
Provision for income tax expense (benefit)	576	936	643
Adjusted earnings	1,378	2,298	1,565
Operating Segments | Latin America
Revenues
Premiums	3,226	2,609	2,265
Universal life and investment-type product policy fees	1,175	1,109	994
Net investment income	1,593	1,271	992
Other revenues	39	41	38
Net investment gains (losses)	0	0	0
Net derivative gains (losses)	0	0	0
Total revenues	6,033	5,030	4,289
Expenses
Policyholder benefits and claims and policyholder dividends	3,301	3,143	2,406
Interest credited to policyholder account balances	335	249	240
Capitalization of DAC	(499)	(414)	(362)
Amortization of DAC and VOBA	339	285	276
Amortization of negative VOBA	0	0	0
Interest expense on debt	12	5	4
Other expenses	1,553	1,401	1,318
Total expenses	5,041	4,669	3,882
Provision for income tax expense (benefit)	231	70	127
Adjusted earnings	761	291	280
Operating Segments | EMEA
Revenues
Premiums	1,964	2,271	2,259
Universal life and investment-type product policy fees	300	395	433
Net investment income	160	215	269
Other revenues	35	47	52
Net investment gains (losses)	0	0	0
Net derivative gains (losses)	0	0	0
Total revenues	2,459	2,928	3,013
Expenses
Policyholder benefits and claims and policyholder dividends	990	1,241	1,196
Interest credited to policyholder account balances	71	86	109
Capitalization of DAC	(411)	(469)	(491)
Amortization of DAC and VOBA	333	356	454
Amortization of negative VOBA	(5)	(7)	(8)
Interest expense on debt	0	0	1
Other expenses	1,171	1,324	1,344
Total expenses	2,149	2,531	2,605
Provision for income tax expense (benefit)	64	96	81
Adjusted earnings	246	301	327
Operating Segments | MetLife Holdings
Revenues
Premiums	3,066	3,333	3,600
Universal life and investment-type product policy fees	1,057	1,101	1,073
Net investment income	4,971	6,450	5,184
Other revenues	155	257	238
Net investment gains (losses)	0	0	0
Net derivative gains (losses)	0	0	0
Total revenues	9,249	11,141	10,095
Expenses
Policyholder benefits and claims and policyholder dividends	6,056	6,268	6,738
Interest credited to policyholder account balances	813	840	868
Capitalization of DAC	(28)	(33)	(39)
Amortization of DAC and VOBA	192	257	370
Amortization of negative VOBA	0	0	0
Interest expense on debt	8	5	6
Other expenses	953	992	942
Total expenses	7,994	8,329	8,885
Provision for income tax expense (benefit)	247	570	234
Adjusted earnings	1,008	2,242	976
Operating Segments | Corporate & Other
Revenues
Premiums	(16)	35	22
Universal life and investment-type product policy fees	2	2	3
Net investment income	216	244	42
Other revenues	396	420	344
Net investment gains (losses)	0	0	0
Net derivative gains (losses)	0	0	0
Total revenues	598	701	411
Expenses
Policyholder benefits and claims and policyholder dividends	(6)	34	(3)
Interest credited to policyholder account balances	0	0	0
Capitalization of DAC	(8)	(11)	(11)
Amortization of DAC and VOBA	9	9	8
Amortization of negative VOBA	0	0	0
Interest expense on debt	909	902	895
Other expenses	709	562	625
Total expenses	1,613	1,496	1,514
Provision for income tax expense (benefit)	(356)	(591)	(556)
Adjusted earnings	(659)	(204)	(547)
Significant Reconciling Items
Revenues
Premiums	41	982	52
Universal life and investment-type product policy fees	53	195	138
Net investment income	(2,273)	115	(211)
Other revenues	163	243	159
Net investment gains (losses)	(1,262)	1,529	(110)
Net derivative gains (losses)	(2,372)	(2,228)	1,349
Total revenues	(5,650)	836	1,377
Expenses
Policyholder benefits and claims and policyholder dividends	(53)	1,179	692
Interest credited to policyholder account balances	(1,319)	946	541
Capitalization of DAC	(11)	(119)	(5)
Amortization of DAC and VOBA	(106)	219	166
Amortization of negative VOBA	0	0	0
Interest expense on debt	0	1	0
Other expenses	263	564	263
Total expenses	(1,226)	2,790	1,657
Provision for income tax expense (benefit)	$ (1,252)	$ (380)	$ 127

Segment Information (Total Asse

Segment Information (Total Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Separate account assets	$ 146,038	$ 179,873
Separate account liabilities	146,038	179,873
Total assets	666,611	759,708
U.S.
Segment Reporting Information [Line Items]
Separate account assets	61,030	81,217
Separate account liabilities	61,030	81,217
Total assets	$ 252,559	$ 282,741
Net investment income from equity method investments	5%	23%	5%
Asia
Segment Reporting Information [Line Items]
Separate account assets	$ 8,292	$ 10,241
Separate account liabilities	8,292	10,241
Total assets	$ 150,134	$ 169,291
Net investment income from equity method investments	12%	30%	12%
Latin America
Segment Reporting Information [Line Items]
Separate account assets	$ 39,428	$ 37,632
Separate account liabilities	39,428	37,632
Total assets	$ 63,810	$ 59,763
Net investment income from equity method investments	3%	7%	1%
EMEA
Segment Reporting Information [Line Items]
Separate account assets	$ 3,314	$ 3,098
Separate account liabilities	3,314	3,098
Total assets	16,765	27,038
MetLife Holdings
Segment Reporting Information [Line Items]
Separate account assets	33,974	47,685
Separate account liabilities	33,974	47,685
Total assets	$ 149,739	$ 179,551
Net investment income from equity method investments	6%	26%	5%
Corporate & Other
Segment Reporting Information [Line Items]
Separate account assets	$ 0	$ 0
Separate account liabilities	0	0
Total assets	$ 33,604	$ 41,324

Segment Information (Product Ta

Segment Information (Product Table) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	$ 57,616	$ 50,384	$ 49,486
Life insurance
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	21,969	22,872	21,256
Accident & health insurance
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	17,453	17,498	15,346
Annuities
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	16,647	7,499	7,916
Other
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	$ 1,547	$ 2,515	$ 4,968

Segment Information (Premiums,

Segment Information (Premiums, Fees and Other Revenues by US and Foreign Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	$ 57,616	$ 50,384	$ 49,486
UNITED STATES
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	43,319	35,252	34,717
Japan
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	5,532	6,426	6,750
Other Foreign
Segment Reporting Information [Line Items]
Premiums, Fees & Other Revenues	$ 8,765	$ 8,706	$ 8,019

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Segment Reporting [Abstract]
Number of segments | Segment	5
Segment Reporting Information [Line Items]
Total assets	$ 666,611	$ 759,708
Total revenues	69,898	71,080	$ 67,842
U.S.
Segment Reporting Information [Line Items]
Total assets	252,559	282,741
One.U.S.Customer | U.S.
Segment Reporting Information [Line Items]
Total revenues	8,100
Japan
Segment Reporting Information [Line Items]
Total assets	$ 127,100	$ 142,700
Assets, Total | Geographic Concentration Risk | Japan
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	19%	19%
Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration Risk, Benchmark Description		10	10
Revenue Benchmark | Customer Concentration Risk | One.U.S.Customer | U.S.
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	14%

Acquisition of Versant Health N

Acquisition of Versant Health Narrative (Details)	12 Months Ended
	Dec. 31, 2020
Versant Health, Inc. [Member] | Maximum
Business Acquisition [Line Items]
Versant Health total revenue	2%

Disposition of MetLife Seguros

Disposition of MetLife Seguros S.A. (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income (loss)	$ 2,558	$ 6,575	$ 5,418
MetLife Seguros S.A
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income (loss)		$ (205)

Disposition of MetLife Poland a

Disposition of MetLife Poland and Greece - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net investment gains (losses)	$ (1,262)	$ 1,529	$ (110)
Income (loss) from continuing operations before provision for income tax	2,859	8,126	6,927
MetLife Poland and Greece
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Agreed upon proceeds from divestiture of business.				$ 738
Dividends Receivable				$ 43
Net investment gains (losses)	(25)
Gain (Loss) on Disposition of Business	(239)
Income (loss) from continuing operations before provision for income tax	$ 19	$ 50	$ 30

Disposition of MetLife Poland_2

Disposition of MetLife Poland and Greece (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	$ 0	$ 69	$ 765	$ 0
Liabilities held-for-sale	$ 0	6,634
MetLife Poland and Greece
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets		7,238
Cash and cash equivalents		69
Other		259
Liabilities held-for-sale		6,634
Other		113
MetLife Poland and Greece | Fixed Maturities [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets		2,043
MetLife Poland and Greece | Contractholder-directed equity securities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets		1,114
MetLife Poland and Greece | Other Investments
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets		118
MetLife Poland and Greece | Investments
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets		3,275
MetLife Poland and Greece | Deferred policy acquisition costs and value of business acquired
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets		138
MetLife Poland and Greece | Separate account assets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets		3,497
MetLife Poland and Greece | Future policy benefits [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilities held-for-sale		916
MetLife Poland and Greece | Policyholder Account Balances [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilities held-for-sale		2,005
MetLife Poland and Greece | Other Policy-Related Balances
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilities held-for-sale		103
MetLife Poland and Greece | Separate account liabilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilities held-for-sale		$ 3,497

Disposition of Metropolitan Pro

Disposition of Metropolitan Property and Casualty Insurance Company - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net investment gains (losses)	$ (1,262)	$ 1,529	$ (110)
Gain (Loss) on Sale of Business	2,558	6,575	5,418
Income (loss) from continuing operations before provision for income tax	$ 2,859	8,126	6,927
Metropolitan Property and Casualty Insurance Company
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses		3,900	3,900
Net investment gains (losses)		1,400
Gain (Loss) on Sale of Business		1,000
Income (loss) from continuing operations before provision for income tax		$ 121	$ 399

Disposition of Joint-stock Comp

Disposition of Joint-stock Company MetLife Insurance Company (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Sale of Business		$ 2,558	$ 6,575	$ 5,418
Joint-stock Company MetLife Insurance Company [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Sale of Business	$ (133)

Disposition - MetLife Seguros d

Disposition - MetLife Seguros de Retiro S.A. (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Sale of Business	$ 2,558	$ 6,575	$ 5,418
Net investment gains (losses)	(1,262)	1,529	(110)
Provision for income tax expense (benefit)	$ 301	$ 1,551	1,509
MetLife Seguros de Retiro S.A. [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Sale of Business			(162)
Net investment gains (losses)			(130)
Provision for income tax expense (benefit)			$ 32

Insurance (Insurance Liabilitie

Insurance (Insurance Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Insurance Liabilities [Line Items]
Insurance liabilities comprised of future policy benefits, policyholder account balances and other policy-related balances	$ 426,961	$ 420,945
U.S.
Insurance Liabilities [Line Items]
Insurance liabilities comprised of future policy benefits, policyholder account balances and other policy-related balances	171,693	162,999
Asia
Insurance Liabilities [Line Items]
Insurance liabilities comprised of future policy benefits, policyholder account balances and other policy-related balances	125,523	125,839
Latin America
Insurance Liabilities [Line Items]
Insurance liabilities comprised of future policy benefits, policyholder account balances and other policy-related balances	17,674	15,564
EMEA
Insurance Liabilities [Line Items]
Insurance liabilities comprised of future policy benefits, policyholder account balances and other policy-related balances	10,635	13,031
MetLife Holdings
Insurance Liabilities [Line Items]
Insurance liabilities comprised of future policy benefits, policyholder account balances and other policy-related balances	100,407	102,291
Corporate & Other
Insurance Liabilities [Line Items]
Insurance liabilities comprised of future policy benefits, policyholder account balances and other policy-related balances	$ 1,029	$ 1,221

Insurance (Insurance Liabilit_2

Insurance (Insurance Liabilities Assumptions and Ratios - Narrative) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Liability for Future Policy Benefits and Policyholder Contract Deposits, Assumptions [Abstract]
Participating business as a percentage of gross life insurance policies in-force	2%	3%
Participating business as a percentage of the gross life insurance premiums	11%	12%	14%
Domestic Business | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate range credited to policyholder account balances	1%
Domestic Business | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate range credited to policyholder account balances	8%
Domestic Business | Participating Life Insurance Policies | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	3%
Domestic Business | Participating Life Insurance Policies | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	7%
Domestic Business | Nonparticipating Life Insurance Policies | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	2%
Domestic Business | Nonparticipating Life Insurance Policies | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	11%
Domestic Business | Individual and Group Traditional Fixed annuities [Member] | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	1%
Domestic Business | Individual and Group Traditional Fixed annuities [Member] | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	11%
Domestic Business | Non-medical Health Insurance [Member] | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	1%
Domestic Business | Non-medical Health Insurance [Member] | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	7%
Domestic Business | Group Long-Term Disability | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	2%
Domestic Business | Group Long-Term Disability | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	8%
International Business | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate range credited to policyholder account balances	1%
International Business | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate range credited to policyholder account balances	12%
International Business | Participating Life Insurance Policies | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	1%
International Business | Participating Life Insurance Policies | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	10%
International Business | Nonparticipating Life Insurance Policies | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	1%
International Business | Nonparticipating Life Insurance Policies | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	10%
International Business | Individual and Group Traditional Fixed annuities [Member] | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	1%
International Business | Individual and Group Traditional Fixed annuities [Member] | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	9%
International Business | Group Long-Term Disability | Minimum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	1%
International Business | Group Long-Term Disability | Maximum
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumptions for the aggregate future policy benefit liabilities for traditional life insurance policies	9%

Insurance (Liabilities for Guar

Insurance (Liabilities for Guarantees) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Universal and Variable Life Contracts | Secondary Guarantees | Foreign Currency Translation
Movement In Guaranteed Benefit Liability Gross Rollforward
Incurred guaranteed benefits	$ (268)	$ (260)	$ 125
Direct and Assumed
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	6,450	6,441	5,548
Incurred guaranteed benefits	(179)	226	1,063
Paid guaranteed benefits	(217)	(185)	(170)
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		(32)
Balance at December 31,	6,054	6,450	6,441
Direct and Assumed | Secondary Guarantees
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	4,126	4,265	3,762
Incurred guaranteed benefits	(261)	(37)	602
Paid guaranteed benefits	(120)	(102)	(99)
Balance at December 31,	3,745	4,126	4,265
Direct and Assumed | Secondary Guarantees | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Direct and Assumed | Paid-Up Guarantees
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	404	408	427
Incurred guaranteed benefits	104	43	26
Paid guaranteed benefits	(44)	(47)	(45)
Balance at December 31,	464	404	408
Direct and Assumed | Paid-Up Guarantees | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Direct and Assumed | Guaranteed Minimum Death and Withdrawal Benefit [Member]
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	743	639	465
Incurred guaranteed benefits	247	133	195
Paid guaranteed benefits	(39)	(29)	(21)
Balance at December 31,	951	743	639
Direct and Assumed | Guaranteed Minimum Death and Withdrawal Benefit [Member] | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Direct and Assumed | Guaranteed Minimum Income Benefit
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	1,177	1,129	894
Incurred guaranteed benefits	(269)	87	240
Paid guaranteed benefits	(14)	(7)	(5)
Balance at December 31,	894	1,177	1,129
Direct and Assumed | Guaranteed Minimum Income Benefit | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		(32)
Ceded
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	748	724	640
Incurred guaranteed benefits	53	83	125
Paid guaranteed benefits	(48)	(59)	(41)
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Balance at December 31,	753	748	724
Ceded | Secondary Guarantees
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	451	427	349
Incurred guaranteed benefits	29	57	96
Paid guaranteed benefits	(24)	(33)	(18)
Balance at December 31,	456	451	427
Ceded | Secondary Guarantees | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Ceded | Paid-Up Guarantees
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	288	292	281
Incurred guaranteed benefits	33	30	43
Paid guaranteed benefits	(32)	(34)	(32)
Balance at December 31,	289	288	292
Ceded | Paid-Up Guarantees | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Ceded | Guaranteed Minimum Death and Withdrawal Benefit [Member]
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	0	(2)	0
Incurred guaranteed benefits	(8)	(6)	(11)
Paid guaranteed benefits	8	8	9
Balance at December 31,	0	0	(2)
Ceded | Guaranteed Minimum Death and Withdrawal Benefit [Member] | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Ceded | Guaranteed Minimum Income Benefit
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	9	7	10
Incurred guaranteed benefits	(1)	2	(3)
Paid guaranteed benefits	0	0	0
Balance at December 31,	8	9	7
Ceded | Guaranteed Minimum Income Benefit | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Net
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	5,702	5,717	4,908
Incurred guaranteed benefits	(232)	143	938
Paid guaranteed benefits	(169)	(126)	(129)
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		(32)
Balance at December 31,	5,301	5,702	5,717
Net | Secondary Guarantees
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	3,675	3,838	3,413
Incurred guaranteed benefits	(290)	(94)	506
Paid guaranteed benefits	(96)	(69)	(81)
Balance at December 31,	3,289	3,675	3,838
Net | Secondary Guarantees | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Net | Paid-Up Guarantees
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	116	116	146
Incurred guaranteed benefits	71	13	(17)
Paid guaranteed benefits	(12)	(13)	(13)
Balance at December 31,	175	116	116
Net | Paid-Up Guarantees | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Net | Guaranteed Minimum Death and Withdrawal Benefit [Member]
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	743	641	465
Incurred guaranteed benefits	255	139	206
Paid guaranteed benefits	(47)	(37)	(30)
Balance at December 31,	951	743	641
Net | Guaranteed Minimum Death and Withdrawal Benefit [Member] | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		0
Net | Guaranteed Minimum Income Benefit
Movement In Guaranteed Benefit Liability Gross Rollforward
Balance at January 1,	1,168	1,122	884
Incurred guaranteed benefits	(268)	85	243
Paid guaranteed benefits	(14)	(7)	(5)
Balance at December 31,	$ 886	1,168	$ 1,122
Net | Guaranteed Minimum Income Benefit | MetLife Poland and Greece
Movement In Guaranteed Benefit Liability Gross Rollforward
Liabilities for Guarantees on Long-Duration Contracts, Other Liability Adjustments		$ (32)

Insurance (Guarantees Related t

Insurance (Guarantees Related to Annuity Contracts) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Variable Annuity Guarantees: | Guaranteed Death Benefits
Net Amount at Risk by Product and Guarantee [Line Items]
Total account value	$ 46,345	$ 62,281
Separate account value (1)	30,066	42,043
Net amount at risk	$ 5,338	$ 1,490
Average attained age of contractholders	68 years	68 years
Variable Annuity Guarantees: | Guaranteed Annuitization Benefits
Net Amount at Risk by Product and Guarantee [Line Items]
Total account value	$ 16,953	$ 23,121
Separate account value (1)	15,584	21,508
Net amount at risk	$ 433	$ 500
Average attained age of contractholders	68 years	66 years
Other Annuity Guarantees: | Guaranteed Annuitization Benefits
Net Amount at Risk by Product and Guarantee [Line Items]
Total account value	$ 4,101	$ 5,002
Net amount at risk	$ 188	$ 196
Average attained age of contractholders	57 years	56 years

Insurance (Guarantees Related_2

Insurance (Guarantees Related to Universal and Variable Life Contracts) (Details) - Universal and Variable Life Contracts - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Secondary Guarantees
Net Amount at Risk by Product and Guarantee [Line Items]
Total account value (1), (3)	$ 11,948	$ 13,678
Net amount at risk (7)	$ 80,623	$ 78,762
Average attained age of policyholders	55 years	55 years
Paid-Up Guarantees
Net Amount at Risk by Product and Guarantee [Line Items]
Total account value (1), (3)	$ 2,570	$ 2,694
Net amount at risk (7)	$ 11,824	$ 12,657
Average attained age of policyholders	67 years	66 years

Insurance (Fund Groupings) (Det

Insurance (Fund Groupings) (Details) - Variable Annuity and Variable Life - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Separate Account Investment [Line Items]
Fund Groupings	$ 37,873	$ 51,998
Equity
Fair Value, Separate Account Investment [Line Items]
Fund Groupings	20,875	29,346
Balanced
Fair Value, Separate Account Investment [Line Items]
Fund Groupings	12,657	17,393
Bond
Fair Value, Separate Account Investment [Line Items]
Fund Groupings	4,036	5,041
Money Market
Fair Value, Separate Account Investment [Line Items]
Fund Groupings	$ 305	$ 218

Insurance (Obligations Under Fu

Insurance (Obligations Under Funding Agreements - FHLB Common Stock) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Federal Home Loan Bank Stock	$ 729	$ 769
Federal Home Loan Bank of New York
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Federal Home Loan Bank Stock	$ 729	$ 769

Insurance (Obligations Under _2

Insurance (Obligations Under Funding Agreements - Liability and Collateral) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Outstanding Funding Agreements To Certain SPEs	$ 40,700	$ 39,500
Funding Agreements Farmer Mac
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Outstanding Funding Agreements To Certain SPEs	2,050	2,050
Invested Assets Pledged As Collateral	2,148	2,159
Federal Home Loan Bank of New York
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Federal Home Loan Bank amount of advances by branch for funding agreements	14,940	15,750
Collateral pledged relating to obligations under funding agreements	$ 17,857	$ 17,981

Insurance (Obligations Under _3

Insurance (Obligations Under Funding Agreements - Narrative) (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Insurance [Abstract]
Funding agreements issued to certain SPEs	$ 48.5	$ 40.8	$ 40.4
Funding agreements repaid to certain SPEs	47.4	41.2	$ 36.7
Outstanding funding agreements to certain SPEs	$ 40.7	$ 39.5

Insurance (Liabilities for Unpa

Insurance (Liabilities for Unpaid Claims and Claims Expense - Development Tables) (Details) $ in Millions	Dec. 31, 2022 USD ($) Claims	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Claims Development [Line Items]
Total unpaid claims and claim adjustment expenses, net of reinsurance	$ 14,125
Group Life - Term
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	80,599
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	77,480
All outstanding liabilities for incurral years not separately stated, net of reinsurance	22
Total unpaid claims and claim adjustment expenses, net of reinsurance	3,141
Group Life - Term | Short-duration Insurance Contracts, Accident Year 2013
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	6,726	$ 6,726	$ 6,724	$ 6,723	$ 6,720	$ 6,730	$ 6,720	$ 6,719	$ 6,713	$ 6,637
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 1
Cumulative Number of Reported Claims | Claims	213,283
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 6,724	6,723	6,721	6,720	6,715	6,711	6,678	6,664	6,614	5,216
Group Life - Term | Short-duration Insurance Contracts, Accident Year 2014
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	6,920	6,918	6,920	6,919	6,914	6,910	6,913	6,919	6,986
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 1
Cumulative Number of Reported Claims | Claims	216,148
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 6,917	6,916	6,915	6,912	6,902	6,869	6,858	6,809	5,428
Group Life - Term | Short-duration Insurance Contracts, Accident Year 2015
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	7,026	7,026	7,025	7,024	7,021	7,014	7,015	7,040
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 1
Cumulative Number of Reported Claims | Claims	218,782
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 7,024	7,022	7,018	7,008	6,974	6,958	6,913	5,524
Group Life - Term | Short-duration Insurance Contracts, Accident Year 2016
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	7,107	7,104	7,105	7,104	7,095	7,085	7,125
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 2
Cumulative Number of Reported Claims | Claims	220,671
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 7,100	7,096	7,086	7,053	7,034	6,980	5,582
Group Life - Term | Short-duration Insurance Contracts, Accident Year 2017
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	7,428	7,428	7,427	7,425	7,418	7,432
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 3
Cumulative Number of Reported Claims | Claims	263,546
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 7,414	7,400	7,374	7,355	7,292	5,761
Group Life - Term | Short-duration Insurance Contracts, Accident Year 2018
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	7,651	7,650	7,646	7,655	7,757
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 6
Cumulative Number of Reported Claims | Claims	251,446
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 7,629	7,595	7,578	7,521	6,008
Group Life - Term | Short-Duration Insurance Contracts, Accident Year 2019
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	7,917	7,907	7,900	7,935
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 11
Cumulative Number of Reported Claims | Claims	252,015
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 7,853	7,820	7,756	6,178
Group Life - Term | Short-Duration Insurance Contract, Accident Year 2020
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	9,389	9,367	8,913
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 23
Cumulative Number of Reported Claims | Claims	297,022
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 9,242	9,103	6,862
Group Life - Term | Short-Duration Insurance Contract, Accident Year 2021
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	10,795	10,555
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 64
Cumulative Number of Reported Claims | Claims	327,725
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 10,476	8,008
Group Life - Term | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	9,640
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 1,129
Cumulative Number of Reported Claims | Claims	276,784
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 7,101
Group Life - Term | Asia
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	2,952
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	2,006
All outstanding liabilities for incurral years not separately stated, net of reinsurance	11
Total unpaid claims and claim adjustment expenses, net of reinsurance	957
Group Life - Term | Asia | Short-duration Insurance Contracts, Accident Year 2013
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	155	157	156	153	153	145	146	151	130	129
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 5
Cumulative Number of Reported Claims | Claims	6,597
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 150	149	146	138	142	129	118	105	86	38
Group Life - Term | Asia | Short-duration Insurance Contracts, Accident Year 2014
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	224	230	230	229	233	222	222	241	257
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 8
Cumulative Number of Reported Claims | Claims	6,865
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 216	213	208	198	197	175	156	125	60
Group Life - Term | Asia | Short-duration Insurance Contracts, Accident Year 2015
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	241	245	241	239	229	235	232	243
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 13
Cumulative Number of Reported Claims | Claims	6,792
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 229	225	218	204	180	167	134	71
Group Life - Term | Asia | Short-duration Insurance Contracts, Accident Year 2016
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	216	215	210	208	195	206	203
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 19
Cumulative Number of Reported Claims | Claims	4,707
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 197	190	181	167	134	117	57
Group Life - Term | Asia | Short-duration Insurance Contracts, Accident Year 2017
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	272	277	270	252	244	263
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 30
Cumulative Number of Reported Claims | Claims	5,619
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 242	240	224	183	138	77
Group Life - Term | Asia | Short-duration Insurance Contracts, Accident Year 2018
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	309	315	305	293	321
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 56
Cumulative Number of Reported Claims | Claims	5,982
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 252	243	209	155	84
Group Life - Term | Asia | Short-Duration Insurance Contracts, Accident Year 2019
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	335	339	324	347
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 79
Cumulative Number of Reported Claims | Claims	5,966
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 257	221	170	93
Group Life - Term | Asia | Short-Duration Insurance Contract, Accident Year 2020
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	331	359	385
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 127
Cumulative Number of Reported Claims | Claims	5,030
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 203	153	85
Group Life - Term | Asia | Short-Duration Insurance Contract, Accident Year 2021
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	382	367
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 211
Cumulative Number of Reported Claims | Claims	5,659
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 171	77
Group Life - Term | Asia | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	487
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 399
Cumulative Number of Reported Claims | Claims	3,461
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 89
Group Long-Term Disability
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	12,300
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	6,251
All outstanding liabilities for incurral years not separately stated, net of reinsurance	1,496
Total unpaid claims and claim adjustment expenses, net of reinsurance	7,545
Group Long-Term Disability | Short-duration Insurance Contracts, Accident Year 2013
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,027	1,025	1,032	1,044	1,069	1,070	1,049	1,032	1,027	1,008
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	21,139
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 798	764	722	676	622	551	475	382	234	43
Group Long-Term Disability | Short-duration Insurance Contracts, Accident Year 2014
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,078	1,081	1,097	1,098	1,109	1,101	1,079	1,077	1,076
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	22,853
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 818	778	732	677	609	526	428	266	51
Group Long-Term Disability | Short-duration Insurance Contracts, Accident Year 2015
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,086	1,067	1,081	1,087	1,100	1,093	1,105	1,082
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	21,216
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 764	718	665	601	524	427	264	50
Group Long-Term Disability | Short-duration Insurance Contracts, Accident Year 2016
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,123	1,124	1,139	1,162	1,159	1,139	1,131
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	17,973
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 750	696	628	548	433	267	49
Group Long-Term Disability | Short-duration Insurance Contracts, Accident Year 2017
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,181	1,165	1,195	1,203	1,202	1,244
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	16,328
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 719	655	579	476	290	56
Group Long-Term Disability | Short-duration Insurance Contracts, Accident Year 2018
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,170	1,147	1,163	1,175	1,240
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	15,214
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 666	594	497	314	54
Group Long-Term Disability | Short-Duration Insurance Contracts, Accident Year 2019
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,177	1,169	1,212	1,277
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	15,392
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 620	522	342	57
Group Long-Term Disability | Short-Duration Insurance Contract, Accident Year 2020
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,155	1,223	1,253
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 6
Cumulative Number of Reported Claims | Claims	15,719
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 535	355	59
Group Long-Term Disability | Short-Duration Insurance Contract, Accident Year 2021
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,608	1,552
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 43
Cumulative Number of Reported Claims | Claims	19,189
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 505	95
Group Long-Term Disability | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	1,695
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 760
Cumulative Number of Reported Claims | Claims	9,970
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 76
Protection Life
Claims Development [Line Items]
Total unpaid claims and claim adjustment expenses, net of reinsurance	405
Protection Life | Latin America
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	3,746
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	3,347
All outstanding liabilities for incurral years not separately stated, net of reinsurance	6
Total unpaid claims and claim adjustment expenses, net of reinsurance	405
Protection Life | Latin America | Short-duration Insurance Contracts, Accident Year 2013
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	216	224	224	224	223	221	222	221	215	152
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	30,204
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 210	218	217	216	214	212	213	212	208	149
Protection Life | Latin America | Short-duration Insurance Contracts, Accident Year 2014
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	324	333	333	332	332	328	360	350	229
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	38,375
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 314	323	321	320	318	314	311	306	204
Protection Life | Latin America | Short-duration Insurance Contracts, Accident Year 2015
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	391	401	407	406	406	401	431	300
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	44,496
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 373	383	382	379	373	366	345	244
Protection Life | Latin America | Short-duration Insurance Contracts, Accident Year 2016
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	426	436	435	434	427	416	318
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	38,800
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 427	434	431	429	421	402	225
Protection Life | Latin America | Short-duration Insurance Contracts, Accident Year 2017
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	308	318	318	319	319	327
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	30,819
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 305	314	310	307	291	194
Protection Life | Latin America | Short-duration Insurance Contracts, Accident Year 2018
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	292	294	293	295	305
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 1
Cumulative Number of Reported Claims | Claims	29,563
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 274	277	272	261	153
Protection Life | Latin America | Short-Duration Insurance Contracts, Accident Year 2019
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	301	304	301	329
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 2
Cumulative Number of Reported Claims | Claims	32,017
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 278	280	260	171
Protection Life | Latin America | Short-Duration Insurance Contract, Accident Year 2020
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	502	498	497
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 10
Cumulative Number of Reported Claims | Claims	42,318
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 442	431	216
Protection Life | Latin America | Short-Duration Insurance Contract, Accident Year 2021
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	550	632
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 34
Cumulative Number of Reported Claims | Claims	51,077
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 456	326
Protection Life | Latin America | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	436
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 163
Cumulative Number of Reported Claims | Claims	30,066
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 268
Protection Health
Claims Development [Line Items]
Total unpaid claims and claim adjustment expenses, net of reinsurance	139
Protection Health | Latin America
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	3,817
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	3,679
All outstanding liabilities for incurral years not separately stated, net of reinsurance	1
Total unpaid claims and claim adjustment expenses, net of reinsurance	139
Protection Health | Latin America | Short-duration Insurance Contracts, Accident Year 2013
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	257	256	256	256	256	256	259	258	256	227
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	104,402
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 257	256	256	256	256	256	259	258	256	$ 227
Protection Health | Latin America | Short-duration Insurance Contracts, Accident Year 2014
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	263	262	262	261	261	262	264	262	236
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	98,132
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 260	259	259	259	259	259	263	260	$ 234
Protection Health | Latin America | Short-duration Insurance Contracts, Accident Year 2015
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	231	231	231	230	231	232	230	203
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	87,596
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 231	231	230	230	230	229	230	$ 203
Protection Health | Latin America | Short-duration Insurance Contracts, Accident Year 2016
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	304	303	303	303	303	306	266
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	106,665
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 304	303	303	302	302	299	$ 250
Protection Health | Latin America | Short-duration Insurance Contracts, Accident Year 2017
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	358	358	358	359	358	385
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	121,591
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 358	357	356	356	354	$ 314
Protection Health | Latin America | Short-duration Insurance Contracts, Accident Year 2018
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	409	409	410	433	412
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 0
Cumulative Number of Reported Claims | Claims	144,503
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 407	405	404	401	$ 352
Protection Health | Latin America | Short-Duration Insurance Contracts, Accident Year 2019
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	172	173	179	137
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 1
Cumulative Number of Reported Claims | Claims	132,150
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 169	166	163	$ 115
Protection Health | Latin America | Short-Duration Insurance Contract, Accident Year 2020
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	486	488	497
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 5
Cumulative Number of Reported Claims | Claims	149,147
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 480	475	$ 420
Protection Health | Latin America | Short-Duration Insurance Contract, Accident Year 2021
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	641	638
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 13
Cumulative Number of Reported Claims | Claims	167,881
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 624	$ 564
Protection Health | Latin America | Short-Duration Insurance Contract, Accident Year 2022
Claims Development [Line Items]
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance	696
Total IBNR Liabilities Plus Expected Development on Reported Claims	$ 67
Cumulative Number of Reported Claims | Claims	140,625
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance	$ 589

Insurance (Short-Duration Contr

Insurance (Short-Duration Contracts Historical Claims) (Details)	Dec. 31, 2022
Group Life - Term
Short-duration Insurance Contracts, Historical Claims Duration [Line Items]
Short-duration Insurance Contracts, Historical Claims Duration, Year One	76.80%
Short-duration Insurance Contracts, Historical Claims Duration, Year Two	20.80%
Short-duration Insurance Contracts, Historical Claims Duration, Year Three	0.80%
Short-duration Insurance Contracts, Historical Claims Duration, Year Four	0.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Five	0.50%
Short-duration Insurance Contracts, Historical Claims Duration, Year Six	0.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Seven	0.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Eight	0%
Short-duration Insurance Contracts, Historical Claims Duration, Year Nine	0%
Short-duration Insurance Contracts, Historical Claims Duration, Year Ten	0%
Group Life - Term | Asia
Short-duration Insurance Contracts, Historical Claims Duration [Line Items]
Short-duration Insurance Contracts, Historical Claims Duration, Year One	25.40%
Short-duration Insurance Contracts, Historical Claims Duration, Year Two	25.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Three	14%
Short-duration Insurance Contracts, Historical Claims Duration, Year Four	10.60%
Short-duration Insurance Contracts, Historical Claims Duration, Year Five	7%
Short-duration Insurance Contracts, Historical Claims Duration, Year Six	3.90%
Short-duration Insurance Contracts, Historical Claims Duration, Year Seven	2%
Short-duration Insurance Contracts, Historical Claims Duration, Year Eight	3%
Short-duration Insurance Contracts, Historical Claims Duration, Year Nine	1.60%
Short-duration Insurance Contracts, Historical Claims Duration, Year Ten	0.60%
Group Long-Term Disability
Short-duration Insurance Contracts, Historical Claims Duration [Line Items]
Short-duration Insurance Contracts, Historical Claims Duration, Year One	4.80%
Short-duration Insurance Contracts, Historical Claims Duration, Year Two	21.70%
Short-duration Insurance Contracts, Historical Claims Duration, Year Three	15.20%
Short-duration Insurance Contracts, Historical Claims Duration, Year Four	9%
Short-duration Insurance Contracts, Historical Claims Duration, Year Five	7%
Short-duration Insurance Contracts, Historical Claims Duration, Year Six	6.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Seven	5%
Short-duration Insurance Contracts, Historical Claims Duration, Year Eight	4.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Nine	3.90%
Short-duration Insurance Contracts, Historical Claims Duration, Year Ten	3.30%
Protection Life | Latin America
Short-duration Insurance Contracts, Historical Claims Duration [Line Items]
Short-duration Insurance Contracts, Historical Claims Duration, Year One	58.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Two	32.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Three	4%
Short-duration Insurance Contracts, Historical Claims Duration, Year Four	1%
Short-duration Insurance Contracts, Historical Claims Duration, Year Five	0.50%
Short-duration Insurance Contracts, Historical Claims Duration, Year Six	0%
Short-duration Insurance Contracts, Historical Claims Duration, Year Seven	0%
Short-duration Insurance Contracts, Historical Claims Duration, Year Eight	(0.50%)
Short-duration Insurance Contracts, Historical Claims Duration, Year Nine	(1.10%)
Short-duration Insurance Contracts, Historical Claims Duration, Year Ten	(4.00%)
Protection Health | Latin America
Short-duration Insurance Contracts, Historical Claims Duration [Line Items]
Short-duration Insurance Contracts, Historical Claims Duration, Year One	84.70%
Short-duration Insurance Contracts, Historical Claims Duration, Year Two	13.40%
Short-duration Insurance Contracts, Historical Claims Duration, Year Three	0.80%
Short-duration Insurance Contracts, Historical Claims Duration, Year Four	0.20%
Short-duration Insurance Contracts, Historical Claims Duration, Year Five	0%
Short-duration Insurance Contracts, Historical Claims Duration, Year Six	0.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Seven	0.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Eight	0.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Nine	0.20%
Short-duration Insurance Contracts, Historical Claims Duration, Year Ten	0.20%

Insurance (Liabilities for Un_2

Insurance (Liabilities for Unpaid Claims - Methodology) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contract, Discounted Liability, Discount	$ 1,326
Short-Duration Insurance Contract, Discounted Liability, Interest Accretion, Statement of Financial Position [Extensible Enumeration]	Policyholder benefits and claims	Policyholder benefits and claims	Policyholder benefits and claims
Group Long-Term Disability
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-Duration Contracts, Discounted Liabilities, Amount	$ 6,500	$ 6,200
Short-duration Insurance Contract, Discounted Liability, Discount	1,200	1,100
Short-duration Insurance Contracts, Discounted Liabilities, Interest Accretion	$ 461	518	$ 452
Group Long-Term Disability | Minimum
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-Duration Contract, Discounted Liability, Discount Rate	3%
Group Long-Term Disability | Maximum
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-Duration Contract, Discounted Liability, Discount Rate	8%
Group Life - Term | Asia
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-Duration Contracts, Discounted Liabilities, Amount	$ 1,300	1,200
Short-duration Insurance Contract, Discounted Liability, Discount	118	73
Short-duration Insurance Contracts, Discounted Liabilities, Interest Accretion	$ 22	$ 22	$ 24
Group Life - Term | Minimum | Asia
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-Duration Contract, Discounted Liability, Discount Rate	1%
Group Life - Term | Maximum | Asia
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-Duration Contract, Discounted Liability, Discount Rate	7%

Insurance (Reconciliation of Di

Insurance (Reconciliation of Disclosure to Liability) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	$ 14,125
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	958
Total unpaid claims and allocated claims adjustment expense	15,083
Unallocated claims adjustment expenses	3
Discounting	(1,326)
Liability for unpaid claims and claim adjustment liabilities - short-duration	13,760
Liability for unpaid claims and claim adjustment liabilities - long-duration	6,653
Liability for Claims and Claims Adjustment Expense	20,413	$ 20,013	$ 18,591	$ 19,216
UNITED STATES
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	10,686
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	213
Latin America
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	544
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	29
Group Life - Term
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	3,141
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	8
Group Life - Term | Asia
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	957
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	427
Group Long-Term Disability
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	7,545
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	205
Discounting	(1,200)	$ (1,100)
Protection Life
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	405
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	11
Protection Health
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	139
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	18
Other insurance lines - all segments combined
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	1,938
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments	$ 289

Insurance (Rollforward of Unpai

Insurance (Rollforward of Unpaid Claims) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Liability for Claims and Claims Adjustment Expense [Line Items]
Balance at January 1,	$ 20,013	$ 18,591	$ 19,216
Less: Reinsurance recoverables	3,121	2,417	2,377
Net Balance at January 1,	16,892	16,174	16,839
Incurred related to:
Current year	27,285	28,270	27,272
Prior years	766	934	192
Total incurred	28,051	29,204	27,464
Paid related to:
Current year	(20,051)	(21,111)	(20,230)
Prior years	(7,395)	(7,256)	(6,241)
Total paid	(27,446)	(28,367)	(26,471)
Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments	15,083
Net Balance at December 31,	17,497	16,892	16,174
Add: Reinsurance recoverables	2,916	3,121	2,417
Balance at December 31,	20,413	20,013	18,591
Disposal Group, Held-for-sale, Not Discontinued Operations
Paid related to:
Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments	0	(55)	(1,658)
Disposal Group, Disposed of by Sale, Not Discontinued Operations
Paid related to:
Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments	$ 0	$ (64)	$ 0

Insurance (Separate Accounts -

Insurance (Separate Accounts - Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Schedule Separate Accounts [Line Items]
Separate account assets	$ 146,038	$ 179,873
Funding Agreements and Participating Close Out Contracts Included in Separate Accounts with a Guaranteed Minimum Return or Account Value
Schedule Separate Accounts [Line Items]
Average interest rate credited on separate accounts with a guaranteed minimum return or account value	2.49%	2.18%
Pass Through Separate Accounts
Schedule Separate Accounts [Line Items]
Separate account assets	$ 108,900	$ 134,400
Separate Accounts With Minimum Return Or Account Value
Schedule Separate Accounts [Line Items]
Separate account assets	$ 37,100	$ 45,500

Deferred Policy Acquisition C_3

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles (DAC and VOBA) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net [Abstract]
Beginning Balance of DAC	$ 13,643	$ 13,446	$ 14,790
Capitalization of DAC	2,558	2,718	3,013
Net investment gains (losses) of DAC and net derivative gains (losses) of DAC	105	(100)	(152)
Other expenses of DAC	(1,920)	(2,268)	(2,773)
Total amortization of DAC	(1,815)	(2,368)	(2,925)
Unrealized investment gains (losses) of DAC	7,166	811	(1,312)
Effect of foreign currency translation and other of DAC	(688)	(861)	76
Reclassified to assets held-for-sale (1)	0	(103)	(196)
Ending Balance of DAC	20,864	13,643	13,446
Beginning Balance of VOBA	2,418	2,943	3,043
Net investment gains (losses) of VOBA and net derivative gains (losses) of VOBA	0	0	(2)
Other expenses of VOBA	(116)	(187)	(233)
Total amortization of VOBA	(116)	(187)	(235)
Unrealized investment gains (losses) of VOBA	17	11	(4)
Effect of foreign currency translation and other of VOBA	(200)	(314)	139
Reclassified to assets held-for-sale (1)	0	(35)	0
Ending Balance of VOBA	2,119	2,418	2,943
Balance at December 31,	$ 22,983	$ 16,061	$ 16,389

Deferred Policy Acquisition C_4

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles (DAC and VOBA by Segment) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
DAC and VOBA	$ 22,983	$ 16,061	$ 16,389
U.S.
Segment Reporting Information [Line Items]
DAC and VOBA	459	440
Asia
Segment Reporting Information [Line Items]
DAC and VOBA	13,384	9,339
Latin America
Segment Reporting Information [Line Items]
DAC and VOBA	2,211	2,021
EMEA
Segment Reporting Information [Line Items]
DAC and VOBA	1,593	1,623
MetLife Holdings
Segment Reporting Information [Line Items]
DAC and VOBA	5,308	2,607
Corporate & Other
Segment Reporting Information [Line Items]
DAC and VOBA	$ 28	$ 31

Deferred Policy Acquisition C_5

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles (Deferred Sales Inducements) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
DSI:
Balance at January 1,	$ 107	$ 108	$ 158
Capitalization	3	0	6
Amortization	(32)	(14)	(37)
Unrealized investment gains (losses)	59	20	(18)
Effect of foreign currency translation and other	(2)	(7)	(1)
Balance at December 31,	$ 135	$ 107	$ 108

Deferred Policy Acquisition C_6

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles (VODA and VOCRA) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Insurance [Abstract]
Balance at January 1,	$ 972	$ 1,099	$ 335
Acquisitions (1)	0	0	814
Amortization	(92)	(100)	(41)
Effect of foreign currency translation and other	(4)	(27)	(9)
Balance at December 31,	876	972	1,099
Accumulated amortization	$ 667	$ 575	$ 475

Deferred Policy Acquisition C_7

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles (Negative VOBA) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Liabilities
Balance at January 1,	$ 623	$ 738	$ 750
Amortization of negative VOBA	(41)	(34)	(45)
Effect of foreign currency translation and other	(63)	(81)	33
Balance at December 31,	519	623	738
Accumulated amortization	$ 3,383	$ 3,342	$ 3,308

Deferred Policy Acquisition C_8

Deferred Policy Acquisition Costs, Value of Business Acquired and Other Policy-Related Intangibles (Estimated Future Amortization) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Estimated future amortization expense allocated to other expenses for VOBA [Abstract]
VOBA 2023	$ 155
VOBA 2024	161
VOBA 2025	153
VOBA 2026	144
VOBA 2027	133
Value of Distribution Agreements and Customer Relationships Acquired [Abstract]
VODA and VOCRA 2023	86
VODA and VOCRA 2024	84
VODA and VOCRA 2025	82
VODA and VOCRA 2026	80
VODA and VOCRA 2027	78
Negative Value of Business Acquired [Abstract]
Negative VOBA 2023	(30)
Negative VOBA 2024	(29)
Negative VOBA 2025	(28)
Negative VOBA 2026	(26)
Negative VOBA 2027	$ (25)

Reinsurance (Effects of Reinsur

Reinsurance (Effects of Reinsurance on Earnings) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Premiums:
Direct Premiums	$ 48,503	$ 41,259	$ 42,201
Reinsurance assumed	3,037	2,907	2,032
Reinsurance ceded	(2,143)	(2,157)	(2,199)
Net premiums	49,397	42,009	42,034
Universal life and investment-type product policy fees:
Direct universal life and investment-type product policy fees	6,004	6,271	6,122
Reinsurance assumed	76	45	50
Reinsurance ceded	(495)	(560)	(569)
Net universal life and investment product policy fees	5,585	5,756	5,603
Policyholder Benefits and Claims:
Direct policyholder benefits and claims	50,436	44,035	42,221
Reinsurance assumed	2,612	2,570	1,745
Reinsurance ceded	(2,436)	(2,651)	(2,505)
Net policyholder benefits and claims	50,612	43,954	41,461
Other expenses:
Direct other expenses	12,013	12,450	13,013
Reinsurance assumed	285	375	371
Reinsurance ceded	264	239	234
Total other expenses	$ 12,034	$ 12,586	$ 13,150

Reinsurance (Effects of Reins_2

Reinsurance (Effects of Reinsurance on Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets
Premiums, reinsurance and other receivables relating to variable interest entities	$ 17,461	$ 17,149
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net	22,983	16,061	$ 16,389
Total assets	40,444	33,210
Liabilities
Future policy benefits	204,228	199,721
Policyholder account balances	203,082	203,473
Other policy-related balances	19,651	17,751
Other liabilities	25,980	22,538
Total liabilities	452,941	443,483
Direct Reinsurance [Member]
Assets
Premiums, reinsurance and other receivables relating to variable interest entities	5,481	4,929
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net	22,889	16,151
Total assets	28,370	21,080
Liabilities
Future policy benefits	200,355	195,915
Policyholder account balances	203,013	203,391
Other policy-related balances	18,472	16,380
Other liabilities	18,700	15,519
Total liabilities	440,540	431,205
Assumed Reinsurance [Member]
Assets
Premiums, reinsurance and other receivables relating to variable interest entities	1,505	1,789
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net	370	227
Total assets	1,875	2,016
Liabilities
Future policy benefits	3,873	3,806
Policyholder account balances	69	82
Other policy-related balances	1,183	1,368
Other liabilities	2,007	2,139
Total liabilities	7,132	7,395
Ceded Reinsurance [Member]
Assets
Premiums, reinsurance and other receivables relating to variable interest entities	10,475	10,431
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net	(276)	(317)
Total assets	10,199	10,114
Liabilities
Future policy benefits	0	0
Policyholder account balances	0	0
Other policy-related balances	(4)	3
Other liabilities	5,273	4,880
Total liabilities	$ 5,269	$ 4,883

Reinsurance (Narrative) (Detail

Reinsurance (Narrative) (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reinsurance Disclosures [Abstract]
Deposit assets in premiums, reinsurance, and other receivables or secondary guarantee risk for reinsurance	$ 1.9	$ 1.8
Deposit liabilities in other liabilities for reinsurance	1.4	1.4
Ceded Credit Risk [Line Items]
Reinsurance recoverables	6.1	6.3
Ceded Credit Risk, Unsecured [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3.9	3.6
Five Largest Ceded Reinsurers [Member]
Ceded Credit Risk [Line Items]
Five largest reinsurers, reinsurance recoverables amount	$ 4.2	$ 4.1
Five largest reinsurers, reinsurance recoverables percentage	69%	65%
Five Largest Ceded Reinsurers [Member] | Ceded Credit Risk, Unsecured [Member]
Ceded Credit Risk [Line Items]
Five largest reinsurers, reinsurance recoverables amount	$ 2.4	$ 1.9
Modified Coinsurance of Closed Block [Member]
Reinsurance Retention Policy [Line Items]
Reinsurance Retention Policy, Reinsured Risk, Percentage	59.25%

Closed Block (Liabilities and A

Closed Block (Liabilities and Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Closed Block Liabilities
Future policy benefits	$ 37,214	$ 38,046
Other policy-related balances	273	290
Policyholder dividends payable	181	253
Policyholder dividend obligation	0	1,682	$ 2,969	$ 2,020
Deferred income tax liability	0	210
Other liabilities	455	263
Total closed block liabilities	38,123	40,744
Assets Designated to the Closed Block
Fixed maturity securities available-for-sale, at estimated fair value	19,648	25,669
Equity securities, at estimated fair value	13	21
Mortgage loans	6,564	6,417
Policy loans	4,084	4,191
Real estate and real estate joint ventures	635	565
Other invested assets	692	535
Total investments	31,636	37,398
Cash and cash equivalents	437	126
Accrued investment income	375	384
Premiums, reinsurance and other receivables	52	50
Current income tax recoverable	88	81
Deferred income tax asset	423	0
Total assets designated to the closed block	33,011	38,039
Excess of closed block liabilities over assets designated to the closed block	5,112	2,705
AOCI:
Unrealized investment gains (losses), net of income tax	(1,357)	2,562
Unrealized gains (losses) on derivatives, net of income tax	262	107
Allocated to policyholder dividend obligation, net of income tax	0	(1,329)
Total amounts included in AOCI	(1,095)	1,340
Maximum future earnings to be recognized from closed block assets and liabilities	$ 4,017	$ 4,045

Closed Block (Policyholder Divi

Closed Block (Policyholder Dividend Obligation) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Closed block policyholder dividend obligation
Balance at January 1,	$ 1,682	$ 2,969	$ 2,020
Change in unrealized investment and derivative gains (losses)	(1,682)	(1,287)	949
Balance at December 31,	$ 0	$ 1,682	$ 2,969

Closed Block (Revenues and Expe

Closed Block (Revenues and Expenses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Premiums	$ 1,104	$ 1,298	$ 1,498
Net investment income	1,382	1,541	1,596
Net investment gains (losses)	(51)	(36)	(25)
Net derivative gains (losses)	33	18	(17)
Total revenues	2,468	2,821	3,052
Expenses
Policyholder benefits and claims	1,890	2,150	2,330
Policyholder dividends	453	621	791
Other expenses	90	96	104
Total expenses	2,433	2,867	3,225
Revenues, net of expenses before provision for income tax expense (benefit)	35	(46)	(173)
Provision for income tax expense (benefit)	7	(10)	(36)
Revenues, net of expenses and provision for income tax expense (benefit)	$ 28	$ (36)	$ (137)

Investments (Fixed Maturity Sec

Investments (Fixed Maturity Securities Available-For-Sale by Sector) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 306,025	$ 310,884
Allowance for Credit Loss for Debt Securities	(183)	(91)	$ (81)
Gross Unrealized Gains	5,239	31,901
Gross Unrealized Losses	34,301	2,420
Estimated Fair Value of Fixed Maturity Securities AFS	276,780	340,274
U.S. corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	88,466	82,694
Allowance for Credit Loss for Debt Securities	(29)	(30)	(44)
Gross Unrealized Gains	1,133	10,651
Gross Unrealized Losses	9,540	281
Estimated Fair Value of Fixed Maturity Securities AFS	80,030	93,034
Foreign corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	59,696	59,124
Allowance for Credit Loss for Debt Securities	(5)	(28)	(16)
Gross Unrealized Gains	1,213	5,275
Gross Unrealized Losses	8,332	731
Estimated Fair Value of Fixed Maturity Securities AFS	52,572	63,640
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	50,047	56,848
Allowance for Credit Loss for Debt Securities	(130)	(19)	(21)
Gross Unrealized Gains	1,876	5,603
Gross Unrealized Losses	5,046	823
Estimated Fair Value of Fixed Maturity Securities AFS	46,747	61,609
U.S. government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	35,658	41,068
Allowance for Credit Loss for Debt Securities	0	0
Gross Unrealized Gains	431	5,807
Gross Unrealized Losses	3,860	276
Estimated Fair Value of Fixed Maturity Securities AFS	32,229	46,599
RMBS
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	29,496	29,152
Allowance for Credit Loss for Debt Securities	0	0
Gross Unrealized Gains	187	1,440
Gross Unrealized Losses	3,518	188
Estimated Fair Value of Fixed Maturity Securities AFS	26,165	30,404
ABS & CLO
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	17,991	18,443
Allowance for Credit Loss for Debt Securities	0	0
Gross Unrealized Gains	23	185
Gross Unrealized Losses	1,192	59
Estimated Fair Value of Fixed Maturity Securities AFS	16,822	18,569
Municipals
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	13,548	11,761
Allowance for Credit Loss for Debt Securities	0	0
Gross Unrealized Gains	317	2,464
Gross Unrealized Losses	1,713	13
Estimated Fair Value of Fixed Maturity Securities AFS	12,152	14,212
CMBS
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	11,123	11,794
Allowance for Credit Loss for Debt Securities	(19)	(14)	$ 0
Gross Unrealized Gains	59	476
Gross Unrealized Losses	1,100	49
Estimated Fair Value of Fixed Maturity Securities AFS	$ 10,063	$ 12,207

Investments (Maturities of Fixe

Investments (Maturities of Fixed Maturity Securities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Available-for-sale Securities, Debt Maturities [Abstract]
Amortized Cost, Due in one year or less	$ 8,235
Amortized Cost, Due after one year through five years	50,977
Amortized Cost, Due after five years through ten years	54,016
Amortized Cost, Due after ten years	134,023
Amortized Cost, Structured Securities	58,591
Amortized Cost, net of ACL	305,842
Estimated Fair Value, Due in one year or less	8,131
Estimated Fair Value, Due after one year through five years	49,344
Estimated Fair Value, Due after five years through ten years	50,498
Estimated Fair Value, Due after ten years	115,757
Estimated Fair Value, Structured Securities	53,050
Estimated Fair Value of Fixed Maturity Securities AFS	$ 276,780	$ 340,274

Investments (Continuous Gross U

Investments (Continuous Gross Unrealized Losses for Fixed Maturity Securities Available-For-Sale) (Details) $ in Millions	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	$ 165,460	$ 62,019
Less than 12 months, Gross Unrealized Loss	$ 23,406	$ 1,264
Total number of securities in an unrealized loss position less than 12 months	15,204	4,774
Equal to or Greater than 12 Months, Estimated Fair Value	$ 41,420	$ 13,224
Equal to or Greater than 12 Months ,Gross Unrealized Loss	$ 10,889	$ 1,154
Total number of securities in an unrealized loss position equal or greater than 12 months	4,303	979
U.S. corporate
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	$ 55,210	$ 8,076
Less than 12 months, Gross Unrealized Loss	7,573	165
Equal to or Greater than 12 Months, Estimated Fair Value	6,484	1,499
Equal to or Greater than 12 Months ,Gross Unrealized Loss	1,965	116
Foreign corporate
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	31,932	10,011
Less than 12 months, Gross Unrealized Loss	5,999	404
Equal to or Greater than 12 Months, Estimated Fair Value	8,956	2,834
Equal to or Greater than 12 Months ,Gross Unrealized Loss	2,332	327
Foreign government
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	16,568	7,812
Less than 12 months, Gross Unrealized Loss	2,170	319
Equal to or Greater than 12 Months, Estimated Fair Value	8,308	5,377
Equal to or Greater than 12 Months ,Gross Unrealized Loss	2,874	502
U.S. government and agency
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	20,436	14,419
Less than 12 months, Gross Unrealized Loss	2,784	138
Equal to or Greater than 12 Months, Estimated Fair Value	4,177	1,571
Equal to or Greater than 12 Months ,Gross Unrealized Loss	1,076	138
RMBS
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	16,223	10,363
Less than 12 months, Gross Unrealized Loss	1,890	158
Equal to or Greater than 12 Months, Estimated Fair Value	6,650	417
Equal to or Greater than 12 Months ,Gross Unrealized Loss	1,628	30
ABS & CLO
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	10,924	8,150
Less than 12 months, Gross Unrealized Loss	712	39
Equal to or Greater than 12 Months, Estimated Fair Value	4,326	804
Equal to or Greater than 12 Months ,Gross Unrealized Loss	480	20
Municipals
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	7,277	524
Less than 12 months, Gross Unrealized Loss	1,514	10
Equal to or Greater than 12 Months, Estimated Fair Value	482	65
Equal to or Greater than 12 Months ,Gross Unrealized Loss	199	3
CMBS
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	6,890	2,664
Less than 12 months, Gross Unrealized Loss	764	31
Equal to or Greater than 12 Months, Estimated Fair Value	2,037	657
Equal to or Greater than 12 Months ,Gross Unrealized Loss	335	18
Investment Grade
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	157,654	58,358
Less than 12 months, Gross Unrealized Loss	22,713	1,123
Equal to or Greater than 12 Months, Estimated Fair Value	38,785	12,022
Equal to or Greater than 12 Months ,Gross Unrealized Loss	$ 10,298	1,025
Total number of securities in an unrealized loss position equal or greater than 12 months	3,875
Below Investment Grade
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Estimated Fair Value	$ 7,806	3,661
Less than 12 months, Gross Unrealized Loss	693	141
Equal to or Greater than 12 Months, Estimated Fair Value	2,635	1,202
Equal to or Greater than 12 Months ,Gross Unrealized Loss	$ 591	$ 129
Total number of securities in an unrealized loss position equal or greater than 12 months	428

Investments (ACL for Fixed Matu

Investments (ACL for Fixed Maturity Securities AFS by Sector) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	$ 91	$ 81
ACL not previously recorded	292	85
Changes for securities with previously recorded ACL	(29)	2
Securities sold or exchanged	(139)	(62)
DebtSecuritiesAvailableforsaleAllowanceforCreditLossReversalRelatedtoBusinessDisposition	0	(2)
Debt Securities Available for sale Allowance for Credit Loss, Foreign Currency Translation	(10)	0
Write-offs	(22)	(13)
Allowance, end of period	183	91
U.S. corporate
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	30	44
ACL not previously recorded	13	48
Changes for securities with previously recorded ACL	17	3
Securities sold or exchanged	(9)	(52)
DebtSecuritiesAvailableforsaleAllowanceforCreditLossReversalRelatedtoBusinessDisposition	0	0
Debt Securities Available for sale Allowance for Credit Loss, Foreign Currency Translation	0	0
Write-offs	(22)	(13)
Allowance, end of period	29	30
Foreign corporate
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	28	16
ACL not previously recorded	67	26
Changes for securities with previously recorded ACL	2	(4)
Securities sold or exchanged	(93)	(10)
DebtSecuritiesAvailableforsaleAllowanceforCreditLossReversalRelatedtoBusinessDisposition	0	0
Debt Securities Available for sale Allowance for Credit Loss, Foreign Currency Translation	1	0
Write-offs	0	0
Allowance, end of period	5	28
Foreign government
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	19	21
ACL not previously recorded	207	0
Changes for securities with previously recorded ACL	(48)	0
Securities sold or exchanged	(37)	0
DebtSecuritiesAvailableforsaleAllowanceforCreditLossReversalRelatedtoBusinessDisposition	0	(2)
Debt Securities Available for sale Allowance for Credit Loss, Foreign Currency Translation	(11)	0
Write-offs	0	0
Allowance, end of period	130	19
CMBS
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	14	0
ACL not previously recorded	5	11
Changes for securities with previously recorded ACL	0	3
Securities sold or exchanged	0	0
DebtSecuritiesAvailableforsaleAllowanceforCreditLossReversalRelatedtoBusinessDisposition	0	0
Debt Securities Available for sale Allowance for Credit Loss, Foreign Currency Translation	0	0
Write-offs	0	0
Allowance, end of period	$ 19	$ 14

Investments (Equity Securities)

Investments (Equity Securities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Unrealized Gains (Losses)	$ 562	$ 2,256
Equity securities	1,684	1,269
Common Stock
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Cost	1,347	784
Equity Securities, FV-NI, Unrealized Gains (Losses)	195	295
Equity securities	1,542	1,079
Non-redeemable Preferred Stock
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Cost	148	189
Equity Securities, FV-NI, Unrealized Gains (Losses)	(6)	1
Equity securities	142	190
Equity Securities
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Cost	1,495	973
Equity Securities, FV-NI, Unrealized Gains (Losses)	189	296
Equity securities	$ 1,684	$ 1,269

Investments (Contractholder-Dir

Investments (Contractholder-Directed Equity Securities and FVO Securities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt and Equity Securities, FV-NI [Line Items]
Debt Securities, Trading, and Equity Securities, FV-NI, Cost	$ 9,106	$ 9,886
Contracted-Directed Equity Securities and FVO Securities, FV-NI, Unrealized Gains (Losses)	562	2,256
Contractholder-directed equity securities and fair value option securities, at estimated fair value	9,668	12,142
Unit-linked investments
Debt and Equity Securities, FV-NI [Line Items]
Debt Securities, Trading, and Equity Securities, FV-NI, Cost	7,945	8,643
Contracted-Directed Equity Securities and FVO Securities, FV-NI, Unrealized Gains (Losses)	288	1,897
Contractholder-directed equity securities and fair value option securities, at estimated fair value	8,233	10,540
FVO Securities
Debt and Equity Securities, FV-NI [Line Items]
Debt Securities, Trading, and Equity Securities, FV-NI, Cost	1,161	1,243
Contracted-Directed Equity Securities and FVO Securities, FV-NI, Unrealized Gains (Losses)	274	359
Contractholder-directed equity securities and fair value option securities, at estimated fair value	$ 1,435	$ 1,602

Investments (Mortgage Loans by

Investments (Mortgage Loans by Portfolio Segment) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 84,290	$ 79,860
Allowance for Credit Loss	(527)	(634)	$ (590)	$ (353)
Subtotal mortgage loans, net	83,763	79,226
Mortgage loans (net of allowance for credit loss of $527 and $634, respectively; includes $0 and $127, respectively, under the fair value option)	$ 83,763	$ 79,353
Percentage Of mortgage total recorded investment To Mortgage Loans On Real Estate Commercial And Consumer Net	100.60%	100.60%
Percentage of Allowance for Credit Losses for Financing Receivables	0.60%	0.80%
Percentage Of Mortgage Loans Held For Investment Net To Mortgage Loans On Real Estate Commercial And Consumer Net	100%	99.80%
Percentage Of Loans And Leases Receivable Consumer Other To Mortgage Loans On Real Estate Commercial And Consumer Net	0%	0.20%
Percentage Of Mortgage Loans On Real Estate To Mortgage Loans On Real Estate Commercial And Consumer Net	100%	100%
Residential mortgage loans - FVO
Accounts, Notes, Loans and Financing Receivable [Line Items]
Residential — FVO	$ 0	$ 127
Mortgage loans (net of allowance for credit loss of $527 and $634, respectively; includes $0 and $127, respectively, under the fair value option)	0	127
Commercial Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	52,502	50,553
Allowance for Credit Loss	$ (218)	$ (340)	(252)	(246)
Percentage Of Mortgage Loans, Gross	62.70%	63.70%
Residential Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 12,482	$ 11,196
Allowance for Credit Loss	$ (190)	$ (206)	(232)	(55)
Percentage Of Mortgage Loans, Gross	14.90%	14.10%
Agricultural Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 19,306	$ 18,111
Allowance for Credit Loss	$ (119)	$ (88)	$ (106)	$ (52)
Percentage Of Mortgage Loans, Gross	23%	22.80%

Investments (Mortgage Loans All

Investments (Mortgage Loans Allowance for Credit Loss Rollforward by Portfolio Segment) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance at January 1,	$ 634	$ 590	$ 353
Adoption of credit loss guidance	0	0	78
Provision (release)	43	67	176
Initial credit losses on PCD loans (1)	0	3	18
Charge-offs, net of recoveries	(150)	(26)	(34)
HFS transfer	0	0	(1)
Balance at December 31,	527	634	590
Commercial Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance at January 1,	340	252	246
Adoption of credit loss guidance	0	0	(118)
Provision (release)	(2)	88	124
Initial credit losses on PCD loans (1)	0	0	0
Charge-offs, net of recoveries	(120)	0	0
HFS transfer	0	0	0
Balance at December 31,	218	340	252
Residential Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance at January 1,	206	232	55
Adoption of credit loss guidance	0	0	161
Provision (release)	(8)	(27)	30
Initial credit losses on PCD loans (1)	0	3	18
Charge-offs, net of recoveries	(8)	(2)	(32)
HFS transfer	0	0	0
Balance at December 31,	190	206	232
Agricultural Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance at January 1,	88	106	52
Adoption of credit loss guidance	0	0	35
Provision (release)	53	6	22
Initial credit losses on PCD loans (1)	0	0	0
Charge-offs, net of recoveries	(22)	(24)	(2)
HFS transfer	0	0	(1)
Balance at December 31,	$ 119	$ 88	$ 106

Investments (Credit Quality of

Investments (Credit Quality of Commercial Mortgage Loans) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable, Credit Quality Indicator [Line Items]
Mortgage Loans, Gross	$ 84,290	$ 79,860
Commercial Mortgage Loans
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	7,499
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	6,919
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	4,686
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	7,696
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	6,667
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	16,175
Financing Receivable, Revolving	2,860
Mortgage Loans, Gross	$ 52,502	$ 50,553
Loans Receivable Commercial Mortgage Percentage	100%
Commercial Mortgage Loans | Greater than 1.20x
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 6,705
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	6,410
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	4,441
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	7,123
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	5,981
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	14,107
Financing Receivable, Revolving	2,860
Mortgage Loans, Gross	$ 47,627
Loans Receivable Commercial Mortgage Percentage	90.70%
Commercial Mortgage Loans | 1.00x - 1.20x
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 667
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	128
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	115
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	436
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	274
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	963
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 2,583
Loans Receivable Commercial Mortgage Percentage	4.90%
Commercial Mortgage Loans | Less than 1.00x
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 127
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	381
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	130
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	137
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	412
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	1,105
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 2,292
Loans Receivable Commercial Mortgage Percentage	4.40%
Commercial Mortgage Loans | Less than 65%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 5,081
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	5,633
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	3,496
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	5,195
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	4,866
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	13,237
Financing Receivable, Revolving	2,860
Mortgage Loans, Gross	$ 40,368
Loans Receivable Commercial Mortgage Percentage	76.90%
Commercial Mortgage Loans | 65% to 75%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2,321
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	1,227
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	1,073
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	1,613
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	1,360
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	1,872
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 9,466
Loans Receivable Commercial Mortgage Percentage	18%
Commercial Mortgage Loans | 76% to 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 64
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	19
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	99
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	467
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	290
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	287
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 1,226
Loans Receivable Commercial Mortgage Percentage	2.30%
Commercial Mortgage Loans | Greater than 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 33
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	40
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	18
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	421
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	151
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	779
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 1,442
Loans Receivable Commercial Mortgage Percentage	2.80%

Investments (Credit Quality o_2

Investments (Credit Quality of Agricultural and Residential Mortgage Loans) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable, Credit Quality Indicator [Line Items]
Mortgage Loans, Gross	$ 84,290	$ 79,860
Mortgage Loans in Process of Foreclosure, Amount	146	70
Residential Mortgage Loans
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	2,083
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	1,459
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	384
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	1,030
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	454
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	7,072
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 12,482	11,196
Loans Receivable Residential Mortgage Percentage	100%
Residential Mortgage Loans | Performing
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2,071
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	1,450
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	374
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	982
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	439
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	6,693
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 12,009
Loans Receivable Residential Mortgage Percentage	96.20%
Residential Mortgage Loans | Nonperforming
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 12
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	9
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	10
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	48
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	15
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	379
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 473
Loans Receivable Residential Mortgage Percentage	3.80%
Agricultural Mortgage Loans
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2,771
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	3,028
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	2,976
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	1,943
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	2,457
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	4,825
Financing Receivable, Revolving	1,306
Mortgage Loans, Gross	$ 19,306	$ 18,111
Loans Receivable Agricultural Mortgage Percentage	100%
Agricultural Mortgage Loans | Less than 65%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2,594
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	2,708
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	2,600
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	1,690
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	2,364
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	4,276
Financing Receivable, Revolving	1,171
Mortgage Loans, Gross	$ 17,403
Loans Receivable Agricultural Mortgage Percentage	90.10%
Agricultural Mortgage Loans | 65% to 75%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 177
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	320
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	347
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	177
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	93
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	494
Financing Receivable, Revolving	131
Mortgage Loans, Gross	$ 1,739
Loans Receivable Agricultural Mortgage Percentage	9%
Agricultural Mortgage Loans | 76% to 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 0
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	0
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	0
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	0
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	0
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	11
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 11
Loans Receivable Agricultural Mortgage Percentage	0.10%
Agricultural Mortgage Loans | Greater than 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 0
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	0
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	29
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	76
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	0
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	44
Financing Receivable, Revolving	4
Mortgage Loans, Gross	$ 153
Loans Receivable Agricultural Mortgage Percentage	0.80%

Investments (Past Due and Inter

Investments (Past Due and Interest Accrual Status of Mortgage Loans) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	$ 84,290	$ 79,860
Greater than 90 Days Past Due and Still Accruing Interest	39	37
Financing Receivable, Nonaccrual	762	822
Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	603	587
Commercial Mortgage Loans
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	52,502	50,553
Greater than 90 Days Past Due and Still Accruing Interest	6	13
Financing Receivable, Nonaccrual	169	155	$ 317
Commercial Mortgage Loans | Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	6	13
Residential Mortgage Loans
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	12,482	11,196
Greater than 90 Days Past Due and Still Accruing Interest	12	8
Financing Receivable, Nonaccrual	462	442	534
Residential Mortgage Loans | Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	473	450
Agricultural Mortgage Loans
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	19,306	18,111
Greater than 90 Days Past Due and Still Accruing Interest	21	16
Financing Receivable, Nonaccrual	131	225	$ 266
Agricultural Mortgage Loans | Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	$ 124	$ 124

Investments (Purchased Financia

Investments (Purchased Financial Assets with Credit Deterioration) (Details) - Residential Mortgage Loans $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Contractual Principal	$ 48
ACL at Acquisition	0
Non-Credit (Discount) Premium	(3)
Purchase Price	$ 45

Investments (Real Estate and Re

Investments (Real Estate and Real Estate Joint Ventures) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Real Estate [Line Items]
Leased real estate investments, Carrying Value	$ 4,523	$ 5,146
Other real estate investments, Carrying Value	487	474
Real estate joint ventures, Carrying Value	8,127	6,596
Real Estate Investments, Net	13,137	12,216
Income (Loss) from Equity Method Investments	1,305	5,136	$ 829
Real Estate and Real Estate Joint Ventures
Real Estate [Line Items]
Gross Investment Income, Operating	$ 1,200	$ 954	$ 532
Leased real estate
Real Estate [Line Items]
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Other real estate
Real Estate [Line Items]
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Real estate joint ventures
Real Estate [Line Items]
Income (Loss) from Equity Method Investments	$ 556	$ 326	$ (36)

Investments (Leased Real Estate

Investments (Leased Real Estate Investments - Operating Leases) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 4,523	$ 5,146
Office
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 2,206	$ 2,322
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Retail
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 804	$ 938
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Apartment
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 625	$ 828
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Land
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 562	$ 635
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Industrial
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 254	$ 339
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Hotel
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 72	$ 84
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Other
Schedule of Operating Leases by Property Type [Line Items]
Leased real estate investments, Carrying Value	$ 0	$ 0
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues
Leased real estate
Schedule of Operating Leases by Property Type [Line Items]
Operating Lease, Lease Income	Total revenues	Total revenues	Total revenues

Investments (Components of Leve

Investments (Components of Leveraged and Direct Financing Leases) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Real Estate [Line Items]
Leveraged Leases, Net Investment in Leveraged Leases Disclosure, Rental Receivables, Net	$ 477	$ 542
Leveraged Leases, Net Investment in Leveraged Leases Disclosure, Residual Value of Leased Assets	517	560
Leveraged Leases, Unearned Income	(245)	(284)
Investment in Leveraged Leases before ACL	749	818
Net Investment in Lease, Allowance for Credit Loss	26	40
Leveraged Leases, Net Investment in Leveraged Leases Disclosure, Investment in Leveraged Leases, Net	731	787
Direct Financing Lease, Lease Receivable	1,750	1,755
Direct Financing Lease, Unguaranteed Residual Asset	39	39
Direct Financing Lease, Deferred Selling Profit	(586)	(642)
Direct Financing Lease, Net Investment in Lease	1,203	1,152
Direct Financing Lease, Net Investment in Lease, Allowance for Credit Loss	8	9
Direct Financing Lease, Net Investment in Lease, after Allowance for Credit Loss	1,195	1,143
Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One	122
Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two	92
Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three	91
Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four	117
Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Five	101
Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Five	1,200
Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received	1,800
Leveraged Leases
Real Estate [Line Items]
Investment In Leases	994	1,102
Net Investment in Lease, Allowance for Credit Loss	18	31
Direct Financing Leases
Real Estate [Line Items]
Investment In Leases	$ 1,789	$ 1,794

Investments (Net Investment Inc

Investments (Net Investment Income on Leveraged and Direct Financing Leases) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments, All Other Investments [Abstract]
Leveraged Leases, Income Statement, Income from Leveraged Leases	$ 35	$ 34	$ 39
Leveraged Leases, Income Statement, Income Tax Expense on Leveraged Leases	(7)	(7)	(8)
Leveraged Leases, Income (Loss)	$ 28	$ 27	$ 31
Direct Financing Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]	Total revenues	Total revenues	Total revenues
Direct Financing Leases Income Statement Tax Expense on Direct Financing Leases	$ (27)	$ (20)	$ (22)
Direct Financing Leases Income Statement Net Income from Direct Financing Leases	$ 102	$ 76	$ 84

Investments (Concentrations of

Investments (Concentrations of Credit Risk) (Details) - Foreign government - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
JAPAN
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Fair Value, Concentration of Risk, Investments	$ 24,295	$ 32,723
Republic of Korea
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Fair Value, Concentration of Risk, Investments	5,887	$ 7,117
MEXICO
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Fair Value, Concentration of Risk, Investments	$ 3,463

Investments (Securities Lending

Investments (Securities Lending and Repurchase Agreements) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	$ 12,092	$ 21,055
Reinvestment portfolio — estimated fair value	11,833	21,319
Estimated fair value
Securities Financing Transaction [Line Items]
Securities loaned	11,756	20,654
Repurchase Agreements
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	3,125	3,325
Reinvestment portfolio — estimated fair value	3,057	3,357
Repurchase Agreements | Estimated fair value
Securities Financing Transaction [Line Items]
Securities Sold under Agreements to Repurchase	$ 3,176	$ 3,416

Investments (Securities Lendi_2

Investments (Securities Lending and Repurchase Agreements Remaining Tenor ) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	$ 12,092	$ 21,055
U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	10,494	20,007
Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	1,344	1,047
Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	254	0
U.S. corporate
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	1
Open (1)
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	1,945	5,901
Open (1) | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	1,945	5,900
Open (1) | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Open (1) | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Open (1) | U.S. corporate
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	1
1 Month or Less
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	5,933	7,337
1 Month or Less | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	5,448	7,052
1 Month or Less | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	422	285
1 Month or Less | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	63	0
1 Month or Less | U.S. corporate
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 1 Month to 6 Months
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	4,214	7,817
Over 1 Month to 6 Months | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	3,101	7,055
Over 1 Month to 6 Months | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	922	762
Over 1 Month to 6 Months | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	191	0
Over 1 Month to 6 Months | U.S. corporate
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year | U.S. corporate
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Repurchase Agreements
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	3,125	3,325
Repurchase Agreements | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	3,125	3,325
Repurchase Agreements | Open (1) | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Repurchase Agreements | 1 Month or Less | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	3,125	3,325
Repurchase Agreements | Over 1 Month to 6 Months | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Repurchase Agreements | Over 6 Months to 1 Year | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	$ 0	$ 0

Investments (Invested Assets on

Investments (Invested Assets on Deposit, Held In Trust and Pledged as Collateral) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Investment Holdings, Other than Securities [Line Items]
Invested assets on deposit (regulatory deposits)	$ 1,514	$ 1,872
Invested assets held in trust (external reinsurance agreements) (1)	881	1,114
Invested assets pledged as collateral	25,442	24,261
Total invested assets on deposit, held in trust and pledged as collateral	27,837	27,247
Affiliated Entity
Investment Holdings, Other than Securities [Line Items]
Invested assets held in trust (external reinsurance agreements) (1)	$ 1,900	$ 2,100

Investments (Consolidated Varia

Investments (Consolidated Variable Interest Entities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Variable Interest Entity [Line Items]
Total Assets	$ 666,611	$ 759,708
Total Liabilities	639,324	691,959
Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	342	372
Total Liabilities	1	1
Investment funds (primarily other invested assets) | Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	266	292
Total Liabilities	1	1
Renewable energy partnership (primarily other invested assets) | Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	76	79
Total Liabilities	0	0
Other Investments | Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	0	1
Total Liabilities	$ 0	$ 0

Investments (Unconsolidated Var

Investments (Unconsolidated Variable Interest Entities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Variable Interest Entity [Line Items]
Total Assets	$ 666,611	$ 759,708
Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	66,921	77,974
Maximum Exposure to Loss	72,663	85,614
Variable Interest Entity, Not Primary Beneficiary | Fixed Maturity Securities
Variable Interest Entity [Line Items]
Total Assets	51,422	62,654
Maximum Exposure to Loss	51,422	62,654
Variable Interest Entity, Not Primary Beneficiary | Other limited partnership interests
Variable Interest Entity [Line Items]
Total Assets	13,244	13,287
Maximum Exposure to Loss	18,906	20,720
Variable Interest Entity, Not Primary Beneficiary | Other invested assets
Variable Interest Entity [Line Items]
Total Assets	1,310	1,257
Maximum Exposure to Loss	1,387	1,314
Variable Interest Entity, Not Primary Beneficiary | Other Investments
Variable Interest Entity [Line Items]
Total Assets	945	776
Maximum Exposure to Loss	$ 948	$ 926

Investments (Net Investment I_2

Investments (Net Investment Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net Investment Income [Line Items]
Less: Investment expenses	$ 1,284	$ 949	$ 1,054
Net investment income	15,916	21,395	17,117
Securities Investment
Net Investment Income [Line Items]
Gross Investment Income, Operating	18,498	21,392	17,603
Net investment income	17,214	20,443	16,549
Fixed maturity securities AFS
Net Investment Income [Line Items]
Gross Investment Income, Operating	11,490	10,996	11,304
Equity Securities
Net Investment Income [Line Items]
Gross Investment Income, Operating	36	36	50
FVO Securities
Net Investment Income [Line Items]
Net investment income	(127)	167	140
Mortgage loans
Net Investment Income [Line Items]
Gross Investment Income, Operating	3,539	3,435	3,518
Policy loans
Net Investment Income [Line Items]
Gross Investment Income, Operating	460	474	498
Real Estate and Real Estate Joint Ventures
Net Investment Income [Line Items]
Gross Investment Income, Operating	1,200	954	532
Other limited partnership interests
Net Investment Income [Line Items]
Gross Investment Income, Operating	858	4,927	1,000
Cash, cash equivalents and short-term investments
Net Investment Income [Line Items]
Gross Investment Income, Operating	358	103	213
Operating joint ventures
Net Investment Income [Line Items]
Gross Investment Income, Operating	51	77	93
Other Investments
Net Investment Income [Line Items]
Gross Investment Income, Operating	633	223	255
Unit-linked investments
Net Investment Income [Line Items]
Net investment income	$ (1,298)	$ 952	$ 568

Investments (Supplemental Net I

Investments (Supplemental Net Investment Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net Investment Income [Line Items]
Debt and Equity Securities, Realized Gain (Loss)	$ (725)	$ 1,229	$ 1,056
Equity Securities, FV-NI, Unrealized Gain (Loss)	(86)	177	(153)
Income (Loss) from Equity Method Investments	1,305	5,136	829
Net investment income
Net Investment Income [Line Items]
Debt and Equity Securities, Realized Gain (Loss)	155	518	422
Debt and Equity Securities, Unrealized Gain (Loss)	(1,586)	616	233
Debt and Equity Securities, Gain (Loss)	(1,431)	1,134	655
Unit-linked investments
Net Investment Income [Line Items]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (1,286)	$ 730	$ 489

Investments (Components of Net

Investments (Components of Net Investment Gains Losses - Asset Type) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Marketable Securities, Gain (Loss) [Abstract]
Fixed maturity securities AFS	$ (1,912)	$ 66	$ 297
Equity Securities, FV-NI, Gain (Loss)	(133)	108	(137)
Other net investment gains (losses):
Mortgage loans	21	(18)	(213)
Real estate and real estate joint ventures (excluding changes in estimated fair value)	653	502	7
Other limited partnership interests (excluding changes in estimated fair value)	53	(6)	(15)
Other gains (losses)	178	131	198
Subtotal - investment portfolio gains (losses)	(1,140)	783	137
Change In Estimated Fair Value Of Other Limited Partnership Interests And Real Estate Joint Ventures	(14)	45	(4)
Non-investment portfolio gains (losses)	(108)	701	(243)
Subtotal	(122)	746	(247)
Net investment gains (losses)	$ (1,262)	$ 1,529	$ (110)

Investments (Components of Ne_2

Investments (Components of Net Investment Gains Losses - Transaction Type) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Realized gains (losses) on investments sold or disposed	$ (880)	$ 711	$ 634
Impairments	(40)	(24)	(63)
Change in allowance for credit loss recognized in earnings	(134)	(86)	(280)
Unrealized net gains (losses) recognized in earnings	(100)	227	(158)
Total recognized gains (losses)	(234)	141	(438)
Non-investment portfolio gains (losses) (1)	(108)	701	(243)
Net investment gains (losses)	$ (1,262)	$ 1,529	$ (110)

Investments (Supplemental Net_2

Investments (Supplemental Net Investment Gains (Losses)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net Investment Income [Line Items]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (86)	$ 177	$ (153)
Net investment gains (losses)	(1,262)	1,529	(110)
Gains (losses) on leveraged leases and renewable energy partnerships	33	12	87
Foreign Currency Transaction Gain (Loss), Realized	182	(10)	79
Realized Investment Gains (Losses)	(880)	711	634
Debt and Equity Securities, Realized Gain (Loss)	(725)	1,229	1,056
Net investment income
Net Investment Income [Line Items]
Debt and Equity Securities, Realized Gain (Loss)	155	518	422
Cash Flow Hedging [Member]
Net Investment Income [Line Items]
Net investment gains (losses)	19	82	207
Cash Flow Hedging [Member] | Foreign Currency Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income
Net Investment Income [Line Items]
Net investment gains (losses)	38	88	129
Equity Securities
Net Investment Income [Line Items]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (89)	$ 77	$ (127)

Investments (Fixed Maturity S_2

Investments (Fixed Maturity Securities AFS - Sales and Disposals and Credit Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Proceeds	$ 67,754	$ 54,612	$ 40,809
Gross investment gains	935	761	1,125
Gross investment (losses)	(2,704)	(656)	(674)
Realized gains (losses) on sales and disposals	(1,769)	105	451
Net credit loss (provision) release (change in ACL recognized in earnings)	(103)	(15)	(91)
Impairment (losses)	(40)	(24)	(63)
Net credit loss (provision) release and impairment (losses)	(143)	(39)	(154)
Realized Investment Gains (Losses)	(880)	711	634
Equity securities	(47)	(69)	16
Equity Securities, FV-NI, Unrealized Gain (Loss)	(86)	177	(153)
Equity Securities, FV-NI, Gain (Loss)	(133)	108	(137)
Fixed Maturity Securities
Debt Securities, Available-for-sale [Line Items]
Realized Investment Gains (Losses)	$ (1,912)	$ 66	$ 297

Investments (Fixed Maturity S_3

Investments (Fixed Maturity Securities AFS - Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Estimated Fair Value of Fixed Maturity Securities AFS	$ 276,780	$ 340,274
Gross Unrealized Losses	34,301	2,420
Gross Unrealized Gains	5,239	31,901
Nonperforming Financial Instruments [Member]
Debt Securities, Available-for-sale [Line Items]
Estimated Fair Value of Fixed Maturity Securities AFS	82	22
Gross Unrealized Losses	$ 3
Gross Unrealized Gains		$ 8

Investments (Evaluation of Fixe

Investments (Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position - Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Debt Securities, Available-for-sale [Line Items]
Change in Gross Unrealized Temporary Loss	$ 47,831	$ 8,171	$ (5,198)
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	34,300
Equal to or Greater than 12 Months ,Gross Unrealized Loss	$ 10,889	$ 1,154
Percentage of Gross Unrealized Loss for 12 months or greater	32%
Total number of securities in an unrealized loss position equal or greater than 12 months	4,303	979
Investment Grade
Debt Securities, Available-for-sale [Line Items]
Equal to or Greater than 12 Months ,Gross Unrealized Loss	$ 10,298	$ 1,025
Percentage of Gross Unrealized Loss for 12 months or greater	95%
Total number of securities in an unrealized loss position equal or greater than 12 months	3,875
Below Investment Grade
Debt Securities, Available-for-sale [Line Items]
Equal to or Greater than 12 Months ,Gross Unrealized Loss	$ 591	$ 129
Percentage of Gross Unrealized Loss for 12 months or greater	5%
Total number of securities in an unrealized loss position equal or greater than 12 months	428
Fixed maturity securities without an allowance for credit loss
Debt Securities, Available-for-sale [Line Items]
Change in Gross Unrealized Temporary Loss	$ 31,900

Investments (Mortgage Loans - N

Investments (Mortgage Loans - Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Contracts	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums	$ (744)	$ (759)
Financing Receivable, Purchase	3,100	1,800	$ 3,300
Mortgage Loans, Gross	$ 84,290	$ 79,860
Percentage of Mortgage Loans Classified as Performing	99%	99%
Financing Receivable, Nonaccrual	$ 762	$ 822
Mortgage Loans Contributed To Joint Ventures	489
Amortized Cost Of Mortgage Loans Foreclosed	467
Gain On Mortgage Loans Foreclosure	34
Commercial Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest Receivable	219	180
Mortgage Loans, Gross	52,502	50,553
Financing Receivable, Nonaccrual	169	155	317
Financing Receivable, Nonaccrual, No Allowance	$ 0	0
Financing Receivable, Modifications, Number of Contracts | Contracts	2
Financing Receivable, Troubled Debt Restructuring, Premodification	$ 162
Financing Receivable, Troubled Debt Restructuring, Postmodification	162
Residential Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest Receivable	81	86
Mortgage Loans, Gross	12,482	11,196
Financing Receivable, Nonaccrual	462	442	534
Financing Receivable, Nonaccrual, No Allowance	0	0
Agricultural Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest Receivable	176	161
Mortgage Loans, Gross	19,306	18,111
Financing Receivable, Nonaccrual	131	225	$ 266
Financing Receivable, Nonaccrual, No Allowance	$ 7	$ 134
Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of mortgage loans with LTV ratio in excess of 100%	1%
Mortgage Loans with LTV ratio in excess of 100% [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 732

Investments (Real Estate and _2

Investments (Real Estate and Real Estate Joint Ventures - Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Real Estate [Line Items]
Real Estate Acquired Through Foreclosure	$ 182	$ 181
Depreciation	171	192	$ 194
Real Estate Investment Property, Net	863	883
Real Estate and Real Estate Joint Ventures
Real Estate [Line Items]
Depreciation	$ 118	$ 123	$ 123

Investments (Operating Leases -

Investments (Operating Leases - Narrative) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Investments, All Other Investments [Abstract]
Lessor, Operating Lease, Payment to be Received, Year One	$ 268
Lessor, Operating Lease, Payment to be Received, Year Two	204
Lessor, Operating Lease, Payment to be Received, Year Three	172
Lessor, Operating Lease, Payment to be Received, Year Four	146
Lessor, Operating Lease, Payment to be Received, Year Five	123
Lessor, Operating Lease, Payment to be Received, after Year Five	934
Lessor, Operating Lease, Payments to be Received	$ 1,800

Investments (Leveraged and Dire

Investments (Leveraged and Direct Financing Leases - Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Lessor, Lease, Description [Line Items]
Leveraged Leases, Net Investment in Leveraged Leases Disclosure, Deferred Taxes Arising from Leveraged Leases	$ 220	$ 272
Leveraged Leases
Lessor, Lease, Description [Line Items]
Loan and Leases Receivable, Ratio of Performing Leases	98%	99%

Investments (Other Invested Ass

Investments (Other Invested Assets - Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Carrying value of Tax Credits	$ 759	$ 947
Losses From Tax Credits	$ 174	$ 195	$ 226

Investments (Cash Equivalents -

Investments (Cash Equivalents - Narrative) (Details) - USD ($) $ in Billions	Dec. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Cash equivalents	$ 10	$ 9

Investments (Invested Assets _2

Investments (Invested Assets on Deposit, Held in Trust and Pledged as Collateral - Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Federal Home Loan Bank Stock	$ 729	$ 769

Investments (Collectively Signi

Investments (Collectively Significant Equity Method Investments - Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 25,700
Unfunded Commitments For Investments Accounted For Under Equity Method	7,800
Total Assets	666,611	$ 759,708
Total Liabilities	639,324	691,959
Net income (loss)	2,558	6,575	$ 5,418
Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]
Schedule of Equity Method Investments [Line Items]
Total Assets	1,200,000	1,100,000
Total Liabilities	148,900	149,400
Net income (loss)	$ (11,800)	$ 231,000	$ 41,600

Derivatives (Primary Risks) (De

Derivatives (Primary Risks) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 328,116	$ 308,215
Estimated Fair Value Assets	11,411	10,466
Estimated Fair Value Liabilities	6,975	3,852
Derivatives Designated as Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	63,923	61,088
Estimated Fair Value Assets	5,244	4,009
Estimated Fair Value Liabilities	3,909	1,764
Derivatives Designated as Hedging Instruments [Member] | Fair Value Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	6,081	5,987
Estimated Fair Value Assets	1,445	2,175
Estimated Fair Value Liabilities	556	87
Derivatives Designated as Hedging Instruments [Member] | Fair Value Hedges [Member] | Interest rate swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	4,143	3,550
Estimated Fair Value Assets	1,353	2,164
Estimated Fair Value Liabilities	467	6
Derivatives Designated as Hedging Instruments [Member] | Fair Value Hedges [Member] | Foreign currency swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	602	801
Estimated Fair Value Assets	82	11
Estimated Fair Value Liabilities	0	23
Derivatives Designated as Hedging Instruments [Member] | Fair Value Hedges [Member] | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,336	1,636
Estimated Fair Value Assets	10	0
Estimated Fair Value Liabilities	89	58
Derivatives Designated as Hedging Instruments [Member] | Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	54,162	52,101
Estimated Fair Value Assets	3,563	1,695
Estimated Fair Value Liabilities	3,315	1,677
Derivatives Designated as Hedging Instruments [Member] | Cash Flow Hedges [Member] | Interest rate swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	4,107	4,117
Estimated Fair Value Assets	8	6
Estimated Fair Value Liabilities	262	1
Derivatives Designated as Hedging Instruments [Member] | Cash Flow Hedges [Member] | Interest rate forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	7,447	6,889
Estimated Fair Value Assets	1	89
Estimated Fair Value Liabilities	1,354	119
Derivatives Designated as Hedging Instruments [Member] | Cash Flow Hedges [Member] | Foreign currency swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	42,608	41,095
Estimated Fair Value Assets	3,554	1,600
Estimated Fair Value Liabilities	1,699	1,557
Derivatives Designated as Hedging Instruments [Member] | Foreign Operations Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	3,680	3,000
Estimated Fair Value Assets	236	139
Estimated Fair Value Liabilities	38	0
Derivatives Designated as Hedging Instruments [Member] | Foreign Operations Hedges [Member] | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	680	0
Estimated Fair Value Assets	0	0
Estimated Fair Value Liabilities	38	0
Derivatives Designated as Hedging Instruments [Member] | Foreign Operations Hedges [Member] | Currency options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	3,000	3,000
Estimated Fair Value Assets	236	139
Estimated Fair Value Liabilities	0	0
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	264,193	247,127
Estimated Fair Value Assets	6,167	6,457
Estimated Fair Value Liabilities	3,066	2,088
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Interest rate swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	31,661	38,860
Estimated Fair Value Assets	1,660	3,644
Estimated Fair Value Liabilities	1,354	115
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Interest rate forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	381	374
Estimated Fair Value Assets	0	0
Estimated Fair Value Liabilities	32	26
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Interest rate floors
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	25,270	7,701
Estimated Fair Value Assets	125	145
Estimated Fair Value Liabilities	0	0
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Interest rate caps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	48,290	65,559
Estimated Fair Value Assets	950	124
Estimated Fair Value Liabilities	0	0
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Interest rate futures
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,453	1,615
Estimated Fair Value Assets	2	4
Estimated Fair Value Liabilities	1	0
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Interest rate options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	44,391	11,754
Estimated Fair Value Assets	473	493
Estimated Fair Value Liabilities	88	10
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Synthetic GICs
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	46,316	40,121
Estimated Fair Value Assets	0	0
Estimated Fair Value Liabilities	0	0
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Foreign currency swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	12,815	12,787
Estimated Fair Value Assets	1,454	768
Estimated Fair Value Liabilities	383	614
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	16,195	16,230
Estimated Fair Value Assets	544	36
Estimated Fair Value Liabilities	661	666
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Currency futures
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	333	839
Estimated Fair Value Assets	8	0
Estimated Fair Value Liabilities	0	2
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Currency options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	0	900
Estimated Fair Value Assets	0	0
Estimated Fair Value Liabilities	0	0
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Credit default swaps — purchased
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,925	3,042
Estimated Fair Value Assets	18	13
Estimated Fair Value Liabilities	79	113
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Credit default swaps — written
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	11,512	8,626
Estimated Fair Value Assets	133	177
Estimated Fair Value Liabilities	28	12
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Equity futures
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,988	4,204
Estimated Fair Value Assets	8	12
Estimated Fair Value Liabilities	4	5
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Equity index options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	16,701	29,743
Estimated Fair Value Assets	765	1,004
Estimated Fair Value Liabilities	323	458
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Equity variance swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	163	699
Estimated Fair Value Assets	4	17
Estimated Fair Value Liabilities	1	13
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Total rate of return swaps [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	0	1,048
Estimated Fair Value Assets	0	9
Estimated Fair Value Liabilities	0	4
Derivatives Not Designated or Not Qualifying as Hedging Instruments [Member] | Equity Total Return Swaps [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,799	3,025
Estimated Fair Value Assets	23	11
Estimated Fair Value Liabilities	$ 112	$ 50

Derivatives Derivatives (Effect

Derivatives Derivatives (Effects on the Consolidated Statement of Operations and Comprehensive Income (Loss)) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	$ (15,916,000,000)	$ (21,395,000,000)	$ (17,117,000,000)
Net investment gains (losses)	(1,262,000,000)	1,529,000,000	(110,000,000)
Policyholder benefits and claims	(50,612,000,000)	(43,954,000,000)	(41,461,000,000)
Gain (Loss) on Derivative Instruments, Net, Pretax	(2,372,000,000)	(2,228,000,000)	1,349,000,000
Policyholder Account Balance, Interest Expense	(3,692,000,000)	(5,538,000,000)	(5,214,000,000)
Operating Expenses	12,034,000,000	12,586,000,000	13,150,000,000
Other Comprehensive Income (Loss), before Tax	(48,879,000,000)	(9,012,000,000)	6,262,000,000
Nonperformance Risk [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	18,000,000	(17,000,000)	(10,000,000)
Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(1,000,000)	(6,000,000)	0
Net investment gains (losses)	43,000,000	(6,000,000)	(42,000,000)
Policyholder benefits and claims	(60,000,000)	(50,000,000)	39,000,000
Policyholder Account Balance, Interest Expense	(1,000,000)	0	0
Operating Expenses	0	0	0
Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(65,000,000)	(64,000,000)	(40,000,000)
Net investment gains (losses)	19,000,000	82,000,000	207,000,000
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	5,000,000	5,000,000	4,000,000
Other Comprehensive Income (Loss), before Tax	(85,000,000)	137,000,000	(286,000,000)
Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	132,000,000	139,000,000	16,000,000
Foreign Exchange Forward [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax		97,000,000	36,000,000
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	85,000,000
Interest rate contracts | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(59,000,000)	(56,000,000)	(36,000,000)
Net investment gains (losses)	41,000,000	84,000,000	121,000,000
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	4,000,000	3,000,000	2,000,000
Other Comprehensive Income (Loss), before Tax	(104,000,000)	(143,000,000)	(159,000,000)
Credit forwards [Member] | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	0	0	0
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Other Comprehensive Income (Loss), before Tax	0	0	0
Currency Swap [Member] | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(6,000,000)	(8,000,000)	(4,000,000)
Net investment gains (losses)	(609,000,000)	(403,000,000)	851,000,000
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	1,000,000	2,000,000	2,000,000
Other Comprehensive Income (Loss), before Tax	602,000,000	393,000,000	(857,000,000)
Derivative [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	0	0	0
Net investment gains (losses)	46,000,000	0	(47,000,000)
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Derivative [Member] | Interest rate swaps | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(9,000,000)	(6,000,000)	(10,000,000)
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	1,187,000,000	456,000,000	(360,000,000)
Policyholder Account Balance, Interest Expense	(26,000,000)	0	0
Operating Expenses	0	0	0
Derivative [Member] | Currency Swap [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(109,000,000)	(50,000,000)	(46,000,000)
Net investment gains (losses)	(220,000,000)	(191,000,000)	98,000,000
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Fixed Maturity Securities | Interest rate swaps | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(9,000,000)	(6,000,000)	(12,000,000)
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	1,127,000,000	406,000,000	399,000,000
Policyholder Account Balance, Interest Expense	(27,000,000)	0	0
Operating Expenses	0	0	0
Fixed Maturity Securities | Currency Swap [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	(110,000,000)	(44,000,000)	(44,000,000)
Net investment gains (losses)	217,000,000	185,000,000	(93,000,000)
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Foreign Currency Gain (Loss) [Member] | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0
Net investment income	0	0	0
Net investment gains (losses)	587,000,000	401,000,000	(765,000,000)
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Other Comprehensive Income (Loss), before Tax	0	0	0
Non-derivative [Domain] [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	47,000,000	42,000,000	(20,000,000)
Accumulated Other Comprehensive Income (Loss) | Credit forwards [Member] | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	0	(14,000,000)	(102,000,000)
Accumulated Other Comprehensive Income (Loss) | Currency Swap [Member] | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	1,784,000,000	500,000,000	(445,000,000)
Accumulated Other Comprehensive Income (Loss) | Interest rate swaps | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	(2,367,000,000)	(599,000,000)	1,277,000,000
Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	3,559,000,000	3,959,000,000	(533,000,000)
Net investment income	(50,000,000)	(54,000,000)	(34,000,000)
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	158,000,000	(349,000,000)	151,000,000
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Foreign Exchange [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	368,000,000	986,000,000	323,000,000
Net investment income	(2,000,000)	0	0
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	(4,000,000)	(2,000,000)	(3,000,000)
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Credit derivatives — purchased | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(75,000,000)	(9,000,000)	28,000,000
Net investment income	0	0	0
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Credit derivatives — written | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	92,000,000	(41,000,000)	106,000,000
Net investment income	0	0	0
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Equity Market Risk [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(423,000,000)	1,280,000,000	1,151,000,000
Net investment income	(45,000,000)	(56,000,000)	(28,000,000)
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	250,000,000	(302,000,000)	203,000,000
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Foreign Currency Gain (Loss) [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(282,000,000)	(249,000,000)	8,000,000
Net investment income	0	0	0
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	0	0	0
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Interest Rate Risk [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	3,879,000,000	1,992,000,000	(2,149,000,000)
Net investment income	(3,000,000)	(2,000,000)	(6,000,000)
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	88,000,000	49,000,000	55,000,000
Policyholder Account Balance, Interest Expense	0	0	0
Operating Expenses	0	0	0
Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	(376,000,000)	(151,000,000)	(217,000,000)
Net investment gains (losses)	0	0	0
Policyholder benefits and claims	(150,000,000)	(213,000,000)	(190,000,000)
Gain (Loss) on Derivative Instruments, Net, Pretax	1,015,000,000	984,000,000	926,000,000
Policyholder Account Balance, Interest Expense	(145,000,000)	(159,000,000)	(152,000,000)
Operating Expenses	0	0	0
Other Comprehensive Income (Loss), before Tax	0	0	0
Net Embedded Derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Policyholder benefits and claims	0	0	0
Gain (Loss) on Derivative Instruments, Net, Pretax	172,000,000	747,000,000	(110,000,000)
Effects of Derivatives on Consolidated Statements of Operations and Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	(490,000,000)	(167,000,000)	(223,000,000)
Net investment gains (losses)	62,000,000	76,000,000	165,000,000
Policyholder benefits and claims	(248,000,000)	186,000,000	0
Policyholder Account Balance, Interest Expense	144,000,000	159,000,000	152,000,000
Operating Expenses	5,000,000	5,000,000	4,000,000
Other Comprehensive Income (Loss), before Tax	$ 47,000,000	$ 276,000,000	$ (270,000,000)

Derivatives (Fair Value Hedges)

Derivatives (Fair Value Hedges) (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fixed Maturities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)	$ (136)	$ (161)
Debt Instruments, Carrying Amount	1,411	2,164
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	1	(1)
Mortgages [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instruments, Carrying Amount	331	634
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	(19)	3
Future policy benefits [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instruments, Carrying Amount	(3,524)	(4,735)
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	276	(877)
Policyholder Account Balances [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instruments, Carrying Amount	(1,080)	0
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	$ 27	$ 0

Derivatives (Cash Flow Hedges)

Derivatives (Cash Flow Hedges) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge	6 years	7 years
Derivative, Average Remaining Maturity	4 years 8 months 12 days	4 years 7 months 6 days
B [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Average Remaining Maturity	4 years 8 months 12 days	4 years

Derivatives (Hedges of Net Inve

Derivatives (Hedges of Net Investments in Foreign Operations) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Debt Designated as Non-derivative Hedging Instrument	$ 318	$ 365
Derivatives used in Net Investment Hedge, Net of Tax	$ 435	$ 303

Derivatives (Credit Derivatives

Derivatives (Credit Derivatives) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 105	$ 165
Maximum Amount of Future Payments under Credit Default Swaps	$ 11,512	$ 8,626
Weighted Average Years to Maturity	4 years 8 months 12 days	4 years 7 months 6 days
Aaa/Aa/A
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 82	$ 21
Maximum Amount of Future Payments under Credit Default Swaps	$ 4,409	$ 1,350
Weighted Average Years to Maturity	3 years 4 months 24 days	2 years 7 months 6 days
Aaa/Aa/A | Single name credit default swaps (3)
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 3	$ 4
Maximum Amount of Future Payments under Credit Default Swaps	$ 158	$ 159
Weighted Average Years to Maturity	2 years 2 months 12 days	3 years 1 month 6 days
Aaa/Aa/A | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 79	$ 17
Maximum Amount of Future Payments under Credit Default Swaps	$ 4,251	$ 1,191
Weighted Average Years to Maturity	3 years 4 months 24 days	2 years 6 months
Baa
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 29	$ 148
Maximum Amount of Future Payments under Credit Default Swaps	$ 6,856	$ 7,089
Weighted Average Years to Maturity	5 years 6 months	5 years
Baa | Single name credit default swaps (3)
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 1	$ 2
Maximum Amount of Future Payments under Credit Default Swaps	$ 81	$ 101
Weighted Average Years to Maturity	2 years 6 months	3 years 4 months 24 days
Baa | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 28	$ 146
Maximum Amount of Future Payments under Credit Default Swaps	$ 6,775	$ 6,988
Weighted Average Years to Maturity	5 years 7 months 6 days	5 years
Ba
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 2	$ 0
Maximum Amount of Future Payments under Credit Default Swaps	$ 87	$ 102
Weighted Average Years to Maturity	2 years 1 month 6 days	2 years
Ba | Single name credit default swaps (3)
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 0	$ 1
Maximum Amount of Future Payments under Credit Default Swaps	$ 62	$ 82
Weighted Average Years to Maturity	1 year 3 months 18 days	1 year 2 months 12 days
Ba | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 2	$ (1)
Maximum Amount of Future Payments under Credit Default Swaps	$ 25	$ 20
Weighted Average Years to Maturity	4 years	5 years
B [Member]
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 2	$ 5
Maximum Amount of Future Payments under Credit Default Swaps	$ 130	$ 55
Weighted Average Years to Maturity	4 years 8 months 12 days	4 years
B [Member] | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 2	$ 5
Maximum Amount of Future Payments under Credit Default Swaps	$ 130	$ 55
Weighted Average Years to Maturity	4 years 8 months 12 days	4 years
Caa3
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ (10)	$ (9)
Maximum Amount of Future Payments under Credit Default Swaps	$ 30
Weighted Average Years to Maturity	3 years 6 months	4 years 6 months
Caa3 | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ (10)	$ (9)
Maximum Amount of Future Payments under Credit Default Swaps	$ 30	$ 30
Weighted Average Years to Maturity	3 years 6 months	4 years 6 months

Derivatives (Estimated Fair Val

Derivatives (Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Offsetting Assets [Line Items]
Derivative Asset, Fair Value, Gross Asset Excluding Accruals	$ 11,577	$ 10,596
Derivative Liability, Fair Value, Gross Liability Excluding Accruals	6,975	3,829
Net amount of derivative assets after application of master netting agreements and cash collateral	175	124
Net amount of derivative liabilities after application of master netting agreements and cash collateral	25	121
Over the Counter [Member]
Offsetting Assets [Line Items]
Derivative Asset, Fair Value, Gross Asset Excluding Accruals	11,438	10,132
Derivative Liability, Fair Value, Gross Liability Excluding Accruals	6,628	3,798
Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(4,579)	(2,204)
Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(4,579)	(2,204)
Cash collateral on derivative assets	(5,432)	(6,948)
Cash collateral on derivative liabilities	0	0
Securities collateral on derivative assets	(1,322)	(891)
Securities collateral on derivative liabilities	(2,024)	(1,473)
Exchange Traded [Member]
Offsetting Assets [Line Items]
Derivative Asset, Fair Value, Gross Asset Excluding Accruals	18	16
Derivative Liability, Fair Value, Gross Liability Excluding Accruals	5	7
Gross estimated fair value of derivative assets	1	2
Gross estimated fair value of derivative liabilities	1	2
Cash collateral on derivative assets	0	0
Cash collateral on derivative liabilities	(3)	(3)
Securities collateral on derivative assets	0	0
Securities collateral on derivative liabilities	(1)	(2)
Cleared [Member]
Offsetting Assets [Line Items]
Derivative Asset, Fair Value, Gross Asset Excluding Accruals	121	448
Derivative Liability, Fair Value, Gross Liability Excluding Accruals	342	24
Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(33)	(6)
Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(33)	(6)
Cash collateral on derivative assets	(35)	(421)
Cash collateral on derivative liabilities	(295)	(13)
Securities collateral on derivative assets	0	0
Securities collateral on derivative liabilities	$ (14)	$ (5)

Derivatives (Credit Risk on Fre

Derivatives (Credit Risk on Freestanding Derivatives) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Credit Derivatives [Line Items]
Collateral Amount Not Provided Due to Downgrade Threshold	$ 15
Estimated fair value of derivatives in a net liability position (1)	2,049	$ 1,595
Derivative assets	11,411	10,466
Derivative liabilities	6,975	3,852
Fixed maturity securities AFS
Credit Derivatives [Line Items]
Estimated fair value of collateral provided:	2,267	1,591
Accrued Liabilities [Member]
Credit Derivatives [Line Items]
Derivative assets	166	130
Derivative liabilities	0	(23)
Derivatives Subject to Credit-Contingent Provisions
Credit Derivatives [Line Items]
Estimated fair value of derivatives in a net liability position (1)	2,049	1,386
Derivatives Subject to Credit-Contingent Provisions | Fixed maturity securities AFS
Credit Derivatives [Line Items]
Estimated fair value of collateral provided:	2,267	1,370
Derivatives Not Subject to Credit-Contingent Provisions
Credit Derivatives [Line Items]
Estimated fair value of derivatives in a net liability position (1)	0	209
Derivatives Not Subject to Credit-Contingent Provisions | Fixed maturity securities AFS
Credit Derivatives [Line Items]
Estimated fair value of collateral provided:	$ 0	$ 221

Derivatives (Embedded Derivativ

Derivatives (Embedded Derivatives) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]
Total	$ 578	$ 649
Ceded guaranteed minimum benefits | Premiums, reinsurance and other receivables
Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]
Embedded derivatives within asset host contracts	29	38
Direct guaranteed minimum benefits | Policyholder account balances [Member]
Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]
Total	467	324
Assumed guaranteed minimum benefits | Policyholder account balances [Member]
Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]
Total	94	98
Funds withheld on ceded reinsurance | Other liabilities
Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]
Total	(123)	57
Fixed annuities with equity indexed returns [Member] | Policyholder account balances [Member]
Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]
Total	140	165
Other Embedded Derivatives [Member] | Policyholder account balances [Member]
Embedded Derivative, Fair Value of Embedded Derivative, Net [Abstract]
Total	$ 0	$ 5

Derivatives (Narrative) (Detail

Derivatives (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Estimated Fair Value Assets	$ 11,411	$ 10,466
Estimated Fair Value Liabilities	6,975	3,852
Maximum Amount of Future Payments under Credit Default Swaps	11,512	8,626
Estimated Fair Value of Credit Default Swaps	105	165
Excess cash collateral received on derivatives	252	$ 172
Securities collateral received which the company is permitted to sell or repledge, amount that has been sold or repledged	$ 0
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Average Remaining Maturity	4 years 8 months 12 days	4 years 7 months 6 days
Net investment gains (losses)	$ (1,262)	$ 1,529	$ (110)
Derivative Instrument Detail [Abstract]
Net amounts reclassified into net derivatives gains (losses) on discontinued cash flow hedges	$ 30	$ (1)	21
Hedging exposure to variability in future cash flows for specific length of time	6 years	7 years
Accumulated Other Comprehensive Income Loss	$ 2,000	$ 2,100
Deferred net gains (losses) expected to be reclassified to earnings	156
Cumulative foreign currency translation gain (loss) recorded in accumulated other comprehensive income (loss) for net investment in foreign operations hedges	435	303
Excess securities collateral provided on derivatives	125	126
Ba [Member]
Derivatives, Fair Value [Line Items]
Maximum Amount of Future Payments under Credit Default Swaps	87	102
Estimated Fair Value of Credit Default Swaps	$ 2	$ 0
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Average Remaining Maturity	2 years 1 month 6 days	2 years
Nonperformance Risk [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Embedded derivative gains (losses)	$ 18	$ (17)	(10)
Over the Counter [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	5,432	6,948
Excess securities collateral received on derivatives	(398)	(160)
Excess securities collateral provided on derivatives	(1,200)	(243)
Exchange Cleared [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	35	421
Excess securities collateral provided on derivatives	(1,000)	(1,200)
Exchange Traded [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0	0
Excess securities collateral provided on derivatives	(184)	(185)
Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment gains (losses)	19	82	$ 207
Credit Index Product [Member] | Ba [Member]
Derivatives, Fair Value [Line Items]
Maximum Amount of Future Payments under Credit Default Swaps	25	20
Estimated Fair Value of Credit Default Swaps	$ 2	$ (1)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Average Remaining Maturity	4 years	5 years
Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Estimated Fair Value Assets	$ 166	$ 130
Estimated Fair Value Liabilities	$ 0	$ (23)

Fair Value (Recurring Fair Valu

Fair Value (Recurring Fair Value Measurements) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	$ 276,780	$ 340,274
Equity securities	1,684	1,269
Unit-linked and FVO Securities (1)	9,668	12,142
Short-term investments (2)	4,935	7,176
Residential mortgage loans — FVO	83,763	79,353
Derivative assets	11,411	10,466
Separate account assets	146,038	179,873
Liabilities [Abstract]
Derivative liabilities	6,975	3,852
Embedded derivatives within liability host contracts (4)	578	649
Separate account liabilities	146,038	179,873
Residential mortgage loans - FVO
Assets [Abstract]
Residential mortgage loans — FVO	0	127
Recurring
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	276,780	340,274
Equity securities	1,684	1,269
Unit-linked and FVO Securities (1)	9,668	12,142
Short-term investments (2)	4,573	6,560
Other investments	1,132	959
Derivative assets	11,411	10,466
Embedded derivatives within asset host contracts	29	38
Separate account assets	146,038	179,873
Total assets (6)	451,315	551,708
Liabilities [Abstract]
Derivative liabilities	6,975	3,852
Embedded derivatives within liability host contracts (4)	578	649
Total liabilities	7,594	4,526
Recurring | Interest rate contracts
Assets [Abstract]
Derivative assets	4,572	6,678
Liabilities [Abstract]
Derivative liabilities	3,558	281
Recurring | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	5,888	2,554
Liabilities [Abstract]
Derivative liabilities	2,870	2,920
Recurring | Credit contracts
Assets [Abstract]
Derivative assets	151	190
Liabilities [Abstract]
Derivative liabilities	107	125
Recurring | Equity market contracts
Assets [Abstract]
Derivative assets	800	1,044
Liabilities [Abstract]
Derivative liabilities	440	526
Recurring | Derivative Liabilities Within Separate Accounts
Liabilities [Abstract]
Separate account liabilities	41	25
Recurring | Residential mortgage loans - FVO
Assets [Abstract]
Residential mortgage loans — FVO	0	127
Recurring | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	80,030	93,034
Recurring | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	46,747	61,609
Recurring | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	52,572	63,640
Recurring | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	32,229	46,599
Recurring | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	26,165	30,404
Recurring | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	16,822	18,569
Recurring | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	12,152	14,212
Recurring | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	10,063	12,207
Recurring | Level 1
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	15,959	25,489
Equity securities	1,293	931
Unit-linked and FVO Securities (1)	7,101	9,173
Short-term investments (2)	3,830	5,607
Other investments	0	0
Derivative assets	18	16
Embedded derivatives within asset host contracts	0	0
Separate account assets	65,107	76,312
Total assets (6)	93,308	117,528
Liabilities [Abstract]
Derivative liabilities	5	7
Embedded derivatives within liability host contracts (4)	0	0
Total liabilities	13	14
Recurring | Level 1 | Interest rate contracts
Assets [Abstract]
Derivative assets	2	4
Liabilities [Abstract]
Derivative liabilities	1	0
Recurring | Level 1 | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	8	0
Liabilities [Abstract]
Derivative liabilities	0	2
Recurring | Level 1 | Credit contracts
Assets [Abstract]
Derivative assets	0	0
Liabilities [Abstract]
Derivative liabilities	0	0
Recurring | Level 1 | Equity market contracts
Assets [Abstract]
Derivative assets	8	12
Liabilities [Abstract]
Derivative liabilities	4	5
Recurring | Level 1 | Derivative Liabilities Within Separate Accounts
Liabilities [Abstract]
Separate account liabilities	8	7
Recurring | Level 1 | Residential mortgage loans - FVO
Assets [Abstract]
Residential mortgage loans — FVO	0	0
Recurring | Level 1 | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	15,955	25,482
Recurring | Level 1 | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	4	7
Recurring | Level 1 | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 2
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	232,048	283,388
Equity securities	132	187
Unit-linked and FVO Securities (1)	1,780	2,068
Short-term investments (2)	686	950
Other investments	206	61
Derivative assets	11,094	10,326
Embedded derivatives within asset host contracts	0	0
Separate account assets	79,703	101,424
Total assets (6)	325,649	398,404
Liabilities [Abstract]
Derivative liabilities	6,501	3,569
Embedded derivatives within liability host contracts (4)	0	0
Total liabilities	6,516	3,581
Recurring | Level 2 | Interest rate contracts
Assets [Abstract]
Derivative assets	4,570	6,577
Liabilities [Abstract]
Derivative liabilities	3,153	259
Recurring | Level 2 | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	5,670	2,551
Liabilities [Abstract]
Derivative liabilities	2,820	2,676
Recurring | Level 2 | Credit contracts
Assets [Abstract]
Derivative assets	69	173
Liabilities [Abstract]
Derivative liabilities	92	113
Recurring | Level 2 | Equity market contracts
Assets [Abstract]
Derivative assets	785	1,025
Liabilities [Abstract]
Derivative liabilities	436	521
Recurring | Level 2 | Derivative Liabilities Within Separate Accounts
Liabilities [Abstract]
Separate account liabilities	15	12
Recurring | Level 2 | Residential mortgage loans - FVO
Assets [Abstract]
Residential mortgage loans — FVO	0	0
Recurring | Level 2 | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	67,578	81,266
Recurring | Level 2 | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	46,644	61,518
Recurring | Level 2 | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	40,623	49,973
Recurring | Level 2 | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	16,274	21,117
Recurring | Level 2 | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	24,515	27,270
Recurring | Level 2 | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	14,895	16,707
Recurring | Level 2 | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	12,152	14,212
Recurring | Level 2 | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	9,367	11,325
Recurring | Level 3
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	28,773	31,397
Equity securities	259	151
Unit-linked and FVO Securities (1)	787	901
Short-term investments (2)	57	3
Other investments	926	898
Derivative assets	299	124
Embedded derivatives within asset host contracts	29	38
Separate account assets	1,228	2,137
Total assets (6)	32,358	35,776
Liabilities [Abstract]
Derivative liabilities	469	276
Embedded derivatives within liability host contracts (4)	578	649
Total liabilities	1,065	931
Recurring | Level 3 | Interest rate contracts
Assets [Abstract]
Derivative assets	0	97
Liabilities [Abstract]
Derivative liabilities	404	22
Recurring | Level 3 | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	210	3
Liabilities [Abstract]
Derivative liabilities	50	242
Recurring | Level 3 | Credit contracts
Assets [Abstract]
Derivative assets	82	17
Liabilities [Abstract]
Derivative liabilities	15	12
Recurring | Level 3 | Equity market contracts
Assets [Abstract]
Derivative assets	7	7
Liabilities [Abstract]
Derivative liabilities	0	0
Recurring | Level 3 | Derivative Liabilities Within Separate Accounts
Liabilities [Abstract]
Separate account liabilities	18	6
Recurring | Level 3 | Residential mortgage loans - FVO
Assets [Abstract]
Residential mortgage loans — FVO	0	127
Recurring | Level 3 | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	12,452	11,768
Recurring | Level 3 | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	103	91
Recurring | Level 3 | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	11,949	13,667
Recurring | Level 3 | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 3 | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	1,646	3,127
Recurring | Level 3 | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	1,927	1,862
Recurring | Level 3 | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 3 | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	696	882
Other limited partnership interests | Recurring
Assets [Abstract]
Investments, Fair Value Disclosure	$ 65	$ 99

Fair Value (Quantitative Inform

Fair Value (Quantitative Information) (Details)	Dec. 31, 2022	Dec. 31, 2021
Minimum | Interest rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	372	151
Minimum | Interest rate | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	0	0.01
Minimum | Foreign currency exchange rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	74	2
Minimum | Credit | Measurement Input, Credit Spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	84	96
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 0 - 40
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0	0
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 41 - 60
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0003	0.0003
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 61 - 115
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0012	0.0012
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 1 - 10
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0040	0.0025
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 11 - 20
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0050	0.0050
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 21 - 116
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0050	0.0050
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Utilization Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0020	0
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Withdrawal Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0	0
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0826	0.0769
Minimum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Nonperformance risk spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0009	0.0004
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	0	1
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	20	0
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Consensus Pricing Model | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	5	99
Minimum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	0	0
Minimum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	3	3
Maximum | Interest rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	392	200
Maximum | Interest rate | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	0	0.01
Maximum | Foreign currency exchange rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	1,938	305
Maximum | Credit | Measurement Input, Credit Spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	138	133
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 0 - 40
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0017	0.0017
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 41 - 60
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0075	0.0075
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 61 - 115
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	1	1
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 1 - 10
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.3750	1
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 11 - 20
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.3575	1
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 21 - 116
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.3575	1
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Utilization Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.22	0.22
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Withdrawal Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.20	0.20
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.25	0.25
Maximum | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Nonperformance risk spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0177	0.0145
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	126	165
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	109	117
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Consensus Pricing Model | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	99	104
Maximum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	106	121
Maximum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	102	110
Weighted Average | Interest rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	381	188
Weighted Average | Interest rate | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	0	0.01
Weighted Average | Foreign currency exchange rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	208	134
Weighted Average | Credit | Measurement Input, Credit Spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	101	109
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 0 - 40
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0005	0.0008
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 41 - 60
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0020	0.0027
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 61 - 115
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0144	0.0208
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 1 - 10
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0896	0.0630
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 11 - 20
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0652	0.0522
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 21 - 116
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0289	0.0522
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Utilization Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0038	0.0022
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Withdrawal Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0402	0.0372
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.1849	0.1860
Weighted Average | Embedded derivatives direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Nonperformance risk spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives direct, assumed and ceded guaranteed minimum benefits	0.0075	0.0035
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	87	109
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	90	100
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Consensus Pricing Model | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	93	100
Weighted Average | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	93	99
Weighted Average | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	91	102

Fair Value (Unobservable Input

Fair Value (Unobservable Input Reconciliation) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Residential mortgage loans - FVO
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	$ 127	$ 165
Total realized/unrealized gains (losses) included in net income (loss)	(8)	(5)	$ 9
Total realized/unrealized gains (losses) included in AOCI	0	0	0
Purchases	0	0
Sales	(108)	(11)
Issuances	0	0
Settlements	(11)	(22)
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance at December 31,	0	127	165
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	(10)	3
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	(10)	3
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Net Derivatives
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	325	(361)	67
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(459)	(128)	579
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at January 1,	(152)	594
Total realized/unrealized gains (losses) included in net income (loss)	238	(460)	279
Total realized/unrealized gains (losses) included in AOCI	(537)	(334)	761
Purchases	82	30
Sales	0	0
Issuances	(3)	(13)
Settlements	201	32
Transfers into Level 3	0	1
Transfers out of Level 3	1	(2)
Balance at December 31,	(170)	(152)	594
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	325	(361)	67
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(459)	(128)	579
Net Embedded Derivatives
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	171	746	(124)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	22	27	(33)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at January 1,	(611)	(1,141)
Total realized/unrealized gains (losses) included in net income (loss)	172	747	(110)
Total realized/unrealized gains (losses) included in AOCI	22	27	(34)
Purchases	0	0
Sales	0	0
Issuances	0	0
Settlements	(132)	(244)
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance at December 31,	(549)	(611)	(1,141)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	171	746	(124)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	22	27	(33)
Corporate fixed maturity securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	25,435	24,101
Total realized/unrealized gains (losses) included in net income (loss)	(7)	(34)	(88)
Total realized/unrealized gains (losses) included in AOCI	(6,221)	(1,334)	1,774
Purchases	5,273	4,988
Sales	(1,762)	(1,543)
Issuances	0	0
Settlements	0	0
Transfers into Level 3	2,127	179
Transfers out of Level 3	(444)	(922)
Balance at December 31,	24,401	25,435	24,101
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(3)	(5)	(48)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(6,136)	(1,293)	1,754
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(3)	(5)	(48)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(6,136)	(1,293)	1,754
Foreign government
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	91	117
Total realized/unrealized gains (losses) included in net income (loss)	(38)	0	(2)
Total realized/unrealized gains (losses) included in AOCI	(13)	(2)	(1)
Purchases	36	1
Sales	(9)	(8)
Issuances	0	0
Settlements	0	0
Transfers into Level 3	46	12
Transfers out of Level 3	(10)	(29)
Balance at December 31,	103	91	117
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(38)	0	(1)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(13)	(2)	(1)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(38)	0	(1)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(13)	(2)	(1)
Structured Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	5,871	5,289
Total realized/unrealized gains (losses) included in net income (loss)	29	46	49
Total realized/unrealized gains (losses) included in AOCI	(478)	(26)	41
Purchases	967	1,824
Sales	(984)	(1,326)
Issuances	0	0
Settlements	0	0
Transfers into Level 3	251	358
Transfers out of Level 3	(1,387)	(294)
Balance at December 31,	4,269	5,871	5,289
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	27	42	54
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(450)	(24)	47
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	27	42	54
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	(450)	(24)	47
Equity Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	151	150
Total realized/unrealized gains (losses) included in net income (loss)	16	27	12
Total realized/unrealized gains (losses) included in AOCI	0	0	0
Purchases	108	12
Sales	(14)	(35)
Issuances	0	0
Settlements	0	0
Transfers into Level 3	0	0
Transfers out of Level 3	(2)	(3)
Balance at December 31,	259	151	150
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	11	13	2
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	11	13	2
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Unit-linked and FVO Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	901	701
Total realized/unrealized gains (losses) included in net income (loss)	(133)	101	67
Total realized/unrealized gains (losses) included in AOCI	0	0	0
Purchases	28	42
Sales	(24)	(18)
Issuances	0	0
Settlements	0	0
Transfers into Level 3	23	86
Transfers out of Level 3	(8)	(11)
Balance at December 31,	787	901	701
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(131)	101	69
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(131)	101	69
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Short-term Investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	3	43
Total realized/unrealized gains (losses) included in net income (loss)	0	1	(7)
Total realized/unrealized gains (losses) included in AOCI	0	(3)	4
Purchases	56	2
Sales	(2)	(37)
Issuances	0	0
Settlements	0	0
Transfers into Level 3	0	0
Transfers out of Level 3	0	(3)
Balance at December 31,	57	3	43
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	(7)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	4
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	(7)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	4
Other Investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	898	573
Total realized/unrealized gains (losses) included in net income (loss)	57	94	19
Total realized/unrealized gains (losses) included in AOCI	0	0	0
Purchases	246	348
Sales	(177)	(92)
Issuances	0	0
Settlements	0	0
Transfers into Level 3	0	0
Transfers out of Level 3	(98)	(25)
Balance at December 31,	926	898	573
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	56	89	24
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	56	89	24
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Separate Accounts (9)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1,	2,131	1,079
Total realized/unrealized gains (losses) included in net income (loss)	61	29	(5)
Total realized/unrealized gains (losses) included in AOCI	0	0	0
Purchases	202	1,056
Sales	(1,164)	(44)
Issuances	(2)	(2)
Settlements	4	6
Transfers into Level 3	1	10
Transfers out of Level 3	(23)	(3)
Balance at December 31,	1,210	2,131	1,079
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	$ 0	$ 0	$ 0

Fair Value (Fair Value Option f

Fair Value (Fair Value Option for Residential Mortgage Loans) (Details) - Residential mortgage loans - FVO - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Option, Quantitative Disclosures [Line Items]
Unpaid principal balance	$ 0	$ 130
Difference between estimated fair value and unpaid principal balance	0	(3)
Carrying value at estimated fair value	0	127
Loans in nonaccrual status	0	32
Loans more than 90 days past due	0	14
Loans in nonaccrual status or more than 90 days past due, or both — difference between aggregate estimated fair value and unpaid principal balance	$ 0	$ (7)

Fair Value (Nonrecurring Fair V

Fair Value (Nonrecurring Fair Value Measurements) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans (1)	$ 83,763	$ 79,353
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Adjustment	(14)	(74)	$ 0
Fair Value, Nonrecurring [Member] | Mortgages [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Adjustment	(13)	(116)	$ (127)
Fair Value, Inputs, Level 3 [Member] | Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans (1)	263	328
Other Assets (2)	$ 1	$ 82

Fair Value (Financial Instrumen

Fair Value (Financial Instruments Carried at Other Than Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Assets
Policy loans	$ 8,874	$ 9,111
Liabilities
Collateral financing arrangement	716	766
Junior subordinated debt securities	3,158	3,156
Separate account liabilities	146,038	179,873
Carrying Value
Assets
Mortgage loans (1)	83,763	79,226
Policy loans	8,874	9,111
Other invested assets	946	1,025
Premiums, reinsurance and other receivables	2,905	2,262
Other assets	267	290
Liabilities
Policyholder account balances	125,039	123,865
Long-term debt	14,591	13,852
Collateral financing arrangement	716	766
Junior subordinated debt securities	3,158	3,156
Other liabilities	2,908	2,143
Separate account liabilities	81,976	95,619
Estimated Fair Value
Assets
Mortgage loans (1)	78,694	82,788
Policy loans	9,682	10,751
Other invested assets	946	1,025
Premiums, reinsurance and other receivables	2,963	2,454
Other assets	265	291
Liabilities
Policyholder account balances	118,694	127,728
Long-term debt	14,241	16,621
Collateral financing arrangement	591	630
Junior subordinated debt securities	3,502	4,447
Other liabilities	3,170	2,835
Separate account liabilities	81,976	95,619
Estimated Fair Value | Level 1
Assets
Mortgage loans (1)	0	0
Policy loans	0	0
Other invested assets	0	0
Premiums, reinsurance and other receivables	0	0
Other assets	0	0
Liabilities
Policyholder account balances	0	0
Long-term debt	0	0
Collateral financing arrangement	0	0
Junior subordinated debt securities	0	0
Other liabilities	0	0
Separate account liabilities	0	0
Estimated Fair Value | Level 2
Assets
Mortgage loans (1)	0	0
Policy loans	0	0
Other invested assets	729	769
Premiums, reinsurance and other receivables	1,042	492
Other assets	90	101
Liabilities
Policyholder account balances	0	0
Long-term debt	14,241	16,621
Collateral financing arrangement	0	0
Junior subordinated debt securities	3,502	4,447
Other liabilities	1,377	514
Separate account liabilities	81,976	95,619
Estimated Fair Value | Level 3
Assets
Mortgage loans (1)	78,694	82,788
Policy loans	9,682	10,751
Other invested assets	217	256
Premiums, reinsurance and other receivables	1,921	1,962
Other assets	175	190
Liabilities
Policyholder account balances	118,694	127,728
Long-term debt	0	0
Collateral financing arrangement	591	630
Junior subordinated debt securities	0	0
Other liabilities	1,793	2,321
Separate account liabilities	$ 0	$ 0

Leases Lease Costs (Details)

Leases Lease Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lease Costs [Abstract]
Operating lease cost	$ 246	$ 271	$ 286
Variable lease cost	45	32	39
Sublease income	(103)	(99)	(99)
Net lease cost	$ 188	$ 204	$ 226

Leases Leases (Details)

Leases Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Assets and Liabilities, Lessee [Abstract]
Cash paid for amounts included in the measurement of lease liability - operating cash flows	$ 249	$ 273
ROU assets obtained in exchange for new lease liabilities	$ 58	$ 63
Weighted-average remaining lease term	6 years	7 years
Weighted-average discount rate	3.50%	3.40%
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023	$ 245
2024	216
2025	198
2026	183
2027	149
Thereafter	252
Total undiscounted cash flows	1,243
Less: interest	96
Lease liability	1,147	$ 1,295
Lessee Disclosure [Abstract]
ROU assets	$ 961	$ 1,110
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Lease liability	$ 1,147	$ 1,295
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities

Leases Leases - (Narrative) (De

Leases Leases - (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Lease ROU asset impairment charges	$ 10	$ 29	$ 0
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	12 years
Sublease Income | Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Sublease Income | Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	8 years

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill Rollforward and by Segment
Goodwill - beginning of period	$ 10,215	$ 10,792	$ 9,988
Accumulated impairment	(680)	(680)	(680)
Total goodwill, net - beginning of period	9,535	10,112	9,308
Acquisitions	40		932
Effect of foreign currency translation and other	(278)	(577)	200
Goodwill - end of period	9,977	10,215	10,792
Accumulated impairment	(680)	(680)	(680)
Total goodwill, net - end of period	9,297	9,535	10,112
Goodwill
Goodwill Rollforward and by Segment
Disposal Group, Including Discontinued Operation, Goodwill			328
U.S.
Goodwill Rollforward and by Segment
Goodwill - beginning of period	2,070	2,070	1,466
Accumulated impairment	0	0	0
Total goodwill, net - beginning of period	2,070	2,070	1,466
Acquisitions	0		932
Effect of foreign currency translation and other	0	0	0
Goodwill - end of period	2,070	2,070	2,070
Accumulated impairment	0	0	0
Total goodwill, net - end of period	2,070	2,070	2,070
U.S. | Goodwill
Goodwill Rollforward and by Segment
Disposal Group, Including Discontinued Operation, Goodwill			328
Asia
Goodwill Rollforward and by Segment
Goodwill - beginning of period	4,552	4,763	4,636
Accumulated impairment	0	0	0
Total goodwill, net - beginning of period	4,552	4,763	4,636
Acquisitions	0		0
Effect of foreign currency translation and other	(243)	(211)	127
Goodwill - end of period	4,309	4,552	4,763
Accumulated impairment	0	0	0
Total goodwill, net - end of period	4,309	4,552	4,763
Asia | Goodwill
Goodwill Rollforward and by Segment
Disposal Group, Including Discontinued Operation, Goodwill			0
Latin America
Goodwill Rollforward and by Segment
Goodwill - beginning of period	977	1,143	1,099
Accumulated impairment	0	0	0
Total goodwill, net - beginning of period	977	1,143	1,099
Acquisitions	0		0
Effect of foreign currency translation and other	3	(166)	44
Goodwill - end of period	980	977	1,143
Accumulated impairment	0	0	0
Total goodwill, net - end of period	980	977	1,143
Latin America | Goodwill
Goodwill Rollforward and by Segment
Disposal Group, Including Discontinued Operation, Goodwill			0
EMEA
Goodwill Rollforward and by Segment
Goodwill - beginning of period	946	1,146	1,117
Accumulated impairment	0	0	0
Total goodwill, net - beginning of period	946	1,146	1,117
Acquisitions	0		0
Effect of foreign currency translation and other	(38)	(200)	29
Goodwill - end of period	908	946	1,146
Accumulated impairment	0	0	0
Total goodwill, net - end of period	908	946	1,146
EMEA | Goodwill
Goodwill Rollforward and by Segment
Disposal Group, Including Discontinued Operation, Goodwill			0
MetLife Holdings
Goodwill Rollforward and by Segment
Goodwill - beginning of period	1,567	1,567	1,567
Accumulated impairment	(680)	(680)	(680)
Total goodwill, net - beginning of period	887	887	887
Acquisitions	0		0
Effect of foreign currency translation and other	0	0	0
Goodwill - end of period	1,567	1,567	1,567
Accumulated impairment	(680)	(680)	(680)
Total goodwill, net - end of period	887	887	887
MetLife Holdings | Goodwill
Goodwill Rollforward and by Segment
Disposal Group, Including Discontinued Operation, Goodwill			0
Corporate & Other
Goodwill Rollforward and by Segment
Goodwill - beginning of period	103	103	103
Accumulated impairment	0	0	0
Total goodwill, net - beginning of period	103	103	103
Acquisitions	40		0
Effect of foreign currency translation and other	0	0	0
Goodwill - end of period	143	103	103
Accumulated impairment	0	0	0
Total goodwill, net - end of period	143	103	103
Corporate & Other | Goodwill
Goodwill Rollforward and by Segment
Disposal Group, Including Discontinued Operation, Goodwill			0
JAPAN
Goodwill Rollforward and by Segment
Total goodwill, net - beginning of period	4,400	4,600
Total goodwill, net - end of period	$ 4,200	$ 4,400	$ 4,600

Long-term and Short-term Debt_2

Long-term and Short-term Debt (Long-term and Short-term Outstanding) (Details) - USD ($) $ in Millions	1 Months Ended
	Jul. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		$ (87)	$ (82)
Finance Lease, Liability		$ 56	$ 81
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Long-term debt	Long-term debt
Long Term Debt Excluding Consolidated Securitization Entities Face Value		$ 14,734	$ 14,015
Long-term debt		14,647	13,933
Short-term debt		175	341
Debt And Capital Lease Obligations Face Value		14,909	14,356
Total		14,822	14,274
Debt Issuance Costs, Gross				$ 6
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		0	0
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 75
Senior notes
Debt Instrument [Line Items]
Weighted Average Interest Rate		4.42%
Debt Instrument, Principal Outstanding		$ 13,671	12,891
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		(83)	(77)
Long-term Debt		$ 13,588	12,814
Debt Instrument, Interest Rate, Stated Percentage		5.70%
Surplus notes
Debt Instrument [Line Items]
Weighted Average Interest Rate		7.79%
Debt Instrument, Principal Outstanding		$ 507	507
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		(1)	(2)
Long-term Debt		$ 506	505
Other notes
Debt Instrument [Line Items]
Weighted Average Interest Rate		4.67%
Debt Instrument, Principal Outstanding		$ 500	536
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		(3)	(3)
Long-term Debt		497	533
Short-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		$ 0	$ 0
Other Notes MPEH [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 50				$ 75
Repayments of Long-term Debt	$ 75
Minimum | Senior notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		0.50%
Minimum | Surplus notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		7.63%
Minimum | Other notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		0.45%
Maximum | Senior notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		6.50%
Maximum | Surplus notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		7.88%
Maximum | Other notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		7.50%
senior debt 1.0 billion March 2030 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 1,000
Debt Instrument, Interest Rate, Stated Percentage				4.55%
Committed Credit Facility Six [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,896
General Credit Facility Three [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		3,000
Committed Credit FacilityMPEH [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 350

Long-term and Short-term Debt_3

Long-term and Short-term Debt (Short-term with Maturities of Year or Less) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Commercial paper	$ 99	$ 100
Other Short-term Borrowings	76	241
Short-term Debt	175	341
Average daily balance	$ 237	$ 300
Average days outstanding	157 days	155 days

Long-term and Short-term Debt_4

Long-term and Short-term Debt (Credit Facilities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Collateral financing arrangement	$ 716	$ 766
General Credit Facility Three [Member]
Debt Instrument [Line Items]
Borrowers	MetLife, Inc. and MetLife Funding, Inc.
Line of Credit Facility, Maximum Borrowing Capacity	$ 3,000
Letters of Credit Issued	263
Collateral financing arrangement	0
Unused Commitments	$ 2,737

Long-term and Short-term Debt_5

Long-term and Short-term Debt (Committed Facilities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Collateral financing arrangement	$ 716	$ 766
Committed Credit Facility Six [Member]
Debt Instrument [Line Items]
Borrowers	MetLife Reinsurance Company of Vermont and MetLife, Inc.
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,896
Letters of Credit Issued	2,487
Collateral financing arrangement	0
Unused Commitments	409
Committed Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	3,246
Letters of Credit Issued	2,837
Collateral financing arrangement	0
Unused Commitments	$ 409
Committed Credit Facility Three [Member]
Debt Instrument [Line Items]
Borrowers	MetLife Reinsurance Company of Vermont and MetLife, Inc.
Line of Credit Facility, Maximum Borrowing Capacity	$ 350
Letters of Credit Issued	350
Collateral financing arrangement	0
Unused Commitments	0
Brighthouse Financial, Inc | Committed Credit Facility Six [Member]
Debt Instrument [Line Items]
Letters of Credit Issued	$ 2,500

Long-term and Short-term Debt_6

Long-term and Short-term Debt (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jul. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 11, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2020
Debt Instrument [Line Items]
Other Short-term Borrowings		$ 76	$ 241
Short-term Debt, Weighted Average Interest Rate, at Point in Time		5.23%	1.41%	2.01%
Debt Issuance Costs, Gross				$ 6
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		$ 87	$ 82
Long Term Debt Aggregate Maturities, Year One		1,100
Long Term Debt Aggregate Maturities, Year Two		1,700
Long Term Debt Aggregate Maturities, Year Three		1,200
Long Term Debt Aggregate Maturities, Year Four		539
Long Term Debt Aggregate Maturities, Year Five		51
Long-term Debt, Maturities, Repayments of Principal after Year Five		10,000
Interest Expense, Debt		655	647	632
Senior notes
Debt Instrument [Line Items]
Debt Instrument, Principal Outstanding		$ 13,671	12,891
Debt Instrument, Interest Rate, Stated Percentage		5.70%
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		$ 83	77
Other Notes MPEH [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 50							$ 75
Repayments of Long-term Debt	$ 75
Other Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Principal Outstanding		500	536
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net		3	$ 3
Senior Debt $500 Million 3.048% which matures in December 2022
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.048%
Early Repayment of Senior Debt			$ 500
Redemption Premium			17
senior debt 1.0 billion July 2052
Debt Instrument [Line Items]
Debt Instrument, Face Amount					$ 1,000
Debt Instrument, Interest Rate, Stated Percentage					5%
Debt Issuance Costs, Gross					$ 11
Securities Sold under Agreements to Repurchase [Member]
Debt Instrument [Line Items]
Other Short-term Borrowings		$ 76	$ 241
Parent Company [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5.23%	212%			100%
Long Term Debt Aggregate Maturities, Year One		$ 1,300
Long Term Debt Aggregate Maturities, Year Two		1,400
Long Term Debt Aggregate Maturities, Year Three		1,200
Long Term Debt Aggregate Maturities, Year Four		508
Long Term Debt Aggregate Maturities, Year Five		0
Long-term Debt, Maturities, Repayments of Principal after Year Five		10,800
Interest Expense, Debt		829	$ 847	$ 833
Parent Company [Member] | Senior Notes Affiliated [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							182%
Committed Credit Facility Six [Member]
Debt Instrument [Line Items]
Letters of Credit Outstanding, Amount		2,487
Line of Credit Facility, Maximum Borrowing Capacity		2,896
Committed Credit Facility Six [Member] | Brighthouse Financial, Inc
Debt Instrument [Line Items]
Letters of Credit Outstanding, Amount		$ 2,500

Long-term and Short-term Debt L

Long-term and Short-term Debt Long-term and Short-term Debt (Narrative - Line of Credit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2037	Dec. 01, 2037
Committed Credit Facility Six [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 409,000,000
Line of Credit Facility, Maximum Borrowing Capacity	2,896,000,000
Line of Credit Facility, Current Borrowing Capacity	2,800,000,000
General Credit Facility Three [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	2,737,000,000
Line of Credit Facility, Maximum Borrowing Capacity	3,000,000,000
Committed Credit Facility Three [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	0
Line of Credit Facility, Maximum Borrowing Capacity	350,000,000
Committed Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	409,000,000
Line of Credit Facility, Maximum Borrowing Capacity	3,246,000,000
Committed Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	3,200,000,000
Line of Credit Facility, Commitment Fee Amount	9,000,000	$ 12,000,000	$ 12,000,000
General Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Amount	$ 8,000,000	$ 10,000,000	$ 14,000,000
Forecast [Member] | Committed Credit Facility Six [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 0	$ 2,000,000,000

Collateral Financing Arrangem_3

Collateral Financing Arrangements Collateral Financing Arrangements (Associated with Closed Block) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2007
Debt Instrument [Line Items]
Invested assets pledged as collateral	$ 25,442	$ 24,261
Parent Company [Member] | Secured Debt Mrc [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate Terms				three-month LIBOR plus 1.12%
Met Life Reinsurance Company Of Charleston [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Principal Outstanding	716	766
Other Receivables	93	100
Invested Assets On Deposit Held In Trust And Pledged As Collateral	1,369	1,388
Increase (Decrease) in Other Receivables	7	10	$ 20
Debt Instrument, Interest Rate Terms				three-month LIBOR plus 0.55%
Invested assets pledged as collateral	$ 43	$ 38

Collateral Financing Arrangem_4

Collateral Financing Arrangements (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2007
Collateral Financing Arrangements (Textuals) [Abstract]
AmountTransferredTo(From)TheTrust	$ 119	$ 78	$ (78)
Parent Company
Collateral Financing Arrangements (Textuals) [Abstract]
Interest expense	829	847	833
MRC [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate Terms				three-month LIBOR plus 0.55%
Collateral Financing Arrangements (Textuals) [Abstract]
Interest expense	22	11	20
Debt Instrument, Face Amount				$ 2,500
Debt Instrument, Term in Years				35 years
Partial repurchase	50	79	148
Increase (Decrease) in Other Receivables	7	10	20
MRC [Member] | Cash Received (Paid) Collateral Financing Arrangements MRC [Member]
Collateral Financing Arrangements (Textuals) [Abstract]
Cash Received (Paid) In Connection With Collateral Financing Arrangements	$ 7	$ 10	$ 20
MRC [Member] | Parent Company | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate Terms				three-month LIBOR plus 1.12%

Junior Subordinated Debt Secu_3

Junior Subordinated Debt Securities (Junior Subordinated Debt Securities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (87)	$ (82)
Junior Subordinated Notes	3,158	3,156
MetLife Inc $500M Maturing 2069 [Member]
Debt Instrument [Line Items]
Face Value	500	500
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (5)	(6)
Debt Instrument, Interest Rate, Stated Percentage	10.75%
Debt Instrument, Interest Rate Terms	LIBOR + 7.548%
Junior Subordinated Notes	$ 495	494
Senior notes
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (83)	(77)
Debt Instrument, Interest Rate, Stated Percentage	5.70%
MetLife Capital Trust X $750M Maturing 2068 [Member]
Debt Instrument [Line Items]
Face Value	$ 750	750
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (9)	(9)
Debt Instrument, Interest Rate, Stated Percentage	9.25%
Debt Instrument, Interest Rate Terms	LIBOR + 5.540%
Junior Subordinated Notes	$ 741	741
MetLife Capital Trust IV $700M Maturing 2067 [Member]
Debt Instrument [Line Items]
Face Value	700	700
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (13)	(13)
Debt Instrument, Interest Rate, Stated Percentage	7.875%
Debt Instrument, Interest Rate Terms	LIBOR + 3.960%
Junior Subordinated Notes	$ 687	687
MetLife Inc $1,250M Maturing 2066 [Member]
Debt Instrument [Line Items]
Face Value	1,250	1,250
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (15)	(16)
Debt Instrument, Interest Rate, Stated Percentage	6.40%
Debt Instrument, Interest Rate Terms	LIBOR + 2.205%
Junior Subordinated Notes	$ 1,235	1,234
Junior Subordinated Debt [Member]
Debt Instrument [Line Items]
Face Value	3,200	3,200
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ (42)	$ (44)

Junior Subordinated Debt Secu_4

Junior Subordinated Debt Securities (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis	three-month LIBOR
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 87	$ 82
Interest Expense, Junior Subordinated Debentures	261	261	$ 261
Senior notes
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 83	77
Debt Instrument, Interest Rate, Stated Percentage	5.70%
Junior Subordinated Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 3,200	3,200
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	42	44
Junior Subordinated Debt Instrument One [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	500	500
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 5	6
Debt Instrument, Interest Rate, Stated Percentage	10.75%
Junior Subordinated Debt Instrument Four [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,250	1,250
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 15	16
Debt Instrument, Interest Rate, Stated Percentage	6.40%
Junior Subordinated Debt Instrument Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 700	700
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 13	13
Debt Instrument, Interest Rate, Stated Percentage	7.875%
Junior Subordinated Debt Instrument Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 750	750
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 9	$ 9
Debt Instrument, Interest Rate, Stated Percentage	9.25%

Equity (Preferred Stock) (Detai

Equity (Preferred Stock) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 10, 2020	Jan. 15, 2020
Dividends Payable [Line Items]
Preferred Stock, Shares Authorized	200,000,000	200,000,000
Preferred Stock, Shares Issued	25,572,200	25,572,200
Preferred Stock, Shares Outstanding	25,572,200	25,572,200
Preferred Stock
Preferred stock, dividends	$ 185	$ 195	$ 202
Series A Preferred Stock [Member]
Dividends Payable [Line Items]
Preferred Stock, Dividend Payment Rate, Variable	Three-month LIBOR + 1.00%, with floor of 4.00%
Preferred Stock, Shares Authorized	27,600,000	27,600,000
Preferred Stock, Shares Issued	24,000,000	24,000,000
Preferred Stock, Shares Outstanding	24,000,000	24,000,000
Preferred Stock
Preferred Stock, Dividends Per Share, Declared	$ 1.033	$ 1.015	$ 1.015
Preferred stock, dividends	$ 24	$ 24	$ 24
Series C Preferred Stock [Member]
Dividends Payable [Line Items]
Preferred Stock, Shares Authorized			1,500,000
Preferred Stock
Preferred Stock, Dividends Per Share, Declared	$ 0	$ 19.085	$ 45.860
Preferred stock, dividends	$ 0	$ 10	$ 59
5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, par value $0.01
Dividends Payable [Line Items]
Preferred Stock, Dividend Payment Rate, Variable	5.875% Fixed-to-Floating Rate
Preferred Stock, Shares Authorized	500,000	500,000
Preferred Stock, Shares Issued	500,000	500,000
Preferred Stock, Shares Outstanding	500,000	500,000
Preferred Stock
Preferred Stock, Dividends Per Share, Declared	$ 58.750	$ 58.750	$ 58.750
Preferred stock, dividends	$ 29	$ 29	$ 30
Series E Preferred Stock [Member]
Dividends Payable [Line Items]
Preferred Stock, Dividend Payment Rate, Variable	5.625
Preferred Stock, Shares Authorized	32,200	32,200
Preferred Stock, Shares Issued	32,200	32,200
Preferred Stock, Shares Outstanding	32,200	32,200
Preferred Stock
Preferred Stock, Dividends Per Share, Declared	$ 1,406.252	$ 1,406.252	$ 1,406.252
Preferred stock, dividends	$ 45	$ 45	$ 45
Series A Junior Preferred Stock [Member]
Dividends Payable [Line Items]
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Not Designated Preferred Stock [Member]
Dividends Payable [Line Items]
Preferred Stock, Shares Authorized	160,827,800	160,827,800
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F
Dividends Payable [Line Items]
Preferred Stock, Shares Authorized	40,000	40,000
Preferred Stock, Shares Issued	40,000	40,000			40,000
Preferred Stock, Shares Outstanding	40,000	40,000
Preferred Stock
Preferred Stock, Dividends Per Share, Declared	$ 1,187.5	$ 1,187.5	$ 1,088.542
Preferred stock, dividends	$ 48	$ 48	$ 44
3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, par value $0.01
Dividends Payable [Line Items]
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	1,000,000	1,000,000		1,000,000
Preferred Stock, Shares Outstanding	1,000,000	1,000,000
Preferred Stock
Preferred Stock, Dividends Per Share, Declared	$ 38.500	$ 39.035	$ 0
Preferred stock, dividends	$ 39	$ 39	$ 0

Equity (Preferred Stock - Narra

Equity (Preferred Stock - Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Sep. 10, 2020	Jan. 15, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Preferred Stock, Shares Issued			25,572,200	25,572,200
Preferred stock issued, net of issuance costs			$ 0	$ 0	$ 1,961
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares outstanding			25,572,200	25,572,200
Preferred stock, par value			$ 0.01	$ 0.01
Preferred Stock, Shares Authorized			200,000,000	200,000,000
Preferred stock redemption premium			$ 0	$ 6	$ 14
Stock Repurchase Program, Remaining Authorized Repurchase Amount			1,200
December2020Authorization
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Stock Repurchase Program, Remaining Authorized Repurchase Amount			0
August2021Authorization
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Stock Repurchase Program, Remaining Authorized Repurchase Amount			0
May2022Authorization
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Stock Repurchase Program, Remaining Authorized Repurchase Amount			$ 1,205
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Dividend Rate, Percentage			562.50%
Preferred Stock, Shares Issued			32,200	32,200
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares outstanding			32,200	32,200
Preferred Stock, Dividend Payment Rate, Variable			5.625
Preferred stock, aggregate liquidation preference			$ 25,000
Preferred Stock, Shares Authorized			32,200	32,200
Series E Preferred Stock [Member] | Depositary Share [Member]
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			$ 25
5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, par value $0.01
Class of Stock [Line Items]
Preferred Stock, Shares Issued			500,000	500,000
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares outstanding			500,000	500,000
Preferred Stock, Dividend Payment Rate, Variable			5.875% Fixed-to-Floating Rate
Preferred stock, aggregate liquidation preference			$ 1,000
Preferred Stock, Shares Authorized			500,000	500,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock redemption price per share				$ 1,000	$ 1,000
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, par value				$ 0.01
Preferred Stock, Shares Authorized					1,500,000
Redeem and Canceled Preferred Stock [Line Items]				500,000	1,000,000
Preferred stock redemption premium				$ 6	$ 14
Preferred Stock, Redemption Amount				$ 500	$ 1,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued			24,000,000	24,000,000
Preferred stock redemption price per share			$ 25
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares outstanding			24,000,000	24,000,000
Preferred Stock, Dividend Payment Rate, Variable			Three-month LIBOR + 1.00%, with floor of 4.00%
Preferred Stock, Shares Authorized			27,600,000	27,600,000
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F
Class of Stock [Line Items]
Preferred Stock, Dividend Rate, Percentage		4.75%	475%
Preferred Stock, Shares Issued		40,000	40,000	40,000
Preferred stock issued, net of issuance costs		$ 972
Payments of Stock Issuance Costs		$ 28
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares outstanding			40,000	40,000
Preferred stock, par value		$ 0.01
Preferred stock, aggregate liquidation preference		$ 25,000	$ 25,000
Preferred Stock, Shares Authorized			40,000	40,000
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F | Depositary Share [Member]
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			$ 25
3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, par value $0.01
Class of Stock [Line Items]
Preferred Stock, Dividend Rate, Percentage	3.85%		385%
Preferred Stock, Shares Issued	1,000,000		1,000,000	1,000,000
Preferred stock issued, net of issuance costs	$ 989
Payments of Stock Issuance Costs	$ 11
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares outstanding			1,000,000	1,000,000
Preferred stock, par value	$ 0.01
Preferred stock, aggregate liquidation preference	$ 1,000		$ 1,000
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Fixed Rate1 [Member] | 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, par value $0.01
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred Stock, Dividend Payment Rate, Variable			5.875%
Variable Rate1 [Member] | 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, par value $0.01
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred Stock, Dividend Payment Rate, Variable			three-month LIBOR + 2.959%
Variable Rate1 [Member] | 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, par value $0.01
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred Stock, Dividend Payment Rate, Variable			five year treasury rate, reset every five years, + 3.576%
RatingAgency [Member] | Series E Preferred Stock [Member]
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			$ 25,500
RatingAgency [Member] | Series E Preferred Stock [Member] | Depositary Share [Member]
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			25.50
RatingAgency [Member] | 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, par value $0.01
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			1,020
RatingAgency [Member] | Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			25,500
RatingAgency [Member] | Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F | Depositary Share [Member]
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			25.50
RatingAgency [Member] | 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, par value $0.01
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, aggregate liquidation preference			$ 1,020

Equity (Common Stock) (Details)

Equity (Common Stock) (Details) - USD ($) $ in Millions	Dec. 31, 2022	May 04, 2022	Aug. 04, 2021	Dec. 11, 2020
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Authorized Amount		$ 3,000	$ 3,000	$ 3,000
Repurchase amount outstanding	$ 1,200
August2021Authorization
Equity, Class of Treasury Stock [Line Items]
Repurchase amount outstanding	0
December2020Authorization
Equity, Class of Treasury Stock [Line Items]
Repurchase amount outstanding	$ 0

Equity (Common Stock - Narrativ

Equity (Common Stock - Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Cost of shares issued	$ 105	$ 193	$ 160
Repurchase Shares	49,732,851	72,296,518	26,361,487
Treasury Stock, Value, Acquired, Cost Method	$ 3,301	$ 4,328	$ 1,151
Stock Repurchase Program, Remaining Authorized Repurchase Amount	1,200
Dividends, Common Stock, Cash	(1,598)	(1,647)	(1,657)
Retained Earnings
Class of Stock [Line Items]
Dividends, Common Stock, Cash	(1,598)	$ (1,647)	$ (1,657)
August2021Authorization
Class of Stock [Line Items]
Treasury Stock, Value, Acquired, Cost Method	25
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 0
Common Shares Issued For Stock Options [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	3,290,998	4,926,185	3,933,989
Cost of shares issued	$ 156	$ 195	$ 153
Treasury Shares Issued For Stock Options [Member]
Class of Stock [Line Items]
Issued Treasury Stock	0	0	0
Common Stock [Member]
Class of Stock [Line Items]
Dividends, Common Stock, Cash	$ (1,600)	$ (1,600)	$ (1,700)

Equity (Compensation Expense Re

Equity (Compensation Expense Related to Stock-Based Compensation - Related to Phantom Stock-Based Awards) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation Expense	$ 184	$ 173	$ 127
Income tax benefit	39	36	27
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation Expense	7	9	6
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation Expense	108	98	63
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation Expense	$ 69	$ 66	$ 58

Equity (Unrecognized Compensati

Equity (Unrecognized Compensation Expense Related to Stock-Based Compensation) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	$ 3
Weighted Average Period	1 year 9 months 10 days
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	$ 29
Weighted Average Period	1 year 8 months 4 days
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	$ 32
Weighted Average Period	1 year 9 months 29 days

Equity (Summary of Activity Rel

Equity (Summary of Activity Related to Stock Options) (Details) - Stock Options - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shares Under Option
Shares Under Option Outstanding at January 1,	4,268,091
Granted Shares Under Option	402,976
Exercised Shares Under Option	(1,259,933)
Expired Shares Under Option	(6,424)
Forfeited Shares Under Option	(18,669)
Shares Under Option Outstanding at December 31,	3,386,041	4,268,091
Vested and expected to vest at December 31,	3,376,464
Shares Under Option Exercisable at December 31,	2,533,864
Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding at January 1,	$ 44.02
Granted Weighted Average Exercise Price	68.96	$ 57.43	$ 47.58
Exercised Weighted Average Exercise Price	37.79
Expired Weighted Average Exercise Price	33.35
Forfeited Weighted Average Exercise Price	60.07
Weighted Average Exercise Price Outstanding at December 31,	49.24	$ 44.02
Weighted Average Exercise Price Aggregate number of stock options expected to vest at December 31,	49.20
Weighted Average Exercise Price Exercisable at December 31,	$ 45.25
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term Outstanding at January 1,	5 years 6 months 29 days	5 years 10 days
Weighted Average Remaining Contractual Term Aggregate number of stock options expected to vest at December 31,	5 years 6 months 25 days
Weighted Average Remaining Contractual Term Exercisable at December 31,	4 years 7 months 9 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding at January 1,	$ 79
Aggregate Intrinsic Value Outstanding at December 31,	78	$ 79
Aggregate Intrinsic Value Aggregate number of stock options expected to vest at December 31,	78
Aggregate Intrinsic Value Exercisable at December 31,	$ 69
Sale of Stock, Price Per Share	$ 72.37	$ 62.49

Equity (Weighted Average Assump

Equity (Weighted Average Assumptions Used to Determine Fair Value of Stock Options) (Details) - Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity - Stock-based Compensation Plans [Line Items]
Dividend yield	2.78%	3.20%	3.70%
Risk-free rate of return, Minimum	1.17%	0.08%	1.30%
Risk-free rate of return, Maximum	1.97%	2.48%	1.57%
Expected volatility	26.67%	29.72%	25.55%
Exercise multiple	1.45	1.44	1.44
Post-vesting termination rate	3.58%	3.58%	3.79%
Contractual term (years)	10 years	10 years	10 years
Expected life (years)	6 years	7 years	7 years
Weighted average exercise price of stock options granted	$ 68.96	$ 57.43	$ 47.58
Weighted average fair value of stock options granted	$ 15.18	$ 12.76	$ 9.02

Equity (Summary of Stock Option

Equity (Summary of Stock Option Exercise Activity) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Additional Disclosure [Abstract]
Total intrinsic value of stock options exercised	$ 40	$ 60	$ 29
Cash received from exercise of stock options	48	119	89
Income tax benefit realized from stock options exercised	$ 8	$ 13	$ 6

Equity (Performance Share and R

Equity (Performance Share and Restricted Stock Unit) (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Performance Shares
Summary of performance share activity
Shares Outstanding at January 1, | shares	3,848,015
Granted Shares | shares	978,422
Forfeited Shares | shares	(130,371)
Paid | shares	(1,489,328)
Shares Outstanding at December 31, | shares	3,206,738
Vested and expected to vest at December 31, | shares	3,161,138
Summary of Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value Outstanding January 1, | $ / shares	$ 43.74
Granted Weighted Average Grant Date Fair Value | $ / shares	62.83
Forfeited Weighted Average Grant Date Fair Value | $ / shares	51.20
Payable Weighted Average Grant Date Fair Value | $ / shares	39.38
Weighted Average Grant Date Fair Value Outstanding December 31, | $ / shares	51.26
Weighted Average Grant Date Fair Value Share expected to vest at December 31, | $ / shares	$ 51.15
Restricted Stock Units
Summary of performance share activity
Shares Outstanding at January 1, | shares	2,451,046
Granted Shares | shares	893,161
Forfeited Shares | shares	(127,184)
Paid | shares	(1,217,059)
Shares Outstanding at December 31, | shares	1,999,964
Vested and expected to vest at December 31, | shares	1,967,910
Summary of Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value Outstanding January 1, | $ / shares	$ 45.39
Granted Weighted Average Grant Date Fair Value | $ / shares	62.60
Forfeited Weighted Average Grant Date Fair Value | $ / shares	52.97
Payable Weighted Average Grant Date Fair Value | $ / shares	43.71
Weighted Average Grant Date Fair Value Outstanding December 31, | $ / shares	53.62
Weighted Average Grant Date Fair Value Share expected to vest at December 31, | $ / shares	$ 53.56

Equity (Liability Award Activit

Equity (Liability Award Activity) (Details)	12 Months Ended
	Dec. 31, 2022 shares
Stock Options
Summary of performance share activity
Exercised Shares Liability Awards	(1,259,933)
Expired Shares Liability Awards	(6,424)
Performance Shares
Summary of performance share activity
Shares Outstanding at January 1,	3,848,015
Granted Shares Liability Awards	978,422
Forfeited Shares Liability Awards	(130,371)
Paid Liability Awards	(1,489,328)
Shares Outstanding at December 31,	3,206,738
Vested and expected to vest at December 31,	3,161,138
Restricted Stock Units
Summary of performance share activity
Shares Outstanding at January 1,	2,451,046
Granted Shares Liability Awards	893,161
Forfeited Shares Liability Awards	(127,184)
Paid Liability Awards	(1,217,059)
Shares Outstanding at December 31,	1,999,964
Vested and expected to vest at December 31,	1,967,910
Liability Awards Plan | Stock Options
Summary of performance share activity
Shares Outstanding at January 1,	124,986
Granted Shares Liability Awards	13,192
Exercised Shares Liability Awards	(23,800)
Expired Shares Liability Awards	(59,647)
Forfeited Shares Liability Awards	0
Paid Liability Awards	0
Shares Outstanding at December 31,	54,731
Vested and expected to vest at December 31,	54,359
Liability Awards Plan | Performance Shares
Summary of performance share activity
Shares Outstanding at January 1,	448,986
Granted Shares Liability Awards	115,057
Exercised Shares Liability Awards	0
Expired Shares Liability Awards	0
Forfeited Shares Liability Awards	(15,223)
Paid Liability Awards	(156,900)
Shares Outstanding at December 31,	391,920
Vested and expected to vest at December 31,	382,702
Liability Awards Plan | Restricted Stock Units
Summary of performance share activity
Shares Outstanding at January 1,	514,556
Granted Shares Liability Awards	216,980
Exercised Shares Liability Awards	0
Expired Shares Liability Awards	0
Forfeited Shares Liability Awards	(30,580)
Paid Liability Awards	(259,401)
Shares Outstanding at December 31,	441,555
Vested and expected to vest at December 31,	431,164

Equity (Stock-Based Compensatio

Equity (Stock-Based Compensation Plans - Narrative) (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
2015 Stock Plan
Equity - Stock-based Compensation Plans [Line Items]
Aggregate number of shares authorized for issuance		31,886,521
Other Stock And Incentive Plans
Equity - Stock-based Compensation Plans [Line Items]
Deferred shares		686,770
2015 Director Stock Plan
Equity - Stock-based Compensation Plans [Line Items]
Aggregate number of shares authorized for issuance		1,469,329
Other Director Stock Plans
Equity - Stock-based Compensation Plans [Line Items]
Deferred shares		323,898
Stock Options
Equity - Stock-based Compensation Plans [Line Items]
Award Expiration Date		10 years	10 years	10 years
Stock Options | Maximum
Equity - Stock-based Compensation Plans [Line Items]
Vesting period		3 years
Stock Options | Liability Awards Plan
Equity - Stock-based Compensation Plans [Line Items]
Paid		0
Performance Shares
Equity - Stock-based Compensation Plans [Line Items]
Paid		(1,489,328)
Performance Factor			141.30%
Performance Shares | Scenario, Forecast
Equity - Stock-based Compensation Plans [Line Items]
Paid	(1,174,602)
Performance Shares | Minimum
Equity - Stock-based Compensation Plans [Line Items]
Future Performance Factor		0%
Performance Shares | Maximum
Equity - Stock-based Compensation Plans [Line Items]
Future Performance Factor		175%
Performance Shares | Liability Awards Plan
Equity - Stock-based Compensation Plans [Line Items]
Paid		(156,900)
Performance Shares | Liability Awards Plan | Scenario, Forecast
Equity - Stock-based Compensation Plans [Line Items]
Paid	(154,904)

Equity (Statutory Equity & Inco

Equity (Statutory Equity & Income - Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Principal U.S. Insurance Subsidiaries, Excluding American Life
Statutory Accounting Practices [Line Items]
Combined RBC ratio of the principal U.S. insurance subsidiaries	in excess of 340%	in excess of 360%
Metropolitan Life Insurance Company
Statutory Accounting Practices [Line Items]
Statutory Accounting Practices, Prescribed Practice, Amount	$ 1,300	$ 1,200
Statutory Accounting Practices, Statutory Net Income Amount	2,737	3,513	$ 3,392
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	10,869	11,804
MetLife Reinsurance Company of Vermont
Statutory Accounting Practices [Line Items]
Statutory Accounting Practices, Prescribed Practice, Amount	2,000	2,000
MetLife's Domestic Captive Life Reinsurance Subsidiaries
Statutory Accounting Practices [Line Items]
Statutory Accounting Practices, Statutory Net Income Amount	44	41	$ (7)
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	$ 726	$ 693
Japan
Statutory Accounting Practices [Line Items]
Adjusted capital	in excess of three times	in excess of four times the 200% solvency margin ratio
Other Foreign Operations, Excluding Japan
Statutory Accounting Practices [Line Items]
Statutory capital and surplus required	$ 3,300
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	$ 7,400

Equity (Statutory Net Income (L

Equity (Statutory Net Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Metropolitan Life Insurance Company
Statutory Accounting Practices [Line Items]
Statutory net income (loss)	$ 2,737	$ 3,513	$ 3,392
Statutory capital and surplus	10,869	11,804
American Life Insurance Company
Statutory Accounting Practices [Line Items]
Statutory net income (loss)	824	48	980
Statutory capital and surplus	5,040	5,584
Metropolitan Property and Casualty Insurance Company
Statutory Accounting Practices [Line Items]
Statutory net income (loss)			336
Metropolitan Tower Life Insurance Company
Statutory Accounting Practices [Line Items]
Statutory net income (loss)	232	185	(237)
Statutory capital and surplus	1,896	1,638
Other
Statutory Accounting Practices [Line Items]
Statutory net income (loss)	91	76	$ 84
Statutory capital and surplus	$ 209	$ 193

Equity (Dividend Restrictions)

Equity (Dividend Restrictions) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2023
Metropolitan Life Insurance Company
Statutory Accounting Practices [Line Items]
Cash Dividends Paid	$ 3,539	$ 3,393
Metropolitan Life Insurance Company | Scenario, Forecast
Statutory Accounting Practices [Line Items]
Permitted w/o Approval			$ 2,471
American Life Insurance Company
Statutory Accounting Practices [Line Items]
Cash Dividends Paid	1,289	1,135
American Life Insurance Company | Scenario, Forecast
Statutory Accounting Practices [Line Items]
Permitted w/o Approval			499
Metropolitan Property and Casualty Insurance Company
Statutory Accounting Practices [Line Items]
Cash Dividends Paid		35
Metropolitan Tower Life Insurance Company
Statutory Accounting Practices [Line Items]
Cash Dividends Paid	$ 0	$ 0
Metropolitan Tower Life Insurance Company | Scenario, Forecast
Statutory Accounting Practices [Line Items]
Permitted w/o Approval			$ 189

Equity (Components of Accumulat

Equity (Components of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance beginning of period	$ 10,919	$ 18,072	$ 13,052
OCI before reclassifications	(51,451)	(9,272)	7,602
Deferred income tax benefit (expense)	11,338	1,837	(1,664)
AOCI before reclassifications, net of income tax	(29,194)	10,637	18,990
Amounts reclassified from AOCI	2,198	216	(1,287)
Deferred income tax benefit (expense)	(463)	(27)	421
Amounts reclassified from AOCI, net of income tax	1,735	189	(866)
Balance end of period	(27,083)	10,919	18,072
Unrealized Investment Gains (Losses), Net of Related Offsets
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance beginning of period	16,042	22,217	18,283
OCI before reclassifications	(49,427)	(7,829)	5,775
Deferred income tax benefit (expense)	11,304	1,918	(1,349)
AOCI before reclassifications, net of income tax	(22,081)	16,306	22,709
Amounts reclassified from AOCI	1,607	(125)	(357)
Deferred income tax benefit (expense)	(368)	29	83
Amounts reclassified from AOCI, net of income tax	1,239	(96)	(274)
Balance end of period	(20,851)	16,042	22,217
Unrealized Gains (Losses) on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance beginning of period	1,629	1,513	1,698
OCI before reclassifications	(583)	(113)	730
Deferred income tax benefit (expense)	89	18	(257)
AOCI before reclassifications, net of income tax	1,135	1,418	2,171
Amounts reclassified from AOCI	498	250	(1,016)
Deferred income tax benefit (expense)	(76)	(39)	358
Amounts reclassified from AOCI, net of income tax	422	211	(658)
Balance end of period	1,557	1,629	1,513
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance beginning of period	(5,154)	(3,795)	(4,927)
OCI before reclassifications	(1,629)	(1,567)	1,002
Deferred income tax benefit (expense)	(16)	(53)	(36)
AOCI before reclassifications, net of income tax	(6,799)	(5,415)	(3,961)
Amounts reclassified from AOCI	0	0	0
Deferred income tax benefit (expense)	0	0	0
Amounts reclassified from AOCI, net of income tax	0	0	0
Balance end of period	(6,412)	(5,154)	(3,795)
Defined Benefit Plans Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance beginning of period	(1,598)	(1,863)	(2,002)
OCI before reclassifications	188	237	95
Deferred income tax benefit (expense)	(39)	(46)	(22)
AOCI before reclassifications, net of income tax	(1,449)	(1,672)	(1,929)
Amounts reclassified from AOCI	93	91	86
Deferred income tax benefit (expense)	(19)	(17)	(20)
Amounts reclassified from AOCI, net of income tax	74	74	66
Balance end of period	(1,377)	(1,598)	(1,863)
Disposal Group, Held-for-Sale or Disposed of by Sale
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from AOCI, net of income tax	376	93	(52)
Disposal Group, Held-for-Sale or Disposed of by Sale | Unrealized Investment Gains (Losses), Net of Related Offsets
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from AOCI, net of income tax	(9)	(168)	(218)
Disposal Group, Held-for-Sale or Disposed of by Sale | Unrealized Gains (Losses) on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from AOCI, net of income tax	0	0	0
Disposal Group, Held-for-Sale or Disposed of by Sale | Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from AOCI, net of income tax	387	261	166
Disposal Group, Held-for-Sale or Disposed of by Sale | Defined Benefit Plans Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from AOCI, net of income tax	$ (2)	$ 0	$ 0

Equity (Reclassifications Out o

Equity (Reclassifications Out of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	$ (1,262)	$ 1,529	$ (110)
Net investment income	15,916	21,395	17,117
Net derivative gains (losses)	(2,372)	(2,228)	1,349
Other expenses	$ 12,034	$ 12,586	$ 13,150
Amortization of net actuarial gains (losses) [Extensible Enumeration]	Total recognized in OCI	Total recognized in OCI	Total recognized in OCI
Amortization of prior service (costs) credit [Extensible Enumeration]	Total recognized in OCI	Total recognized in OCI	Total recognized in OCI
Income (loss) from continuing operations before provision for income tax	$ 2,859	$ 8,126	$ 6,927
Income tax (expense) benefit	(301)	(1,551)	(1,509)
Net income (loss)	2,558	6,575	5,418
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net income (loss)	(1,735)	(189)	866
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Investment Gains (Losses), Net of Related Offsets
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	(1,802)	72	362
Net investment income	7	(16)	(24)
Net derivative gains (losses)	188	69	19
Income (loss) from continuing operations before provision for income tax	(1,607)	125	357
Income tax (expense) benefit	368	(29)	(83)
Net income (loss)	(1,239)	96	274
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income (loss) from continuing operations before provision for income tax	(498)	(250)	1,016
Income tax (expense) benefit	76	39	(358)
Net income (loss)	(422)	(211)	658
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Interest rate contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	41	84	121
Net investment income	59	56	36
Other expenses	4	3	2
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Foreign currency swaps
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	(609)	(403)	851
Net investment income	6	8	4
Other expenses	1	2	2
Reclassification out of Accumulated Other Comprehensive Income | Defined Benefit Plans Adjustment
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of net actuarial gains (losses)	(104)	(120)	(105)
Amortization of prior service (costs) credit	11	29	19
Income (loss) from continuing operations before provision for income tax	(93)	(91)	(86)
Income tax (expense) benefit	19	17	20
Net income (loss)	$ (74)	$ (74)	$ (66)

Equity (Net Unrealized Investme

Equity (Net Unrealized Investment Gains Losses) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Components of net unrealized investment gains (losses) included in accumulated other comprehensive income
Fixed maturity securities AFS	$ (29,262)	$ 29,461	$ 44,415
Derivatives	1,976	2,061	1,924
Other	549	389	267
Subtotal	(26,737)	31,911	46,606
Policyholder liabilities (1)	(1,487)	(4,978)	(10,797)
DAC, VOBA and DSI	4,034	(3,208)	(4,050)
Subtotal	2,547	(8,186)	(14,847)
Deferred income tax benefit (expense)	4,914	(6,031)	(8,009)
Net unrealized investment gains (losses)	(19,276)	17,694	23,750
Net unrealized investment gains (losses) attributable to noncontrolling interests	(18)	(23)	(20)
Net unrealized investment gains (losses) attributable to MetLife, Inc.	$ (19,294)	$ 17,671	$ 23,730

Other Revenues and Other Expe_3

Other Revenues and Other Expenses Other Revenues (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 2,110	$ 2,074	$ 1,354
Other revenues	2,634	2,619	1,849
Vision fee for service arrangements (1)
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	566	546	0
Prepaid legal plans
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	471	432	395
Fee-based investment management
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	396	363	318
Recordkeeping and administrative services (2)
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	168	213	196
Administrative services-only contracts
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	238	231	218
Other revenue from service contracts from customers
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	271	289	227
Other Income
Disaggregation of Revenue [Line Items]
Other revenues	$ 524	$ 545	$ 495

Other Revenues and Other Expe_4

Other Revenues and Other Expenses Other Revenues (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Receivables related to revenues from service contracts from customers	$ 226	$ 235

Other Expenses (Other Expenses)

Other Expenses (Other Expenses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Income and Expenses [Abstract]
Employee related costs (1)	$ 3,520	$ 3,515	$ 3,514
Third party staffing costs	1,573	1,423	1,335
General and administrative expenses	700	686	761
Pension, postretirement and postemployment benefit costs	98	147	165
Premium taxes, other taxes, and licenses & fees	608	629	764
Commissions and other variable expenses	5,265	5,463	5,596
Capitalization of DAC	(2,558)	(2,718)	(3,013)
Amortization of DAC and VOBA	1,931	2,555	3,160
Amortization of negative VOBA	(41)	(34)	(45)
Interest expense on debt	938	920	913
Total other expenses	12,034	12,586	13,150
Net change in cash surrender value of investments, net of premiums paid	$ 93	$ (144)	$ (147)

Employee Benefit Plans Employee

Employee Benefit Plans Employee Benefit Plans (Obligations, Funded Status, and Periodic Benefit Costs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations	$ 9,298	$ 12,182	$ 12,873
Estimated fair value of plan assets	8,294	10,971	11,256
Over (under) funded status	(1,004)	(1,211)
Net periodic benefit costs	122	194	246
Pension Benefits | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations	8,425	11,086
Estimated fair value of plan assets	7,831	10,392
Over (under) funded status	(594)	(694)
Net periodic benefit costs	49	97
Pension Benefits | Non- U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations	873	1,096
Estimated fair value of plan assets	463	579
Over (under) funded status	(410)	(517)
Net periodic benefit costs	73	97
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations	794	1,138	1,252
Estimated fair value of plan assets	1,303	1,443	1,492
Over (under) funded status	509	305
Net periodic benefit costs	(42)	(53)	$ (92)
Other Postretirement Benefits | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations	758	1,099
Estimated fair value of plan assets	1,277	1,417
Over (under) funded status	519	318
Net periodic benefit costs	(43)	(55)
Other Postretirement Benefits | Non- U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations	36	39
Estimated fair value of plan assets	26	26
Over (under) funded status	(10)	(13)
Net periodic benefit costs	$ 1	$ 2

Employee Benefit Plans (Obligat

Employee Benefit Plans (Obligations and Funded Status) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension Benefits
Change in benefit obligations:
Benefit obligations at January 1,	$ 12,182	$ 12,873
Service costs	187	215	$ 226
Interest costs	328	342	363
Plan participants’ contributions	0	0
Plan amendments	8	1
Net actuarial (gains) losses	(2,609)	(363)
Acquisition, divestitures, settlements and curtailments	(45)	(111)
Benefits paid	(630)	(665)
Effect of foreign currency translation	(123)	(110)
Benefit obligations at December 31,	9,298	12,182	12,873
Change in plan assets
Estimated fair value of plan assets at January 1,	10,971	11,256
Actual return on plan assets	(2,095)	310
Acquisition, divestitures and settlements	(38)	(35)
Plan participants’ contributions	0	0
Employer contributions	152	163
Benefits paid	(630)	(665)
Effect of foreign currency translation	(66)	(58)
Estimated fair value of plan assets at December 31,	8,294	10,971	11,256
Over (under) funded status at December 31,	(1,004)	(1,211)
Amounts recognized in the consolidated balance sheets
Other assets	428	640
Other liabilities	(1,432)	(1,851)
Net amount recognized	(1,004)	(1,211)
Accumulated other comprehensive (income) loss:
Net actuarial (gains) losses	2,277	2,416
Prior service costs (credit)	(36)	(55)
AOCI, before income tax	2,241	2,361
Accumulated benefit obligation	9,185	11,934
Other Postretirement Benefits
Change in benefit obligations:
Benefit obligations at January 1,	1,138	1,252
Service costs	4	4	5
Interest costs	34	37	42
Plan participants’ contributions	32	32
Plan amendments	0	0
Net actuarial (gains) losses	(289)	(96)
Acquisition, divestitures, settlements and curtailments	0	8
Benefits paid	(125)	(99)
Effect of foreign currency translation	0	0
Benefit obligations at December 31,	794	1,138	1,252
Change in plan assets
Estimated fair value of plan assets at January 1,	1,443	1,492
Actual return on plan assets	(43)	14
Acquisition, divestitures and settlements	0	(1)
Plan participants’ contributions	32	32
Employer contributions	(3)	5
Benefits paid	(125)	(99)
Effect of foreign currency translation	(1)	0
Estimated fair value of plan assets at December 31,	1,303	1,443	$ 1,492
Over (under) funded status at December 31,	509	305
Amounts recognized in the consolidated balance sheets
Other assets	796	788
Other liabilities	(287)	(483)
Net amount recognized	509	305
Accumulated other comprehensive (income) loss:
Net actuarial (gains) losses	(498)	(332)
Prior service costs (credit)	0	0
AOCI, before income tax	(498)	(332)
Changes to financial assumptions [Member] | Pension Benefits
Change in benefit obligations:
Net actuarial (gains) losses	(2,600)	(389)
Changes to financial assumptions [Member] | Other Postretirement Benefits
Change in benefit obligations:
Net actuarial (gains) losses	(276)	(34)
Changes to demographic assumptions [Member] | Pension Benefits
Change in benefit obligations:
Net actuarial (gains) losses		0
Changes to demographic assumptions [Member] | Other Postretirement Benefits
Change in benefit obligations:
Net actuarial (gains) losses		(4)
Changes to Plan Experience [Member] | Pension Benefits
Change in benefit obligations:
Net actuarial (gains) losses	14	26
Changes to Plan Experience [Member] | Other Postretirement Benefits
Change in benefit obligations:
Net actuarial (gains) losses	$ (13)	$ (58)

Employee Benefit Plans (Paid Be

Employee Benefit Plans (Paid Benefit Obligations and Accumulated Benefit Obligations in Excess of Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accumulated benefit obligation [Abstract]
Projected benefit obligations	$ 1,434	$ 1,831
Accumulated benefit obligations	1,384	1,740
Estimated fair value of plan assets	0	0
Defined Benefit Plan, Plan with Accumulated Postretirement Benefit Obligation in Excess of Plan Assets, Accumulated Postretirement Benefit Obligation	562	813
Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]
Projected benefit obligations	1,444	1,840
Accumulated benefit obligations	1,384	1,740
Estimated fair value of plan assets	10	9
Defined Benefit Plan, Plan with Accumulated Postretirement Benefit Obligation in Excess of Plan Assets, Plan Assets	$ 276	$ 331

Employee Benefit Plans (Net Per

Employee Benefit Plans (Net Periodic Benefit Costs and Other Changes Recognized in OCI) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other changes in plan assets and benefit obligations recognized in OCI:
Total recognized in OCI	$ (279)	$ (328)	$ (181)
Pension Benefits
Net periodic benefit costs [Abstract]
Service costs	187	215	226
Interest costs	328	342	363
Settlement and curtailment (gains) losses	5	(7)	10
Expected return on plan assets	(516)	(506)	(528)
Amortization of net actuarial (gains) losses	129	162	189
Amortization of prior service costs (credit)	(11)	(12)	(14)
Total net periodic benefit costs (credit)	122	194	246
Other changes in plan assets and benefit obligations recognized in OCI:
Net actuarial (gains) losses	2	(166)	(35)
Prior service costs (credit)	8	1	0
Amortization of net actuarial (gains) losses	(129)	(162)	(189)
Amortization of prior service (costs) credit	11	12	14
Settlement and curtailment (gains) losses	(5)	(10)	(10)
Total recognized in OCI	(120)	(333)	(215)
Total recognized in net periodic benefit costs and OCI	2	(139)	31
Pension Benefits | Accumulated Other Comprehensive Income (Loss) Foreign Currency Translation Adjustments
Other changes in plan assets and benefit obligations recognized in OCI:
Total recognized in OCI	(7)	(8)	5
Other Postretirement Benefits
Net periodic benefit costs [Abstract]
Service costs	4	4	5
Interest costs	34	37	42
Settlement and curtailment (gains) losses	0	1	0
Expected return on plan assets	(55)	(56)	(62)
Amortization of net actuarial (gains) losses	(25)	(39)	(74)
Amortization of prior service costs (credit)	0	0	(3)
Total net periodic benefit costs (credit)	(42)	(53)	(92)
Other changes in plan assets and benefit obligations recognized in OCI:
Net actuarial (gains) losses	(191)	(54)	(42)
Prior service costs (credit)	0	(1)	0
Amortization of net actuarial (gains) losses	25	39	74
Amortization of prior service (costs) credit	0	0	3
Settlement and curtailment (gains) losses	0	10	0
Total recognized in OCI	(166)	(6)	35
Total recognized in net periodic benefit costs and OCI	(208)	(59)	(57)
Other Postretirement Benefits | Accumulated Other Comprehensive Income (Loss) Foreign Currency Translation Adjustments
Other changes in plan assets and benefit obligations recognized in OCI:
Total recognized in OCI	$ 0	$ 0	$ 0

Employee Benefit Plans (Assumpt

Employee Benefit Plans (Assumptions in Determining Benefit Obligations) (Details) - UNITED STATES	Dec. 31, 2022	Dec. 31, 2021
Pension Benefits
Assumptions used in determining benefit obligations [Abstract]
Weighted average discount rate	5.60%	2.95%
Weighted average interest crediting rate	4%	3.18%
Pension Benefits | Minimum
Assumptions used in determining benefit obligations [Abstract]
Rate of compensation increase	2.50%	2.50%
Pension Benefits | Maximum
Assumptions used in determining benefit obligations [Abstract]
Rate of compensation increase	8%	8%
Other Postretirement Benefits
Assumptions used in determining benefit obligations [Abstract]
Weighted average discount rate	5.70%	3.05%

Employee Benefit Plans (Assum_2

Employee Benefit Plans (Assumptions in Determining Net Periodic Benefit Costs) (Details) - UNITED STATES	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Weighted average discount rate	2.95%	3.01%	3.30%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate	3.43%	3.24%	3.38%
Weighted average expected rate of return on plan assets	5%	5%	5.50%
Pension Benefits | Minimum
Defined Benefit Plan Disclosure [Line Items]
Rate of compensation increase	2.50%	2.50%	2.25%
Pension Benefits | Maximum
Defined Benefit Plan Disclosure [Line Items]
Rate of compensation increase	8%	8%	8.50%
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Weighted average discount rate	3.05%	3.14%	3.45%
Weighted average expected rate of return on plan assets	3.86%	3.87%	4.31%

Employee Benefit Plans (Assumed

Employee Benefit Plans (Assumed Healthcare Cost Trend Rates) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Before Age 65
Assumed healthcare costs trend rates
Following year	5.20%	5.10%
Ultimate rate to which cost increase is assumed to decline	3.70%	3.70%
Year in which the ultimate trend rate is reached	2074	2074
Age 65 and older
Assumed healthcare costs trend rates
Following year	3.90%	3.30%
Ultimate rate to which cost increase is assumed to decline	4.50%	3.80%
Year in which the ultimate trend rate is reached	2100	2074

Employee Benefit Plans (Actual

Employee Benefit Plans (Actual & Target Allocation of Fair Value by Asset Class) (Details) - UNITED STATES	Dec. 31, 2022	Dec. 31, 2021
Pension Benefits
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Actual	100%	100%
Pension Benefits | Fixed maturity securities AFS
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Target	85%
Actual	83%	84%
Pension Benefits | Equity Securities
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Target	7%
Actual	6%	7%
Pension Benefits | Alternative Securities
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Target	8%
Actual	11%	9%
Other Postretirement Benefits
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Actual	100%	100%
Other Postretirement Benefits | Fixed maturity securities AFS
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Target	95%
Actual	96%	95%
Other Postretirement Benefits | Equity Securities
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Target	5%
Actual	4%	5%
Other Postretirement Benefits | Alternative Securities
Actual weighted average asset allocation by major asset class for the Invested Plans [Abstract]
Target	0%
Actual	0%	0%

Employee Benefit Plans (Estimat

Employee Benefit Plans (Estimated Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 8,294	$ 10,971	$ 11,256
Pension Benefits | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,802	9,065
Pension Benefits | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,001	4,305
Pension Benefits | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,507	1,904
Pension Benefits | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	769	1,116
Pension Benefits | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	277	83
Pension Benefits | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	159	248
Pension Benefits | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	396	626
Pension Benefits | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	693	783
Pension Benefits | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	570	895
Pension Benefits | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	896	997
Pension Benefits | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	26	14
Pension Benefits | Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,130	2,778
Pension Benefits | Level 1 | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,653	2,121
Pension Benefits | Level 1 | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Pension Benefits | Level 1 | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,462	1,824
Pension Benefits | Level 1 | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Pension Benefits | Level 1 | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	87	0
Pension Benefits | Level 1 | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Pension Benefits | Level 1 | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	12	142
Pension Benefits | Level 1 | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	92	155
Pension Benefits | Level 1 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	416	601
Pension Benefits | Level 1 | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	40	42
Pension Benefits | Level 1 | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	21	14
Pension Benefits | Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,244	7,226
Pension Benefits | Level 2 | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,091	6,942
Pension Benefits | Level 2 | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,946	4,305
Pension Benefits | Level 2 | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	45	80
Pension Benefits | Level 2 | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	769	1,115
Pension Benefits | Level 2 | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	190	83
Pension Benefits | Level 2 | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	159	248
Pension Benefits | Level 2 | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	384	484
Pension Benefits | Level 2 | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	598	627
Pension Benefits | Level 2 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	151	283
Pension Benefits | Level 2 | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	1
Pension Benefits | Level 2 | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	0
Pension Benefits | Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	920	967
Pension Benefits | Level 3 | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	58	2
Pension Benefits | Level 3 | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	55	0	0
Pension Benefits | Level 3 | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Pension Benefits | Level 3 | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1	0
Pension Benefits | Level 3 | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Pension Benefits | Level 3 | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Pension Benefits | Level 3 | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Pension Benefits | Level 3 | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	1	0
Pension Benefits | Level 3 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	11	0
Pension Benefits | Level 3 | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	855	954
Pension Benefits | Level 3 | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4	0
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,303	1,443	$ 1,492
Other Postretirement Benefits | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,256	1,387
Other Postretirement Benefits | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	205	222
Other Postretirement Benefits | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	68	69
Other Postretirement Benefits | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	61	51
Other Postretirement Benefits | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4	10
Other Postretirement Benefits | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	8
Other Postretirement Benefits | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	859	968
Other Postretirement Benefits | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	44	59
Other Postretirement Benefits | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	47	55
Other Postretirement Benefits | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1
Other Postretirement Benefits | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	589	625
Other Postretirement Benefits | Level 1 | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	542	569
Other Postretirement Benefits | Level 1 | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 1 | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	68	69
Other Postretirement Benefits | Level 1 | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 1 | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	0
Other Postretirement Benefits | Level 1 | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 1 | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	463	486
Other Postretirement Benefits | Level 1 | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	14
Other Postretirement Benefits | Level 1 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	47	55
Other Postretirement Benefits | Level 1 | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1
Other Postretirement Benefits | Level 1 | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	714	818
Other Postretirement Benefits | Level 2 | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	714	818
Other Postretirement Benefits | Level 2 | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	205	222
Other Postretirement Benefits | Level 2 | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 2 | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	61	51
Other Postretirement Benefits | Level 2 | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	10
Other Postretirement Benefits | Level 2 | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	8
Other Postretirement Benefits | Level 2 | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	396	482
Other Postretirement Benefits | Level 2 | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	36	45
Other Postretirement Benefits | Level 2 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 2 | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 2 | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Fixed maturity securities AFS
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Corporate fixed maturity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | U.S. government bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Foreign government
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Federal agencies
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Municipals
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Short-term Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Other (1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Other investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Postretirement Benefits | Level 3 | Derivative assets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Employee Benefit Plans (Signifi

Employee Benefit Plans (Significant Unobservable Inputs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pension Benefits
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	$ 10,971	$ 11,256
Purchases, sales, issuances and settlements, net	(38)	(35)
Estimated fair value of plan assets at December 31,	8,294	10,971
Pension Benefits | Foreign government
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	1,116
Estimated fair value of plan assets at December 31,	769	1,116
Pension Benefits | Other (1)
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	783
Estimated fair value of plan assets at December 31,	693	783
Pension Benefits | Equity Securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	895
Estimated fair value of plan assets at December 31,	570	895
Pension Benefits | Corporate fixed maturity securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	4,305
Estimated fair value of plan assets at December 31,	3,001	4,305
Other Postretirement Benefits
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	1,443	1,492
Purchases, sales, issuances and settlements, net	0	(1)
Estimated fair value of plan assets at December 31,	1,303	1,443
Other Postretirement Benefits | Foreign government
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	51
Estimated fair value of plan assets at December 31,	61	51
Other Postretirement Benefits | Other (1)
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	59
Estimated fair value of plan assets at December 31,	44	59
Other Postretirement Benefits | Equity Securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	55
Estimated fair value of plan assets at December 31,	47	55
Other Postretirement Benefits | Corporate fixed maturity securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	222
Estimated fair value of plan assets at December 31,	205	222
Level 3 | Pension Benefits
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	967
Estimated fair value of plan assets at December 31,	920	967
Level 3 | Pension Benefits | Foreign government
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	1	0
Realized gains (losses)	0	0
Unrealized gains (losses)	0	0
Purchases, sales, issuances and settlements, net	0	1
Transfers into and/or out of Level 3	(1)	0
Estimated fair value of plan assets at December 31,	0	1
Level 3 | Pension Benefits | Other (1)
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	1	0
Realized gains (losses)	0	0
Unrealized gains (losses)	0	0
Purchases, sales, issuances and settlements, net	3	1
Transfers into and/or out of Level 3	(1)	0
Estimated fair value of plan assets at December 31,	3	1
Level 3 | Pension Benefits | Equity Securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	11	0
Realized gains (losses)	0	0
Unrealized gains (losses)	0	0
Purchases, sales, issuances and settlements, net	(8)	11
Transfers into and/or out of Level 3	0	0
Estimated fair value of plan assets at December 31,	3	11
Level 3 | Pension Benefits | Other investments
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	954	708
Realized gains (losses)	0	0
Unrealized gains (losses)	54	63
Purchases, sales, issuances and settlements, net	(153)	183
Transfers into and/or out of Level 3	0	0
Estimated fair value of plan assets at December 31,	855	954
Level 3 | Pension Benefits | Corporate fixed maturity securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	0	0
Realized gains (losses)	0	0
Unrealized gains (losses)	(1)	0
Purchases, sales, issuances and settlements, net	56	0
Transfers into and/or out of Level 3	0	0
Estimated fair value of plan assets at December 31,	55	0
Level 3 | Pension Benefits | Derivative Financial Instruments, Assets
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	0	0
Realized gains (losses)	0	0
Unrealized gains (losses)	1	0
Purchases, sales, issuances and settlements, net	3	0
Transfers into and/or out of Level 3	0	0
Estimated fair value of plan assets at December 31,	4	0
Level 3 | Other Postretirement Benefits
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	0
Estimated fair value of plan assets at December 31,	0	0
Level 3 | Other Postretirement Benefits | Foreign government
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	0
Estimated fair value of plan assets at December 31,	0	0
Level 3 | Other Postretirement Benefits | Other (1)
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	0
Estimated fair value of plan assets at December 31,	0	0
Level 3 | Other Postretirement Benefits | Equity Securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	0
Estimated fair value of plan assets at December 31,	0	0
Level 3 | Other Postretirement Benefits | Corporate fixed maturity securities
Rollforward fair value measurement using significant unobservable inputs (level 3) [Roll Forward]
Estimated fair value of plan assets at January 1,	0
Estimated fair value of plan assets at December 31,	$ 0	$ 0

Employee Benefit Plans (Expecte

Employee Benefit Plans (Expected Gross Benefit Payments) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Pension Benefits
Defined benefit plan estimated future benefit payments [Abstract]
2023	$ 713
2024	722
2025	727
2026	742
2027	745
2028-2032	3,747
Other Postretirement Benefits
Defined benefit plan estimated future benefit payments [Abstract]
2023	66
2024	63
2025	62
2026	61
2027	59
2028-2032	$ 279

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Cost		$ 46	$ 88	$ 95
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Aggregate projected benefit obligations		9,298	12,182	$ 12,873
Pension Benefits | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Aggregate projected benefit obligations		$ 8,425	$ 11,086
Weighted average expected return on plan assets		5%	5%	5.50%
Pension Benefits | Non- U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Aggregate projected benefit obligations		$ 873	$ 1,096
Pension Benefits | Scenario, Forecast | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Weighted average expected return on plan assets	6.25%
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Aggregate projected benefit obligations		794	1,138	$ 1,252
Other Postretirement Benefits | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Aggregate projected benefit obligations		$ 758	$ 1,099
Weighted average expected return on plan assets		3.86%	3.87%	4.31%
Expected future discretionary contributions		$ 20
Other Postretirement Benefits | Non- U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Aggregate projected benefit obligations		36	$ 39
Other Postretirement Benefits | Scenario, Forecast | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Weighted average expected return on plan assets	4.25%
United States Pension Plan of US Entity, Non Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Aggregate projected benefit obligations		1,000	$ 1,300
Expected future discretionary contributions		$ 90

Income Tax (Provision for Incom

Income Tax (Provision for Income Tax from Continuing Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
U.S. federal	$ 159	$ 62	$ 271
U.S. state and local	45	38	27
Non-U.S.	1,074	795	882
Subtotal	1,278	895	1,180
Deferred:
U.S. federal	536	837	(115)
U.S. state and local	0	(2)	1
Non-U.S.	(1,513)	(179)	443
Subtotal	(977)	656	329
Current and Deferred:
Provision for income tax expense (benefit)	$ 301	$ 1,551	$ 1,509

Income Tax (Income Loss from Co

Income Tax (Income Loss from Continuing Operations Before Income Tax Expense from Domestic and Foreign Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income (loss) from continuing operations:
U.S.	$ 2,681	$ 4,841	$ 2,970
Non-U.S.	178	3,285	3,957
Income (loss) before provision for income tax	$ 2,859	$ 8,126	$ 6,927

Income Tax (Reconciliation of I

Income Tax (Reconciliation of Income Tax Provision between US Statutory Rate and As Reported for Continuing Operations) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income tax expense benefit continuing operations income tax reconciliation
Tax provision at U.S. statutory rate		$ 601	$ 1,706	$ 1,455
Dividend received deduction		(20)	(40)	(34)
Tax-exempt income		15	(36)	(45)
Prior year tax (1), (2)		(15)	(127)	(27)
Low income housing tax credits		(143)	(178)	(202)
Other tax credits		(44)	(46)	(45)
Foreign tax rate differential (3), (4), (5)		(110)	267	414
Change in valuation allowance		0	1	(5)
Other, net		(17)	(4)	2
Deferred Federal Income Tax Expense (Benefit)		536	837	(115)
Provision for income tax expense (benefit)		301	1,551	1,509
MetLife Seguros de Retiro [Member]
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)				60
MetLife Russia [Member]
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)				24
MetLife Poland and Greece
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)			50
MetLife Seguros S.A
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)			41
Settlement with Taxing Authority
Income tax expense benefit continuing operations income tax reconciliation
Prior year tax (1), (2)		(32)	(117)	(40)
Provision for income tax expense (benefit)	$ (53)
GILTI [Member]
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)		12	30	$ 43
GILTI [Member] | Tax Year 2020
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)			(12)
GILTI [Member] | Tax Year 2021
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)		(21)	$ 42
GILTI [Member] | Tax Year 2022
Income tax expense benefit continuing operations income tax reconciliation
Foreign tax rate differential (3), (4), (5)		$ 33

Income Tax (Net Deferred Income

Income Tax (Net Deferred Income Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets and liabilities
Tax Credit Carryforward, Amount	$ 590	$ 825
Deferred income tax assets:
Policyholder liabilities and receivables	1,496	3,787
Net operating loss carryforwards (1)	238	235
Employee benefits	475	583
Capital loss carryforwards	15	9
Tax credit carryforwards (2)	590	825
Net unrealized investment losses	5,319	0
Litigation-related and government mandated	90	95
Other	67	0
Total gross deferred income tax assets	8,290	5,534
Less: Valuation allowance (1)	291	299
Total net deferred income tax assets	7,999	5,235
Deferred income tax liabilities:
Investments, including derivatives	1,691	4,167
Intangibles	1,096	1,188
Net unrealized investment gains	0	5,551
DAC	2,707	3,471
Other	0	362
Total deferred income tax liabilities	5,494	14,739
Deferred Tax Assets, Net, Total	2,505
Deferred Tax Liabilities, Net, Total		(9,504)
Deferred tax assets and liabilities [Abstract]
Deferred income tax liability	325	$ 9,693
General Business Tax Credit Carryforward [Member] | 2039 and 2042
Deferred tax assets and liabilities
Tax Credit Carryforward, Amount	44
Deferred income tax assets:
Tax credit carryforwards (2)	44
Certain State and Foreign Net Operating Loss Carryforwards
Deferred tax assets and liabilities
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 238

Income Tax (Reconciliation of U

Income Tax (Reconciliation of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits
Balance at January 1,	$ 163	$ 272	$ 256
Additions for tax positions of prior years	42	19	16
Reductions for tax positions of prior years (1)	(93)	(112)	(1)
Additions for tax positions of current year	22	5	12
Reductions for tax positions of current year	(3)	(18)	0
Settlements with tax authorities	(2)	(3)	(1)
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations	0	0	(10)
Balance at December 31,	129	163	272
Unrecognized tax benefits that, if recognized, would impact the effective rate	$ 80	$ 103	$ 203

Income Tax (Interest Accrued Re

Income Tax (Interest Accrued Related to Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Examination [Line Items]
Interest expense (benefit) recognized on the consolidated statements of operations (1)	$ 0	$ (36)	$ 12
Interest included in other liabilities on the consolidated balance sheets	$ 15	15
Operating Expense
Income Tax Examination [Line Items]
Interest expense (benefit) recognized on the consolidated statements of operations (1)		10
Current Income Tax Payable
Income Tax Examination [Line Items]
Interest expense (benefit) recognized on the consolidated statements of operations (1)		$ 26

Income Tax (Narrative) (Details

Income Tax (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Provision for income tax expense (benefit)				$ 301	$ 1,551	$ 1,509
Operating Expenses				12,034	12,586	$ 13,150
Deferred Tax Liabilities, Investments	$ 1,691	$ 4,167		1,691	$ 4,167
Foreign Tax Authority
Deferred Tax Liabilities, Investments	302			$ 302
Settlement with Taxing Authority
Provision for income tax expense (benefit)		(53)
Operating Expenses			$ 28
Operating Expenses Net			$ 22
Settlement with Taxing Authority | American Life Insurance Company [Member]
Tax Adjustments, Settlements, and Unusual Provisions	(70)	(42)
Provision for income tax expense (benefit)	(67)	(34)
Operating Expenses	4	10
Operating Expenses Net	$ 3	$ 8

Earnings Per Common Share (Earn

Earnings Per Common Share (Earnings Per Common Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Weighted Average Shares:
Weighted average common stock outstanding - basic	803.2	862.7	907.8
Incremental common shares from assumed exercise or issuance of stock-based awards	5.7	6.7	5.4
Weighted average common stock outstanding - diluted	808.9	869.4	913.2
Net Income (Loss):
Net income (loss)	$ 2,558	$ 6,575	$ 5,418
Less: Net income (loss) attributable to noncontrolling interests	19	21	11
Less: Preferred stock dividends	185	195	202
Preferred stock redemption premium	0	6	14
Net income (loss) available to MetLife, Inc.’s common shareholders	$ 2,354	$ 6,353	$ 5,191
Basic	$ 2.93	$ 7.36	$ 5.72
Diluted	$ 2.91	$ 7.31	$ 5.68

Contingencies, Commitments an_3

Contingencies, Commitments and Guarantees (Asbestos Claims) (Details) - Asbestos Related Claims $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Claims	Dec. 31, 2021 USD ($) Claims	Dec. 31, 2020 USD ($) Claims
Loss Contingencies [Line Items]
Asbestos personal injury claims at year end | Claims	58,073	58,785	60,618
Number of new claims during the year | Claims	2,610	2,824	2,496
Settlement payments during the year | $	$ 50.5	$ 53	$ 52.9
Asbestos-related claims liability, ending balance | $	$ 320	$ 372

Contingencies, Commitments an_4

Contingencies, Commitments and Guarantees (Contingencies - Narrative) (Details)	Dec. 31, 2022 USD ($)
Minimum
Loss Contingencies
Loss Contingency, Range of Possible Loss, Portion Not Accrued	$ 0
Maximum
Loss Contingencies
Loss Contingency, Range of Possible Loss, Portion Not Accrued	$ 125,000,000

Contingencies, Commitments an_5

Contingencies, Commitments and Guarantees (Commitments and Guarantees - Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Contingencies, Commitments and Guarantees [Abstract]
Liabilities for indemnities, guarantees and commitments	$ 20	$ 20
Cumulative maximum indemnities and guarantees contractual limitation	634
Minimum
Contingencies, Commitments and Guarantees [Abstract]
Indemnities and guarantees contractual limitation range	1
Maximum
Contingencies, Commitments and Guarantees [Abstract]
Indemnities and guarantees contractual limitation range	329
Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability	9,400	9,100
Mortgage Loan Commitments
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability	$ 3,400	$ 4,600

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($) $ in Millions	1 Months Ended
	Feb. 28, 2023	Jan. 31, 2023	Feb. 10, 2023	Jan. 06, 2023
Subsequent Event [Line Items]
Early Repayment of Senior Debt	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage			4.368%	5.25%
Debt Instrument, Face Amount				$ 1,000
Redemption Premium		$ 11

Consolidated Summary of Inves_2

Consolidated Summary of Investments - Other Than Investments in Related Parties (Details) $ in Millions	Dec. 31, 2022 USD ($)
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	$ 462,275
Estimated Fair Value	433,293
Fixed Maturities [Member]
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	306,025
Estimated Fair Value	276,780
Amount at Which Shown on Balance Sheet	276,780
Foreign government
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	50,047
Estimated Fair Value	46,747
Amount at Which Shown on Balance Sheet	46,747
U.S. government and agency
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	35,658
Estimated Fair Value	32,229
Amount at Which Shown on Balance Sheet	32,229
Public utilities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	11,476
Estimated Fair Value	10,717
Amount at Which Shown on Balance Sheet	10,717
Municipals
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	13,548
Estimated Fair Value	12,152
Amount at Which Shown on Balance Sheet	12,152
All other corporate bonds
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	135,710
Estimated Fair Value	120,916
Amount at Which Shown on Balance Sheet	120,916
Total bonds
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	246,439
Estimated Fair Value	222,761
Amount at Which Shown on Balance Sheet	222,761
Mortgage-backed, asset-backed and collateralized loan obligations securities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	58,610
Estimated Fair Value	53,050
Amount at Which Shown on Balance Sheet	53,050
Redeemable preferred stock
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	976
Estimated Fair Value	969
Amount at Which Shown on Balance Sheet	969
FVO Securities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	9,106
Estimated Fair Value	9,668
Amount at Which Shown on Balance Sheet	9,668
Equity Securities, Investment Summary [Member]
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	1,495
Estimated Fair Value	1,684
Amount at Which Shown on Balance Sheet	1,684
Industrial, miscellaneous and all other
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	335
Estimated Fair Value	504
Amount at Which Shown on Balance Sheet	504
Public utilities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	0
Estimated Fair Value	2
Amount at Which Shown on Balance Sheet	2
Banks, trust and insurance companies
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	1,012
Estimated Fair Value	1,036
Amount at Which Shown on Balance Sheet	1,036
Non-redeemable Preferred Stock
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	148
Estimated Fair Value	142
Amount at Which Shown on Balance Sheet	142
Mortgage loans
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	84,290
Estimated Fair Value	83,763
Policy loans
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	8,874
Estimated Fair Value	8,874
Real estate and real estate joint ventures
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	12,955
Estimated Fair Value	12,955
Real estate acquired in satisfaction of debt
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	182
Estimated Fair Value	182
Other limited partnership interests
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	14,414
Estimated Fair Value	14,414
Short-term investments
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	4,870
Estimated Fair Value	4,935
Other invested assets
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]
Cost or Amortized Cost	20,064
Estimated Fair Value	$ 20,038

Condensed Financial Informati_2

Condensed Financial Information (Parent Company) (Condensed Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Investments:
Estimated Fair Value of Fixed Maturity Securities AFS	$ 276,780	$ 340,274
Other invested assets, at estimated fair value	20,038	18,655
Total investments	433,293	494,821
Cash and cash equivalents	20,195	20,047
Accrued investment income	3,446	3,185
Other assets	11,026	11,426
Total assets	666,611	759,708
Liabilities
Payables for collateral under derivatives transactions	20,937	31,920
Junior subordinated debt securities	3,158	3,156
Other liabilities	25,980	22,538
Total liabilities	639,324	691,959
Stockholders’ Equity
Preferred stock, par value $0.01 per share; $3,905 aggregate liquidation preference	0	0
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,189,831,471 and 1,186,540,473 shares issued, respectively; 779,098,414 and 825,540,267 shares outstanding, respectively	12	12
Additional paid-in capital	33,616	33,511
Retained earnings	41,953	41,197
Treasury stock, at cost; 410,733,057 and 361,000,206 shares, respectively	(21,458)	(18,157)
Accumulated other comprehensive income (loss)	(27,083)	10,919	$ 18,072	$ 13,052
Total stockholders’ equity	27,040	67,482
Total liabilities and stockholders' equity	$ 666,611	$ 759,708
Common stock, Shares Authorized	3,000,000,000	3,000,000,000
Parent Company
Investments:
Estimated Fair Value of Fixed Maturity Securities AFS	$ 3,729	$ 2,745
Other invested assets, at estimated fair value	376	314
Total investments	4,105	3,059
Cash and cash equivalents	1,290	1,961	$ 441	$ 377
Accrued investment income	20	4
Investment in subsidiaries	39,895	80,165
Loans to subsidiaries	95	35
Other assets	724	798
Total assets	46,129	86,022
Liabilities
Payables for collateral under derivatives transactions	154	153
Long-term debt — unaffiliated	13,588	12,814
Long-term debt — affiliated	1,676	1,884
Junior subordinated debt securities	2,465	2,463
Other liabilities	1,206	1,226
Total liabilities	19,089	18,540
Stockholders’ Equity
Preferred stock, par value $0.01 per share; $3,905 aggregate liquidation preference	0	0
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,189,831,471 and 1,186,540,473 shares issued, respectively; 779,098,414 and 825,540,267 shares outstanding, respectively	12	12
Additional paid-in capital	33,616	33,511
Retained earnings	41,953	41,197
Treasury stock, at cost; 410,733,057 and 361,000,206 shares, respectively	(21,458)	(18,157)
Accumulated other comprehensive income (loss)	(27,083)	10,919
Total stockholders’ equity	27,040	67,482
Total liabilities and stockholders' equity	$ 46,129	$ 86,022
Common stock, Shares Authorized	3,000,000,000	3,000,000,000

Condensed Financial Informati_3

Condensed Financial Information (Parent Company) (Condensed Balance Sheet - Insets) (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Condensed Balance Sheet Statements, Captions [Line Items]
Amortized cost of fixed maturity securities	$ 306,025	$ 310,884
Preferred stock, par value	$ 0.01	$ 0.01
Preferred Stock, Liquidation Preference, Value	$ 3,905	$ 3,905
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,189,831,471	1,186,540,473
Common stock, shares outstanding	779,098,414	825,540,267
Treasury stock, shares	410,733,057	361,000,206
Parent Company
Condensed Balance Sheet Statements, Captions [Line Items]
Amortized cost of fixed maturity securities	$ 3,877	$ 2,742
Preferred stock, par value	$ 0.01	$ 0.01
Preferred Stock, Liquidation Preference, Value	$ 3,905	$ 3,905
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,189,831,471	1,186,540,473
Common stock, shares outstanding	779,098,414	825,540,267
Treasury stock, shares	410,733,057	361,000,206

Condensed Financial Informati_4

Condensed Financial Information (Parent Company) (Condensed Statements of Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Income Statements, Captions [Line Items]
Net investment income	$ 15,916	$ 21,395	$ 17,117
Other revenues	2,634	2,619	1,849
Net investment gains (losses)	(1,262)	1,529	(110)
Net derivative gains (losses)	(2,372)	(2,228)	1,349
Total revenues	69,898	71,080	67,842
Expenses
Other expenses	12,034	12,586	13,150
Total expenses	67,039	62,954	60,915
Income (loss) before provision for income tax and equity in earnings of subsidiaries	2,859	8,126	6,927
Provision for income tax expense (benefit)	301	1,551	1,509
Equity in earnings of subsidiaries	1,305	5,136	829
Net income (loss)	2,539	6,554	5,407
Less: Preferred stock dividends	185	195	202
Preferred stock redemption premium	0	6	14
Net income (loss) available to MetLife, Inc.’s common shareholders	2,354	6,353	5,191
Comprehensive income (loss)	(35,463)	(599)	10,427
Parent Company
Condensed Income Statements, Captions [Line Items]
Net investment income	58	25	50
Other revenues	17	19	29
Net investment gains (losses)	332	1,655	(154)
Net derivative gains (losses)	129	116	(61)
Total revenues	536	1,815	(136)
Expenses
Interest expense	829	847	833
Other expenses	79	207	154
Total expenses	908	1,054	987
Income (loss) before provision for income tax and equity in earnings of subsidiaries	(372)	761	(1,123)
Provision for income tax expense (benefit)	(37)	202	(267)
Equity in earnings of subsidiaries	2,874	5,995	6,263
Net income (loss)	2,539	6,554	5,407
Less: Preferred stock dividends	185	195	202
Preferred stock redemption premium	0	6	14
Net income (loss) available to MetLife, Inc.’s common shareholders	2,354	6,353	5,191
Comprehensive income (loss)	$ (35,463)	$ (599)	$ 10,427

Condensed Financial Informati_5

Condensed Financial Information (Parent Company) (Condensed Statements of Cash Flows) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income (loss)	$ 2,539	$ 6,554	$ 5,407
(Gains) losses on investments and from sales of businesses, net	1,262	(1,529)	110
Other, net	245	138	351
Net cash provided by (used in) operating activities	13,204	12,596	11,639
Cash flows from investing activities
Sales and maturities of fixed maturity securities available-for-sale	88,937	88,839	77,979
Purchases of fixed maturity securities available-for-sale	(82,956)	(97,368)	(89,633)
Cash received in connection with freestanding derivatives	4,524	3,453	4,847
Cash paid in connection with freestanding derivatives	(7,793)	(7,990)	(4,247)
Other, net	(28)	(46)	139
Net cash provided by (used in) investing activities	(2,620)	(11,187)	(18,569)
Cash flows from financing activities
Net change in payables for collateral under securities loaned and other transactions	(10,730)	1,883	3,538
Long-term debt issued	1,013	29	1,124
Long-term debt repaid	(85)	(582)	(99)
Treasury stock acquired in connection with share repurchases	(3,326)	(4,303)	(1,151)
Preferred stock issued, net of issuance costs	0	0	1,961
Redemption of preferred stock	0	(494)	(989)
Preferred stock redemption premium	0	(6)	(14)
Dividends on preferred stock	(185)	(195)	(202)
Dividends on common stock	(1,598)	(1,647)	(1,657)
Other, net	(236)	22	191
Net cash provided by (used in) financing activities	(10,108)	(1,375)	10,729
Cash and cash equivalents, from continuing operations, beginning of year	20,047
Cash and cash equivalents, from continuing operations, end of year	20,195	20,047
Supplemental disclosures of cash flow information
Net cash paid (received) for Income tax	1,056	1,102	787
Parent Company
Cash flows from operating activities
Net income (loss)	2,539	6,554	5,407
Earnings of subsidiaries	(2,874)	(5,995)	(6,263)
Dividends from subsidiaries	5,168	4,830	3,970
(Gains) losses on investments and from sales of businesses, net	(332)	(1,655)	154
Other, net	(73)	23	211
Net cash provided by (used in) operating activities	4,428	3,757	3,479
Cash flows from investing activities
Sales and maturities of fixed maturity securities available-for-sale	1,609	5,078	3,693
Purchases of fixed maturity securities available-for-sale	(2,757)	(4,371)	(3,858)
Cash received in connection with freestanding derivatives	296	111	71
Cash paid in connection with freestanding derivatives	(103)	(27)	(100)
Sales of businesses	0	3,902	0
Purchases of businesses	0	0	(1,875)
Expense paid on behalf of subsidiaries	(10)	(15)	(15)
Receipts on loans to subsidiaries	150	195	100
Issuances of loans to subsidiaries	(210)	(230)	0
Returns of capital from subsidiaries	8	13	16
Capital contributions to subsidiaries	(5)	(88)	(422)
Net change in short-term investments	0	156	4
Other, net	15	9	(2)
Net cash provided by (used in) investing activities	(1,007)	4,733	(2,388)
Cash flows from financing activities
Net change in payables for collateral under securities loaned and other transactions	1	88	49
Long-term debt issued	1,000	496	1,246
Long-term debt repaid	0	(996)	(251)
Treasury stock acquired in connection with share repurchases	(3,326)	(4,303)	(1,151)
Preferred stock issued, net of issuance costs	0	0	1,961
Redemption of preferred stock	0	(494)	(989)
Preferred stock redemption premium	0	(6)	(14)
Dividends on preferred stock	(185)	(195)	(202)
Dividends on common stock	(1,598)	(1,647)	(1,657)
Other, net	16	87	(19)
Net cash provided by (used in) financing activities	(4,092)	(6,970)	(1,027)
Change in cash and cash equivalents	(671)	1,520	64
Cash and cash equivalents, from continuing operations, beginning of year	1,961	441	377
Cash and cash equivalents, from continuing operations, end of year	1,290	1,961	441
Supplemental disclosures of cash flow information
Net cash paid for Interest	800	853	815
Net cash paid (received) for Income tax	(129)	18	(296)
Non-cash transactions:
Dividends from subsidiary	0	14	341
Returns of capital from subsidiaries	12	7	13
Capital contributions to subsidiaries	11	15	1
Amounts paid to (received from) subsidiaries, net | Parent Company
Supplemental disclosures of cash flow information
Net cash paid (received) for Income tax	(214)	(110)	(392)
Income tax paid (received) by MetLife, Inc., net | Parent Company
Supplemental disclosures of cash flow information
Net cash paid (received) for Income tax	$ 85	$ 128	$ 96

Condensed Financial Informati_6

Condensed Financial Information (Parent Company) (Investment in Subsidiaries - Narrative) (Details) - Parent Company - USD ($) $ in Millions		12 Months Ended
	Dec. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Financial Statements, Captions [Line Items]
Payments to Acquire Businesses, Gross		$ 0	$ 0	$ 1,875
Sales of businesses		$ 0	$ 3,902	$ 0
Versant Health, Inc. [Member]
Condensed Financial Statements, Captions [Line Items]
Payments to Acquire Businesses, Gross	$ 1,800

Condensed Financial Informati_7

Condensed Financial Information (Parent Company) (Loans to Subsidiaries - Narrative) (Details) - Parent Company - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Mar. 31, 2021
Notes to Condensed Financial Information of Parent Company (Textuals) [Abstract]
Due from Affiliate, Current	$ 60	$ 35		$ 150	$ 195
Interest Income [Member]
Notes to Condensed Financial Information of Parent Company (Textuals) [Abstract]
Revenue from Related Parties	$ 2	$ 1	$ 2

Condensed Financial Informati_8

Condensed Financial Information (Parent Company) (Long-term Debt Outstanding) (Details) - Parent Company $ in Millions, ¥ in Billions	Dec. 31, 2022 USD ($)	Mar. 31, 2022	Dec. 31, 2021 USD ($)	Dec. 16, 2021 JPY (¥)	Jul. 15, 2021 JPY (¥)	Jun. 30, 2021 USD ($)
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.23%	100%	212%
Long-term Debt [Abstract]
Senior Notes | $	$ 13,588		$ 12,814
Notes Payable, Related Parties | $	1,676		1,884
Long-term Debt | $	$ 15,264		14,698
Senior Notes, Unaffiliated [Member]
Long-term Debt [Abstract]
Weighted Average Interest Rate	4.42%
Senior Notes | $	$ 13,588		12,814
Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						182%
Long-term Debt [Abstract]
Weighted Average Interest Rate	1.98%
Senior Notes | $						$ 250
Notes Payable, Related Parties | $	$ 1,676		$ 1,884
Minimum | Senior Notes, Unaffiliated [Member]
Long-term Debt [Abstract]
Debt Instrument, Interest Rate, Effective Percentage	0.50%
Minimum | Senior Notes, Affiliated [Member]
Long-term Debt [Abstract]
Debt Instrument, Interest Rate, Effective Percentage	1.59%
Maximum | Senior Notes, Unaffiliated [Member]
Long-term Debt [Abstract]
Debt Instrument, Interest Rate, Effective Percentage	6.50%
Maximum | Senior Notes, Affiliated [Member]
Long-term Debt [Abstract]
Debt Instrument, Interest Rate, Effective Percentage	6.56%
SeniorDebtYen53.7BillionJune2021 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					2.9725%
Long-term Debt [Abstract]
Senior Notes					¥ 53.7
SeniorDebtYen13.7BillionJuly2026 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					1.61%
Long-term Debt [Abstract]
Senior Notes					¥ 13.7
SeniorDebtYen14.3BillionJuly2028 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					1.755%
Long-term Debt [Abstract]
Senior Notes					¥ 14.3
SeninorDebtYen25.7BillionJuly2031 | Senior Notes, Affiliated [Member]
Long-term Debt [Abstract]
Senior Notes					¥ 25.7
SeniorDebtYen25.7BillionJuly2028 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					1.852%
SeniorDebtYen54.6BillionDecember2021 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				3.135%
Long-term Debt [Abstract]
Senior Notes				¥ 54.6
SeniorDebtYen12.2BillionDecember2021 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				1.588%
Long-term Debt [Abstract]
Senior Notes				¥ 12.2
SeniorDebtYen19.1BillionDecember2021 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				1.7185%
Long-term Debt [Abstract]
Senior Notes				¥ 19.1
SeniorDebtYen23.3BillionDecember2021 | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				1.85%
Long-term Debt [Abstract]
Senior Notes				¥ 23.3

Condensed Financial Informati_9

Condensed Financial Information (Parent Company) (Interest Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Interest Expense [Abstract]
Total interest expense	$ 655	$ 647	$ 632
Parent Company
Interest Expense [Abstract]
Total interest expense	829	847	833
Parent Company | Long-term Debt
Interest Expense [Abstract]
Total interest expense	583	590	570
Parent Company | Long-term Debt | Affiliated Entity
Interest Expense [Abstract]
Total interest expense	37	47	52
Parent Company | Secured Debt [Member]
Interest Expense [Abstract]
Total interest expense	4	5	6
Parent Company | Junior Subordinated Debt [Member]
Interest Expense [Abstract]
Total interest expense	$ 205	$ 205	$ 205

Condensed Financial Informat_10

Condensed Financial Information (Parent Company) (Long-term Debt - Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 87	$ 82
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	1,100
Long-term Debt, Maturities, Repayments of Principal in Year Two	1,700
Long-term Debt, Maturities, Repayments of Principal in Year Three	1,200
Long-term Debt, Maturities, Repayments of Principal in Year Four	539
Long-term Debt, Maturities, Repayments of Principal in Year Five	51
Long-term Debt, Maturities, Repayments of Principal after Year Five	10,000
Parent Company
Condensed Financial Statements, Captions [Line Items]
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	1,300
Long-term Debt, Maturities, Repayments of Principal in Year Two	1,400
Long-term Debt, Maturities, Repayments of Principal in Year Three	1,200
Long-term Debt, Maturities, Repayments of Principal in Year Four	508
Long-term Debt, Maturities, Repayments of Principal in Year Five	0
Long-term Debt, Maturities, Repayments of Principal after Year Five	10,800
Senior Notes	13,588	12,814
Parent Company | Senior Notes Unaffiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	83	77
Senior Notes	$ 13,588	$ 12,814
Parent Company | Senior Notes, Affiliated [Member]
Condensed Financial Statements, Captions [Line Items]
Senior Notes			$ 250

Condensed Financial Informat_11

Condensed Financial Information (Parent Company) (Support Agreements - Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Condensed Financial Statements, Captions [Line Items]
Derivative Liability, Fair Value, Amount Offset Against Collateral	$ 25	$ 121
Parent Company | Support Agreement Exeter Obligations [Member]
Condensed Financial Statements, Captions [Line Items]
Amount guaranteed under support agreement	$ 1,000
Parent Company | Support Agreement MetLife Reinsurance Company of Vermont [Member]
Condensed Financial Statements, Captions [Line Items]
Guaranteed adjusted capital levels	200
Parent Company | Support Agreement MetLife Reinsurance Company of Charleston [Member]
Condensed Financial Statements, Captions [Line Items]
Guaranteed adjusted capital levels	200
Parent Company | Support Agreement - Guarantees of Subsidiary Derivative Obligations [Member]
Condensed Financial Statements, Captions [Line Items]
Derivative Assets, Fair Value, Net	$ 174	255
Unsecured derivative liability positions guaranteed by MetLife, Inc.	181	116
Estimated fair value of collateral provided to counterparties by the subsidiaries	181	114
Derivative Liability, Fair Value, Amount Offset Against Collateral	$ 0	$ 2

Consolidated Supplementary In_2

Consolidated Supplementary Insurance Information (Balance Sheet Items) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
DAC and VOBA	$ 22,983	$ 16,061	$ 16,389
Future Policy Benefits, Other Policy-Related Balances and Policyholder Dividend Obligation	223,879	219,154
Policyholder account balances	203,082	203,473
Policyholder Dividends Payable	387	478
Unearned Premiums	2,415	2,892
Unearned Revenue	5,267	2,368
U.S.
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
DAC and VOBA	459	440
Future Policy Benefits, Other Policy-Related Balances and Policyholder Dividend Obligation	91,767	85,108
Policyholder account balances	79,926	77,891
Policyholder Dividends Payable	0	0
Unearned Premiums	352	325
Unearned Revenue	36	38
Asia
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
DAC and VOBA	13,384	9,339
Future Policy Benefits, Other Policy-Related Balances and Policyholder Dividend Obligation	41,308	42,103
Policyholder account balances	84,215	83,736
Policyholder Dividends Payable	72	85
Unearned Premiums	1,889	2,386
Unearned Revenue	3,677	790
Latin America
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
DAC and VOBA	2,211	2,021
Future Policy Benefits, Other Policy-Related Balances and Policyholder Dividend Obligation	12,181	10,541
Policyholder account balances	5,493	5,023
Policyholder Dividends Payable	0	0
Unearned Premiums	2	1
Unearned Revenue	829	797
EMEA
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
DAC and VOBA	1,593	1,623
Future Policy Benefits, Other Policy-Related Balances and Policyholder Dividend Obligation	3,391	3,639
Policyholder account balances	7,244	9,392
Policyholder Dividends Payable	0	0
Unearned Premiums	14	21
Unearned Revenue	530	553
MetLife Holdings
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
DAC and VOBA	5,308	2,607
Future Policy Benefits, Other Policy-Related Balances and Policyholder Dividend Obligation	74,181	76,523
Policyholder account balances	26,226	27,450
Policyholder Dividends Payable	315	393
Unearned Premiums	158	159
Unearned Revenue	195	190
Corporate & Other
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
DAC and VOBA	28	31
Future Policy Benefits, Other Policy-Related Balances and Policyholder Dividend Obligation	1,051	1,240
Policyholder account balances	(22)	(19)
Policyholder Dividends Payable	0	0
Unearned Premiums	0	0
Unearned Revenue	$ 0	$ 0

Consolidated Supplementary In_3

Consolidated Supplementary Insurance Information (Income Statement Items) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Premiums and Universal Life and Investment-Type Product Policy Fees	$ 54,982	$ 47,765	$ 47,637
Net Investment Income	15,916	21,395	17,117
Policyholder Benefits and Claims and Interest Credited to Policyholder Account Balances	54,304	49,492	46,675
Amortization of DAC and VOBA Charged to Other Expenses	1,931	2,555	3,160
Other Expenses (1)	10,804	10,907	11,080
U.S.
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Premiums and Universal Life and Investment-Type Product Policy Fees	36,706	28,363	28,335
Net Investment Income	6,980	7,738	6,563
Policyholder Benefits and Claims and Interest Credited to Policyholder Account Balances	38,056	29,987	27,966
Amortization of DAC and VOBA Charged to Other Expenses	59	158	471
Other Expenses (1)	3,894	3,707	3,716
Asia
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Premiums and Universal Life and Investment-Type Product Policy Fees	7,367	8,308	8,554
Net Investment Income	3,571	5,110	3,931
Policyholder Benefits and Claims and Interest Credited to Policyholder Account Balances	6,347	7,295	7,249
Amortization of DAC and VOBA Charged to Other Expenses	1,042	1,404	1,468
Other Expenses (1)	1,593	1,751	1,825
Latin America
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Premiums and Universal Life and Investment-Type Product Policy Fees	4,401	3,718	3,257
Net Investment Income	1,318	1,207	991
Policyholder Benefits and Claims and Interest Credited to Policyholder Account Balances	4,046	3,442	2,857
Amortization of DAC and VOBA Charged to Other Expenses	339	285	276
Other Expenses (1)	1,057	989	971
EMEA
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Premiums and Universal Life and Investment-Type Product Policy Fees	2,324	2,825	2,709
Net Investment Income	(864)	932	697
Policyholder Benefits and Claims and Interest Credited to Policyholder Account Balances	126	2,162	1,623
Amortization of DAC and VOBA Charged to Other Expenses	340	382	452
Other Expenses (1)	780	900	860
MetLife Holdings
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Premiums and Universal Life and Investment-Type Product Policy Fees	4,198	4,514	4,757
Net Investment Income	4,690	6,157	4,900
Policyholder Benefits and Claims and Interest Credited to Policyholder Account Balances	5,735	6,571	6,983
Amortization of DAC and VOBA Charged to Other Expenses	142	317	485
Other Expenses (1)	1,629	1,839	1,976
Corporate & Other
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Premiums and Universal Life and Investment-Type Product Policy Fees	(14)	37	25
Net Investment Income	221	251	35
Policyholder Benefits and Claims and Interest Credited to Policyholder Account Balances	(6)	35	(3)
Amortization of DAC and VOBA Charged to Other Expenses	9	9	8
Other Expenses (1)	$ 1,851	$ 1,721	$ 1,732

Consolidated Reinsurance (Conso

Consolidated Reinsurance (Consolidated Reinsurance) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Direct Premiums, Life Insurance in Force	$ 5,371,318	$ 5,273,869	$ 5,222,988
Ceded Premiums, Life Insurance in Force	390,521	394,023	442,381
Assumed Premiums, Life Insurance in Force	647,646	662,901	597,903
Premiums, Net, Life Insurance in Force	$ 5,628,443	$ 5,542,747	$ 5,378,510
Life Insurance in Force Premiums, Percentage Assumed to Net	11.50%	12%	11.10%
Consolidated Reinsurance
Gross Amount	$ 48,503	$ 41,259	$ 42,201
Ceded	2,143	2,157	2,199
Assumed	3,037	2,907	2,032
Premiums	$ 49,397	$ 42,009	$ 42,034
% Amount Assumed to Net	6.10%	6.90%	4.80%
Life insurance (1)
Consolidated Reinsurance
Gross Amount	$ 31,656	$ 23,597	$ 23,629
Ceded	1,422	1,490	1,620
Assumed	2,518	2,346	1,809
Premiums	$ 32,752	$ 24,453	$ 23,818
% Amount Assumed to Net	7.70%	9.60%	7.60%
Accident & health insurance
Consolidated Reinsurance
Gross Amount	$ 16,801	$ 16,752	$ 14,958
Ceded	715	639	516
Assumed	519	553	208
Premiums	$ 16,605	$ 16,666	$ 14,650
% Amount Assumed to Net	3.10%	3.30%	1.40%
Property and casualty insurance
Consolidated Reinsurance
Gross Amount	$ 46	$ 910	$ 3,614
Ceded	6	28	63
Assumed	0	8	15
Premiums	$ 40	$ 890	$ 3,566
% Amount Assumed to Net	0%	0.90%	0.40%